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ABSTRACT 
 
9 
The key to understanding the heterogeneous behaviour of similar stage locally 
advance rectal cancer lies in the understanding of tumour biology. The aim of 
this project was to investigate the biological behaviour of rectal cancers and its 
alterations in response to neoadjuvant chemoradiotherapy, by studying the 
intrinsic radiosensitivity, pathophysiology and angiogenesis of rectal cancers.  It 
was intended to provide information that may help risk-stratify patients for 
individualised treatments including optimal timing of surgery after 
chemoradiotherapy.   
Consecutive patients with locally advanced, non-metastatic rectal cancer, who 
were considered suitable for long-course neoadjuvant chemoradiotherapy, were 
prospectively recruited. Radiosensitivity was studied by investigating the timing 
of DNA repair analysis with single cell gel electrophoresis (comet assay). The 
tumour pathophysiology and angiogenesis was investigated in vivo by novel 
functional imaging techniques (multiparametric magnetic resonance imaging 
and dynamic contrast enhanced computed tomography). 
It is demonstrated that rectal cancer tissue consists of cells with heterogeneous 
radiosensitivities and functional microvascularity. Until six weeks after NCRT, 
the DNA repair remains inhibited with progressive devascularisation and 
increasing hypoxic blood volume resulting in loss of tumour cells. Thereafter, 
variable fractions of cancer cell may continue to perish or survive with 
corresponding changes in vascularity. Therefore, the period between the sixth 
and eleventh weeks after neoadjuvant therapy is a critical time when surviving 
cells from rectal cancers may develop aggressive traits with long-term 
consequences. Hence, biological assessment of locally advance rectal cancers 
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after six weeks post-NCRT may help risk-stratify patients for individualised 
therapy. 
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1 CHAPTER 1: INTRODUCTION 
Colorectal cancers are the third most common cancer in the United Kingdom. 
About one-third occur in the rectum and anus (36%) [1]. The risk of bowel 
cancer increases with age with a peak incidence of rectal cancer at 65 years 
of age and over. Men are more commonly affected (60%). The majority are 
classified as adenocarcinoma (AC) but mucinous carcinoma (MC) is a distinct 
form of CRC, which occurs in 10-15% of patients. It differs from AC in both 
clinical and histopathological appearance and is associated with a poorer 
response to therapies.  
Locally advanced rectal cancer (LARC) has significant risks for both local 
recurrence and distant metastases. The evidence-based management of 
LARC involves fluoropyrimidine-based neoadjuvant chemoradiotherapy 
(NCRT) followed by total mesorectal excision (TME) of the residual tumour [2] 
after an interval of 6-12 weeks. NCRT has an accepted role in reducing the 
risk of local recurrence in LARC, particularly when the circumferential 
resection margin (CRM) is breached or threatened, according to magnetic 
resonance imaging (MRI). NCRT can obtain a significant downsizing 
response and a curative resection can then be achieved in >80% of cases. 
NCRT may also facilitate sphincter sparing [3]. However, despite advances in 
imaging, staging, surgical technique, chemotherapy and radiotherapy, 
population studies show there has been only a small improvement in overall 
survival, treatment related morbidity and quality of life (see Figure 1.1). 
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Figure 1.1: Bowel Cancer, age-standardised one-year net survival, Adult 
(Aged 15-99), England and Wales, 1971-2011 
 
1.1 Exclusive clinical behaviour of rectal cancers 
The unique clinical course of rectal cancer disease observed is a cumulative 
effect of innate tumour biology and management strategy [4]. There is a high 
incidence of lymph node and/or distant metastasis at the time of diagnosis of 
rectal cancer [5]. The tumour biology depends on tumour location, 
histopathology and molecular profiles. 
1.1.1 Tumour location versus biological behaviour 
The UK Royal College of Pathologist [6] classify rectal cancer as (Figure 1.2): 
(i) Entirely above the level of peritoneal reflection anteriorly 
(ii) Astride (or at) the level of peritoneal reflection anteriorly 
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(iii) Entirely below the level of peritoneal reflection anteriorly 
Lopez-Kostner et al [7] showed differential long-term prognosis according to 
the location of tumour within the rectum: for sigmoid (>15cm; n=225), upper 
rectum (10-15 cm; n=229) and lower rectum (<10 cm; n = 437), the five-year 
local recurrence rates were 2.0%, 2.8% and 8.6%; the five-year local and 
distance recurrence rate were 3.9%, 4.7% and 12.9%; the five-year cancer 
related mortality were 13.5%, 12.7% and 25.6%, respectively. Tumours below 
the peritoneal reflection have the highest local recurrence rates [8].  
Figure 1.2: Diagrammatic illustration of rectal tumours in relation to 
peritoneal reflection [6]). 
 
Tumour location within the rectum directly affects the pattern of tumour 
spread. The three recognised means of disease progression include:  
(i) Contiguous spread 
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(ii)  Lymphatic spread 
(iii) Haematogenous spread  
1.1.1.1 Contiguous Spread 
The lower part of rectum lies in a funnel shaped extra-peritoneal cavity where 
its muscularis propria is in direct contact with the surrounding lymph node 
embedded in a cushion of fatty tissue called ‘mesorectum’. Hwang et al [8] 
and others [9, 10] reported that rectal tumours located in the non-
peritonealised part of rectum (up to 5 cm from anal verge) were an 
independent risk factor for recurrence-poor-survival. Posterior and lateral low 
rectal cancers that penetrate the rectal wall directly invade the mesorectum 
and may produce micrometastases in the mesorectum. Anteriorly, any 
extension of tumour results in penetration into either prostate and/or bladder 
in males or the vagina in females and such tumours are also technically 
challenging for surgical excision. Thus the majority of local recurrences may 
arise from contiguous spread [11] and occur either at the base of bladder, 
prostrate, vagina or sacrum [12].  
1.1.1.2 Lymphatic spread 
The initial spread is principally through mesenteric drainage to perirectal 
nodes within the mesorectum. The majority of the perirectal lymph nodes 
reside in the proximal two-thirds of the posterior mesorectum [13]. The 
subsequent spread is preferentially alongside superior haemorrhoidal vessels 
towards the base of inferior mesenteric artery. About 10-15% of locally 
advanced low rectal cancer spread to iliac and obturator lymph nodes (middle 
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and inferior haemorrhoidal arteries) [14]. Subsequently, proximal spread occur 
alongside iliac vessels and para-aortic lymph nodes [15]. 
1.1.1.3 Haematogenous spread  
Distant metastasis is to liver by means of portal circulation common in upper 
rectal cancers (superior haemorrhoidal vein), whereas low rectal cancer have 
a higher incidence of pulmonary metastasis via systemic circulation (middle 
and inferior haemorrhoidal vein) [8, 16]. 
1.1.2 Histopathological features versus biological behaviour  
1.1.2.1 Staging of rectal cancer 
The stage of the disease is an effective prognostic indicator. There are two 
histopathological staging systems include (see appendix I, page 372): 
(i) Dukes Classification 
(ii) Tumour, Node, Metastases (TNM) classification and staging 
The Dukes’ staging system is based on the depth of mural invasion and lymph 
node involvement of the tumour [17]. The TNM classification is based on 
anatomic disease extent and published by the Union for International Cancer 
Control (UICC) [18]. There are limitations in the accuracy of risk prediction by 
staging systems and rectal cancers at identical stages may show 
heterogeneous prognosis. There is a general tendency to over-stage nodes 
when using size criteria alone. Mixed signal intensity and irregular borders of 
the nodes are supporting features of involvement, but one third of involved 
rectal cancer nodes are often <5mm and many may not even be visualized. 
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There are features of rectal cancer disease with prognostic significance not 
incorporated into the aforementioned staging systems. For example, the 
important relationship of rectal tumour to mesorectal fascia that has been 
highlighted by Heald et al [19] and its significance in staging has been further 
established in several later studies [20].  
1.1.2.2 Tumour histology type 
The following histopathological features are established markers predicting 
biological behaviour: 
 Poorly differentiated adenocarcinomas - are associated with reduced 
survival (independent of the disease stage) [21-25], lymph node 
metastasis [23, 26] and poor response to NCRT [27].  
 Mucinous tumours - rectal adenocarcinoma is considered mucinous 
when >50% of the tumour volume consists of extracellular mucus, where 
malignant epithelium can be found in clumps or as single cells. The mucin 
produced by tumours is able to dissect through the gut wall and facilitate 
tumour extension [28].  
 Infiltrative border configuration – is an independent risk factor of poor 
prognosis in several studies [29, 30]. A comprehensive analysis of 1420 
colorectal cancer blocks (39.2% rectum) by Zlobec et al. [31], reported a 
significant drop in 5 year survival from 80% to 62.7% for patients with 
stage II disease how had ‘pushing border’ and ‘infiltrative growth pattern’, 
respectively.  
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 Tumour budding – is the presence of small cluster of undifferentiated 
tumour cells ahead of the invasive front of the lesion [32]. It corresponds 
to the initial phase of tumour invasion and represents a biological index of 
tumour aggressiveness confirmed in several studies showing increasing 
severity of tumour budding to be associated with nodal metastases and 
extramural vascular invasion, more aggressive malignant behaviour [33-
35], early metastasis [36], poor local control and survival [37, 38]. In 
patients who receive NCRT, the morphology of post irradiation tumour 
budding depends on the histologic response to radiation. For radiation 
insensitive rectal tumours (moderate tumour regression grade - TRG 2 or 
3), post irradiation budding intensity help stratify risk of recurrence and 
survival [39].  
1.1.2.3 The depth of tumour invasion 
Prior to the standard use of NCRT, Jass et al. [40] demonstrated that >5mm 
of invasion into perirectal fat significantly increases the local recurrence rate 
of rectal adenocarcinoma. Subsequent studies propose a depth of tumour 
invasion border greater that 4-6 mm beyond the muscularis propria to be 
associated with higher rates of local recurrence and diminished disease-free 
survival over five years [41-45].  
About 10% of submucosal (pT1) rectal tumour spread to lymphatics. Within 
the pT1 group, tumour limited to superficial-third submucosa (sm1) show 2% 
lymph node involvement, tumours involving the middle-third submucosa (sm2) 
show 8% lymph node involvement and tumour involving the deepest-third 
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submucosa (sm3) show 23% lymph node involvement [46]. The simultaneous 
lymphatic spread is around 30% in tumours invading muscularis propria and 
increases to 50% in tumours invading out into peri-rectal tissue [40].  
Rectal cancers classified under pT3 (cancers cells beyond muscularis 
propria), show wide prognostic heterogeneity and further subdivision 
according to the depth of mesorectal extension give more specific estimates 
of long-term prognosis [47]. Recent European Society of Medical Oncology 
consensus guidelines [48] recommend the penetration of the tumour into the 
mesorectal fat should be described in millimetres to define T3 subgroups. The 
T3 stage includes minimal invasion (0.5-1mm) beyond the muscularis propria 
i.e. T3a (which carries a prognosis almost as good as stage T2N0) ranging to 
gross invasion into the mesorectum or peritoneum >10mm [44]. Hence 
cancers at opposite ends of this T3 spectrum have completely different risks 
of lymph node involvement and hence different prognostic implications. 
Patients with pT3b compared to pT3c (extramural invasion <5 vs >5mm; see 
appendix I, page 372) had 5 year survival rates of 85% and 54%, respectively 
[44]. The prognostic difference between tumours with different depth of 
invasion remains even after NCRT - as shown by different outcomes for 
ypT3a (defined as 5 mm or less) and ypT3b staged tumours (defined as more 
than 5mm)in terms of local recurrence (7% vs 18%, p 0.04), distant 
metastasis (20% vs 41%; p 0.03), disease-free survival (73% vs 47%; p 0.01), 
overall survival (79% vs 74%; p 0.03) and cancer-related survival (81% vs 
74%; p 0.007) over 5 years [49].  
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1.1.2.4 Circumferential Resection Margin and Distal Intramural Spread  
The radial or circumferential resection margin (CRM) is the distance between 
the outer lateral aspect of the tumour and the fascia propria recti or 
mesorectal fascia (see Figure 1.3). So the distance between the edge of the 
surgical specimen that should lay on the mesorectal fascia and the closest 
tumour satellite is taken as the CRM and measured in millimetres. The CRM 
is considered involved if the tumour extends to within 1mm or less of the 
excision margin and historically was seen in 20% of resected specimen [50]. 
The modes of this involvement include direct spread, tumour satellite, lymph 
node spread and vascular spread. The CRM involvement increases rates of 
local recurrence [50] and is regarded as the most important indicator of local 
failure after surgery.  
Figure 1.3: Circumferential resection margin [51] 
 
(Circumferential resection margin; DRM: Distal resection margin. DMM: Distal mesorectal 
margin; LNs: Lymph nodes; MMF: Mesorectal microfoci) 
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Wibe et al [52] from the Norwegian rectal cancer project showed an 
exponential increase in local recurrence, metastasis and death with a 
decreasing CRM. The risk factors for CRM involvement include lymph node 
positive tumour and abdominoperineal excision of rectum [53, 54]. The later 
may be explained by rectal anatomy: at the level of levator muscles the 
mesorectum tapers sharply; consequently the distance between the outer 
muscularis propria and the mesorectal fascia decreases, which increases the 
likelihood of tumour being in close proximity or breaching the distal TME 
plane[55]. Hence, presence of tumour at CRM may be an indicator of advance 
disease [56] or due to surgical failure to remove all tumour [57], and proven to 
be a powerful prognostic marker of rectal cancer recurrence, distant 
metastasis and survival [52, 58-62]. In a pooled analysis of 17,500 patients, 
Quirke et al [63] reported a significantly better predictive value of CRM for 
local recurrence in patients receiving NCRT than when no preoperative 
therapy was given (HR 6.3 vs 2.0, respectively, p <0.05), distant metastasis 
(HR 2.8; 95% CI, 1.9 to 4.3) and survival (HR 1.7; 95% CI, 1.3 to 2.3). 
Analysis of CRM involvement in participants from a Dutch nationwide 
randomised multicentre trial [64], a trial comparing preoperative radiotherapy 
followed by surgical excision of rectal cancer against surgery alone, has 
shown that tumour that extend to within <2mm from CRM in non-irradiated 
patients increased risk of local recurrence to 16% compared to 5.8% with no 
CRM involvement [65]. Furthermore, in the patients with CRM ≤ 1mm, neither 
neoadjuvant nor adjuvant radiotherapy improve the local recurrence rates [66, 
67].  
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The microscopic ‘distal intramural spread (DIS)’ of cancer cells has also 
shown to predict prognosis and a spread of >1 cm in patients not receiving 
NCRT is associated with decreased disease free survival (DFS) [68] and high 
incidence of local lymph node [69, 70] and distant metastasis [68, 71].  A later 
study investigating DIS in patients treated with NCRT, found that vast majority 
of their study sample had no DIS beyond 1 cm (sample size=20; DIS ≤1 
cm=10; DIS >1cm = 1) and there was no significant effect of DIS on survival 
[72]. A study by Vernava et al [73] showed that even 1cm tumour free distal 
intramural margin is sufficient to prevent local recurrence, distant metastasis 
and prolong 5-year survival rates (Distal resection margin > 0.8 cm, n=219 Vs 
< 0.8 cm, n=20; LR 8.7 / 5.0 %, p >0.05, DM 14.2 / 10.0%, p> 0.05  and 5-
year-survival 67.3 / 49.3%, p 0.01).    
1.1.2.5 Lymphatic involvement 
Lymphatic invasion is a strong predictor of lymph node metastases as 
recently shown in a meta-analysis analysis of 42 histopathological markers 
from 72 studies. Glasgow et al [23] have shown lymphatic invasion (OR 8.62) 
significantly outperformed tumour depth (T2 Vs T1; OR 2.62) and overall 
differentiation (OR 2.38) in predicting nodal spread in early cancers. The 
‘lymph node involvement’ is present in 30-40% of patients with new diagnosis 
of rectal cancer [74] and proved to be a powerful prognostic marker of 
recurrence in several longitudinal studies involving retrospective multivariate 
analysis [75]. About 15-42% of patients with rectal cancer have small (<5mm) 
mesorectal lymph nodes that contain a tumour [76] . The incidence of small 
lymph node involvement increases by 10% in the lower mesorectum. The 
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increasing ‘quantity of lymph nodes’ involved correlate to worsening outcomes 
[77-80]. In patients treated with NCRT, the presence of lymph node 
metastasis in postoperative specimen confers poor survival [78, 81, 82]. The 
‘total number of lymph node retrieved’ from postoperative specimen also plays 
a crucial role in forecasting prognosis [83, 84]. In patient achieving pCR after 
NCRT, residual nodal positivity may still exit [85], and therefore, the status of 
lymph node is the most relevant independent prognostic factor for distant 
metastasis and survival [86].  
1.1.2.6 Extramural Vascular and Perineural Invasion  
Extramural venous invasion (EMVI) is an independent marker of prognosis 
[87] and is present in 30-40% of specimens resected. Knudsen et al [88] 
demonstrated a proportional increase in extramural venous and perineural 
invasion with higher Duke’s stages. Multivariate analyses have shown strong 
links between EMVI and synchronous metastatic disease [89-92], local 
recurrence , disease free survival [93-95] and overall survival [88, 96]. In an 
analysis of 682 rectal cancer specimens, the likelihood of developing liver 
metastasis at the time of death was three times higher in cases with venous 
invasion than when no invasion was seen in surgically resected specimen[88]. 
The presence of EMVI is also a  strong predictor of lymph node involvement 
in T1/T2 rectal cancer [97]. Perineural invasion (PNI) is present in 24 – 35 % 
of resected specimen and is shown to be a predictive marker of local 
recurrence [98, 99]. Both venous and neural invasion can predict significantly 
reduced actuarial survivals in patients with node-negative tumours [100]. 
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The presence of PNI is also associated with decreased survival [88] even 
after curative management in rectal cancer disease (Stage I, II [101] and III 
[102, 103]).  
1.1.2.7 Pathological Tumour Regression Grade 
After NCRT, varying degree of fibrosis or fibro-inflammatory tissue may 
develop at the site of the tumour. This was first described in rectal cancers by 
Dworak [104], who proposed a pathological tumour regression grading system 
(TRG) based on the proportion of residual tumour left in fibrotic stroma after 
NCRT; the grading system ranges from no response to complete response 
(see table 1.1). A pathological complete response (pCR) is defined as no 
residual viable tumour cells within the specimen. A similar grading system 
was described for oesophageal cancer by Mandard et al.[105]  previously and 
has been applied for rectal cancer response in some studies. TRG is observer 
dependent and poorly reproducible. Hence, TRG has failed to demonstrate 
any independent prognostic value in large randomised trials and should not 
be considered as a surrogate endpoint. 
MRI based TRG has been examined in 3 separate datasets (Mercury, CORE, 
LOREC) and although it does not correlate very well with ultimate histology it 
does with response / down-staging and more importantly with outcome (see 
below, section 1.4.2). 
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Table 1.1: Pathological Tumour Regression Grading (pTRG) 
Dworak  Mandard  Definition 
0 TRG 5 No regression 
1 TRG 4 
Dominant tumour mass with obvious fibrosis and/or 
vasculopathy 
2 TRG 3 
Dominantly fibrotic changes with few tumour cells or 
groups (easy to find) 
3 TGR 2 
Very few (difficult to find microscopically) tumour cells 
in fibrotic tissue with or without mucous substance 
4 TRG 1 No tumour cells, only fibrotic mass 
1.1.3 Molecular profiles versus biological behaviour 
The molecular markers can be broadly divided in to those that predict: (i) 
Response to neoadjuvant treatment and (ii) long-term survival. The details are 
presented in table 1.2.
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Table 1.2: Molecular Markers shown to have prognostic significance in rectal cancer 
Molecular Marker Normal function Prognostic importance 
p53 gene and 
protein 
Tumour suppressor gene that 
encodes for DNA-binding 
phosphoprotiens that 
eliminates DNA damaged cell 
from cell cycle 
Abnormal p53 related with increased risk of death (RR 1.32; CI 1.23 –1.42) 
and high failure rates to radiotherapy (RR 1.49; CI 1.25-1.77) [106]; wild 
type p53 in rectal cancer patient was associated with 5-year survival 
benefit for those receiving Fluoropyrimidine based chemotherapy with or 
without radiotherapy [107] 
p21 protein The p21 is cyclin-dependent 
kinase inhibitor that is 
activated by wild-type p53 and 
its activation induces G1 
arrest when cells are exposed 
to DNA damaging agents. 
Some studies have shown p21 expression as a useful predictor of 
radiosensitivity and long-term prognosis [108-110], whereas, other have 
not shown any useful role [111-114]. 
Bcl–2 and Bax 
 
Integral part in cell apoptosis 
in response to cytotoxic signal 
from chemo- and/or 
radiotherapy 
Bcl-2 expression is associated with complete response rates [115], 
metastasis free survival [116] and overall survival [117]. High Bax 
expression is seen in responders [112, 118-120] and disease–free 
survivors [121], whereas, there are many studies where neither Bcl-2 nor 
Bax has shown any prognostic significance [111, 122-124].  
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Molecular Marker Normal function Prognostic importance 
Ki-67 
(Proliferation 
Index) 
The Ki-67 and its epitope MIB-
1, are nuclear protein found in 
proliferating cells except 
during G0 and early G1 phase 
Proliferative index can potentially predict treatment sensitive tumour. 
Cancers with low proliferative index can be radioresistant [125]. Ki-67 
expression predicts response to NRCT [126] [127]. However, earlier 
studies failed to show any relation between presence of Ki-67 in pre-
treatment biopsy and response to treatment [128-131].  
Cyclo-oxygenase 2 
(COX-2) 
 
Enzyme that catalyses the 
conversion of arachidonic acid 
to prostaglandins [132] 
High level of COX-2 in pre-treatment biopsy respond poorly to neoadjuvant 
therapy as compared to those with normal COX-2 levels [111, 133-135] 
[136]. In multivariate analysis, COX-2 positivity was an independent 
predictor of distant-metastasis free survival, DFS and OS, and combination 
of COX-2 and VEGF positivity showed a strong correlation with decreased 
DFS (p=0.007) [137]. 
Survivin 
 
Blocks apoptosis by inhibiting 
activation of Caspase-3 and 
Caspase-7 regulating cell 
cycle in G2/M phase 
There is a potential role of survivin in predicting rectal tumour 
aggressiveness [138], lack of response to neoadjuvant treatment [139, 
140] and long-term prognosis [141, 142]. Failure of survivin 
downregulation after NCRT is related with poor DFS and survival [141]. 
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Molecular Marker Normal function Prognostic importance 
Thymidylate 
synthase 
Enzyme in folate metabolism 
that converts deoxyuridine 
monophosphate to 
deoxythymidine 
monophosphate providing the 
de novo sole source of 
thymidine required for DNA 
synthesis and repair during 
cell cycle and proliferation 
[143] 
Fluorouracil (FU) works by primarily targeting TS enzyme initiating cell 
cycle arrest and cell death [144]. Hence, the polymorphism of TS gene 
may indicate sensitivity of rectal tumour cells to fluoropyrimidines [145]. 
However, studies investigating LARC treated with neoadjuvant 5-FU have 
shown conflicting results; both low [146, 147] and high [113, 126, 148, 149] 
TS expression have shown higher response rate in separate settings. 
Similar contradictory report exist on the level of TS expression in pre-
treatment biopsies and long-term prognosis; whilst some studies have 
shown early disease recurrence and shortened survival in patients with 
high TS levels [150], others have shown similar unfavourable effects with 
low TS expression in pre-treatment rectal cancer tissue [151]. 
RAS Proto-
oncogenes 
(KRAS, NRAS and 
HRAS) 
Control signalling pathway 
that are key regulators of 
several aspects of normal cell 
growth [152] 
NRAS mutation occurs in less than 5% of colorectal cancers and is 
associated with rectal tumours and distant metastasis. HRAS mutation has 
been observed in bladder and oesophageal cancers.   A recent 
retrospective review of 1519 cases did not show any association between 
NRAS or HRAS and clinicopathological features of colorectal cancers 
[152].  
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Molecular Marker Normal function Prognostic importance 
KRAS Involved in growth 
transduction and cellular 
differentiation by activating 
protein kinase receptors [153] 
KRAS mutation provides an effective indicator of tumour sensitivity to anti-
EGFR chemotherapy. Several clinical studies support the positive 
correlation between KRAS mutation and lack of response to anti-EGFR 
chemotherapy in colorectal cancers [154-156]. KRAS status has no value 
in predicting response to standard fluoropyrimidine-based chemoradiation 
[157, 158] and its role as a marker of long-term outcomes also remains 
unclear [159-161].   
Epidermal Growth 
Factor Receptor 
(EGFR) 
 
Activates downstream 
effectors in gene expression, 
causing cellular proliferation, 
inhibition of apoptosis and 
angiogenesis [162] 
High expression of EGFR in pre-treatment biopsies is associated with poor 
response to NCRT [148, 163-165]. Overexpression of EGFR show higher 
metastatic potential, [166], local recurrence [167], poor DFS [168], and 
survival [169]. The EGFR and its components are established molecular 
target for monoclonal antibody (Cetuximab; Erbitux, Merck 
Pharmaceuticals) and molecular blockade (Gefitinib) based novel 
chemotherapeutics. 
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1.1.4 Tumour pathophysiology versus biological behaviour  
Tumour pathophysiology is critical for tumour survival, progression and 
response to treatment. The availability and uptake of nutrients including 
oxygen, disposal of waste, humoral functions and delivery of cytotoxic agents 
is mainly dependent on cancer microenvironment. The features with most 
impact on tumour microenvironment include: 
(i) Angiogenesis  
(ii) Tumour blood flow 
1.1.4.1 Angiogenesis 
Angiogenesis is a complex process of new blood vessel formation from pre-
existing ones. It involves activation, proliferation and direct migration of 
endothelial cells to form new capillaries. Physiological angiogenesis occur 
during embryogenesis, wound healing and reproductive cycle in adults [170]. 
Pathological angiogenesis is characterized by persistent proliferation of 
endothelial cells and is a prominent feature of many diseases including 
rheumatoid arthritis, psoriasis, and proliferative retinopathy. Invasive cancers 
have the ability to stimulate angiogenesis from surrounding vessels and 
establish blood flow to support their nutrition, waste management, humoral 
activity and growth [171, 172].  
1.1.4.1.1 The regulation of angiogenesis  
There are endogenous pro-angiogenic stimulant factors that promote 
endothelial cells to dissolve their extracellular matrix, migrate towards tumour 
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cell and proliferate to form new vascular network. The most significant 
angiogenic promoters include a family of cytokines known as vascular 
endothelial growth factors (VEGF), their receptors (VEGFR) and TGF-β 
superfamily. There are also a variety of endogenous angiogenic inhibitor 
presumed to regulate angiogenesis and include thrombospondon-1, 
angiostatin (a fragment protein from cleavage of plasminogen within tumour 
[173]) and endostatin (derived from collagen XVIII [174]). The shift of fine 
balance between pro and anti-angiogenic factor levels, termed ‘angiogenic 
switch’, determines progression and pattern of angiogenesis.  
1.1.4.1.2 Physiological versus neoplastic angiogenesis 
Physiological angiogenesis results in organised microvascular architecture 
that maintains a homogenous density throughout tissue planes, vascular 
hierarchical pattern, endothelial cell spacing and vascular permeability. In 
neoplastic angiogenesis there is loss of fine balance of ‘angiogenic switch’ 
[175, 176] that results in structurally and functionally abnormal vascular 
networks. There is chaotic microvascular architecture, the vascular density is 
heterogeneous throughout tissue planes and the vessels formed are 
immature with small diameters that are permeable to large molecules [177]. In 
addition, the proliferating cancer cells also compress intra-tumoral blood and 
lymph vessels. These structural abnormalities contribute to high interstitial 
pressure equalling intra-capillary pressure resulting is heterogeneous blood 
flow within vascular networks and creates a microenvironment surrounding 
cancer cells that is characterised by interstitial hypertension, impaired blood 
supply, hypoxia and acidosis [178, 179].  
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1.1.4.1.3 The impact of neoplastic angiogenesis on rectal tumour 
behaviour 
The cumulative effect of abnormal vascular structure and blood flow makes 
cancer tissue resistant to treatment by hindering drug and oxygen radical 
delivery. The hypoxic and acidic environment also compromise cytotoxic 
function of host immune cells and may induce genetic alteration within 
malignant cells leading to increased metastatic potential [178]. Rectal cancers 
with dominant angiogenesis are associated with aggressive behaviour, 
treatment resistance and recurrence [180, 181]. The degree of angiogenesis 
within resected rectal cancer specimen has been proposed as an independent 
marker of prognosis [182-184].  
1.1.4.2 Tumour Vascular Morphology 
The neovascularization in tumours usually originates from venules within the 
tissue mass or host tissue [185]. The tumour has two populations of blood 
vessels: (i) pre-existing host vessels incorporated into tumour tissue and (ii) 
tumour vessel from neoplastic angiogenesis. Neoplastic vessels have severe 
morphological defects (see table 1.3 by Vaupel et al [185]). The loss of 
vascular organization results in infinite number of different vessel type 
combination frequently resulting in arteriovenous shunting and veno-venous 
circulation [186]. Skinner et al [187] examined the structure of benign and 
malignant colorectal tumours and found increased density of microvessels 
resulting in formation of nodular clusters of capillaries, formation of sheets of 
frequent anastomosing capillaries and almost complete packing of the 
interstitial spaces of the tumour by capillaries.   
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Table 1.3: Structural and functional abnormalities of neoplastic 
angiogenesis [185] 
A. Structural abnormalities (“vascular chaos”) 
1. Abnormal Vessel Wall 
Incomplete or missing endothelial lining 
Interrupted or absent basement membrane 
Blood channels line by tumour cell cords 
Lack of pericytes, contractile wall components and pharmacological/physiological 
receptors 
2. Abnormal vascular structure 
Contour irregularities (formation of lacuna-like sinusoidal and cystiform blood vessels) 
Tortuosity (distortions, twisting, bending) 
Elongation of vessels 
Existence of arteriovenous shunts (global flow > nutritive flow) 
Loss or hierarchy 
3. Abnormal vascular density 
Heterogeneous distribution of vascularization (“chaotic network”, appearance of 
avascular areas) 
Expansion of the intercapillary space (increase of diffusion distances) 
B. Functional abnormalities (“circulatory chaos”) 
1. Consequence of altered morphology 
Arteriovenous shunt perfusion (~30%) 
Regurgitation and intermittent flow 
Unstable speed and direction of flow 
Absence of vasomotion 
Increased vascular fragility 
Obstruction of microvessels by WBC and tumour cells 
High tumour vascular (geometric) resistance 
2. Consequence of altered rheology 
RBC sludging, leukocyte sticking 
Platelet aggregation 
Micro- and macrothrombosis 
Increase of viscous resistance 
3. Consequence of increased vascular permeability 
Heterogeneous distribution of vascularization (“chaotic network”, appearance of 
avascular areas) 
Expansion of the intercapillary space (increase of diffusion distances) 
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1.1.4.3 Tumour Blood Flow 
The tumour microcirculation supply nutrients and remove waste, provide a 
vehicle for cancer cells to metastasize, determine pharmacodynamics of 
chemotherapeutics and efficacy of radiotherapy dependant on local oxygen 
concentration. The vascular volume of colon carcinoma was shown to be 
significantly greater than adenoma and normal colon (23% ±12.2 vs. 
16.3%±3.4 and 11% ± 4.2 respectively) [187]. Interestingly, Hinganu et al 
[188] studied neoangiogenesis of rectal adenocarcinoma of same grade 
(stage III) at different locations within the rectum, and reported an incremental 
rise in the length of neoplastic blood vessels and maximum neoangiogenesis 
area from inferior to middle and middle to upper rectal cancers.  
The incorporated host vessels are reactive to physiological stimulus like 
hypoxia and therefore maximally dilated in areas of poor perfusion. Therefore, 
the global tumour blood flow in response to physiological stimulus (hypoxia / 
acidosis) depends on the ratio of host to neoplastic vasculature, which 
depend on tumour location, size, differentiation and stage, and keeps 
changing continuously. There is interstitial hypertension due to free water 
diffusion out of vessels tumour load and lack of lymphatic drainage causing 
luminal compression and nullifying perfusion pressures. There also 
considerable spatial and temporal heterogeneity of tumour microcirculation 
within individual vessels and different vascular micronetworks within one 
tumour and same tumour of different size, differentiation, grading and location 
[185].  
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1.1.4.4 Quantification of angiogenesis and tumour blood flow 
There is no consensus method of quantifying tumour microvasculature. The 
method used in clinical studies include: 
(i) VEGF and VEGFR assays 
(ii) Microvascular Density (MVD) 
Both methods use immunohistochemistry staining that involve use of 
monoclonal antibodies directed against antigens specific to VGEF, VGEFR 
and various endothelial antigens to assess MVD (factor VIII, CD31, CD34 and 
CD105) on resected and fixed histopathology specimen, but such staining 
may not reflect the extent of functional angiogenesis with the tumour [189].  
The morphological appearance of tumour microvasculature does not 
necessarily correlate with its functional aspects. There are many functional 
elements of angiogenesis that also contribute to tumour biology and 
prognosis. Functional imaging is an emerging technology enabling in-vivo 
assessment of tumour tissue and its microenvironment. Studies investigating 
dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) to 
measure functional angiogenesis have shown poor or inverse correlation 
between DCE parameters and VGEF/MVD static histological markers [190-
192], further backing the independent role of functional angiogenesis in 
tumour biology.   
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1.2 Diagnostic imaging of rectal cancer 
The imaging modalities use to investigate the extent of rectal cancer include: 
1. Endoanal ultrasound  
2. Magnetic Resonance Imaging  
1.2.1 Endoanal ultrasound  
Endoanal ultrasound (EAUS) is valuable in staging superficial rectal cancers 
(sensitivity 97%, specificity 96% for T1 tumours). It has a mean T- and N - 
stage accuracy of 85% and 75% respectively [193]. EAUS is of limited value 
for advance tumours as the depth of penetration for high frequency probes is 
limited to 5mm. Other limitations include availability of highly skilled operator 
and risk of understaging tumours [194]. 
1.2.2 Magnetic Resonance Imaging  
Magnetic resonance imaging (MRI) of rectum and pelvis is currently the gold-
standard imaging modality to assess mid-to-low rectal cancer disease. 
Technical advances and improved image resolution (high resolution MRI of 
rectum with phased array coils) provide detailed information on local disease 
extent and response to neoadjuvant treatment with valuable impact on clinical 
staging, treatment planning (defining surgical anatomy as well as prognostic 
markers for neoadjuvant and/or adjuvant treatment), response assessment 
and prognosis. The detailed rectal tumour morphology displayed by MRI is 
very close to histopathological findings. These results have been validated in 
multicentre studies showing excellent agreement between MRI and 
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histopathology assessment of rectal cancer [195, 196]. MRI is particularly 
useful in distinguishing between pT3b and pT3c disease extent. Controlled 
studies have shown MRI specificity for CRM involvement of 92% (CI 90-95%) 
[195, 197]. Histopathology remains gold standard to assess nodal 
involvement in rectal cancers; however, diseased nodes within mesorectum 
with irregular border or mixed intra-nodal signal can be seen on MRI 
(accuracy 85%). Morphologic MRI also displays the anatomic distribution of 
nodes both within and outside the mesorectum. The reported sensitivity and 
specificity of MRI in detecting EMVI is in the range of 62-100% and 88-89%, 
respectively [197-199]. The assessment of EMVI also provides critical insight 
into potential tumour response to neoadjuvant treatment. Yu et al [200] clearly 
demonstrated EMVI involvement on pre-treatment MRI as marker of poor 
response to NCRT on a multivariate analysis. Interestingly, MRI defined low 
rectal cancers (<5 cm from anal verge) were also shown to respond well to 
NCRT. Better response of low rectal cancers has been reported previously 
[201]. Despite the anatomical complexities, MRI remains a reliable modality in 
assessment of low rectal tumours. MRI based staging system for low rectal 
cancers has been recently developed and successfully validated in 
MERCURY II trial (see table 1.4) [202].  
The MRI based markers of treatment response are shown in table 1.5 
(adopted from review by Battersby et al). Studies comparing post-NCRT MRI 
staging (ymr) with histopathological staging (yp) have reported the following: 
ymrT-stage show good correlation and accuracy of 40–60% with ypT-stage 
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[203-205]; and ymrN-stage has reported accuracy of 87% with ypN-stage 
[205].  
Table 1.4: MRI Stage for low rectal cancers [202] 
MRI Stage Definition 
I Tumour confined to bowel wall but not through full thickness 
II Tumour replaces the muscle coat but does not extend into 
the intersphincteric space 
III Tumour invades the intersphincteric space or lies within 1 mm 
of the levator muscle 
IV Tumour invades the external anal sphincter and is within 1 
mm and beyond levators muscle with or without invading the 
adjacent structures 
Table 1.5: MRI based markers of response to NCRT [55] 
Pre-treatment MRI markers predicting response to NCRT  
 Tumour Height – low rectal tumours are more likely to be ‘good 
responders 
 EMVI – the presence of EMVI increases the likelihood of poor response 
Post-NCRT MRI markers of response 
 mrTRG 
 Tumour Height  
 EMVI (ymrEMVI) 
 CRM status 
 Depth of invasion (ymrT-stage) 
 Node status (ymrN-stage) 
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1.2.3 Assessment of tumour response to NCRT 
1.2.3.1 Response Evaluation Criteria in Solid Tumours  
The radiological assessment of tumour response to neoadjuvant treatments 
has been traditionally based on morphological criteria. The ‘Response 
Evaluation Criteria in Solid Tumours (RECIST)’ has been developed as 
standard criteria to assess response to neoadjuvant therapy (Table 1.6). 
There are few fundamental flaws with RECIST criteria: firstly it not specifically 
designed for rectal cancers, secondly the criteria is based on arbitrary figures 
not derived from outcome data, and non tumoural masses may persist without 
any impact on disease status, and finally, it does not take in account tumour 
biology which plays critical role in tumour behaviour.  
Table 1.6: Response Evaluation Criteria in Solid Tumours (RECIST) [206] 
Criteria Definition 
Complete Response Disappearance of all target lesion 
Partial response 30% decrease in the sum of the longest diameter of 
the target lesion 
Progressive disease 20% increase in the sum of the longest diameter of 
the target lesion 
Stable disease Neither sufficient shrinkage nor increase 
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1.2.3.2 MRI based TRG 
A more effective tool for assessment of rectal cancer response to NCRT has 
been the development of MRI tumour regression grading (mrTRG) in recent 
years, based on pathological tumour regression grade system [104, 105]. The 
entire tumour is assessed to determine if fibrosis signal intensity or if tumour 
signal intensity predominates (see table 1.7).  In a prospective study of 111 
patients, mrTRG independently predicted DFS (HR 3.28; 95%CI 1.22 to 8.8) 
and OS (HR 4.4; 95%CI 1.64 to 11.7), on multivariate analysis.  Patients with 
mrTRG 1-3 (good response) had better five year DFS (72% vs 27%, 
p<0.001). In addition, mrTRG 1 and 2 were highly predictive of pCR [207].   
Table 1.7: MRI Tumour regression grading 
Grade Definition 
mrTRG1 Dominant low-signal intensity fibrosis with no tumour 
mrTRG2 Low-signal intensity fibrosis with minimal residual 
tumour 
mrTRG3 50% fibrosis/mucin and intermediate signal representing 
residual tumour.  
mrTRG4 Predominance of tumour with minimal low-signal 
intensity fibrosis 
mrTRG5 Tumour is unchanged from baseline 
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1.3 Management of locally advanced rectal cancers 
The current management of patients with locally advanced rectal cancer 
includes three components: 
1. Neoadjuvant chemoradiotherapy (NCRT) 
2. Interval period 
3. Total Mesorectal Excision (TME) of rectal cancer 
1.3.1 The impact of radio-chemotherapy in the management of 
locally advance rectal cancers 
The Swedish Rectal Cancer [208, 209], Dutch TME [64, 210, 211] and MRC 
CR07 trials [212] established the benefit of preoperative short-course 
radiotherapy in resectable rectal cancer, at least in terms of local recurrence 
even if this has not always resulted in a convincing survival. The largest 
possible gain has been seen in patients with extramural spread and node-
positive disease. Preoperative radiotherapy has also been shown to be more 
beneficial than when given postoperatively [213]. The summary from these 
trial highlighted shortcomings in the management of patients including 
imprecise staging, sub-standard surgery and radiotherapy.  
Two large trials specifically investigated the utility of fluoropyrimidine based 
chemotherapy with preoperative long-course radiotherapy, the EORTC 22921 
[214, 215] and FFCD 9203 trials [216] showed reduction in local recurrence 
as well as increased rate of pathological complete response without any 
benefit in 5-year survival; but the trial were underpowered to show a 5% 
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difference in overall survival [2].  The German rectal trial [217] showed 
superiority of preoperative long course chemoradiation over postoperative 
treatment in terms of fewer local recurrences and less acute and late toxicity, 
but no survival benefit. The Polish [218, 219] and TROG trial [220] did not 
show any difference between short and long-course radiotherapy. A Cochrane 
systematic review has concluded that preoperative radiotherapy improves 
overall mortality and local control over surgery alone, and that preoperative 
chemoradiotherapy reduces local recurrence further without affecting overall 
mortality [221]. There were no difference recorded in local recurrence and 
survival in the two trials that’s compared preoperative short-course and long-
course radiotherapy in resectable cancers. The role of postoperative radio ± 
chemotherapy remains remains controversial because although some trials 
[222] and meta-analyses [223-225] showed survival benefit but toxicity is 
acknowledged to be worse post-operatively.  
1.3.2 The impact of ‘interval to surgery’ in the management of 
locally advance rectal cancer 
Francois et al [226, 227] is the only RCT exploring the interval between NCRT 
and surgery. They randomised 201 patients with lower to mid T2-3 rectal 
cancer to surgery within two weeks, or between six and eight weeks, following 
completion of 13 fractions of preoperative radiotherapy. Patients in the long-
interval arm experienced greater clinical and pathological tumour responses, 
and their tumours were more likely to be down-staged according to the TNM 
classification. However, there were no differences between the two groups in 
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morbidity, anal function, local recurrence or survival at a median follow-up of 
6.3 years.  
Petterson et al [228] examined short-course pre-operative radiotherapy 
(SCPRT: 5Gy for 5 days). After SCPRT (5x5Gy) the current recommended 
interval to surgery is 3-7 days following radiation. Extension of the interval 
following SCPRT to surgery >6 weeks does demonstrate downstaging, but 
the optimal interval has not been defined [229]. Whether the same degree of 
tumour shrinkage and pCR can be achieved with SCPRT and extended 
interval to surgery is currently unclear until the final results of the Stockholm III 
trial [228] become available and hence this strategy still remains 
experimental.  
1.3.3 The impact of surgery in the management of locally advance 
rectal cancer 
Total mesorectal excision (TME) is the surgical technique for resection of 
rectum harbouring locally advanced cancer and involves removing rectal 
cancer together with mesorectal fat column, to minimise residual tumour 
overload (see figure 1.4) [230, 231]. The adaptation of TME of rectal cancer 
together with refined chemoradiotherapy techniques has decreased CRM 
rates and markedly improved rectal cancer recurrence [232]. The local 
relapse after TME alone for pT3-4 N1-2 of medium or low rectal cancer 
remains in the range of 15 – 20 % in randomised trials [210, 212]. The 
surgical training for TME has a major impact on the efficacy of treatment and 
prognosis of patient [233]. The CRM involvement was reported to be higher in 
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abdominoperineal excision than anterior resection of rectum in a national 
bowel cancer audit [234]. Hence, in the case of abdominoperineal resection 
for low rectal cancers, additional aim of the surgery is to prevent the waist in 
the specimen to prevent CRM involvement commonly seen at the level of 
anorectal junction [63, 235].  The recent adaptation of extralevator 
abdominoperineal excision (ELAPE) for low rectal cancer has shown less 
CRM involvement and intraoperative perforation than standard surgery [236].  
Figure 1.4: The surgical planes of Total Mesorectal Excision and Extra-
Levator Abdomino-Perineal Excision (ELAPE) surgery of rectum [237] 
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1.4 Basis for the current study and background of proposed 
experiments 
The response to NCRT for similar staged locally advanced rectal cancers 
varies between patients: whilst in some patients the tumour completely 
disappears others show stable or progressive disease. A good response to 
NCRT improves long-term clinical outcomes as evidenced by lower 
recurrence rates and longer survival [238]. Mostly European trials report a 
clinical downstaging in the range of 50-60% including complete pathological 
response in 13-20% after NCRT. Hence a large cohort of patient is subjected 
to toxic NCRT without any benefit. To date, little is known about the molecular 
basis for such heterogeneous response to NCRT. Therefore, recent studies 
have focused on prognostic stratification based on rectal tumour biology and 
proposed the need for individualised treatment regimes. A simple measure, 
such as, increasing the interval to surgery after NCRT has shown to increase 
response rates in patients [239]. However, the exact duration of radiotherapy 
induced cell death after completion of NCRT remains unknown. 
The radiosensitivity of tumour cell is based on several factors that can be 
broadly classified into either intrinsic or extrinsic factors. Intrinsic factors 
include cell DNA repair profiles, phase of cell cycle, balance between pro- and 
anti-apoptotic proteins, whilst, extrinsic factors include cell microenvironment 
including cellular density, tissue hypoxia, microvascular architecture and 
angiogenesis. A combination of these factors may result in heterogeneous 
radiosensitivities between cells within the same tumour tissue.  
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It may be hypothesised that rectal cancers differ from each other at a 
molecular level despite showing the same morphological features currently 
used to stage these tumours. The individual molecular characteristic of 
tumour cells possibly defines the disease course and response to therapy. 
The molecular characteristics are probably dynamic and may change in 
response to treatment. For example, previous studies have shown that a 
radiosensitive tumour tissue may become radioresistant by repopulating cells 
with upgraded DNA repair profiles between or after fractional radiotherapy 
[240], switch the mechanism angiogenesis to develop resistance [241] and/or 
even promote metastasis of any residual clonogens after curative surgery 
[242]. 
The focus of this project was to study the molecular features of rectal cancers 
that have shown to be crucial in other solid tumours and investigate any 
impact on clinical features, response to therapy and long-term prognosis. 
Experiments were designed to investigate serial molecular changes within 
tumour cells and their microenvironment at baseline and during the interval 
between NCRT and surgery.   
The intrinsic factor studied included DNA damage and repair profiles, whilst 
extrinsic factors studied included tumour cellularity and necrosis, hypoxic foci, 
and functional vascularity.  
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1.4.1 Assessment of rectal cancer cell DNA damage and repair in 
response to radiotherapy  
1.4.1.1 DNA damage and repair: 
Radiotherapy-induced cellular cytotoxicity has long been attributed to the 
damage inflicted on DNA by ionising radiation. The DNA damage can 
manifest as single- or double–strand breaks, base damage, DNA or protein 
cross links, protein-protein cross links, and intra- or inter-strand cross links. Of 
the various specific lesions involved, the double-strand break (DSB) has been 
identified as being frequently responsible for the generation of lethal 
chromosomal abnormalities or the induction of apoptosis [243]. On the other 
hand, complex DNA repair mechanisms serve to limit the efficacy of 
radiotherapy, possibly having evolved as a means of protecting cells against 
lesser doses of naturally occurring radiation. The DNA damage response 
(DDR) is a coordinated cascade of events that sense the DNA damage, 
signals its presence, and mediates its repair or activates apoptosis. There are 
five major DNA repair mechanisms (see figure 1.5 and table 1.8): 
1. Base excision repair 
2. Mismatch repair 
3. Nucleotide excision repair 
4. Homologous Recombination for double-strand break repair 
5. Non-homologous end joining for double-strand break repair 
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Figure 1.5: DNA damage and repair mechanisms [244] 
 
Table 1.8: DNA repair pathways: 
Pathway Function 
Base Excision 
Repair 
Repair of damaged DNA bases without significantly 
distorting the overall structure of DNA helix 
Mismatch Repair Post-replication repair of misincorporated bases that 
have escaped proofreading activity of replication 
polymerases 
Nucleotide Excision 
repair 
Recognise and remove a wide variety of bulky helix-
distorting lesions of the DNA 
Non-homologous 
end joining for DSB 
Directly re-joins the two severed DNA ends in a 
sequence independent fashion (often error-prone) 
[245] 
Homologous 
Recombination for 
DSB 
Accurately re-synthesise damaged or missing 
sequence information at the break site by using a 
template located elsewhere in the genome [245] 
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1.4.1.2 Comet Assay - Measurement of DNA damage and repair 
The single cell gel electrophoresis (Comet assay) has become an established 
technique for measuring DNA damage with wide spread applications in 
genotoxicity testing, human biomonitoring, molecular epidemiology, 
ecogenotoxicology, as well as fundamental research in DNA damage and 
repair [246]. It was first described by Ostling and Johanson [247] in 1984 
followed by the most popular alkaline version described by Singh et al [248] . 
The assay is simple, economical and reproducible with high sensitivity.    
1.4.1.2.1 Technology, Quantification and interpretation 
The process involves lysis of cells with detergents and high salt after 
embedding in agarose so that the DNA is immobilised for subsequent 
electrophoresis. The detergents remove membranes, cytoplasm, and 
nucleoplasm and disrupt nucleosomes leaving behind nucleoids, consisting of 
nuclear matrix composed of ribonucleic acid (RNA), proteins and DNA. The 
DNA is negatively supercoiled as the double helix turns around the histones of 
the nucleosomes [246]. An alkaline variant (lysis of cells in a solution at 
pH>13) is favoured as this produces more pronounced comets in response to 
a given dose of radiation, reflecting more extensive DNA damage, including 
DSBs and SSBs. Hence, while it is technically no more sensitive at detecting 
the presence of DNA damage, it is able to discriminate more accurately 
between different levels of damage. Consequently, in order to demonstrate 
measurable differences in these levels, experiments utilising the neutral 
comet assay require single radiation doses of above 20Gy, in contrast to the 
more clinically relevant doses administered with the alkaline comet assay. 
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The technique involves embedding cells in a single layer of agarose on a plain 
glass slide precoated with agarose and dried. The cells are lysed in alkaline 
buffer with high sodium content, then washed with double distal water and 
incubated in alkaline solution before electrophoresis. Upon electrophoresis, 
the DNA extends towards the anode in a structure resembling a comet. The 
slides are dyed with DNA-binding dye and visualised by fluorescence 
microscopy. The ‘head’ of comet is made of supercoiled DNA, which is 
negatively charged as a consequence of the turns made by the double helix 
around histones of the nucleoplasm. The relaxed supercoiling of damaged 
DNA are pulled with electrophoresis forming the ‘tail’ of the comet.  
The image analysis is conducted using special software to measure the 
parameters such as tail length, relative fluorescence intensity of the head and 
tail, and tail moment. The parameter ‘tail moment (TM)’ is commonly used to 
quantify DNA damage and is calculated as the product of the percentage DNA 
in the comet tail and the distance between the means of the head and tail 
distribution (measured in μm), based on the definition by Olive et al [249] (see 
figure 1.6 and 1.7). 
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Figure 1.6: Procedure of Comet Assay by Moller [250]  
 
Figure 1.7: Comet Assay – measurement of Tail Moment according to 
Olive et al. [249]: 
 
 CHAPTER 1: INTRODUCTION  
 
70 
The simple version of the alkaline comet assay detects DNA migration caused 
by strand breaks, alkaline labile sites and transient repair sites. By incubation 
with bacterial glycosylase/endonuclease enzymes, broad classes of oxidative 
DNA damage, alkylation, and ultraviolet light-induced photoproducts are 
detected as additional DNA migration [250]. Novel application of comet assay 
include detection of DNA-DNA crosslink, and gene-specific DNA damage 
detected by the application of fluorescent in situ hybridization methodology in 
the comet assay [250] 
The measurement of DNA repair capacity of a cell using comet assay involves 
inflicting DNA damage in-vitro and monitoring the speed with which they 
remove the lesion. The re-joining of DNA strand breaks by most cell types is 
rapid and this kinetics can be measured by ‘serial or timed’ comet assays.  
1.4.1.2.2 Validation  
Comet assay has been applied in a broad range of scientific fields, including 
genetic toxicology, ecotoxicology, DNA repair, and apoptosis. The European 
Comet Assay Validation Group (ECVAG) trial indicates substantial reliability 
for the measurement of DNA damage by the comet assay [251]. Sasaki et al 
[252] validated the use of comet assay as a good screening tool for in vivo 
genotoxicity by showing DNA damage in eight organs of rodents by exposure 
to 208 rodent carcinogens. There are a number of clinical studies deploying 
comet assay to detect DNA damage in leucocytes (see below). Comet assay 
has been used to establish high levels of DNA damage as risk factor for 
adenocarcinoma of the oesophagus [253], bladder cancer [254], breast 
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cancer [255] and thyroid cancers [256]. The results from prospective cohort 
studies are awaited.  
1.4.1.2.3 Clinical Application 
Comet assay become established as a convenient tool for measuring 
radiation-induced DNA damage and attempts have also been made to assess 
the clinical relevance of such measurements. Clonogenic assays on tumour 
biopsies, measuring the surviving fraction (SFX) of cells exposed to XGy 
radiation, have been demonstrated to predict clinical response to radiotherapy 
in patients with cervical cancer and head and neck cancer, respectively [257, 
258]. In turn, several studies have investigated whether or not the comet 
assay can be used to predict clonogenic cell survival. For instance, Price et al 
[259] used the neutral comet assay in six bladder tumour cell lines to measure 
initial radiation-induced DNA damage and the time taken to repair this. Both 
correlated inversely with clonogenic cell survival at 10Gy, but the correlation 
was less convincing at the more clinically relevant dose of 2Gy. Marples et al 
[260] performed a similar experiment with seven cervical carcinoma cell lines, 
in which there was no direct association between either initial or residual DNA 
damage and SF2 (surviving fraction at 2Gy), but the ratio of these two comet 
assay measurements did have some predictive value.   
More recently, the predictive value of the alkaline comet assay has been 
investigated in several bladder tumour and colon cancer cell lines exposed to 
clinically relevant radiation doses [261-263]. In both types of tumour cell, initial 
DNA damage has been shown to have a close inverse correlation with 
clonogenic survival, while measures of residual DNA damage and repair were 
 CHAPTER 1: INTRODUCTION  
 
72 
also predictive to a variable extent. The comet assay has also been utilised as 
pharmacodynamic endpoint to establish maximum tolerated dose and safety 
of experimental chemotherapeutics [264, 265].  
While many of the clinical studies employing the comet assay have utilised 
lymphocytes, the technique has also been performed on cells obtained by fine 
needle aspiration of a variety of accessible primary and metastatic tumours, 
including colorectal cancer [266-270]. In addition, the comet assay has been 
successfully performed on normal colonic and rectal mucosal cells obtained 
from biopsies of patients without cancer [271-273]. Of note, Olive et al [268] 
took two simultaneous aspirates from each of 33 patients with metastatic 
tumours: the between-sample correlation was very good, indicating that a 
single aspirate should generally be representative of the tumour (correlation 
coefficient r = 0.88). Similarly, McGlynn et al [272] interpreted their 
measurements of DNA damage within normal colonic mucosa as 
demonstrating high intra-subject reproducibility, although this was based on a 
fairly limited statistical analysis. 
One final study of relevance to the proposed project performed the neutral 
comet assay on lymphocytes irradiated at 2Gy, their having been obtained at 
sequential intervals from patients receiving radiotherapy for a variety of 
tumour types [274]. There were no apparent differences in either initial DNA 
damage or repair capacity among the samples collected before radiotherapy, 
after 5 fractions or after 10 fractions. 
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1.4.1.2.4 Limitations 
The main limitation is the scarcity of publications on the use of the comet 
assay for non-lymphatic tissues. Comet assay have been classically used to 
measure DNA damage on easily obtainable cells, e.g leukocytes and tumour 
cell lines. Analysis of DNA damage in patients with solid tumour by comet 
assay of their leukocytes may be disadvantageous, as leukocytes are not 
target tissue for cancer and it is not clear that damage detected in leukocytes 
reflects the damage in actual target tissue. Comet assay require high viability 
of cells in a given sample, which may be difficult to achieve from biopsy 
tissues obtain from solid tumour as these tumour often contain several foci of 
necrosis that may contaminate the sample. Observer bias may be introduced 
when measuring TM if the DNA images are not randomly selected, therefore, 
it is recommended to estimate a range of intra- and inter-subject variation by 
two observers in a pilot study, which is not always feasible. Studies 
investigating sample scoring between different laboratories have also reported 
large variation between observers [251, 275, 276]. 
1.4.2 Assessment of rectal cancer microenvironment and 
pathophysiology 
Functional imaging techniques are increasingly being used to monitor 
response to therapies with novel mechanism of action, often predicting the 
success of therapy before conventional measurements of size are changed 
[277], activity of residual disease remaining after therapy and to detect 
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recurrence early at a time when salvage therapy might still be possible [278-
280].  
In this study, functional MRI and CT were used to investigate temporal and 
spatial changes in the rectal cancer microenvironment including tumour 
microvasculature, blood flow, perfusion, tissue oxygenation and cell density. A 
summary of functional imaging techniques is shown in table 1.9.
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Table 1.9: Functional imaging – summary of techniques [281] 
Imaging technique Principles of MR and CT 
measurement 
Biological properties on 
which imaging is based 
Commonly derived 
quantitative imaging 
parameters 
Pathophysiological 
correlates 
Diffusion-weighted 
(DW) MRI 
Single-shot echo planar DE-MRI 
acquisition; contrast agent not 
required 
Diffusivity of water ADC Tissue architecture: cell 
density, extracellular 
space tortuosity, gland 
formation, cell 
membrane integrity, 
necrosis 
Intrinsic Susceptibility 
Weighted (ISW) or 
Blood Oxygen Level 
Dependent (BOLD) 
MRI 
T2* weighted – imaging performed at 
different echo time to detect 
susceptibility 
Deoxyhaemoglobin slows 
higher relaxivity than 
oxyhaemoglobin; 
measurements reflect blood 
volume, perfusion and intrinsic 
composition of tissues 
Intrinsic tissue relaxation 
rates (R2*  =1/T2*) 
Ferromagnetic 
properties of tissues; 
level of tissue 
oxygenation 
Dynamic Contrast 
Enhanced (DCE) MRI 
T1-weighted MR imaging at high 
temporal sampling after gadolinium 
contrast administration; 
mathematical modelling of acquired 
data 
Contrast medium uptake rate 
in tissue, which is influenced 
by transfer rates and 
extracellular volume; plasma 
volume fraction 
IAUGC; Transfer and rate 
constant (Ktrans,kep); leakage 
space fraction (ve); fractional 
plasma volume(vp) 
Vessel density; vascular 
permeability; perfusion; 
extravascular space; 
plasma volume 
Dynamic Contrast 
Enhanced (DCE) CT 
First pass imaging at high temporal 
sampling after iodine contrast 
administration (image acquisition 
every 1 second); Second pass 
images acquired at every 10 
seconds for 2 minutes; 
mathematical modelling of acquired 
data 
Contrast medium uptake rate 
in tissue, which is influenced 
by transfer rates and 
extracellular volume; plasma 
volume fraction 
Flow rate through 
vasculature (BF); volume of 
flowing blood through 
vasculature in a tissue (BV); 
average time taken to travel 
from artery to vein (MTT); 
total flux from plasma to 
interstitial space (PS) 
Vessel density; vascular 
permeability; perfusion; 
extravascular space; 
plasma volume 
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Table 1.10: Functional Imaging - Summary of validation, clinical applications and limitations  
Imaging technique Validation  Clinical Applications Limitations 
Diffusion-weighted 
(DW) MRI 
ADC values shown to correlate with 
specific tissue histological properties 
such as cell density, proliferation 
index, tumour grade, gland formation, 
presence of necrosis and tumour cell 
apoptosis   
Successful treatment is reflected by increase 
in ADC values 
Rising ADC has been shown with successful 
treatment in cancers of the breast, liver 
metastases, bone sarcomas and brain 
malignancies 
The diffusion of water is directional in 
brain and kidney, therefore MPG needs 
to be applied in multiple directions.   
Respiration, cardiac pulsation and 
peristalsis can adversely affect image 
quality 
Intrinsic Susceptibility 
Weighted (ISW) or 
Blood Oxygen Level 
Dependent (BOLD) 
MRI 
R2* shows good correlation with 
tissue hypoxia markers with 
decrease in baseline R2* after 
hyperoxygenation. 
R2* values depend of vessel volume 
(i.e vessel size and maturation)   
A fast R2* relaxation represent hypoxic 
tumours.  
Measurement of baseline R2* and ΔR2* (after 
hyperoxygenation) of tumour has been used in 
treatment planning for cancers of head and 
neck and predicting radiotherapeutic response 
in cancers of cervix. 
R2* values vary significantly vary 
between tumour types and site 
(optimization of magnetic fields).  
Deoxyhaemoglobin induced resonance 
of water may not be homogenous  
Dynamic Contrast 
Enhanced (DCE) MRI 
DCE-MRI parameters shows good 
correlation with immunohistochemical 
markers of angiogenesis, surrogates 
of tissue perfusion (14C-aminobutyric 
acid) and correlative imaging 
modalities (Dynamic susceptibility 
contrast MRI, (15) O-water PET and 
microbubble ultrasound)  
DCE-MRI parameters were shown to predict 
treatment response and used to monitor the 
effects of a variety of oncology treatments. The 
studies have included cancers of bladder, 
breast, bone sarcomas, rectal and cervical 
cancers.  
DCE-MRI is being used in early clinical 
development of therapies that target tumour 
vasculature 
There is variation in the mathematical 
model used to derive the DCE-
parameters amongst investigators. 
Errors in estimation of model based 
MRI-DCE parameters can results from 
assumptions used during experimental 
set-up, for example the choice of AIF 
and transmembrane water exchange.   
Dynamic Contrast 
Enhanced (DCE) CT 
DCE-CT parameters shows good 
correlation with immunohistochemical 
markers of angiogenesis and 
correlative imaging modalities (xenon 
CT, (15) O-water PET) 
DCE-CT parameters has been used in tumour 
differentiation and grading.  
DCE-CT is being used in early clinical 
development of therapies that target tumour 
vasculature 
DCE-CT parameters are sensitive to 
Image acquisition techniques, post-
processing discrepancies and motion 
artefact. CT involves radiation dosage 
and contrast load.  
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1.4.2.1 Diffusion Weighted MRI 
DW-MRI provides information on tissue cellularity, extracellular space 
tortuosity and the integrity of cellular membranes by measuring the random 
motion of the water molecules in tissue. DW-MRI is the only imaging modality 
that can display this property. There are convincing data to support DW-MRI 
usage in the characterization of malignancy, including determination of lesion 
aggressiveness and for monitoring response to a variety of treatments [282-
284]. 
1.4.2.1.1 Technology, Quantification and Interpretation  
The net displacement of molecules across an area of tissue per second is 
called apparent diffusion coefficient (ADC). The ADC is low in regions of 
restricted diffusion and high in areas of free diffusion (see figure 1.8). DW 
images can be made sensitive to large or small displacements of water 
including macroscopic flows, microscopic extracellular space motion or even 
intracellular water displacements. This is done by applying diffusion-weighting 
gradients (sometimes called motion probing gradients (MPGs)) to standard 
T2-weighted sequences [285] . The weighting of the applied MPGs is 
indicated by their b-value. Application of MPGs results in signal losses on 
images in proportion to the weighting of the applied gradients. The signal 
losses observed are used to calculate tissue ADC. Signal losses observed 
when low b-values (<50–100 s/mm2) are used results from macroscopic water 
movements; that is the ADC calculated will be flow dominated [286]. At higher 
b-values, bulk water motion plays less of a role in the continued signal 
attenuation and so it is possible to differentiate between the contributions 
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made by high and low mobility water populations by varying the MPGs used 
for the calculation of the ADC [287] (see figures 5.3 and 5.4, page 193-194).  
Figure 1.8: The movement of water molecules with different tissues  
 
Freely diffusing water: 
• Occur in normal tissues 
• High ADC 
• Lower signal intensity 
 
Restricted water: 
• Occur in abnormal tissues 
• Low ADC 
• Higher signal intensity 
1.4.2.1.2 Validation  
The basic premise for enhanced tumour detection and improved tissue 
characterisation (for example in the liver [288, 289]) with DW-MRI is the 
connection between the observation that malignant tissues are generally more 
cellular than benign tissues; so water diffusion is more restricted in tumours 
due to a combination of increased cell density, haphazard tissue organisation 
and increased extracellular space tortuosity. However, when cystic, necrotic 
and treated metastases are included, then lesion characterisation is less good 
[290].  In line with these findings, Sumi et al. [291] have shown that lymphoma 
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nodes had significantly lower ADC than benign nodes in the neck.  Sumi et al. 
[291] also showed that metastatic cervical lymph nodes in patients with 
squamous head and neck cancers had significantly higher ADC values than 
benign nodes. These apparently discrepant results are again explained by the 
common occurrence of necrosis in nodes with metastatic squamous cell 
carcinomas. These and other studies have repeatedly shown that false 
positive results occur with infective processes and after thermo-coagulation 
and false negative results occur with cystic, necrotic lesions and in well-
differentiated neoplasms; which emphasises the need to interpret DW-MRI 
with all other anatomic and clinical data. These observations suggest that 
ADC values should correlate with specific histological tissue properties such 
as cell density [292-298], proliferation index [299, 300], tumour grade [297, 
301] and gland formation (tissue organisation), presence of necrosis [298, 
302] and in the therapy setting with tumour cell apoptosis [302-304].  
1.4.2.1.3 Clinical applications  
Any pharmacological, physical or radioactive process that causes necrosis or 
cellular lysis will lead to increases in water diffusion and corresponding 
increases in ADC values [284, 305]. Since cellular death and vascular 
changes in response to treatment can both precede changes in lesion size, so 
changes in DW-MRI may be an effective early biomarker for treatment 
response for therapies that induce apoptosis [283, 305]. Thus, most studies 
have shown that successful treatment is reflected by increases in tumour ADC 
values.  Rising ADC values with successful therapy have been noted in 
several anatomical sites, including breast cancers [306, 307], primary and 
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metastatic cancers to the liver [308-310], primary bone sarcomas [311, 312] 
and in brain malignancies [313-315]. Addition of DW-MRI sequences to 
morphological T2-weighted images has shown to improve the diagnostic 
accuracy of viable rectal cancers after NCRT [316]. Some studies have shown 
that increases in ADC values can occur rapidly after the first dose of 
chemotherapy. For example, Cui et al, showed that increases in metastatic 
liver lesions from stomach and colorectal cancer occurred as early as 3-7 
days after the first cycle of chemotherapy and that ADC increases correlated 
with therapy response judged by changes in lesion size [310]. 
As a caveat to the above observations of rising ADC values with successful 
treatment, it has also been noted that transient decreases in ADC can also be 
seen; this appears to be related to cellular swelling, reductions in blood flow or 
due to reductions in extracellular space. For instance, it has been noted that 
anti-VEGF therapies when given as monotherapy for brain tumours leads to 
initial reductions of lesion leakage space because of vascular normalization 
which lowers ADC values [317].  Cellular swelling has also been noted to 
occur in the early phases of apoptosis in response to anticancer treatment 
[283] and may be a significant additional reason for reductions in ADC values. 
Thus it appears that the extent and duration of such ADC reductions depends 
on the type of treatment administered, tumour type and the timing of imaging 
with respect to the treatment. These additional observations indicate that ADC 
changes are dependent on complex interplays of biophysical processes in 
response to therapy, emphasizing the need to better understand therapy 
induced tissue changes that are reflected in DW-MRI.  
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1.4.2.1.4 Limitations 
There are a number of mostly technical limitations to DW-MRI. In the brain 
and kidney the diffusion of water tends to be directional (anisotropic) because 
of regular tissue organization [318, 319]. The measured ADC will therefore be 
dependent on the direction of the applied MPGs and multiple directions need 
to be applied to calculate directionless diffusivity (ADC) and the directionality 
of diffusion (diffusion tensor imaging) [320]. Fortunately, water diffusion is 
isotropic in most abdominal organs and in tumours. Therefore, only one MPG 
direction needs to be applied to obtain DW-MR images for ADC calculation. 
However, in practice, measurements in three or more gradient directions are 
often obtained and the signals averaged in order to improve signal-to-noise 
ratios of images. Physiological water motions and bulk tissue movements 
such as respiration, cardiac pulsations and peristalsis can also adversely 
affect image quality. Corrections can be made for bulk motion by incorporating 
schemes that detect the magnitude and direction of motion. Rapid imaging 
(i.e. using ultra-fast pulse sequences such as echo-planar imaging and 
parallel imaging techniques) and performing images in breath-hold can help to 
minimise the effects of bulk motion artefacts. 
1.4.2.2 Intrinsic Susceptibility Weighted MRI 
The ISW-MRI is the only non-invasive MRI technique that provides 
information on the oxygenation status of the blood volume and is also referred 
as blood oxygenation level dependent (BOLD) MRI. The ISW-MRI is also 
being used to investigate parameters of tumour angiogenesis such as blood 
vessel development, remodelling and function.  
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1.4.2.2.1 Technology, Quantification and Interpretation 
ISW-MRI exploits the magnetic susceptibility (degree of magnetization of a 
material in response to magnetic field) differences between tissues to 
generate contrast. The magnetic properties of the blood are dependent on its 
oxygenation levels. Haemoglobin becomes paramagnetic after losing oxygen 
molecules in the peripheral tissues due to exposure of its iron molecule. The 
paramagnetic deoxyhaemoglobin creates inhomogeneous magnetic field in its 
immediate vicinity. This inhomogeneous magnetic field increases T2* decay 
and attenuates signal from regions containing deoxyhaemoglobin [321]. In 
practice, this means there is signal loss proportional to the amount of 
deoxyhaemoglobin in the red blood cells of the vessels of the tissue. Thus 
deoxygenated haemoglobin acts as an intrinsic contrast agent (see appendix 
II, page 373). 
1.4.2.2.2 Validation 
There is limited evidence on the validation of ISW-MRI technique. The partial 
pressure of oxygen in blood (PaO2) determines oxyhaemoglobin levels and 
remains in equilibrium with partial pressure of oxygen in tissues (pO2). Clinical 
trials have reported good correlation between R2* measurements and tumour 
hypoxia markers (needle oxygen measurement and immunohistochemical 
markers) [322, 323]. Several studies have reported an obvious decrease in 
baseline R2* (at room air) after exposure to hyperoxygenation in various 
model and human tumours [324-330]. However, simultaneous measurement 
of tumour R2* and pO2 (by MR-compatible fibre-optic pO2 sensor; OxyLite, 
Oxford Optronix) show R2* signal response to oxygenation is temporally 
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correlated with changes in tumour pO2 without any correlation between 
absolute R2* and pO2 measurements [331]. These finding suggest that 
carbogen induced reduction in R2* signal indicates tumour oxygenation but 
additional techniques are required to obtain absolute tumour pO2 
measurements in vivo. Only 50-60% of human tumours show changes in R2* 
after carbogen inhalation and one reason may be vessel quantity and 
perfusion mismatch in tumour tissue.  Thus, ΔR2* is also determined by 
vascular volume, which is dependent on tumour vessel size and maturation, 
that may also explain differential ΔR2* changes after hyperoxic challenge in 
different tumours [332] and need for simultaneous measurement of tumour 
blood volume. Thus, hypoxic tumour with large blood volume will not only 
have raised R2* but are more likely to response to carbogen. This will be 
reflected by large changes in R2* and it is these hypoxic tumours that show 
positive radiosensitisation to carbogen. Neeman et al. [333] reported 
successful mapping of neovascularization and vascular maturation in tumour 
models validated by fluorescence microscopy. The role of ISW-MRI in 
monitoring angiogenesis is yet to be established in clinical trials. 
Overall, aforementioned trials indicate a promising role of ISW-MR imaging as 
a biomarker of tumour oxygenation levels. 
1.4.2.2.3 Clinical applications 
Tumour hypoxia critically decreases efficacy of radiotherapy. ISW-MRI 
provides the potential to detect hypoxic tumours and predict radiosensitivity. 
The sensitivity of ISW-MRI parameters in predicting response to intervention 
has been explored in several pre-clinical studies [334-336] and clinical studies 
 CHAPTER 1: INTRODUCTION  
 
84 
on prostate tumour [337], brain tumour [327], breast cancer [338] and cervical 
cancers [339]. In a pre-clinical study, tumours with a fast baseline R2* 
(hypoxic) that become well oxygenated after hyperoxygenation treatment 
(carbogen: 95%O2, 5%CO2) were more responsive to radiotherapy [334]. It 
has been hypothesised that tumours with measurable blood volume and 
relatively fast pre-treatment R2* may be relatively hypoxic compared to similar 
tumour exhibiting a slower basal R2* [340], and recent preclinical studies are 
supportive of this concept [341].  In a small clinical study, selective treatment 
of patients with head and neck cancer with ARCON regime (accelerated 
radiotherapy with carbogen and nicotinamide) based on pre-treatment R2* 
and carbogen-induced changes in R2* resulted in low tumour recurrence 
during long follow-up [327]. In another study on cervical cancers, the baseline 
R2* values of tumour was significantly lower than post treatment values and 
showed negative correlation with final tumour size response but no 
association with final tumour volume response [339]. The evidence shows 
measurement of pre-treatment R2* and ΔR2* of tumour may contribute to the 
success of radiotherapeutic response and may ultimately prove prognostic.  
1.4.2.2.4 Limitations 
There is great variability and hence interpretation of R2* between different 
tumour types that may be a confounding factor in ISW-MRI utility as a 
prognostic index for radiotherapy in practice. The site of the tumour and 
subsequent ability to optimize magnetic field will also strongly influence the 
basal R2* measurements. The deoxyhaemoglobin induced resonance of water 
and hence R2*, may not be homogenous as assumed with BOLD MRI. 
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Another MRI methodology, high spectral and spatial resolution (HiSS) – MRI 
of tumour has demonstrated that water resonance within each voxel is 
complex and often contain several resolvable components. In such situation 
where each of these spectral components can respond differently to, for 
example, carbogen, the changes in BOLD contrast can be difficult to detect, 
accurately measured and interpreted. However, it is yet to be shown if 
measurements of tumour R2* by HiSS MRI yield superior prognostic value 
over those obtained by BOLD MRI [342].   
1.4.2.3 Dynamic Contrast Enhanced (DCE) – MRI 
The DCE-MRI method utilises the pharmacodynamics properties of low-
molecular weight contrast agents to provide information about tissue blood 
volume and perfusion, microvessel permeability and the extracellular space 
(see appendix III, page 377).  
1.4.2.3.1 Technology, Quantification and Interpretation 
Clinical dynamic MRI is usually performed using low molecular weight 
gadolinium-chelate-based contrast agents (Gd; molecular weight <1kDa). 
When these contrast agents are used, two distinct phenomena can be 
observed, depending on the experimental set-up. Dynamic relaxivity-based 
contrast techniques use a rapid series of T1-weighted images to observe the 
passage of contrast media, usually resulting in tissue ‘brightening’; by default, 
this technique is referred to as DCE-MRI. This technique is sensitive to the 
presence of contrast medium both within vessels and in the extravascular-
extracellular space - the latter predominates due to the low blood volumes in 
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tissues and tumours (approximately 5-10%). To enable quantification of signal 
intensity changes, it is also necessary to incorporate methods that allow the 
concentration of contrast agent to be obtained at each time point during the 
measurement period. For DCE-MRI, this is often done by obtaining “T1 maps” 
prior to contrast medium injection, which effectively allows conversion of the 
MR signal intensity into contrast agent concentration [343].  DCE-MR images 
can be analysed by quantitative model dependent or semi-quantitative (non-
model dependent) methods. The parameters extracted provide information on 
blood flow, blood volume, microvessel permeability, extraction fraction, and on 
plasma and interstitial volumes (see appendix III, page 377).  
1.4.2.3.2 Validation 
DCE-MRI has been widely validated in the last decade in a number of ways, 
including direct correlative studies against immunohistochemical microvessel 
density measurements, and tissue expressions of pro-angiogenic growth 
factors including vascular endothelial growth factor (broad correlations in 
some studies and no correlations in others) [344, 345]. Tissue validation 
studies have also come from correlative studies against widely accepted 
surrogates of tissue perfusion including 14C-aminoisobutyric acid quantitative 
autoradiography [346]. More recently, in vivo correlative imaging studies have 
been performed. Thus, transfer constant as a marker of tumour blood flow has 
now been validated against blood volume/blood flow derived from Dynamic 
Susceptibility Contrast-MRI studies [347], (15) O-water PET [348] and 
microbubble ultrasound [349]. These cross imaging validation studies have 
shown that the relationship is not upheld in every tumour type (e.g., in 
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gliomas, because a variably intact blood brain barrier reduces the first pass 
extraction of the contrast agent [350]). Similarly, the strength of correlations 
also decreases when therapies that reduced microvessel permeability are 
used, again because the first pass extraction fraction of small molecular 
weight contrast agents is reduced. George et al [351] reported significant 
correlation between Ktrans and serum VEGF/platelet level at the time of referral 
for preoperative NCRT or palliative chemotherapy in a series of 31 
consecutive patients with T3/4 rectal cancer, although this was no longer the 
case after the treatment was commenced. This circulating marker of 
angiogenesis showed no association with any DCE-MRI parameter in another 
series of 12 rectal cancer patients proceeding directly to surgical resection, 
but tumour microvessel density was reported to correlate inversely with Ktrans 
[191]. Although this is a small study, this apparently counterintuitive finding 
suggests that any relationship between Ktrans and the degree of angiogenesis 
in rectal cancer is unlikely to be straightforward.  
1.4.2.3.3 Clinical applications 
All response assessment studies show that successful treatment results in 
decreases in the rate and magnitude of enhancement and that poor response 
results in persistent abnormal enhancement, however judged (semi-
quantitatively or quantitatively). This general observation holds true for most 
therapeutic approaches except for radiotherapy where there is an initial 
increase in rate and magnitude of enhancement corresponding the 
recognized acute hyperaemic response probably mediated via release of 
cytokines including VEGF. Changes in DCE-MRI kinetic parameters are able 
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to predict response or monitor the effects of a variety of treatments including 
chemotherapy in bladder and breast cancers and bone sarcomas [352-355]. 
In breast cancer, for example, it has been shown repeatedly that progressive 
decreases in tumour Ktrans accompanies response to chemotherapy and that 
an increase or no changes in permeability predict for non-responsiveness 
[353, 354]. Other treatments that can be monitored include radiotherapy in 
rectal and cervix cancers [356, 357] androgen deprivation in prostate cancer 
[358] and vascular embolization of uterine fibroids [359]. An important new 
application of DCE-MRI is in the early clinical development of therapies that 
target the tumour vasculature [360].  
The effects of antiangiogenic drugs and vascular disruptive agents (VDAs) on 
DCE-MRI kinetic vascular parameters have been found to be similar with the 
dominant effect of successful therapy being reductions in blood flow and 
permeability. Importantly, it is the timing of the onset and duration of vascular 
changes that enables antiangiogenic drugs and VDA to be distinguished on 
imaging. Both xenograft and human imaging studies of antiangiogenic drugs 
show that antivascular effects are not immediate, arising at least 1-2 days 
post drug administration. In contrast, VDAs cause rapid shutdown of the 
vasculature within minutes to hours of drug administration and reversibility of 
effects being visible in the short term (usually seen within 24-48 hours). 
“Normalisation” of the vasculature induced by antiangiogenic drugs as 
described originally by Jain [361] can be detected on DCE-MRI by regional 
increases in non-enhancing pixels (representing vascular pruning) with 
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reductions in permeability and leakage space. Improved flow in non-pruned 
vessels can also be detected often in other regions [317, 362]. 
1.4.2.3.4 Limitations 
There are uncertainties in the accuracy of kinetic parameter estimates derived 
from the application of tracer kinetic models in clinical DCE-MRI experiments. 
These derive from model-based assumptions and from assumptions made for 
the determination of tissue Gd-DTPA concentrations. For example, in the 
original implementation of Tofts’ model, population based AIFs were used 
(although this is not a strict requirement) [363] and it was assumed that tissue 
blood volume contributes negligible signal compared with that arising from 
contrast medium in the interstitial space [364]. It was recognised by Buckley 
that the application of these model-based assumptions leads to systematic 
overestimation of the transfer constant in tumours [365]. Modern two 
compartment model implementations leave AIF choice to investigators and 
allow derivation of plasma volume fraction provided that AIF choice and 
temporal data sampling rates are appropriate. An important point is that the 
presence of gadolinium containing contrast medium is detected only indirectly, 
by its effect on tissue water (that is, the contrast medium itself is not 
detected). In tissues, contrast medium is confined to the extracellular space, 
whereas the bulk of water is intracellular. As a result, transmembrane water 
exchange can affect the accuracy of the tissue contrast agent concentration 
estimates [366, 367], which additionally needs to be taken into account. 
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1.4.2.4 Dynamic Contrast Enhanced (DCE) CT 
The DCE-CT method utilises the pharmacodynamics properties of iodinated 
contrast agents to provide information about tissue blood flow, blood volume 
and microvessel permeability. The DCE sequence can be applied to standard 
CT scanners making it a widely available and low cost technique. DCE-CT 
has reached the technical maturity for use in therapeutic trials in oncology. 
Guidelines on the application of DCE-CT in clinical trials have been published 
in 2012 [368].  
1.4.2.4.1 Technology, Quantification and Interpretation 
The fundamental principle of perfusion CT is based on temporal changes in 
tissue enhancement after administration of intravenous iodinated contrast 
agent (see appendix II, page 373). The tissue enhancement after 
administration of intravenous contrast agent can be divided into two phases: 
during the initial phase, the enhancement is mainly attributable to contrast 
present within the intravascular compartment (40 to 60 seconds from the time 
of contrast arrival); during the second phase, the contrast has passed through 
capillary membrane into the extravascular compartment and the tissue 
enhancement results from contrast present in both intra- and extravascular 
compartments. Thus in the initial phase, the enhancement is determined to a 
great extent by blood flow (BF) and blood volume (BV), whereas in the later 
phase, it is influenced by vascular permeability to the contrast agent [369]. 
The tissue enhancement (unit: Hounsfield) is directly proportional to contrast 
agent concentration, facilitating kinetic modelling. Hence perfusion CT 
involves a succession of images before and during the passage of contrast 
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agent within the tissue vasculature of interest. There are a variety of perfusion 
CT protocols and are typically determined by target organ, clinical objective, 
CT scan configurations and mathematical modelling. The coverage area for 
the study depends on the CT scanner available (4, 16, 64, 128 or 320 multi-
detector rows scanner are available variable coverage area). The initial 
localiser sequence involves an unenhanced CT acquisition with wide 
coverage of the organ of interest. The recommended protocol for contrast 
agent administration involves a small volume (40–70 mL depending on the 
contrast medium) at high flow injection rates (usually >4mL/s: 5mL/s for 
compartment model; 7–10mL/s for deconvolution model; see appendix IV, 
page 389) followed by 20-40mL of saline flush at a similar flow rate is needed 
to obtain a narrow bolus for optimal perfusion analysis [370]. The dynamic 
acquisition is performed sequentially after the intravenous injection of contrast 
agent and covers both phases of tissue contrast enhancement: the early 
phase capture requires high temporal sampling (less than 2 seconds: every 3-
5 seconds for compartmental model; every 1 second for deconvolution model) 
and lasts up to 45 seconds followed by low temporal sampling required for the 
later phase (5-15 seconds per acquisition: every 10 - 20 seconds for 
compartmental model; every 10 second for 2 minutes for deconvolution 
model). The total time and sampling interval within the later phase is 
dependent on the mathematical model used [368, 371, 372]. The tube current 
also depends on the mathematical model used (higher tube current with lower 
image frequency to reduce image noise for compartmental analysis and low 
tube current with higher image frequency for dynamic acquisition) (see figure 
1.9). 
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Figure 1.9: Acquisition sequence for DCE-CT 
 
The time-intensity curves obtained can be checked qualitatively to distinguish 
between normal and diseased tissue. The quantitative parameters obtained 
through fitting of tissue contrast enhancement curve (time-intensity curve) into 
any mathematical model include (i) regional BF (which expresses the rate of 
delivery of oxygen and nutrients), (ii) tumour BV (representing the volume of 
the vascular network that is functional) and (iii) permeability-surface area 
product (which describes the rate of constant leakage into the extracellular 
space [373].  
1.4.2.4.2 Validation 
The DCE-CT parameters of microcirculation have been validated against 
various techniques. For example, DCE-CT produced similar assessment of 
microcirculation compared to Xenon CT for brain ischaemia [374],  (15)O-
water PET for solid tumours [375] and immunohistochemical MVD for brain 
tumours, lung cancer, adrenal tumour, prostate cancer and oesophageal 
cancers (immunohistochemical staining for MVD, VEGF) [376-380]. For 
colorectal cancer, however, there are conflicting reports on association of 
First Phase = 40 – 60 sec   Second Phase = 2 – 10 mins  
Bolus of IV 
Contrast  
Planning 
Acquisition 
< 2 sec interval  5 – 15 sec interval 
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DCE-CT parameters and MVD in published literature: whilst majority of the 
studies show no association between DCE-CT and histopathological markers 
of angiogenesis in colorectal cancers [381-383], some have found a 
significant correlation [384]. Reproducibility studies have shown good 
correlation between DCE-CT measurements with variability of 13–30% in 
studies involving normal brain tissue, colorectal cancer, lung cancers and 
hepatocellular carcinoma [385-388].  
1.4.2.4.3 Clinical applications 
The DCE-CT has been successfully applied in combination with standard 
imaging to differentiate between benign and malignant lesions [377], 
histopathological differentiation [389, 390], tumour grading [391, 392] and 
tumour staging [393-395]. Qualitative analysis showing early peak 
enhancement (high BF and BV) can differentiate malignant from benign 
tumours [390]. High perfusion values are commonly seen in malignancies 
[390, 396, 397], however, in advance tumours, where growth exceeds blood 
supply, lower perfusion parameters were also seen [381, 397]. Some tumours 
with low baseline perfusion also show early nodal involvement [377, 398].  
Hence DCE-CT can provide vital insight into tumour behaviour.  
The DCE-CT has been applied in response assessment of 
chemotherapeutics. After standard chemoradiotherapy, a decrease in all 
DCE-CT parameters has been reported in cancers of aerodigestive tract 
[399], lung [400], oesophagus [401], liver [402] and rectum [403-405]. 
However, as with DW-MRI, where a decline in ADC is seen due to cell 
oedema immediately after radiotherapy, the DCE-CT parameters may also 
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show a transient increase immediately after radiotherapy attributable to 
inflammatory reaction and endothelial cell death [406, 407].  
A more popular application of DCE-CT has been in the early physiological 
response assessment to novel anti-angiogenic agents. The DCE-CT has been 
used to monitor response in rodent studies on cancers of breast [408], colon 
[409] and clinical studies on cancers of head and neck [410], liver [411, 412], 
kidneys [413], lung [400] and various solid tumours [414] and in clinical study 
on metastatic renal cancer [415] . The common response to anti-angiogenic 
treatment is a decrease in BV and BF values (or equivalent parameters 
derived from other mathematical models), whilst, changes in other parameters 
are more variable [400, 414, 416, 417]. Interestingly, some anti-angiogenic 
agents, such as VEGFR blockade of tumour, may cause transient 
normalization of tumour vascular structure and function causing an increase in 
BF and PS vales initially, a circumstance that may hide the real effect of these 
drugs [418], whereas, vascular disruptive agents, such as A4 phosphate, has 
shown an abrupt reduction in BV within 4 hours of its administration [419]. 
Hence, the timing of imaging acquisition after administration of 
chemotherapeutics will affect the values of DCE-CT parameters and should 
be taken into account when designing such studies.   
1.4.2.4.4 Limitations 
The major limitation of DCE-CT includes image acquisition effects, post-
processing discrepancies, radiation dosage and contrast load. Motion artefact 
due to breathing and bowel peristalsis can degrade image quality; such 
artefacts can be minimised by vocal instruction during image acquisition, use 
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of spasmolytic agents and motion correction software.  Reproducibility and 
observer variability of has been addressed in earlier studies and proved DCE-
CT parameters analysis to be reproducible in body tumours [387] with good 
intra- and inter-observer variability [386]. The perfusion parameters are 
sensitive to ROI, arterial input and mathematical models. Care should be 
taken to avoid sampling error; AIF should be derived from large arteries to 
avoid averaging from surrounding tissues that will lead to over-estimation of 
BF[370]; variation in commercial software and different mathematical model 
has shown a discrepancy of up to 44% between parameter values and 
difficulties in interplatform or intermodal comparisons [420-422]. There is risk 
of high radiation exposure, especially for patients requiring serial acquisitions; 
techniques including reduced tube current, tube potential and alteration in 
protocols such as scanning every 2-3 seconds instead of every 1 second 
during high temporal sampling, limiting coverage, first pass analysis only (if 
BF or MTT are required only) can help reduce irradiation exposure. Lastly, 
adequate cautions should be taken to prevent contrast-induced nephropathy.
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1.4.2.5 Author’s conclusion on functional imaging techniques 
In conclusion, DW-MRI is the only functional imaging modality thus far with 
immediate impact on clinical decision making. The use of DW-MRI to 
investigate liver metastasis and residual rectal cancer after NCRT is gaining 
momentum at multidisciplinary team meetings. The reason for popularity of 
DW-MRI include readily available technology, for example, MRI scanners and 
software in everyday use can be configured to produce DW images and 
generate ADC. In addition, the calculation and interpretation of ADC is directly 
related to actual tissue microarchitecture and does not require derivation from 
complex mathematical models which makes it adoptable and less prone to 
error and discrepancy.  
The lack of consistency in various components of DCE imaging has limited 
the success of this technology in clinical practice. Investigators in the field 
have used various image acquisition methods, especially designed 
experimental software not readily available, different mathematical models to 
derive DCE parameters and used different DCE parameters to interpret 
dynamic perfusion. Toft et al [423] have addressed this problem by promoting 
common nomenclature amongst investigators. Hence, despite the origin of 
DCE technology more than a decade ago, it still remains in its rudimentary 
stages with most useful application in rodent experiment for anti-angiogenic 
drug development.     
The use of ISW-MRI techniques to detect tumour hypoxia and direct therapy 
largely remains experimental. The value of R2* doesn’t purely depend on 
tissue hypoxia and other factors such as vascular volume, vessel size and 
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maturation also play a role. Hence, this technology requires further evaluation 
before we would know the capacity of its application.  
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2 CHAPTER 2: HYPOTHESIS AND AIMS 
2.1 Hypothesis 
1. We believe that effects of NCRT are time-limited and aggressive rectal 
cancers can overcome the effects of NCRT after certain time by repairing 
their DNA and re-generating functional vascularity  
2. We believe that after NCRT, there are functional changes in rectal 
cancer tissues, such as cellularity, hypoxic foci and functional vascularity, 
which may be detectable with functional imaging techniques.  
3. We believe that baseline and changes after NCRT in DNA repair 
properties, cellularity, hypoxic foci and functional vascularity may affect 
clinical outcomes   
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2.2 Project Aims 
2.2.1 Primary aims 
We aim to establish the optimal interval between NCRT and surgery based on 
DNA repair properties and functional vascular changes in rectal cancers  
2.2.2 Secondary aims 
1. We aim to quantify DNA repair properties of rectal cancers at baseline 
and changes during the period between NCRT and surgery by comet 
assay technique 
2. We aim to quantify tissue cellularity, hypoxic foci and functional 
vascularity at baseline and changes during the period between NCRT 
and surgery by functional imaging techniques 
3. For studies on functional imaging, we also aim to quantify observer 
agreement for functional MRI and CT techniques and effects of volume 
coverage for functional CT techniques for rectal cancers.   
4. We aim to identify patterns in measured parameters that may help 
recognise patient at risk of treatment failure. 
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3 CHAPTER 3: STUDY DESIGN 
3.1 Introduction 
This prospective observational study is designed to investigate the mechanisms 
of tumour response in rectal cancer during NCRT and the subsequent interval 
to surgery, focusing on radio-sensitivity and angiogenesis. It was intended to 
provide information that may help risk-stratify patients for individualised 
treatments including optimal timing of surgery. It does not involve any 
alterations to the actual treatment of study patients. 
3.2 Patients population  
Adult patients with locally advanced, non-metastatic rectal cancer, who were 
considered suitable for neoadjuvant chemoradiotherapy, were offered to 
participate in the study. This population included all consecutive patients treated 
at Mount Vernon Cancer Centre, a tertiary oncology unit covering five District 
General Hospital in Northwest London Cancer Network. The patients were 
recruited during the period May 2009 until May 2012.   
3.3 Inclusion criteria 
1. Histologically proven adenocarcinoma of the rectum within 15cm of the 
anal verge. 
2. Preoperative chemoradiotherapy indicated by virtue of either: (a) a locally 
advanced (T3/T4) tumour which threatens the anticipated surgical 
resection margins (i.e. within 2 mm of mesorectal fascia), based on a 
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combination of clinical and MRI assessment; or (b) MRI evidence of 
extramural vascular invasion or lymph node involvement. 
3. Fulfilment of all other existing inclusion criteria for long-course 
preoperative NCRT with or without additional biological agents.  
4. WHO performance status 0 or 1. 
5. Able to comply reliably with protocol by attending for serial assessments. 
6. Written informed consent. 
3.4 Exclusion criteria 
1. Previously treated rectal adenocarcinoma. 
2. Previous radiotherapy to pelvis. 
3. WHO performance of status of 2 or more. 
4. Specific exclusion criteria is mentioned in individual chapters 
3.5 Long-term follow-up 
Patients were to reviewed as outpatients at 6, 12, 24 and 36 months after 
completion of NCRT, as isstandard follow-up, for the purposes of recording 
crude data regarding disease recurrence and survival.  
3.6 Experiment design to analyse biological behaviour of rectal 
cancer cells  
Experiments were designed to investigate patient’s rectal cancer cell behaviour 
in response to NCRT. In order to obtain detailed information about the dynamic 
changes occurring within the cell DNA and surrounding microenvironment, 
serial tests were undertaken to analyse cell DNA repair pattern, tumour vascular 
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morphology, blood flow and blood oxygenation levels. The experiments 
included: 
1. Single cell gel electrophoresis (comet) assay of rectal cancer cells to 
assess DNA repair function (radio-resistance)  
2. Perfusion CT to determine tumour blood flow, blood volume and 
perfusion 
3.  MRI assessment of tumour pathophysiology. Multi-parametric analysis 
included following MRI protocols: 
a. Dynamic Contrast Enhanced MRI: to assess microvascular 
physiology 
b. Diffusion-weighted MRI: to determine tumour cellularity  
c. Intrinsic susceptibility contrast MRI: to determine changes in 
tumour blood oxygenation levels  
3.7 Schedule of serial tests  
Serial tests are undertaken at specific time-point during the treatment timeline to 
assess dynamic changes in rectal cancers (see figure 3.2). 
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Figure 3.2: Schedule of serial assessments  
 
3.8 Regulatory Issues 
3.8.1 Ethical considerations 
Those recruited into this study were to undergo additional MRI scans and CT 
scans. Each CT scan will involve exposure to an estimated 7mSv (maximum 
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8.5mSv), which should be considered in the light of the 45Gy prescribed as 
standard treatment.   
The 2 sets of serial rectal biopsies taken while patients are awake may cause 
discomfort, but the risks of serious complications (e.g. perforation) are negligible 
and these procedures are already a routine part of patient care, albeit less 
frequently than in this study. The main inconvenience to participants is likely to 
be the additional attendances required to perform the various procedures. 
The study was approved by Hertfordshire/Bedfordshire Research Ethics 
Committee. The study was conducted in accordance with the recommendations 
for physicians involved in research on human subjects adopted by the 18th 
World Medical Assembly (Helsinki, 1964) and later revisions.  
3.8.2 Informed consent 
Verbal and written information on the study, including objectives, procedures 
and the risks involved, were provided to each patient, who were required to give 
signed consent after sufficient time for consideration. The right of the patient to 
refuse to participate at any stage will be respected, with no obligation to provide 
a reason for doing so.  All patients were informed of their right to withdraw from 
the study at any time without risk of prejudicing their treatment. 
3.9 Violation of protocol  
All recruited patients did not undergo all components of proposed protocol, for 
example, one patient was taken out of the study after metastatic disease was 
found on two baseline scans, one patient did not consent for serial biopsy but 
proceeded with serial imaging, whilst two patients declined participation after 
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completing baseline and immediate post-NCRT scans. Therefore, despite 
recruiting 17 patients, the three experiments have different study population and 
this has been specified in relevant chapters.   
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4 CHAPTER 4: DNA REPAIR ANALYSIS 
Measurement of radiosensitivity and its impact on 
clinical outcomes – The DNA repair analysis of 
locally advanced rectal cancer cells 
4.1 Introduction 
The standard treatment of locally advance rectal cancers (LARC) involves long 
course fluoropyrimidine-based neo-adjuvant chemoradiotherapy (NCRT) 
followed by TME surgery after an interval. The response to NCRT for similar 
staged locally advanced rectal cancers varies between patients: whilst in some 
patients the tumour completely disappears, others show stable or progressive 
disease. A good response to NCRT improves long-term clinical outcomes as 
evidenced by lower recurrence rates and longer survival [238]. Patients who 
achieve pathological complete response have improved long-term outcomes in 
terms of excellent local control rates and this is independent of their initial 
clinical T and N stages [424, 425]. Mostly European trials report a clinical 
downstaging in the range of 50-60% including complete pathological response 
in 13-20% after NCRT. Hence a large cohort of patients is subjected to toxic 
NCRT without any benefit. To date, little is known about the molecular basis for 
such heterogeneous response to NCRT. Therefore, recent studies have 
focused on prognostic stratification based on rectal tumour biology and 
proposed the need for individualised treatment regimes.  
A simple measure, such as, increasing the interval to surgery after NCRT has 
shown to increase response rates in patients [239]. However, the exact duration 
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of radiotherapy-induced continued cell death after completion of NCRT remains 
unknown. Cell death in response to radiotherapy is a complex process that also 
depends on the integrity of cell DNA repair and apoptosis pathways. It may be 
hypothesised that radiosensitive tumour load is eliminated during or 
immediately after radiotherapy leaving behind relatively radioresistant residual 
tumour cells. The progressive downstaging seen in some rectal cancers with 
increased interval to surgery may be due to continued apoptosis of residual 
tumour cells unable to repair DNA damage. In contrast, rectal cancers that 
remain stable or show progressive disease may overcome irradiation-induced 
DNA damage by re-populating tumour with cells harbouring upregulated DNA 
repair mechanisms. Hence, the assessment of intrinsic radiosensitivity by 
measuring DNA damage and repair profiles of rectal tumour cells may help 
determine outcomes of therapy and individualise treatment protocols. 
The single cell gel electrophoresis (Comet assay) is an established technique to 
assess DNA damage induced by clinically relevant doses of radiation [248]. 
While many of the clinical studies employing the comet assay have utilised 
lymphocytes, the technique has also been performed on cells obtained by fine 
needle aspiration of a variety of accessible primary and metastatic tumours, 
including colorectal cancer [262, 266, 268].  
To date there have been no reports on the application of the comet assay to 
predict response of individual rectal cancers to radiotherapy. Hence, the aims of 
this experiment are as follows: (1) to assess the feasibility of conducting comet 
assay on fresh rectal cancer samples, (2) to investigate baseline DNA damage 
and DNA repair profiles of rectal cancer cells subjected to long course 
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neoadjuvant chemoradiotherapy (NCRT) and determine the duration of 
impaired DNA repair after irradiation, and (3) to investigate any relation between 
rectal cancer radiosensitivity and clinicopathological markers and long-term 
outcomes.  
4.2 Methods 
4.2.1 Patient population   
See chapter 3 for detail of patient population. Additional exclusion criteria were 
inability to undergo biopsy without sedation/anaesthesia (n=1; post-NRCT 
grade III perianal pain); metastatic disease (n=1; metastatic liver disease) 
4.2.2 Patient Compliance and Exclusions 
Thirty-two patients were screened; 17 patients consented to participate in the 
study. Pre-treatment biopsy was successfully obtained from 16 patients: 1 
patient declined to give a biopsy. Post-NCRT biopsy was successfully obtained 
in 12 patients: one patient was excluded from study due to finding of metastatic 
disease; one patient declined further participation in the study; two patients 
declined to give biopsy due to severe rectal pain. Pre-operative biopsy was 
successfully obtained in only 6 patients: one patient died due to cause 
unrelated to rectal cancer or treatment; two patients declined biopsy; in three 
patients the operating surgeon could not obtain pre-operative biopsy due to 
technical reasons. There were further exclusions at the biopsy processing 
stage. Patient and data available for analysis is presented in table 4.1. 
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Table 4.1: Patient compliance and exclusions  
Code T0  T1 T2 Reason for exclusion 
1 RY ✓ ✓ ✓ First biopsy was lost during transfer 
2 DG ✓ ✓ ✓  
3 DJ ✓ X X Excluded from study metastatic disease 
4 AH ✓ ✓ ✓  
5 KB ✓ X ✓ Declined biopsy at T1 
6 ED ✓ ✓ X Declined further participation 
7 AF ✓ ✓ X Biopsy sample not viable 
8 JN ✓ ✓ X Biopsy sample not viable 
9 SD ✓ ✓ X Patient died after NCRT 
10 JH ✓ ✓ X Biopsy sample not viable 
11 DP ✓ X X Declined participation after NCRT 
12 GA X X X Declined participation for biopsy 
13 PO ✓ ✓ X Biopsy sample not viable 
14 MM ✓ ✓ X Biopsy sample not viable 
15 RC1 ✓ ✓ ✓  
16 RC2 ✓ X ✓ Declined biopsy at T1 
17 JT ✓ ✓ ✓  
Biopsy Completed 16 12 7  
Included in Study 13 11 6  
‘✓ ’ – completed experiment and included in analysis, ‘✓’ – completed experiment but not 
included in analysis; ‘X’ did not complete experiment;  
4.2.3 Single Cell Gel Electrophoresis (Comet Assay) of rectal cancer 
cells 
The procedure was performed according to standard operating procedures 
developed within the laboratory of Professor John Hartley [426]. All procedures 
were carried on ice and subdued lightening. All chemical used were from Sigma 
Chemical (Poole, United Kingdom) unless otherwise stated. The steps are as 
follows:- 
 CHAPTER 4: DNA REPAIR ANALYSIS  
 
111 
4.2.3.1 Rectal cancer biopsy and preparation of single cell suspension 
Serial samples of rectal cancer tissue were obtained at three stages  
(i) Pre-treatment (T0) 
(ii) Post-NCRT (T1) 
(iii) Pre-operative (T2) 
Rectal cancer tissue biopsy was obtained using a rigid sigmoidoscopy or a 
proctoscopy and disposable biopsy forceps (Stericom ®, Chesham, UK). Single 
cell suspension is prepared under sterile conditions within a laboratory hood.  
Freshly harvested tumour tissue was immediately soaked in a few drops of 
RPMI 1640 medium and finely chopped using surgical scalpel (blade size 11) to 
release single rectal cancer cells embedded in connective tissue.  Once all solid 
tissue had been chopped, the sample was transferred into a conical tube and 
suspended in additional RPMI 1640 medium to reach a total volume of 10mL. 
The mixture was centrifuged at 200 g for 5 minutes at 4oC. The rectal cancer 
cells accumulated at the bottom of the tube and were aspirated using a pipette. 
The rectal cancer cells were then mixed with freezing mixture (fetal calf serum 
with 10% DMSO, 2ml divided in 2 cryovials) and stored at - 800C until analysis.  
4.2.3.2 Cell count, viability and histopathological assessment 
At the time of analysis, the mixture of rectal cancer cells in freezing mixture was 
thawed on ice. Once thawed, the mixture was assessed for the presence of 
cancer cells, cell count and cell viability.  In the first instance, cell count was 
performed using standard haemocytometer followed by Trypan Blue® test for 
cell viability. A portion of sample was saved for histopathological assessment to 
 CHAPTER 4: DNA REPAIR ANALYSIS  
 
112 
ascertain presence of cancer cells, whilst another portion was diluted in tissue 
culture medium to achieve a concentration of 2.5 x 104 cells per mL and divided 
into seven aliquots as below (see figure 4.1). One sample was taken as ‘control’ 
and not irradiated. The other samples were all irradiated ex-vivo using 15Gy of 
radiation (AGO HS X-ray system 320kV, AGO Xray limited, Yeovil, UK) to 
introduce a fixed level of random DNA single strand breaks, followed by serial 
comet assays at six time points to assess the DNA repair over 2 hours (see 
figure 4.1). The control and 1st irradiated aliquot are assayed at ‘0’ time point 
(T0) (immediately after irradiation), the remaining samples were incubated at 
37oC for the appropriate post-incubation time.   
Figure 4.1: Experiment design of timed comet assays 
Timeline of assay 
 
0 min  15 min  30 min  45 min  60 min  120 min 
1st (Control)* 
& 2nd Aliquots 
 3rd  
Aliquot  
 4th  
Aliquot  
 5th  
Aliquot  
 6th  
Aliquot 
 7th  
Aliquot 
*Control is not irradiated  
The histopathological assessment was conducted separately at a later time. 
During this process, the rectal cancer cells and residual tissue are isolated after 
centrifuge and smeared onto a slide followed by fixation and standard 
haematoxylin-eosin staining. A consultant histopathologist examined the fixed 
specimen and determined presence of rectal cancer cells.  
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4.2.3.3 Preparation of slides and electrophoresis: 
After irradiation, the cells were embedded in 1% low gelling temperature 
agarose on a pre-coated microscope slide and lysed for 1 hour in ice-cold lysis 
buffer (100mM disodium EDTA, 2.5M NaCl, 10MM Tris-HCl, pH 10.5) 
containing 1% Triton X-100 added immediately before use in assay and then 
washed every 15 minutes in distilled water for 1 hour. Slides were then 
incubated in alkali buffer (50mM NaOH, 1mM disodium EDTA, pH 12.5) for 45 
minutes, followed by electrophoresis in the same buffer for 25 minutes at 18V 
(0.6 V/cm), 250 mA. The slides were finally rinsed with neutralizing buffer (0.5M 
Tris-HCl, pH 7.5) then saline and left to dry overnight. After drying, the slides 
were stained with propidium iodide (2.5 g/mL) for 30 minutes then rinsed in 
distilled water and dried.  
4.2.3.4 Image analysis and quantification of tail moment 
The images were visualised on NIKON inverted microscope with high-pressure 
mercury light (NIKON UK Limited, Kingston-Upon-Thames, United Kingdom), 
510–560nm excitation filter, and 590 nm barrier filter at x20 magnification. 
Images were captured by using an on-line charge-coupled device (CCD) 
camera and analysed by using Komet Analysis software (Version 6.0, Andor 
Technology, Belfast, Northern Ireland). For each duplicate slide 15 cells are 
examined (total 30 cells). The tail moment for each image was calculated by 
using the Komet Analysis software as the product of the percentage DNA in the 
comet tail and the distance between the means of the head and tail distribution 
(measured in ‘μm’), based on the definition by Olive et al [249] (see figures 4.2 
and 4.3).  
 CHAPTER 4: DNA REPAIR ANALYSIS  
 
114 
Figure 4.2: Measurement of tail moment as defined by Olive et al.  
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Figure 4.3: Typical comet images of rectal cancer cells after exposure to 
15 Gy ex vivo irradiation 
 
 
Pre-Treatment Post-NCRT Pre-Operative 
T0 
   
T0X 
  
 
T15 
   
T30 
   
T45 
   
T60 
   
T120 
   
T (subscript) – timing of biopsy (serial number); T0 – Control; T0X to T120 – samples exposed to 15 
Gy ex vivo irradiation 
 
 CHAPTER 4: DNA REPAIR ANALYSIS  
 
116 
4.2.4 Definition of terms 
The ‘Control’ is the aliquot of tumour cells not exposed to ex vivo irradiation. 
Hence the control for pre-treatment cancer cells represents native tumour 
tissue.  ‘Complete response’ is defined as TM values at 120 minutes assay to 
be below or within the 95% confidence interval of baseline TM value. ‘No 
response’ is defined as TM measurements at the 120 minutes assay to be 
above the 95% confidence interval of baseline TM value (see table 4.21). 
4.2.5 Statistical Analysis  
The distribution of measurement was checked for normality with Shapiro-Wilk 
test and Q-Q plots. The tail moment is reported with standard deviation and 
standard error as calculated by Komet software (version 6.0, Andor Technology, 
Belfast, Northern Ireland). The percentage change is used to elaborate DNA tail 
moment changes after ex vivo irradiation. The percentage change was 
calculated as follow: 
𝑇𝑀 𝑎𝑡 𝑠𝑒𝑟𝑖𝑎𝑙 𝑡𝑖𝑚𝑒 𝑝𝑜𝑖𝑛𝑡𝑠 − 𝑇𝑀 𝑓𝑜𝑟 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
𝑇𝑀 𝑓𝑜𝑟 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
× 100 
where, ‘TM’ is tail moment, ‘TM for control’ is the non-irradiated sample, ‘TM at 
serial time points’ include ‘0’ min’, ’15 min’, ’30 min’, ’45 min’, ’60 min’ and ‘120 
min’. The comparisons between TM measurements at different time-points were 
compared with Wilcoxon signed rank test. Any significant difference in serial 
samples was assessed by Friedman tests. The association between DNA repair 
pattern and clinical outcomes was assessed by Spearman rho correlational (for 
non-parametric data) and Chi-squared or Fisher exact tests. All statistical 
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analysis was conducted using IBM® SPSS® statistical software (version 22.0, 
2014; USA). 
4.3 Results 
4.3.1 Patient population 
Patient characteristics, tumour staging and long-term outcomes are given in 
table 4.2. Most patients had locally advance rectal cancer with nodal 
involvement and only one patient had T4 disease without any nodal disease on 
pre-treatment MRI staging. All patient tolerated NCRT bar one patient who 
suffered coronary artery syndrome secondary to capecitabine, but completed 
the long-course radiotherapy. One patient died during the interval between 
NCRT and surgery due to factors unrelated to rectal cancer. Two other patients 
declined surgery after complete response seen on 6 weeks post-NCRT MRI 
scan. The mean interval between completion of NCRT and surgery was 12.3 
weeks. 
4.3.2 Clinical Outcomes 
The majority of patients (87%) showed tumour downstaging (see table 4.2). 
There was statistical significant T (p 0.004) and N (p 0.002) downstaging 
between pre- and post-NCRT upon tumour stage assessment (see table 4.3). 
Three patients (20%) had complete response: two patients showed complete 
response on post-NCRT MRI scans and declined surgery, whilst another patient 
showed pathological complete response on surgical specimen. In only two 
patients there was neither T- nor N- downstaging after NCRT: both patients 
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developed distant recurrence within the follow-up period as a result of which 
one patient died. The median follow-up was 31 months. During this period, one 
patient developed local recurrence and two patients developed distal 
metastasis. One patient was successfully treated from rectal cancer but later 
developed pancreatic cancer and died from pancreatic cancer metastasis. 
Including the latter case there were a total of three deaths; one patient died as a 
result of distant recurrence whilst another died of a cause unrelated to rectal 
cancer. The mean survival time was 47.6 months (95% CI 40.3 to 54.9 months) 
in this cohort.  
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Table 4.2: Patient characteristics, tumour staging and long-term outcomes 
Code Gender Age cTNM NCT NRT TME ypTNM 
Local 
Recurrence 
Distant 
Recurrence 
Death 
1 RY M 59 T3N1M0 ✓ ✓ ✓ T3N0    
2 DG M 52 T3N1M0 ✓ ✓ ✓ T3N1  ✓: Lung ✓ 
3 DJ* M 72 T3N1M2 - - - - - ✓: Liver ✓ 
4 AH M 74 T3N2M0 ✓ ✓ ✓ T2N1    
5 KB M 78 T3N1M0 ✓ ✓ ✓ T2N0   ✓ 
6 ED F 72 T3N1M0 ✓ ✓ ✓ T1N0    
7 AF F 60 T3N1M0 ✓ ✓ ✓ T2N0    
8 JN M 79 T3N2M0 X ✓ ✓ T2N0 ✓   
9 SD** M 71 T3N1M0 ✓ ✓ - -   ✓ 
10 JH M 67 T3N0M0 ✓ ✓ ✓ T3N0  ✓: Pancreas ✓ 
11 DP M 58 T3N1M0 ✓ ✓ ✓ T2N0    
12 GA*** M 53 T2N2M0 ✓ ✓ X -    
13 PO F 59 T3N2M0 ✓ ✓ ✓ T3N2  ✓: Liver  
14 MM*** F 78 T4N0M0 ✓ ✓ X -    
15 RC1 M 76 T3N1M0 ✓ ✓ ✓ T2N0    
16 RC2 M 56 T3N1M0 ✓ ✓ ✓ T0N0    
17 JT F 79 T3N1M0 ✓ ✓ ✓ T3N0    
*Diagnosed with liver metastasis on baseline scans; **Died after NCRT due to cause unrelated to rectal cancer; ***Had complete response 
on post NCRT MRI scan and declined surgery. Prefix ‘c’ – clinical; yp – post-NCRT; TNM – Tumour, Node, Metastasis staging; NCT – 
neoadjuvant chemotherapy; NRT – Neoadjuvant radiotherapy; TME – total mesorectal excision surgery; ✓-completed; X – not completed.  
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Table 4.3: T- and N- downstaging after NCRT  
 Post-NCRT Staging  
T0 T1 T2 T3 Total (%) 
C
li
n
ic
a
l 
S
ta
g
in
g
 
T2 1*    1 (6.6%) 
T3 1 1 6 5 13 (86.6%) 
T4 1*    1 (6.6%) 
Total (%) 3 (20%) 1 (6.6%) 6 (40%) 5 (33.3%) p =0.004** 
 
 N0 N1 N2 Total (%)  
N0 1   1 (6.6%)  
N1 8 1  9 (60%)  
N2 2 + 1* 1 1 5 (33.3%)  
Total (%) 12 (80%) 2 (13.3%) 1 (6.6%) p = 0.002**  
*On 6 weeks post-NCRT MRI scan 
**Wilcoxon signed rank test  
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4.3.3 Response Evaluation Criteria In Solid Tumour (RECIST)  
According to RECIST criteria: at the immediate post NCRT stage, there were 10 
partial responders and 5 with stable disease; at post-operative stage, three 
partial responders progressed to complete response (see table 4.5). 
Table 4.5: RECIST Criteria of Tumour response 
Code cL (mm) nL (mm) pL (mm) nRECIST 
1 RY 85 46 20 PR 
2 DG 49 26 35 PR 
3 DJ* - - - - 
4 AH 34 34 25 SD 
5 KB 53 40 32 SD 
6 ED 37 20 20 PR 
7 AF 77 19 15 PR 
8 JN 57 40 36 PR 
9 SD 55 42 - SD 
10 JH 61 60 10 SD 
11 DP 60 - 60 - 
12 GA* 54 38 - PR 
13 PO 30 13 10 PR 
14 MM* 37 30 - SD 
15 RC1 62 33 20 PR 
16 RC2 75 30 0 PR 
17 JT 34 20 25 PR 
* Treated as Complete responders on later MRI scans; prefix ‘c’ –
Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; PR – Partial 
response; SD – stable disease; CR – complete response 
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4.3.4 Cell count, viability and histopathology  
In general, most completed slides showed frequent dead cells with debris. 
However, there was adequate number of viable cells for comet assay (>50% 
cell viability in all samples). The histopathology analysis (conducted by a 
Consultant Pathologist) confirmed the presence of cancer cells in all samples.  
4.3.5 Combined results: 
4.3.5.1 Effects of long course NCRT on rectal cancer cells  
In general, the biopsy specimen taken at the pre-treatment stage showed a 
slightly damaged baseline DNA in tumour cells (median baseline TM 5.47μ, see 
table 4.6 and figure 4.4), indicating presence of volatile and damaged cells that 
frequently compose solid cancers.  
After long course NCRT, there was significant increase in the DNA damage as 
quantified by tail moment (mean TM= 6.94 vs 5.12, p=0.01, see table 4.7 and 
figure 4.4), indicating lasting effects of chemoradiotherapy with increased in 
damaged and necrotic cell within surviving fraction of rectal cancer.  
The tumour cells obtained at the preoperative stage show return of DNA 
damage to the pre-treatment levels (pre-treatment cell mean TM=5.98 vs pre-
surgery TM=5.76, p=0.71, see table 4.7), indicating either elimination of 
damaged cells or enhance DNA repair capability of surviving fraction in the 
interval between NCRT and surgery. 
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Table 4.6: DNA Tail Moment values of rectal cancer cells before and after 
treatment with long course NCRT 
Code 
Pre-Treatment (T0) Post-NCRT (T1) Pre-Operative (T2) Statistical 
significance TM [μm] (SD; SE) TM [μm] (SD; SE) TM [μm] (SD; SE) 
2 DG 4.44 (2.83; 0.51) 6.90 (2.4; 0.43) 11.23 (7.69; 1.4)  
4 AH 5.50 (2.5; 0.45) 5.57 (2.52; 0.46) 4.41 (1.91; 0.34) 
5 KB 13.92 (6.02; 1.1) - 7.25 (4.12; 0.75) 
6 ED 6.72 (3.09; 0.56) 7.03 (2.84; 0.52) - 
7 AF 3.81 (2.68; 0.49) 3.90 (2.62; 0.47) - 
8 JN 6.23 (2.94; 0.53) 7.46 (4.06; 0.74) - 
9 SD 3.51 (3.47; 0.63) 9.50 (2.56; 0.46) - 
10 JH 4.50 (2.39; 0.43) 7.38 (1.55; 0.28) - 
13 PO 6.53 (2.28; 0.41) 7.77 (2.82; 0.51) - 
14 MM 5.05 (2.39; 0.43) 9.32 (3.56; 0.65) - 
15 RC1 5.47 (3.28; 0.60) 8.15 (2.47; 0.45) 3.49 (1.84; 0.33) 
16 RC2 5.47 (3.02; 0.55) - 3.76 (2.45; 0.44) 
17 JT 4.57 (9.36; 1.71) 3.31 (2.77; 0.50) 3.91 (1.73; 0.31) 
 
Mean 5.82 6.94 5.68 0.779* 
Median 5.47 7.38 4.16 
SD 2.52 1.88 2.78 
SE 0.69 0.56 1.13 
Minimum 3.51 3.31 3.49 
Maximum 13.92 9.50 11.23 
TM – Tail moment; SD – Standard Deviation; SE – Standard error; T (subscript) – timing of 
biopsy (serial number); Statistical Tests: Friedman Test* ; p – statistical significance of <0.05 
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Table 4.7: Comparison of DNA Tail Moment values of rectal cancer cells 
before and after treatment with long course NCRT 
Comparison n Mean TM [μm] (SD; SE) Statistical significance* 
T0 vs T1 11 
5.12  
(2.52; 0.69) 
6.94  
(1.88; 0.56) 
0.01  
T0 vs T2 6 
6.56 
(3.31; 1.3) 
5.67 
(2.78; 1.13) 
0.34 
T1 vs T2 4 
5.98 
(1.79; 0.89) 
5.76 
(3.17; 1.58) 
0.71 
TM – DNA Tail Moment; SD – Standard Deviation; SE – Standard error; T (subscript) – 
timing of biopsy (serial number); Statistical Tests: Wilcoxon signed ranked test*; p – 
statistical significance of <0.05; Bold – significant difference 
 
Figure 4.4: Box plot graph showing changes in DNA tail moments of rectal 
cancers treated with long course NCRT  
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4.3.6 Individual Patient results 
The data from individual patient and representative graphs are shown in table 
4.8.The data shows DNA damage and repair after exposure to 15Gy ex vivo 
irradiation measured by comet assay.  
The rectal cancer cells harvested at pre-treatment stage (red line on graphs in 
table 4.8) show significant DNA damage (several fold increase in TM) after 
exposure to 15Gy ex vivo irradiation. The same cells show active DNA repair 
with exception in patients 2 (KB) and 4 (AH). In addition, there is relatively less 
change in TM between 60 and 120 minutes after irradiation. The patient 9 (SD) 
shows atypical pattern and this is because of presence of frequent non-viable 
cells in their sample.  
The rectal cancer cells harvested at post-NCRT stage (green line on graphs in 
table 4.8) show less increase in TM after irradiation, except for patients 2 (KB), 
7 (AF) and 17 (JT). This may indicate enhanced DNA repair properties in 
surviving fraction of rectal cancer cells after long course NCRT. 
The rectal cancer cells harvested at pre-operative stage (blue line on graphs in 
table 4.8) show features similar to rectal cancer cells obtain at pre-treatment 
stage with better DNA repair capability. In addition, the decrease in TM 
continues between 60 and 120 minutes after irradiation except in patient 15 
(RC1). The patient 17 (JT) shows atypical pattern and this is because of 
presence of frequent non-viable cells in their sample.
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Table 4.8: Percentage change in TM of rectal cancer cells harvested at different time-points for individual patients  
Patient Code 2 (DG) 
 
 
Pre-
Treatment 
TM [μm] 
Post-
NCRT 
TM [μm] 
Pre-
operative 
TM [μm] 
Control 4.44 6.9 11.23 
0 
15.8 
(256%) 
15 
(118%) 
23.27 
(107%) 
15 
12.21 
(175%) 
15.03 
(118%) 
20.74 
(85%) 
30 
12.51 
(182%) 
14.73 
(113%) 
19.21 
(71%) 
45 
13.88 
(213%) 
13.68 
(98%) 
16.5 (47%) 
60 
13.16 
(196%) 
14.22 
(106%) 
13.22 
(178%) 
120 
12.77 
(188%) 
14.51 
(110%) 
11.32 
(0.8%) 
 
Percentage decrease in TM (DNA repair) over time after exposure to 15 Gy ex vivo irradiation 
TM – Tail moment 
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Patient Code 4 (AH) 
 
 
Pre-
Treatment 
TM [μm] 
Post-
NCRT 
TM [μm] 
Pre-
operative 
TM [μm] 
Control 5.5 5.57 4.41 
0 
11.18 
(103%) 
23.12 
(315%) 
14.65 
(232%) 
15 7.13 (30%) 
15.36 
(176%) 
10.76 
(144%) 
30 
8.8 (60%) 12.75 
(129%) 
10.08 
(129%) 
45 
8.7 (58%) 10.92 
(96%) 
9.15 
(107%) 
60 
9.68 (76%) 8.82 
(58%) 
8 57 
(94%) 
120 
8.31 (51%) 7.16 
(29%) 
7.28 
(65%)  
Percentage decrease in TM (DNA repair) over time after exposure to 15 Gy ex vivo irradiation 
TM – Tail moment 
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Patient Code 5 (KB) 
 
 
Pre-
Treatment 
TM [μm] 
Post-
NCRT 
TM [μm] 
Pre-
operative 
TM [μm] 
Control 13.92  - 7.25  
0 
24.46  
(78%) 
- 12.23 
(69%) 
15 
20.01  
(44%) 
- 11.37 
(57%) 
30 
14.67  
(5%) 
- 10.86 
(50%) 
45 
14.7  
(5%) 
- 9.67  
(33%) 
60 
13.49  
(-3%) 
- 9.46  
(30%) 
120 
12.61 
(-9%) 
- 7.98  
(10%) 
 
Percentage decrease in TM (DNA repair) over time after exposure to 15 Gy ex vivo irradiation 
TM – Tail moment 
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Patient Code 6 (ED) 
 
 
Pre-
Treatment 
TM [μm] 
Post-
NCRT 
TM [μm] 
Pre-
operative 
TM [μm] 
Control 6.72 7.03 - 
0 
15.64 
(133%) 
11.47 
(63%) 
- 
15 
12.7  
(89%) 
11.02 
(57%) 
- 
30 
9.14  
(36%) 
10.78 
(53%) 
- 
45 
9.04  
(35%) 
10.18 
(45%) 
- 
60 
7.33  
(9%) 
9.52  
(35%) 
- 
120 
6.22 
(-7%) 
8.88  
(26%) 
- 
 
Percentage decrease in TM (DNA repair) over time after exposure to 15 Gy ex vivo irradiation 
TM – Tail moment 
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Patient Code 7 (AF) 
 
 
Pre-
Treatment 
TM [μm] 
Post-
NCRT 
TM [μm] 
Pre-
operative 
TM [μm] 
Control 3.81 3.9 - 
0 
11.58 
(204%) 
14.09  
(261%) 
- 
15 
8.83 
(132%) 
11.2 
(187%) 
- 
30 
7.12  
(87%) 
10.68 
(174%) 
- 
45 
5.39  
(41%) 
9.39 
(141%) 
- 
60 
4.96 
(30%) 
8.85 
(127%) 
- 
12 
4.07 
(7%) 
8.84 
(127%) 
- 
 
Percentage decrease in TM (DNA repair) over time after exposure to 15 Gy ex vivo irradiation 
TM – Tail moment 
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Patient Code 8 (JN) 
 
 
Pre-
Treatment 
TM [μm] 
Post-
NCRT 
TM [μm] 
Pre-
operative 
TM [μm] 
Control 6.23 7.46 - 
0 
17.73 
(185%) 
13.88 
(86%) 
- 
15 
14.64 
(135%) 
11.81 
(58%) 
- 
3 
11.66 
(87%) 
10.7 
(43%) 
- 
45 
9.16 
(47%) 
9.8 
(31%) 
- 
60 
8.99 
(44%) 
9.09 
(22%) 
- 
120 
7.8 
(25%) 
10.02 
(34%) 
- 
 
Percentage decrease in TM (DNA repair) over time after exposure to 15 Gy ex vivo irradiation 
TM – Tail moment 
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Patient Code 9 (SD) 
 
 
Pre-
Treatment 
TM [μm] 
Post-
NCRT 
TM [μm] 
Pre-
operative 
TM [μm] 
Control 3.51 9.5 - 
0 
14.95  
(326%) 
11.52 
(21%) 
- 
15 
9.7 
(176%) 
11.06 
(16%) 
- 
30 
8.28 
(136%) 
10.08 
(6%) 
- 
45 
11.18 
(219%) 
9.98 
(5%) 
- 
60 
9.61 
(174%) 
9.79 
(3%) 
- 
120 
9.62 
(174%) 
9.85 
(4%) 
- 
 
Percentage decrease in TM (DNA repair) over time after exposure to 15 Gy ex vivo irradiation 
TM – Tail moment 
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Patient Code 10 (JH) 
 
 
Pre-
Treatment 
TM [μm] 
Post-
NCRT 
TM [μm] 
Pre-
operative 
TM [μm] 
Control 4.5 7.38 - 
0 
11.53 
(156%) 
14.78 
(100%) 
- 
15 
8.99 
(100%) 
12.21 
(65%) 
- 
30 
7.47 
(66%) 
12.46 
(69%) 
- 
45 
7.24 
(61%) 
11.57 
(57%) 
- 
60 
7.04 
(56%) 
11.94 
(62%) 
- 
120 
6.95 
(54%) 
11.89 
(61%) 
- 
 
Percentage decrease in TM (DNA repair) over time after exposure to 15 Gy ex vivo irradiation 
TM – Tail moment 
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Patient Code 13 (PO) 
 
 
Pre-
Treatment 
TM [μm] 
Post-
NCRT 
TM [μm] 
Pre-
operative 
TM [μm] 
Control 6.53 7.77 - 
0 
14.35 
(120%) 
13.73 
(77%) 
- 
15 
13.61 
(108%) 
12.94 
(67%) 
- 
30 
13.18 
(102%) 
10.92 
(40%) 
- 
45 
12.67 
(94%) 
10.7  
(38%) 
- 
60 
11.09 
(70%) 
10.05 
(29%) 
- 
120 
10.71 
(64%) 
9.88 
(27%) 
- 
 
Percentage decrease in TM (DNA repair) over time after exposure to 15 Gy ex vivo irradiation 
TM – Tail moment 
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Patient Code 14 (MM) 
 
 
Pre-
Treatment 
TM [μm] 
Post-
NCRT 
TM [μm] 
Pre-
operative 
TM [μm] 
Control 5.05 9.32 - 
0 
12.13 
(140%) 
13.26 
(42%) 
- 
15 
10.2 
(102%) 
12.43 
(33%) 
- 
30 
8.31 
(65%) 
10.69 
(15%) 
- 
45 
6.48 
(28%) 
10.69 
(15%) 
- 
60 
6.95 
(38%) 
12.05 
(29%) 
- 
120 
6.09 
(21%) 
10.1 
(8%) 
- 
 
Percentage decrease in TM (DNA repair) over time after exposure to 15 Gy ex vivo irradiation 
TM – Tail moment 
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Patient Code 15 (RC1) 
 
 
Pre-
Treatment 
TM [μm] 
Post-
NCRT 
TM [μm] 
Pre-
operative 
TM [μm] 
Control 5.47 8.15 3.49 
0 
18.42 
(237%) 
15.15 
(86%) 
12.91 
(270%) 
15 
13.23 
(142%) 
17.19 
(111%) 
9.93 
(185%) 
30 
11.39 
(108%) 
11.51 
(41%) 
8.82 
(153%) 
45 
10.22 
(87%) 
11.72 
(44%) 
8.49 
(143%) 
60 
10.77 
(97%) 
12.58 
(54%) 
7.91 
(127%) 
120 
11.27 
(106%) 
5.54 
(-32%) 
8.07  
(131) 
 
Percentage decrease in TM (DNA repair) over time after exposure to 15 Gy ex vivo irradiation 
TM – Tail moment 
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Patient Code 16 (RC2) 
 
 
Pre-
Treatment 
TM [μm] 
Post-
NCRT 
TM [μm] 
Pre-
operative 
TM [μm] 
Control 5.47 - 3.76 
0 
12.67 
(132%) 
- 6.07  
(61%) 
15 
9.93 
(82%) 
- 4.89 
(30%) 
30 
8.29 
(52%) 
- 4.64 
(23%) 
45 
8.15 
(49%) 
- 4.09 
(9%) 
60 
7.3 
(33%) 
- 5.51 
(47%) 
120 
8.16 
(49%) 
- 4.99 
(33%) 
 
Percentage decrease in TM (DNA repair) over time after exposure to 15 Gy ex vivo irradiation 
TM – Tail moment 
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Patient Code 17 (JT) 
 
 
Pre-
Treatment 
TM [μm] 
Post-
NCRT 
TM [μm] 
Pre-
operative 
TM [μm] 
Control 4.57 3.31 3.91  
0 
10.7 
(134%) 
10.85 
(228%) 
12.42 
(218%) 
15 
8.43 
(82%) 
7.56  
(128%) 
12.93 
(231%) 
30 
7.53 
(65%) 
7.03 
(112%) 
12.59 
(222%) 
45 
6.79 
(49%) 
6.44 
(95%) 
12.02 
(207%) 
60 
5.87 
(28%) 
6.18 
(87%) 
9.61 
(146%) 
120 
6.12 
(34%) 
7.65 
(131%) 
9.39 
(140%) 
 
Percentage decreased in TM (DNA repair) over time after exposure to 15 Gy ex vivo irradiation 
TM – Tail moment 
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4.3.7 Effects of 15Gy ex vivo irradiation on rectal cancer cells 
harvested at serial time-points before and after treatment with 
long course NCRT 
4.3.7.1 Rectal cancer cells harvested at “pre-treatment stage”  
The descriptive measurements of tail moments from timed comet assay DNA 
repair analysis are given in table 4.9 and the cumulative statistical analysis is 
shown in table 4.10 and figure 4.5. The percentage changes in DNA tail 
moments after 15Gy ex vivo irradiation is shown in table 4.11 and figure 4.6. 
The rectal cancer cells harvested at pre-treatment stage showed severe 
damage (increased tail moment) after exposure to 15Gy ex-vivo irradiation 
(mean TM = 5.82μm in control versus mean TM=14.7μm immediately after 
irradiation, p 0.001; see table 4.10 and figure 4.5). There seems to be active 
repair following irradiation evidenced by a statistically significant decrease in 
serial tail moments on Friedman test (p <0.001), however, at 120 minutes the 
DNA damage remained significant as compared to the baseline value (TM = 
5.82μm in control versus 8.51μm at 120 minutes, p 0.006; see table 4.10 and 
figure 4.5). 
The percentage change in DNA tail moment further elaborates cell DNA 
damage after irradiation and DNA repair capabilities. As seen in table 4.11 and 
figure 4.6, the percentage DNA tail moment sharply increases several folds 
after ex vivo irradiation (red bar in figure 4.6) in each patient, followed by 
lowering percentage over 120 minutes. In majority of patients, the percentage 
DNA tail moment decreases over time towards baseline value, but DNA does 
not fully recover. 
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Table 4.9: Changes in individual patient DNA tail moment (DNA repair) of rectal cancer cells at “pre-treatment stage” after 
exposure to 15Gy ex vivo irradiation  
Code 
Baseline TM TM at serial time points after exposure to 15 Gy ex vivo irradiation 
Control 0 (min) 15 (min) 30 (min) 45 (min) 60 (min) 120 (min) 
TM [μm] (SD; SE) TM [μm] (SD; SE) TM [μm] (SD; SE) TM [μm] (SD; SE) TM [μm] (SD; SE) TM [μm] (SD; SE) TM [μm] (SD; SE) 
2 DG 4.44 (2.83; 0.51) 15.80 (2.32; 0.42) 12.21 (3.95; 0.72) 12.51 (3.08; 0.56) 13.88 (4.63; 0.84) 13.16 (4.33; 0.79) 12.77 (3.86; 0.70) 
4 AH 5.50 (2.5; 0.45) 11.18 (3.22; 0.56) 7.13 (3.65; 0.66) 8.80 (3.31; 0.60) 8.70 (2.71; 0.49) 9.68 (2.74; 0.50) 8.34 (3.35; 0.62) 
5 KB 13.92 (6.02; 1.1) 24.46 (6.62; 1.2) 20.01 (6.4; 1.16) 14.67 (7.04; 1.28) 14.70 (6.57; 1.2) 13.49 (5.62; 1.02) 12.61(3.99; 0.73) 
6 ED 6.72 (3.09; 0.56) 15.64 (5.08; 0.92) 12.70 (5.19; 0.94) 9.14 (3.43; 0.62) 9.04 (4.55; 0.83) 7.33 (3.24; 0.59) 6.22 (3.2; 0.58) 
7 AF 3.81 (2.68; 0.49) 11.58 (4.07; 0.74) 8.83 (3.79; 0.69) 7.12 (3.06; 0.55) 5.39 (2.77; 0.50) 4.96 (2.62; 0.47) 4.07 (2.32; 0.42) 
8 JN 6.23 (2.94; 0.53) 17.73 (4.64; 0.84) 14.64 (3.64; 0.66) 11.66 (2.81; 0.51) 9.16 (3.59; 0.65) 8.99 (1.98; 0.36) 7.80 (2.71; 0.49) 
9 SD 3.51 (3.47; 0.63) 14.94 (3.28; 0.59) 9.70 (6.97; 1.27) 8.28 (3.23; 0.58) 11.18 (2.17; 0.39) 9.61 (2.97; 0.54) 9.62 (2.86; 0.52) 
10 JH 4.50 (2.39; 0.43) 11.53 (2.76; 0.50) 8.99 (2.78; 0.50) 7.47 (1.72; 0.31) 7.24 (1.49; 0.27) 7.04 (2.58; 0.47) 6.95 (1.51; 0.27) 
13 PO 6.53 (2.28; 0.41) 14.35 (4.22; 0.77) 13.61 (2.25; 0.41) 13.18 (1.94; 0.35) 12.67 (1.28; 0.23) 11.09 (1.47; 0.27) 10.71 (1.81; 0.33) 
14 MM 5.05 (2.39; 0.43) 12.13 (3.13; 0.57) 10.20 (2.72; 0.49) 8.31 (2.89; 0.52) 6.48 (2.34; 0.42) 6.95 ()2.5; 0.45 6.09 (2.21; 0.40) 
15 RC1 5.47 (3.28; 0.60) 18.42 (3.2; 0.58) 13.23 (4.14; 0.75) 11.39 (2.91; 0.53) 10.22 (2.41; 0.44) 10.77 (3.11; 0.56) 11.27 (1.99; 0.36) 
16 RC2 5.47 (3.02; 0.55) 12.67 (3.64; 0.66) 9.93 (3.2; 0.58) 8.29 (2.79; 0.51) 8.15 (1.91; 0.34) 7.30 (2.27; 0.41) 8.16 (2.04; 0.37) 
17 JT 4.57 (9.36; 1.71) 10.70 (3.84; 0.70) 8.34 (2.78; 0.50) 7.53 (2.47; 0.45) 6.79 (2.29; 0.41) 5.87 (2.11; 0.38) 6.12 (1.64; 0.29) 
TM – Tail moment; SD – Standard Deviation; SE – Standard error 
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Table 4.10: Changes in mean DNA tail moments of rectal cancer cell DNA 
at “pre-treatment stage” after exposure to 15Gy ex-vivo irradiation 
Time Points 
(min) 
Mean TM [μm] (SD; 
SE) 
Mean 
Percentage 
Change 
Statistical difference in 
mean TM between 
control and specific 
time points* 
Control 5.82 (2.52; 0.69)   
0 14.70 (3.71; 1.03) +169% 0.001 
15 11.50 (3.30; 0.91) +107% 0.001 
30 9.87 (2.39; 0.88) +81% 0.001 
45 9.50 (2.78; 0.77) +76% 0.001 
60 8.94 (2.56; 0.71) +65% 0.002 
120 8.51(2.60; 0.72) +58% 0.006 
Statistical 
difference in 
mean TM from 
time ‘0’ min to 
‘120’ min 
<0.001** 
 
 
TM – Tail moment; SD – Standard Deviation; SE – Standard error; Statistical Tests: Shapiro-
Wilk test of normality; *Wilcoxon signed ranked test; Friedman Test** ; p – statistical 
significance of <0.05 
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Figure 4.5: Box plot graph showing serial tail moments of rectal cancer 
DNA at “pre-treatment stage” after exposure to 15Gy ex-vivo irradiation 
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Table 4.11: Percentage change in DNA Tail Moment (DNA repair) of rectal 
cancer cells at “pre-treatment stage” after exposure to 15Gy ex vivo 
irradiation  
Code 
Baseline 
TM [μm] 
Percentage change in TM [μm] at serial time-points after exposure 
to 15 Gy ex vivo irradiation 
Control 0 (min) 15 (min) 30 (min) 45 (min) 60 (min) 120 (min) 
2 DG 4.44 
15.80  
(+255%) 
12.21  
(+175%) 
12.51  
(+182%) 
13.88  
(+213%) 
13.16  
(+196%) 
12.77  
(+187%) 
4 AH 5.50 
11.18 
(+103%) 
7.13 
(+30%) 
8.80 
(+60%) 
8.70 
(+58%) 
9.68 
(+76%) 
8.31 
(+51%) 
5 KB 13.92 
24.46 
(+76%) 
20.01 
(+44%) 
14.67 
(+5%) 
14.70 
(+5.6%) 
13.49 
(-3.09%) 
12.61 
(-9.41%) 
6 ED 6.72 
15.64 
(+133%) 
12.70 
(+89%) 
9.14 
(+36%) 
9.04 
(+35%) 
7.33 
(+9%) 
6.22 
(-7.44%) 
7 AF 3.81 
11.58 
(+204%) 
8.83 
(+132%) 
7.12 
(+87%) 
5.39 
(+41%) 
4.96 
(+30%) 
4.07 
(+7%) 
8 JN 6.23 
17.73 
(+185%) 
14.64 
(+135%) 
11.66 
(+87%) 
9.16 
(+47%) 
8.99 
(+44%) 
7.80 
(+25%) 
9 SD 3.51 
14.94 
(+326%) 
9.70 
(+176%) 
8.28 
(+136%) 
11.18 
(+219%) 
9.61 
(+174%) 
9.62 
(+174%) 
10 JH 4.50 
11.53 
(+156%) 
8.99 
(+100%) 
7.47 
(+66%) 
7.24 
(+61%) 
7.04 
(+56%) 
6.95 
(+54%) 
13 PO 6.53 
14.35 
(+120%) 
13.61 
(+108%) 
13.18 
(+102%) 
12.67 
(+94%) 
11.09 
(+70%) 
10.71 
(+64%) 
14 MM 5.05 
12.13 
(+140%) 
10.20 
(+102%) 
8.31 
(+65%) 
6.48 
(+28%) 
6.95 
(+38%) 
6.09 
(+21%) 
15 RC1 5.47 
18.42 
(+237%) 
13.23 
(+142%) 
11.39 
(+108%) 
10.22 
(+87%) 
10.77 
(+97%) 
11.27 
(+106%) 
16 RC2 5.47 
12.67 
(+132%) 
9.93 
(+82%) 
8.29 
(+52%) 
8.15 
(+49%) 
7.30 
(+33%) 
8.16 
(+49%) 
17 JT 4.57 
10.70 
(+134%) 
8.34 
(+82%) 
7.53 
(+65%) 
6.79 
(+49%) 
5.87 
(+28%) 
6.12 
(+34%) 
DNA TM – Tail moment 
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Figure 4.6: Bar chart showing percentage changes in DNA tail moment of rectal cancer cell at “pre-treatment stage” after 
exposure to 15Gy ex-vivo irradiation – individual cases 
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4.3.7.2 Rectal cancer cells harvested at “post-NCRT stage”  
The descriptive measurements of tail moments from timed comet assay DNA 
repair analysis are given in table 4.12 and the cumulative statistical analysis is 
shown in table 4.13 and figure 4.7. The percentage changes in DNA tail 
moments after 15Gy ex vivo irradiation is shown in table 4.14 and figure 4.8. 
There is augmented damage to DNA after irradiation in rectal cancer cells 
retrieved after long course NCRT (mean TM=6.93μm for control versus mean 
TM=14.25μm at ‘0’ mins, a 206% increase, p 0.003; see table 4.13). A sharp 
decline in DNA tail moments (DNA repair) is seen only until 45 minutes, 
followed by a limited change (see table 4.13 and figure 4.7). Despite a drop in 
TM values after irradiation, there is persisted statically significant difference 
between control and DNA repair by 120 minutes (mean TM= 6.93μm for control 
versus mean TM=9.48μm at ‘120mins’, p 0.02; see table 4.13 and figure 4.7). 
The poor DNA repair is obvious in patient 1 and the persistent elevated TM 
values appear as outlier in box plot graph (see figure 4.7). 
The slow decline in percentage change of DNA tail moment after irradiation 
further shows a low potential of DNA repair in rectal cancer cell at this stage of 
treatment (see table 4.14 and figure 4.8).  
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Table 4.12: Changes in DNA tail moment (DNA repair) of rectal cancer cells at “post-NCRT stage” after exposure to 15Gy ex 
vivo irradiation  
Codes 
Baseline TM TM at serial time points after exposure to 15Gy ex vivo irradiation 
Control 0 (min) 15 (min) 30 (min) 45 (min) 60 (min) 120 (min) 
TM [μm] (SD; SE) TM [μm] (SD; SE) TM [μm] (SD; SE) TM [μm] (SD; SE) TM [μm] (SD; SE) TM [μm] (SD; SE) TM [μm] (SD; SE) 
2 DG 6.90 (2.4; 0.43) 15 (2.35; 0.43) 17.26 (3.73; 0.68) 14.73 (3.82; 0.70) 13.68 (1.99; 0.37) 14.22 (2.54; 0.46) 14.51(3.63; 0.66) 
4 AH 5.57 (2.52; 0.46) 23.12 (36.12; 6.6) 15.36 (4.92; 0.89) 12.75 (4.97; 0.90) 10.92 (3.99; 0.72) 8.82 (2.42; 0.44) 7.16 (3.59; 0.65) 
5 KB - - - - - - - 
6 ED 7.03 (2.84; 0.52) 11.47 (3.54; 0.64) 11.02 (2.0; 0.36)  10.78 (2.32; 0.42) 10.18 (2.63; 0.48) 9.52 (2.06; 0.37) 8.88 (2.31; 0,42) 
7 AF 3.90 (2.62; 0.47) 14.09 (4.06; 0.74) 11.20 (2.74; 0.50) 10.68 (3.64; 0.66) 9.39 (3.81; 0.69) 8.85 (2.53; 0.46) 8.84 (2.31; 0.42) 
8 JN 7.46 (4.06; 0.74) 13.88 (5.09;x) 11.81 (5.17; 0.94) 10.70 (3.7; 0.67) 9.80 (2.79; 0.50) 9.09 (3.66; 0.67) 10.02 (2.39;0.43) 
9 SD 9.50 (2.56; 0.46) 11.52 (2.58; 0.47) 11.06 (1.66; 0.30) 10.08 (3.06; 0.55) 9.98 (2.59; 0.47) 9.79 (2.23; 0.40) 9.85 (2.85; 0.52) 
10 JH 7.38 (1.55; 0.28) 14.78 (2.16; 0.39) 12.21 (1.96; 0.35) 12.46 (2.27; 0.41) 11.57 (2.59; 0.47) 11.94 (1.9; 0.34) 11.89 (2.41; 0.44) 
13 PO 7.77 (2.82; 0.51) 13.73 (2.74; 0.50) 12.94 (1.94; 0.35) 10.92 (.85; 0.33) 10.70 (1.80; 0.32) 10.05 (2.35; 0.41) 9.88 (2.33; 0.42) 
14 MM 9.32 (3.56; 0.65) 13.26 (3.01; 0.54) 12.43 (2.41; 0.44) 10.69 (2.48; 0.45) 10.69 (3.17; 0.57) 12.05 (3.0; 0.54) 10.10 (5.41; 0.98) 
15 RC1 8.15 (2.47; 0.45) 15.15 (5.05; 0.92) 17.19 (3.63; 0.59) 11.51 (3.24; 0.59) 11.72 (5.81; 1.06) 12.58 (4.26; 0.77) 5.54 (2.77; 0.50) 
16 RC2 - - - - - - - 
17 JT 3.31 (2.77; 0.50) 10.85 (2.23; 0.40) 7.56 (2.61; 0.47) 7.03 (2.86; 0.52) 6.44 (2.64; 0.48) 6.18 (2.95; 0.53) 7.65 (2.53; 0.46) 
TM – Tail moment; SD – Standard Deviation; SE – Standard error; x – results not available 
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Table 4.13: Changes in mean DNA tail moments of rectal cancer cell DNA 
at “post-NCRT stage” after exposure to 15Gy ex-vivo irradiation 
Time Points 
(min) 
Mean TM [μm] (SD; 
SE) 
Mean 
Percentage 
Change 
Statistical difference in 
TM between control and 
specific time points* 
Control 6.93 (1.88; 0.56)   
0 14.25 (3.14; 0.94) 106% 0.003 
15 12.52 (2.48; 0.74) 81% 0.003 
30 11.12 (1.81; 0.54) 60% 0.003 
45 10.46 (1.69; 0.51) 51% 0.003 
60 10.28 (2.13; 0.64) 48% 0.003 
120 9.48 (2.10; 0.63) 42% 0.021 
Statistical 
difference in 
TM from time 
‘0’ min to ‘120’ 
min 
<0.001** 
 
 
TM – Tail moment; SD – Standard Deviation; SE – Standard error ; Statistical Tests: Shapiro-
Wilk test of normality; Wilcoxon signed ranked test; Friedman Test** ; p – statistical 
significance of <0.05 
  
 CHAPTER 4: DNA REPAIR ANALYSIS  
 
148 
Figure 4.7: Box plot graph showing serial tail moments of rectal cancer 
DNA at “post-NCRT stage” after exposure to 15Gy ex-vivo irradiation 
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Table 4.14: Percentage change in DNA Tail Moment (DNA repair) of rectal 
cancer cells at “post-NCRT stage” after exposure to 15Gy ex vivo 
irradiation 
Codes 
Baseline 
TM [μm] 
Percentage change in TM [μm] at serial time-points after exposure 
to 15Gy ex vivo irradiation 
Control 0 (min) 15 (min) 30 (min) 45 (min) 60 (min) 120 (min) 
2 DG 6.90 
15 
(+117%) 
17.26 
(+116%) 
14.73 
(+113%) 
13.68 
(+98%) 
14.22 
(+106%) 
14.51 
(+110%) 
4 AH 5.57 
23.12 
(+315%) 
15.36 
(+176%) 
12.75 
(+129%) 
10.92 
(+96%) 
8.82 
(+58%) 
7.16 
(+29%) 
5 KB - - - - - - - 
6 ED 7.03 
11.47 
(+63%) 
11.02 
(+57%) 
10.78 
(+53%) 
10.18 
(+45%) 
9.52 
(+35%) 
8.88 
(+26%) 
7 AF 3.90 
14.09 
(+261%) 
11.20 
(+187%) 
10.68 
(+174%) 
9.39 
(+141%) 
8.85 
(+127%) 
8.84 
(+127%) 
8 JN 7.46 
13.88 
(+86%) 
11.81 
(+58%) 
10.70 
(+43%) 
9.80 
(+31%) 
9.09 
(+22%) 
10.02* 
(+34%) 
9 SD 9.50 
11.52 
(+21%) 
11.06 
(+16%) 
10.08 
(+6%) 
9.98 
(+5%) 
9.79 
(+3%) 
9.85 
(+3.68%) 
10 JH 7.38 
14.78 
(+100%) 
12.21 
(+65%) 
12.46 
(+67%) 
11.57 
(+57%) 
11.94 
(+62%) 
11.89 
(+61%) 
13 PO 7.77 
13.73 
(+77%) 
12.94 
(+66%) 
10.92 
(+40%) 
10.70 
(+38%) 
10.05 
(+29%) 
9.88 
(+27%) 
14 MM 9.32 
13.26 
(+42%) 
12.43 
(+33%) 
10.69 
(+15%) 
10.69 
(+15%) 
12.05 
(+29%) 
10.10 
(+8.37%) 
15 RC1 8.15 
15.15 
(+86%) 
17.19 
(+111%) 
11.51 
(+41%) 
11.72 
(+44%) 
12.58 
(+54%) 
5.54* 
(-32%) 
16 RC2 - - - - - - - 
17 JT 3.31 
10.85 
(+228%) 
7.56 
(+128%) 
7.03 
(+112%) 
6.44 
(+94%) 
6.18 
(+87%) 
7.65 
(+131%) 
TM – Tail moment 
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Figure 4.8: Bar chart showing percentage changes in DNA tail moment of rectal cancer cell at “post-NCRT stage” after 
exposure to 15Gy ex-vivo irradiation – individual cases 
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4.3.7.3 Rectal cancer cells harvested at “pre-operative stage”  
The descriptive measurements of tail moments from timed comet assay DNA 
repair analysis are given in table 4.15 and the cumulative statistical analysis is 
shown in table 4.16 and figure 4.9. The percentage changes in DNA tail 
moments after 15Gy ex vivo irradiation is shown in table 4.17 and figure 4.10. 
The tumour cells harvested before surgery showed severe damage after 
exposure to ex-vivo irradiation (TM = 5.6μm in control versus 13.59μm 
immediately after irradiation). There was active repair following irradiation with a 
decrease in tail moment of statistical significance (p 0.001), however, at 120 
minutes the DNA damage remained significant as compared to the baseline 
value (p 0.028). Patient 1 appears as outlier in figure 4.16, however, there is 
good DNA repair in this patient albeit relatively higher TM values. This is in 
contrast to biopsy samples from the same patient at “post-NCRT stage” when 
there was obvious poor DNA repair (see figure 4.7). Patient 12 has overall poor 
DNA repair seen as poor decline in TM after 15 minutes (see tables 4.15 and 
4.17) which is also demonstrated by lack of percentage decline in figure 4.10. 
 CHAPTER 4: DNA REPAIR ANALYSIS  
 
152 
Table 4.15: Changes in DNA tail moment (DNA repair) of rectal cancer cells at “pre-operative stage” after exposure to 15Gy ex 
vivo irradiation 
Codes 
Baseline TM [μm] TM [μm] at serial time points after exposure to 15 Gy ex vivo irradiation 
Control 0 (min) 15 (min) 30 (min) 45 (min) 60 (min) 120 (min) 
TM [μm] (SD; SE) TM [μm] (SD; SE) TM [μm] (SD; SE) TM [μm] (SD; SE) TM [μm] (SD; SE) TM [μm] (SD; SE) TM [μm] (SD; SE) 
2 DG 11.23 (7.69; 1.4) 23.27 (3.63; 0.66) 20.74 (3.97; 0.70) 19.21 (4.71; 0.85) 16.65 (3.24; 0.59) 13.22 (3.1; 0.56) 11.32 (2.54; 0.46) 
4 AH 4.41 (1.91; 0.34) 14.65 (2.98; 0.54) 10.76 (4.12; 0.75) 10.08 (3.79; 0.69) 9.15 (2.6; 0.47) 8.57 (2.45; 0.44) 7.28 (1.83; 0.33) 
5 KB 7.25 (4.12; 0.75) 12.23 (2.59; 0.47) 11.37 (2.47; 0.45) 10.86 (1.81; 0.33) 9.67 (1.47; 0.26) 9.46 (2.11; 0.38) 7.98 (2.11; 0.38) 
6 ED - - - - - - - 
7 AF - - - - - - - 
8 JN - - - - - - - 
9 SD - - - - - - - 
10 JH - - - - - - - 
13 PO - - - - - - - 
14 MM - - - - - - - 
15 RC1 3.49 (1.84; 0.33) 12.91 (3.55; 0.64) 9.93 (3.16; 0.57) 8.82 (2.02; 0.37) 8.49 (2.39; 0.43) 7.91 (3.21; 0.58) 8.07 (1.76; 0.32) 
16 RC2 3.76 (2.45; 0.44) 6.07 (3.16; 0.57) 4.89 (3.38; 0.61) 4.64 (2.63; 0.48) 4.09 (2.97; 0.54) 5.51 (2.67; 0.48) 4.99 (2.85; 0.52) 
17 JT 3.91 (1.73; 0.31) 12.42 (2.73; 0.49) 12.93 (2.76; 0.50) 12.59 (5.46; 0.99) 12.02 (4.78; 0.87) 9.61 (4.99; 0.91) 9.39 (3.48; 0.63) 
TM – Tail moment; SD – Standard Deviation; SE – Standard error 
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Table 4.16: Changes in mean DNA tail moments of rectal cancer cell DNA 
at “pre-operative stage” after exposure to 15Gy ex-vivo irradiation 
Time Points 
(min) 
Mean TM [μm] (SD; 
SE) 
Mean 
Percentage 
Change 
Statistical difference in 
TM between control and 
specific time points* 
Control 5.67 (2.78;1.13)   
0 13.59 (5.08; 2.07) +139% 0.028 
15 11.77 (4.72; 1.92) +107% 0.028 
30 11.03 (4.39; 1.79) +94% 0.028 
45 9.98 (3.7; 1.53) +76% 0.028 
60 9.04 (2.30; 0.94) +59% 0.028 
120 8.17 (1.93; 078) +44% 0.028 
Statistical 
difference in 
TM from time 
‘0’ min to ‘120’ 
min 
0.001** 
 
 
TM – Tail moment; SD – Standard Deviation; SE – Standard error; Statistical Tests: Shapiro-
Wilk test of normality; Wilcoxon signed ranked test; Friedman Test** ; p – statistical 
significance of <0.05 
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Figure 4.9: Box plot graph showing serial tail moments of rectal cancer 
DNA at “pre-operative stage” after exposure to 15Gy ex-vivo irradiation  
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Table 4.17: Percentage change in DNA Tail Moment (DNA repair) of rectal 
cancer cells at “pre-treatment stage” after exposure to 15Gy ex vivo 
irradiation 
Codes 
Baseline 
TM [μm] 
Percentage change in TM [μm] at serial time-points after exposure 
to 15Gy ex vivo irradiation 
Control 0 (min) 15 (min) 30 (min) 45 (min) 60 (min) 120 (min) 
2 DG 11.23 
23.27 
(+107%) 
20.74 
(+85%) 
19.21 
(+71%) 
16.50 
(+47%) 
13.22 
(+18%) 
11.32 
(+0.8%) 
4 AH 4.41 
14.65 
(+232%) 
10.76 
(+144%) 
10.08 
(+129%) 
9.15 
(+107%) 
8.57 
(+94%) 
7.28 
(+65%) 
5 KB 7.25 
12.23 
(+69%) 
11.37 
(+57%) 
10.86 
(+50%) 
9.67 
(+33%) 
9.46 
(+30%) 
7.98 
(+10%) 
6 ED - - - - - - - 
7 AF - - - - - - - 
8 JN - - - - - - - 
9 SD - - - - - - - 
10 JH - - - - - - - 
13 PO - - - - - - - 
14 MM - - - - - - - 
15 RC1 3.49 
12.91 
(+270%) 
9.93 
(+184%) 
8.82 
(+153%) 
8.49 
(+143%) 
7.91 
(+127%) 
8.07 
(+131%) 
16 RC2 3.76 
6.07 
(+61%) 
4.89 
(+30%) 
4.64 
(+23%) 
4.09 
(+9%) 
5.51 
(+47%) 
4.99 
(+33%) 
17 JT 3.91 
12.42 
(+218%) 
12.93 
(+231%) 
12.59 
(+222%) 
12.02 
(+207%) 
9.61 
(+146%) 
9.39 
(+140%) 
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Figure 4.10: Bar chart showing percentage changes in DNA tail moment of rectal cancer cell at “pre-operative stage” after 
exposure to 15Gy ex-vivo irradiation – individual cases 
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4.3.8 Comparison of DNA repair potential between rectal cancer 
cells harvested at serial time-points 
The DNA repair potential of rectal cancer cells harvested at three serial time-
point is given in table 4.18 and figure 4.11; statistical analysis in table 4.19. The 
percentage changes are given in table 4.20 and figure 4.12.  
As expected, the maximum change of mean TM occurs immediately after 
exposure to ex-vivo irradiation. Thereafter, the mean TM decreased in the 
following 120 minutes, corresponding with cell DNA repair properties. The 
tumour cells harvested immediately after NCRT (T1 time-point) show relatively 
impaired DNA repair as compared to those harvested at other time points: the 
difference in mean TM between T0 and T1 tumour cells is close to and reaches 
statistical significance for timed assay at 30 and 60 minutes, whilst, there is no 
statistical significant difference in mean TM between T0 and T2 tumour cells for 
any timed assay (see table 4.19).  
Comparative percentage changes shows similar pattern of DNA repair over time 
for rectal cancer cells harvested at different time points (see table 4.20 and 
figure 4.12) 
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Table 4.18: Changes in mean tail moments following ex-vivo irradiation in 
rectal cancer cells harvested at serial time-points 
Timing 
of assay 
(min) 
Pre-treatment 
Mean TM [μm]  
(SD; SE) 
Post-NCRT 
Mean TM [μm] 
(SD; SE) 
Pre-Operative 
Mean TM [μm] 
(SD; SE) 
Control 5.82 (2.52; 0.69) 6.93 (1.88; 0.56) 5.67 (2.78;1.13) 
0 14.70 (3.71; 1.03) 14.25 (3.14; 0.94) 13.59 (5.08; 2.07) 
15 11.50 (3.30; 0.91) 12.52 (2.48; 0.74) 11.77 (4.72; 1.92) 
30 9.87 (2.39; 0.88) 11.12 (1.81; 0.54) 11.03 (4.39; 1.79) 
45 9.50 (2.78; 0.77) 10.46 (1.69; 0.51) 9.98 (3.7; 1.53) 
60 8.94 (2.56; 0.71) 10.28 (2.13; 0.64) 9.04 (2.30; 0.94) 
120 8.51(2.60; 0.72) 9.48 (2.10; 0.63) 8.17 (1.93; 078) 
T (subscript) – timing of biopsy (serial number) 
 
Table 4.19: Comparison of DNA repair profiles (difference in mean tail 
moments) following ex-vivo irradiation in rectal cancer cells harvested at 
serial time points 
Timing of 
Assay 
T0 vs T1 T0 vs T2 
n Mean TM [μm] p n Mean TM [μm] p 
0 11 14.00 14.25 0.59 6 15.53 13.59 0.60 
15 11 10.87 12.52 0.11 6 11.80 11.77 0.91 
30 11 9.58 11.12 0.06 6 10.53 11.03 0.73 
45 11 9.15 10.46 0.11 6 10.40 9.98 0.91 
60 11 8.67 10.28 0.03 6 10.04 9.04 0.34 
120 11 8.17 9.48 0.13 6 9.87 8.17 0.24 
T (subscript) – timing of biopsy (serial number); n – number of patients included in 
analysis; Statistical Tests: Shapiro-Wilk test of normality; Wilcoxon signed ranked test; 
Friedman Test** ; p – statistical significance of <0.05 
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Figure 4.11: Comparison of mean TM (timed DNA repair) of rectal cancer cells harvested at different time-points after exposure 
to 15Gy ex-vivo irradiation 
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Table 4.20: Percentage change in mean tail moment 
Timing of 
assay 
(min) 
Pre-treatment 
Mean TM [μm]  
(percentage 
change) 
Post-NCRT 
Mean TM [μm] 
(percentage 
change) 
Pre-Operative 
Mean TM [μm] 
(percentage 
change) 
Control 5.82 6.93 5.67 
0 14.70 (+152%) 14.25 (+106%) 13.59 (+139%) 
15 11.50 (+97%) 12.52 (+81%) 11.77 (+107%) 
30 9.87 (+69%) 11.12 (+60%) 11.03 (+94%) 
45 9.50 (+53%) 10.46 (+51%) 9.98 (+76%) 
60 8.94 (+54%) 10.28 (+48%) 9.04 (+59%) 
120 8.51 (+46%) 9.48 (+37%) 8.17 (+44%) 
T (subscript) – timing of biopsy (serial number) 
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Figure 4.12: Comparison of percentage DNA repair of rectal cancer cells harvested at serial time-points after exposure to 15Gy 
ex-vivo irradiation 
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4.3.9 Complete DNA repair in rectal cancer cells within 120 minutes 
after exposure to ex-vivo 15Gy irradiation 
Patients who achieved complete DNA repair within 120 minutes after exposure 
to ex-vivo 15Gy irradiation are shown in table 4.21. For rectal cancer cells 
harvested at pre-treatment stage, 5/13 (38%) showed completed repair; for 
rectal cancer cells harvested at post-NCRT stage, 3/11(27%) showed complete 
repair and for rectal cancer cells harvested at pre-operative stage (median 
interval 11 weeks after NCRT), 4/6 (66%) showed complete repair.  
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Table 4.21: Complete DNA repair in rectal cancer cells within 120 minutes 
after exposure to ex-vivo 15Gy irradiation 
Codes Pre-treatment 
mean TM [μm]  
Post-NCRT 
mean TM [μm]  
Pre-Operative 
mean TM [μm]  
Mean 
(95% CI) 
5.82 
(4.4 – 7.25) 
6.94 
(5.77 – 8.10) 
5.68 
(3.23 – 8.12) 
2 DG 12.77 14.51 11.32 
4 AH 8.31 7.16 7.28 
5 KB 12.61 - 7.98 
6 ED 6.22 8.88 - 
7 AF 4.07 8.84 - 
8 JN 7.80 10.02 - 
9 SD 9.62 9.85 - 
10 JH 6.95 11.89 - 
13 PO 10.71 9.88 - 
14 MM 6.09 10.10 - 
15 RC1 11.27 5.54 8.07 
16 RC2 8.16 - 4.99 
17 JT 6.12 7.65 9.39 
Values compared with baseline values and their 95% confidence interval; Bold – complete 
repair; CI – confidence interval 
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4.3.10 Rectal cancer DNA repair profiles and clinical response to 
NCRT 
A descriptive summary of DNA repair profiles for responders and non-
responders to NCRT is given in table 4.22. For patients that showed response 
after NCRT (RECIST criteria; n= 9): 5 (62%) had impaired DNA repair profile at 
pre-treatment stage whilst 3 (37.5%) patients showed intact DNA repair. 
Similarly, for patients that showed no response after NCRT (n=5): only 2 (40%) 
patients showed intact DNA repair profiles. During the interval between NCRT 
and surgery, for the 8 post-NCRT partial responders (RECIST criteria): one 
patient (12.5%) achieved complete pathological response, five patients (62.5%) 
continued to have partial response and two patient (25%) had stable disease at 
surgery; whereas, for the 5 post-NCRT stable disease patients: one patient 
(20%) developed complete response, two (40%) patients developed partial 
response and only one patient (20%) remained in stable disease at the time of 
surgery.  There was impaired DNA repair after NCRT for one patient (50%) with 
complete response, 5 (71%) patients who remained in partial response and 1 
(33%) with stable disease. The DNA repair analysis for the pre-operative 
specimen (n=5) showed that all three responders and one non-responder (TNM 
and RECIST criteria) had intact DNA repair pathways.  
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Table 4.22: DNA repair profiles and clinical response to NCRT 
Code Staging RECIST  DNA Repair profiles 
cTNM ypTNM Post-NCRT Pre-Operative Pre-
Treatment 
Post-
NCRT 
Pre-
Operative 
2 DG T3N1 T3N1 PR SD X X X 
4 AH T3N2 T2N1 SD SD X ✓ ✓ 
5 KB T3N1 T2N0 SD PR X - ✓ 
6 ED T3N1 T1N0 PR PR ✓ X - 
7 AF T3N1 T2N0 PR PR ✓ X - 
8 JN T3N2 T2N0 PR PR X X - 
9 SD T3N1 - SD - X X - 
10 JH T3N0 T3N0 SD PR ✓ X - 
13 PO T3N2 T3N2 PR PR X X - 
14 MM T4N0 - SD CR* ✓ X - 
15 RC1 T3N1 T2N0 PR PR X ✓ ✓ 
16 RC2 T3N1 T0N0 PR CR X - ✓ 
17 JT T3N1 T3N0 PR SD ✓ ✓ - 
‘✓’ – complete DNA repair; ‘X’ – impaired DNA repair; * complete response on imaging only; PR 
– Partial response; SD – stable disease; CR – complete response 
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4.3.11 Relations between DNA repair properties and 
clinicopathological characteristic, response to NCRT and long-
term outcomes 
The correlation between DNA repair property of rectal cancer cells harvested at 
different time-points and clinical features is given in tables 4.23–4.26. In 
general, there were non-significant negative correlations between cancer cell 
repair and poor clinical markers. Rectal cancer cells harvested at pre-treatment 
stage with the ability to repair DNA damage secondary to irradiation showed 
less aggressive nodal spread. Rectal cancer cells harvested at pre-operative 
stage with the ability to repair DNA damage secondary to irradiation had large 
craniocaudal tumour length but did not show higher pathological T-stage. There 
were no correlations between DNA repair properties and response to treatment 
or long-term outcomes. 
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Table 4.23: Correlation analysis between DNA repair pattern and clinic-pathological features, response to NCRT and long-term 
outcomes  
Repair 
Pattern 
Clinicopathological Features Response to NCRT Long-term Outcomes 
cT cN pT pN cL nL pL T N pCR nRECIST LR DM Death 
T0 
ρ  0.365 -0.60 -0.05 -0.48 -0.02 -0.27 -0.37 -0.15 0.18 0.10 -0.02 -0.22 -0.05 -0.18 
p 0.22 0.02 0.87 0.11 0.94 0.36 0.23 0.60 0.54 0.74 0.93 0.45 0.85 0.54 
T1 
ρ / r -0.19 0.21 0.081 0 -0.19 0.03 0.30 0.03 0.46 -0.19 0.039 -0.19 -0.37 -0.37 
p 0.56 0.52 0.82  0.56 0.92 0.38 0.91 0.15 0.56 0.91 0.56 0.25 0.25 
T2 
ρ / r 0 0.31 -0.89 -0.25 0.52 0.82 -0.52 0 0.63 0.31 -0.50 0 -0.63 -0.25 
p  0.54 0.01 0.63 0.28 0.04 0.28  0.17 0.54 0.31  0.17 0.63 
‘+’ positive correlation; ‘-’  negative correlation; prefix ‘c’ –Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; suffix ‘’ – downstage; T – TNM T-
stage; N – TNM N-stage; L – craniocaudal tumour length; RECIST – response evaluation criteria in solid tumours; CR – complete response; LR – local 
recurrence; DM – Distant metastasis; Statistical test – Shapiro-Wilk test for normality; Spearman rho correlation analysis (ρ) non-parametric data, p – 
significant value at 0.05 
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Table 4.24: Difference in mean multiparametric values according to clinical features 
Repair 
Pattern 
cT cN pT pN 
cT2 cT3 cT4 p cN0 cN1 cN2 p pT0 pT1 pT2 pT3 p pN0 pN1 p 
T0 
No 0 8 0 
0.38* 
0 5 3 
0.03 
1 0 4 2 
0.75 
4 3 
0.13 
Yes 0 4 1 2 3 0 1 1 1 2 5 0 
 
T1 
No 0 7 1 
0.72* 
2 4 2 
0.488 
1 1 2 3 
0.53 
5 2 
0.58 
Yes 0 3 0 0 2 1 0 0 2 1 2 1 
 
T2 
No 0 2 0 
* 
0 2 0 
0.66* 
0 0 0 2 
0.11 
1 1 
0.60 
Yes 0 4 0 0 3 1 1 0 3 0 3 1 
prefix ‘c’ –Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; suffix ‘’ – downstage; T – TNM T-stage; N – TNM N-stage; L – craniocaudal 
tumour length; RECIST – response evaluation criteria in solid tumours; CR – complete response; LR – local recurrence; DM – Distant metastasis; 
Statistical test – Chi Square/ Fisher exact test* 
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Table 4.25: Difference in mean multiparametric values according to response to NCRT 
Repair 
Pattern 
T- downstaging N-downstaging Post-NCRT RECIST Post-Operative NCRT 
T T p N N p PR SD p CR PR SD p 
T0 
No 6 2 
0.51* 
5 3 
0.49* 
3 5 
0.68* 
1 4 2 
0.92 
Yes 3 2 4 1 2 3 1 3 1 
 
T1 
No 5 3 
0.72* 
4 4 
0.21* 
5 3 
0.72* 
1 5 1 
0.22 
Yes 2 1 3 0 2 1 0 1 2 
 
T2 
No 0 2 
0.067* 
1 1 
0.33 
2 0 
0.40 
0 0 2 
0.15 
Yes 4 0 4 0 2 2 1 2 1 
prefix ‘c’ –Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; suffix ‘’ – downstage; T – TNM T-stage; N – TNM N-stage; L – 
craniocaudal tumour length; RECIST – response evaluation criteria in solid tumours; CR – complete response; LR – local recurrence; DM 
– Distant metastasis; Statistical test – Chi Square/ Fisher exact test* 
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Table 4.26: Difference in mean multiparametric values according to long-term outcomes 
Repair 
Pattern 
Local Recurrence Distant Metastasis Survival 
Yes No p Yes No p Yes No p 
T0 
No 1 7 
0.61* 
2 6 
0.68* 
5 3 
0.49 
Yes 0 5 1 4 4 1 
 
T1 
No 1 7 
0.72 
3 5 
0.33 
5 3 
0.33 
Yes 0 3 0 3 3 0 
 
T2 
No 0 2 
.* 
1 1 
0.33 
1 1 
0.60 
Yes 0 4 0 4 3 1 
prefix ‘c’ –Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; suffix ‘’ – downstage; T – TNM 
T-stage; N – TNM N-stage; L – craniocaudal tumour length; RECIST – response evaluation criteria 
in solid tumours; CR – complete response; LR – local recurrence; DM – Distant metastasis; 
Statistical test – Chi Square/ Fisher exact test* 
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4.4 Discussion 
This series of experiments represents the first study on the application of the 
comet assay on tumour cells harvested from fresh rectal cancer tissue 
measuring DNA damage and repair profiles against clinicopathological markers 
and long-term outcomes. The findings show a degree of baseline DNA damage 
in untreated rectal cancer (mean TM=5.82) that shows good repair in response 
to ex-vivo irradiation. Until at least six weeks after long course NCRT, DNA 
showed persistent damage (long tail moment) and the additional DNA damage 
induced by ex-vivo irradiation was more enhanced with impaired DNA repair 
properties; thereafter, at the time of operation, the DNA damage to ex-vivo 
irradiation and its repair were comparable to pre-treatment tumour cells.   
The cytoreductive effects of radiotherapy results by the production of a variety 
of ionizing radiation-induced lesions in DNA, including DNA single strand 
breaks, double strand breaks, DNA base alterations, and DNA terminal growth 
arrest senescence [427]. The DNA lesion instigates a cascade of pro- and anti- 
apoptotic pathways that leads to programmed cell death [428]. There is also 
emerging evidence, suggesting generation of anti-tumour immune response 
after expression of tumoural antigens in response to radiotherapy that 
augments cytoreduction [429].  The efficacy of radiotherapy is mainly 
dependent on tissue oxygenation levels and radiosensitivity of tumour cells. 
Radiotherapy works by generating oxygen radicals capable of causing damage 
to DNA and at low partial pressures of oxygen (<10 mmHg), tumour cells are 3 
times more radioresistant than in well oxygenated state (radiobiologic hypoxia) 
[430]. The radiosensitivity of cells depends on several factors. Certain genetic 
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characteristics or mutations in the DNA and/or DNA repair pathways within 
tumour cells dictate their radiosensitivity, for example, rectal cancers with 
mutant p53 genotype were shown to resist tumour down-staging after 
radiotherapy [431]. The radiosensitivity of cells also varies throughout the cell 
cycle; for example, S-phase cells are relatively radioresistant than G1 and G2/M 
cells. There is a predominance of DNA repair pathways during specific cell-
cycle phases with preference for repairing specific DNA lesions, for example, 
there is over-expression of proteins involved in repair pathways for double 
strand breaks (homologous recombination repair pathway), single strand breaks 
repair pathway and mismatch repair pathway during the S and G2/M phase, 
whilst, the same proteins are expressed at low levels in G0-G1 cells; 
alternatively, non-homologous end joining pathway (NHEJ) is operational in all 
phases of cell cycle [427]. Tumour hypoxia has been shown to influence 
expression of DNA repair pathway proteins, for example, chronic hypoxia can 
lead to decreased expression of homologous recombination (HR) repair 
pathway genes, which may decrease the radioresistance [427]. In addition 
acquired radioresistance may also develop with fractionated radiotherapy and 
involves re-population of tumour between radiotherapy fractions [432]. There 
are several mechanisms that are thought to contribute to the acquired 
radioresistance including mutated p53, amplification of DNA repair genes, 
overexpression of the cell-cycle regulator protein, cyclin D1, and activation of 
pro-survival oncogenes such as EGFR [433]. Hence, within a given tumour 
tissue, the radiosensitivity of each cell depends on several internal (e.g. cell 
cycle phase) and external (e.g. tissue blood supply and oxygenation) factors 
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and there are heterogeneous populations of cells with varying sensitivities to 
radiotherapy and the abilities to repair DNA damage [434].  
In the current study, all the tumour cells collected at serial time-points (before 
and after NCRT) from the same tumour tissue showed progressive DNA repair, 
albeit at different rates. The accumulation of DNA damage may contribute to 
carcinogenesis and baseline DNA damage has been reported in studies 
investigating peripheral blood lymphocytes from patients with solid tumours 
[435, 436]. The baseline DNA damage in the pre-treatment rectal cancer cells 
may be due to several reasons: rectal cancer cells may have damaged DNA as 
a result of several oncogenic mutations; the biopsies were typically obtained 
from endoluminal segment of the tumour which mostly consist of peripheral 
tumour tissue with cells under hypoxic conditions resulting in damaged DNA; 
the mechanical process of separating tumour cells from connective tissue for 
single cell suspension may have also resulted in baseline damage. The 
technique of obtaining biopsy and post-processing of single cells was consistent 
for all samples; hence tumour cells from all time-points were comparable.  
After long course NCRT, there was tumour downstaging in 87% patients 
(according to TNM staging; table 4.2) and a decrease in tumour size for 66% 
(10/15) patients (according to RECIST criteria; table 4.3) corresponding to 
elimination of radiosensitive tumour load. The majority of rectal tumours that 
downstaged showed impaired DNA repair properties at the pre-treatment stage 
(60%); interestingly, 40% tumours with intact DNA repair also showed T- 
downstaging. Similarly, only 33% patients without tumour downstaging showed 
intact DNA repair properties. Such findings suggest that in the current cohort, 
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biopsy samples were possibly not representative of the entire tumour cell radio-
sensitivities and support the existence of heterogeneous radiosensitivity within 
rectal cancers. Such heterogeneity in tumour cell population may also explain 
the absence of any correlation between biopsy harvested cell DNA repair 
analysis and clinic-pathological markers. After NCRT, one would expect the 
cells within the residual tumour tissue to represent the radioresistant fraction 
with intact DNA repair pathways; however, the tumour cells harvested after 
NCRT showed greater baseline DNA damage (mean TM = 6.93μm) with 
relatively poor repair profiles (mean TM = 9.48μm at 120 minutes after exposure 
to ex-vivo irradiation). The baseline DNA damage at six weeks after NCRT was 
statistically significantly increased as compared to pre-treatment samples with 
poor DNA repair profiles (section 4.3.7.2; page 149) and may reflect persistent 
effect of irradiation. Therefore, in the case of residual tumour cells obtained at 
six week after NCRT, ionizing radiation induced DNA damage that did not 
culminate in immediate cell death. Such cells may either of the two pathways: (i) 
the cells may be eliminated later during the interval to surgery, or (ii) the cells 
may survive and become resistant to treatment by improving DNA repair 
mechanism and upregulating anti-apoptotic pathways (see figure 4.13). In the 
clinical setting, a study comparing the outcomes of patients with rectal cancer 
patients operated at 4-6 weeks and at 6-8 weeks after NCRT did not find any 
significant difference between two groups in terms of T-downstaging, volume 
reduction rate, complete response rate and long-term outcomes [437]. In 
contrast, two systematic reviews of published trial has shown higher rate of 
pathological complete response in patients undergoing surgical resection at 
longer interval after NCRT but without any impact on surgical complication rates 
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and long-term outcomes [239, 438]. Similarly, in the current study, the majority 
of partial response and stable disease patients (RECIST criteria) at six weeks 
after NCRT showed a progressive response until the time of surgery (11 weeks 
after NCRT) and their tumours comprised of cells with persistent impaired DNA 
repair profiles. A relatively small percentage of patients developed stable 
disease till the time of surgery and their tumours comprised of cells with intact 
DNA repair after NCRT (see section 4.3.6, page 129). Interestingly, the majority 
of tumour cells (80%) harvested at the time of operation also showed intact 
DNA repair properties. Hence, the current analysis confirms the presence of 
truly radioresistant tumour cells within residual tumour tissue at 11 weeks after 
NCRT. Such radioresistance within residual tumour may be intrinsic or acquired 
in response to NCRT. It may be inferred from these results that effects of 
radiotherapy possibly subside between six to eleven weeks after NCRT and the 
optimal time of surgery may lie during this period. 
Figure 4.13: Residual tumour cell survival after radiotherapy 
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The study adds to current literature by showing single cancer cells can be 
harvested from rectal cancer for the assessment of DNA repair by means of 
Comet assays. The study shows rectal cancer DNA damage and repair profiles 
at different stages during treatment timeline and provides critical insight into the 
time period of inhibited DNA repair after NCRT. This pilot study presents the 
first evidence on rectal cancer alterations after NCRT at a molecular level and 
similar studies with larger cohorts may help determine the optimal time of 
interval TME surgery.  
There are some weaknesses in the current study: the results should be inferred 
with care due to small sample size, which decreased further with serial biopsy 
collection. Several suitable patients declined participation in the current study to 
avoid repeated rectal tumour biopsy. The endoluminal harvesting of tumour 
sample is an invasive and uncomfortable procedure especially after radiation-
induced proctalgia and highlights a major pitfall in such study designs that leads 
to low participant recruitment and compliance. Some pre-operative samples 
were deemed non-viable, mainly those collected from the resected specimen 
immediately after surgery: one reason would be a ligation of rectal blood 
vessels at early stages of the surgical procedure with resultant ischaemia and 
tissue death by the time specimen was retrieved. Challenges faced during 
tumour cell preparation for comet assays were twofold: firstly the presence of 
frequent dead cells with debris in collected samples was managed by cell 
viability test (Trypan® blue test) and a lower count of 15 cells per slide was 
undertaken; secondly, biopsy samples contained a mixture of tumour and 
normal epithelial cells which was analysed by consultant histopathologist and 
high presence of tumour cell was confirmed, hence any bias in results caused 
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by normal epithelial cell DNA was minimised. Lastly, no intra- and inter-subject 
variations in TM measurements were established due to the availability of only 
one observer.  
In conclusion, rectal cancer cell populations show heterogeneous 
radiosensitivity and actively repair DNA damage in response to ex-vivo 
irradiation. The cytoreductive effects of the standard fluoropyrimidine based 
long-course NCRT inhibits DNA repair at least until six week after treatment. 
Thereafter, by the 11th week after NCRT, the residual rectal cancer cells mostly 
harbour intact DNA repair abilities.  The results from the current study need to 
be confirmed in a larger sample size. 
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5 CHAPTER 5: MAGNETIC RESONANCE IMAGING 
Multi-parametric analysis of rectal cancer 
pathophysiology  
5.1 Introduction 
The modern MRI scanner provides a range of versatile imaging techniques and 
the simultaneous advances in post processing software has enabled 
assessment of multiple tissue physiological parameters. Each MRI method 
provides specific information on different aspects of tumour pathophysiology; for 
example, ‘diffusion weighted MRI (DW-MRI)’ provides information on tissue 
cellularity, extracellular space tortuosity and the integrity of cellular membranes 
by measuring the random motion of the water molecules in tissue; the ‘dynamic 
contrast enhanced MRI (DCE-MRI)’ method utilises the pharmacodynamics 
properties of low-molecular weight contrast agents to provide information about 
tissue blood volume and perfusion, microvessel permeability and the 
extracellular space; and, the intrinsic susceptibility MRI (ISW-MRI) utilises the 
paramagnetic property of deoxygenated haemoglobin to establish tissue 
oxygenation levels and tumour angiogenesis. DWI-MRI and DCE-MRI have 
been validated in several studies, whereas, ISW-MRI is a developing 
technology (see table 1.9 and 1.10, page 75 – 76).   
The unpredictable outcomes in patients with locally advanced rectal cancer 
despite evidence-based standard management (NCRT down staging followed 
by interval TME surgery) may be due to lack of pathophysiological parameters 
taken into account during tumour staging. We know that pathophysiological 
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alterations occur prior to any morphological changes in response to 
neoadjuvant therapy, especially after biological agents. Early detection of such 
changes may help predict individual tumour behaviour and allow tailored 
treatment regimes.  
MRI assessment of pathophysiological parameters and any changes in 
response to treatment may help serve this purpose. Previous studies have 
shown that alteration in water diffusion secondary to cell necrosis (measured as 
apparent diffusion coefficient (ADC), and vascular changes (measured as the 
rate and magnitude of enhancement in response to anticancer treatment 
precede changes in tumour size. An increase in ADC and decrease in vascular 
transfer constant (Ktrans) corresponds with a good response, whereas, a 
persistent low ADC and abnormal enhancement reflects poor response. The 
aim of this experiment is two-fold: firstly, to evaluate multiple MRI parameters of 
tumour pathophysiology and their alterations in response to neoadjuvant 
therapy in patients with locally advanced rectal cancer; and secondly, to 
correlate baseline and altered values post-NCRT with tumour characteristics, 
staging and clinical outcomes.  
5.2 Methods 
5.2.1 Patient population 
See chapter 3 for details of patient population. Additional exclusion criteria to 
MRI applied as well as impaired renal function (eGFR <50mL/min) and previous 
gadolinium contrast agent hypersensitivity reaction.  
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5.2.2 Patient Compliance and Exclusions 
The study group comprised of 17 patients (12 males, 5 females, median age 71 
years (range 52 - 79). Two patients (codes: 13 PO, 16 RC2) completed only 
one baseline examination and one more patient (code: 3 DJ) was diagnosed 
with liver metastasis on baseline reproducibility scans and excluded from study 
thereafter.  During the interval between NCRT and TME surgery, immediately 
after NCRT (T1) scan, one patient (code: 9 SD) died after developing acute 
peritonitis not related to rectal cancer or NCRT, whilst another patient (code 11 
DP) declined further research related examinations. One patient (code: 6 ED) 
was unable to complete the last examination. During post-processing stage, 
one patient was excluded from all analysis due to mucinous histopathology 
resulting in inconsistent parametric values compared to study cohort; one 
patient was excluded from both DW- and ISW-MRI due to susceptibility artefact; 
one patient was excluded from ISW-MRI due to susceptibility artefact. The 
patient compliance, exclusion and the number included in final analysis are 
given in table 5.1.  
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Table 5.1: Patient Compliance and Exclusions 
Code 
DW-MRI 
 
ISW-MRI 
 
DCE-MRI 
Reason 
T0(1) T0(2) T1 T2 T3 T0(1) T0(2) T1 T2 T3 T0(1) T0(2) T1 T2 T3 
1 RY ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ X ✓ ✓ ✓ Technical failure 
2 DG ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  
3 DJ ✓ ✓ X X X ✓ ✓ X X X ✓ ✓ X X X Metastasis - excluded 
4 AH ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  
5 KB ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  
6 ED ✓ ✓ ✓ ✓ X ✓ ✓ ✓ ✓ X ✓ ✓ ✓ ✓ X Did not attend last scan 
7 AF ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  
8 JN ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  
9 SD ✓ ✓ ✓ X X ✓ ✓ ✓ X X ✓ ✓ ✓ X X Died after NCRT 
10 JH ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  
11 DP ✓ ✓ ✓ X X ✓ ✓ ✓ X X ✓ ✓ ✓ X X Declined participation 
12 GA ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  
13 PO ✓ X ✓ ✓ ✓ ✓ X ✓ ✓ ✓ ✓ X ✓ ✓ ✓ Mucinous tumour 
14 MM ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ R2* susceptibility artefact 
15 RC1 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  
16 RC2 ✓ X ✓ ✓ ✓ ✓ X ✓ ✓ ✓ ✓ X ✓ ✓ ✓ R2* susceptibility artefact 
17 JT ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  
Imaging Completed 17 15 16 14 14 17 15 16 14 13 17 14 16 14 12  
Included in Study 15 14 13 11 11  14 14 12 11 10  16 14 15 13 11  
✓ Completed scan and included in analysis ✓ Completed scan but not included in analysis X Did not complete scan; DNA- did not attend 
 CHAPTER 5: MRI – MULTIPARAMETRIC ANALYSIS 
 
183 
5.2.3 MRI analysis of rectal tumour  
All patients underwent multi-parametric MRI within a single examination on 5 
occasions: Two baseline scans within 14 days (T0(1) + T0(2)) for reproducibility 
analysis, thereafter, one scan each within two-weeks post-NCRT (T1), six-
weeks post-NCRT (T2) and 11-weeks post-NCRT or pre-operatively (T3). The 
MRI examination schedule is shown in figure 5.1. 
Figure 5.1: MRI examination schedule and completion rates  
 
where, T (subscript) represent timing of the examination along the treatment 
line: T0(1) and T0(2) were paired baseline examination on day 1 and day 2, 
respectively; T1, T2 and T3 were post-NCRT examination at second week, sixth 
week and eleventh week, respectively. The ‘n’ denotes number of patients 
completing examination.   
  
T0
(1) T1 T2 T3 
NCRT  Interval to TME surgery 
6 weeks 2 weeks 11 weeks 
Baseline 
n = 11 
n= 1 
n= 2 
n=1 
n = 2 
Successfully 
completed 
study Unable to complete last 
examination 
One patient declined further participation 
One patient died after NCRT 
Patient diagnosed with metastatic disease 
Unable to complete 
paired baseline 
examination 
0 - 2 weeks 
 5  weeks 12 weeks 
Treatment Timeline 
Diagnosis Surgery 
T0
(2) 
DCE-MRI Examination Schedule 
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5.2.4 Image acquisition   
MRI was performed using a 1.5T system (Avanto or Symphony or TIM 
Symphony; Siemens Medical Systems, Erlangen, Germany), with a pelvic 
phased array coil and the protocols specified in table 5.2. The images were 
obtained in the following order: 
1. Standard morphological images  
2. Diffusion-weighted  
3. Intrinsic susceptibility  
4. Dynamic contrast enhanced (after injection of contrast agent)  
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Table 5.2: MRI scanner protocols: 
 Symphony TIM Symphony Avanto 
DCE-MRI 
Sequence T1-weighted volume interpolated breath-hold excitation 
gradient-echo (VIBE) 
TR (ms) 6.6 6.6 6.6 
TE (ms) 1.8 1.38 /1.44 1.22 
NEX 1 1 1 
FOV (mm) 2602 2602 2602 
Flip Angles (degree) 3° (PDW) 
21° (T1W) 
3° (PDW) 
21° (T1W) 
3° (PDW) 
21°(T1W) 
Acquisition matrix* 256x174  192 x 131 256x174 
Receiver bandwidth (kHz) 700 700  698 
Slice thickness (mm) 5 5 5 
Number of slices 12 12 12 
DW- MRI    
Sequence Echo planar imaging (EPI) 
TR (ms) 5900 4500 4500 
TE (ms) 92 75 75 
FOV (mm) 3802 3802 3802 
Acquisition matrix 190x139 190x140 190x139 
Receiver Bandwidth (kHz) 1195 1185 1654 
b-value (s/mm2) 0, 100, 500, 800  0, 100, 500, 800 0, 100, 500, 800 
Fat suppression Spectral FS Spectral FS Spectral FS 
Diffusion mode 3-scan trace 3-scan trace 3-scan trace 
Slice thickness (mm) 5 5 5 
Number of slices 20 20 20 
ISW-MRI 
Sequence Gradient recall echo (GRE) 
TR (ms) 100 100 100 
TE (ms) 4.76,14.3,23.8,33.4
,61.9 
5,10.15, 30, 45, 
60 
4.76,14.3,23.8,33.4
,61.9 
NEX  5 5 5 
FOV (mm) 2602 2602 2602 
Flip angle (degree) 25° 25° 25° 
Acquisition matrix 2562 1282 2562 
Slice thickness (mm) 5 5 5 
Number of slices 6 6 6 
TE – time to echo; TR – repetition time; NEX – number of excitation; FOV – field of view; PDW 
– proton density weighted; T1W – T1-weighted 
*Reconstructed to 2562 
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5.2.4.1 Morphological Imaging:  
Breath-hold gradient echo T1-weighted and turbo–spin echo T2-weighted 
sequences were acquired to stage the tumour and to identify the tumour slice 
location. The central 4 tumour slices served as reference points for future serial 
scans on the same patient (figure 5.2.). Care was taken when repositioning the 
patient exactly in the same position on subsequent visits in order to obtain the 
same anatomical slice location.  
Figure 5.2: Image slice placement and selection  
 
5.2.4.2 Diffusion Weighted Images: 
DW-MRI measurements were acquired with a free- breathing, multiple-
averaging technique, using single- shot echo-planar MR imaging. Four motion 
probing gradients with b-values of 0, 100, 500, 800 s/mm2 were applied in the 
three orthogonal directions of the magnet (frequency, phase and slice-select). 
The orthogonal directional images were used to generate trace images for each 
b-values. Fat suppression was achieved with spectral FS sequences.  
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5.2.4.3 Intrinsic susceptibility weighted images: 
Multiple spoiled gradient-recalled-echo sequences with increasing echo times 
were acquired, from which R2* maps were calculated (see table 5.2).    
5.2.4.4 Dynamic contrast enhanced images 
Initially proton density-weighted 3-dimensional (3-D) gradient recalled echo 
volume interpolated breath hold examination (VIBE) sequences were acquired 
(flip angle 3°; see table 5.2) at the same slice positions to enable the calculation 
of tissue contrast concentration. Thereafter, a dynamic series of T1-weighted 3-
D VIBE sequence images were acquired sequentially (flip angle 21°; see table 
5.2) with a time resolution of 10 seconds (40 time points over 6 minutes), with 
four images prior to a bolus of contrast agent. During the acquisition of fifth 
image (i.e, beginning after 48 seconds) a bolus of 0.1mmol/kg body weight of 
gadopentetate dimeglumine (Gd-DTPA, Magnevist; Bayer) contrast agent was 
administered at 4ml/s using a power injector, followed by a 20 ml bolus of 
normal saline at the same rate. No muscle relaxants were administered during 
any scanning sequence.  
5.2.5 Image Analysis 
Image analysis was performed in consensus by an experienced consultant 
radiologist and a MRI physicist with specialist interest in MR based tumour 
physiology imaging (more than 15 years’ experience). Any motion artefact was 
minimised using propriety motion correction software (Tissue 4DTM, Siemens). 
The images were analysed using a specialist MRI software package developed 
at the Institute of Cancer Research, London, UK [439]. The DCE-MR images 
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were analysed using Magnetic Resonance Imaging Workbench (MRIW© ICR, v 
4.4), whilst DW-MR and ISW-MR images were analysed using Diffusion View 
(DV© ICR, v 2.1.3).  
5.2.5.1 Region of interest (ROI): 
The central 6 slices with maximal tumour volume were used. For each axial 
image section, using the information from morphological T1 or T2 weighted 
images and post contrast T1 weighted images, ROIs were carefully drawn free 
hand around the tumour by the radiologist excluding pulsatile artefacts from 
blood vessels and susceptibility artefacts from adjacent bowel lumen. The 
process was repeated for all axial image sections that contained the tumour.  
5.2.5.2 Diffusion Weighted MRI 
ADC was calculated using all b-values. ROIs were drawn on the trace/index b-
value = 800 s/mm2 images (see figure 5.3). The ROI was then copied on to the 
corresponding ADC map to enable each voxel value within the ROI on ADC 
map to be recorded. The process was repeated for all axial section that 
included the target lesion. Median ADC at each time point was calculated by 
analysing all the voxel within the tumour (see figure 5.4). 
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Figure 5.3: DW-MRI Images at different b value 
Images obtained at different b values. For the purpose of current experiment ROI were drawn on the trace/index b-value = 800 s/mm2 
images. 
 
b0 b100 b500 b800 
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Figure 5.4: DWI versus standard T2 weight image acquisition 
The actual images of patient number 1 are presented below: columns show 
ADC maps (calculated from b0 and b800 s/mm2 images), diffusion weighted 
b800 and T2-weighted images. Progressive decrease in tumor size is seen with 
increases in ADC values consistent with tumor cell death.  
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5.2.5.3 Intrinsic Susceptibility Weighted MRI  
The signal changes on the ISW-MR images were used to calculate intrinsic T2* 
relaxivity. The R2* maps were calculated on a voxel-by-voxel basis from a 
straight line fitted to a plot of natural logarithm of ‘ln’ of signal intensity (T2*) 
against echo times (TE) using a least squares approach, of which the gradient 
is –R2*(unit: seconds-1). Voxels with either negative or zero value were 
excluded from analysis.  
5.2.5.4 Dynamic Contrast Enhanced MRI:  
The dynamic image data were analysed using both quantitative and semi-
quantitative approaches. Semi quantitative analysis was performed directly from 
T1-weighted images but quantitative analysis required conversion of MR signal 
intensities to Gd-DTPA concentrations. MRIW© software was used to convert 
MRI signal intensities of the T1-weighted DCE-MRI dataset into T1 relaxation 
rates (R1) and then into Gd-DTPA concentrations for individual voxels, using 
methods described by Parker et al [343]. The changing tissue Gd-DTPA curve 
was fitted to a standard compartmental model [364] (see appendix IV, page 
389). A pooled arterial input function, based on cosine plasma bolus method 
defined by Parker et al [440], was used for modelling procedure. The following 
T1-weighted parameters were calculated in the MRIW© software: the initial area 
under the GD-DTPA concentration-time curve for the first 60 seconds 
(IAUGC60; mM.second), transfer constant (Ktrans; minute-1), rate constant (kep; 
minute-1) and leakage space (ve; %). Voxels that did not enhance and those 
enhancing voxels that failed the modelling process or had values >5.0 minute-1 
were excluded from statistical analysis of Ktrans, ve and kep parameters, However 
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IAUGC60 estimates include voxels that failed the modelling process as these will 
include Ktrans > 5 minute-1.  
5.2.6 Statistical Analysis 
The parameters values from baseline MRIs were analysed to assess baseline 
reproducibility using Bland-Altman agreement analysis [441, 442] as described 
previously [443]. We included data from all patients (no outliers excluded).  
The distribution of the differences in paired baseline MR parameters was tested 
for normality by Shapiro-Wilk’s test. The mean (SD) was determined for each 
parameter and for each study. Any relation between the difference and mean 
values of paired baseline MR parameters was tested with Kendal’s tau test of 
correlation. In case of either skewed distribution or significant correlation, the 
data was log transformed. Analysis of variance (ANOVA) was used to 
determine the difference between paired measurements and derive the 
statistical measures described below in tables 5.3–5.5. Bonferroni correction 
was applied to the statistical power of 0.05 for multiple comparisons. The 
confidence intervals for statistical estimates were calculated using t- and Chi-
squared distribution scores due to small sample size.  
Day-to-day reproducibility was assessed using Bland-Altman statistics. The 
mean difference and 95% limits of agreement (i.e., mean difference - 2 standard 
deviations and mean difference + 2 standard deviations) were determined. 
Within this framework, the 95% repeatability coefficient was determined as 2.77 
of the standard deviation of the differences.  
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The coefficient of variation between-patients was estimated as follows: The 
partial differences between the readings were calculated, and then their 
standard deviation was divided by their mean and expressed as a percentage.  
The coefficient of variation between readings was assessed according to the 
root mean squared approach, whereby (SD/M) 2, where SD is standard 
deviation and M is mean, was calculated across the patient’s two readings. 
These values were then averaged across patients, and the square root was 
taken and then reported as a percentage.  
Variance-components analysis was undertaken using a linear model with 
random effects on intercept, given patient as a grouping factor. The intra-class 
correlation coefficient and its 95% confidence interval were also estimated. 
Any changes in MR parameter values on serial examinations after NCRT were 
converted to percentage change from baseline (see formula below) and tested 
for significance.  
𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑟𝑖𝑐 𝑣𝑎𝑙𝑢𝑒 𝑎𝑡 𝑠𝑒𝑟𝑖𝑎𝑙 𝑡𝑖𝑚𝑒 𝑝𝑜𝑖𝑛𝑡𝑠 − 𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑟𝑖𝑐 𝑣𝑎𝑙𝑢𝑒 𝑎𝑡 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑟𝑖𝑐 𝑣𝑎𝑙𝑢𝑒 𝑎𝑡 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 
× 100 
where, ‘baseline is the mean parametric values at T0 (1) and T0 (2)’ and serial 
time points is the parametric values at T1 (pre-treatment stage), T2 (post-NCRT 
stage) and T3 (pre-operative stage). Any changes beyond ‘95%CI of mean 
difference’ for group and ‘95% repeatability coefficient (r)’ for individual patients 
were considered significant.  
Clinical data was tested for normality by Shapiro-Wilk test. The correlation 
between DCEI parameters and clinicopathological markers was assessed by 
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Person and Spearman rank correlation analysis for parametric and non-
parametric data respectively. Similarly, the difference in mean parametric 
values amongst clinicopathological markers was analysed by analysis of 
variance for normally distributed data and Kuskal-Wallis of Mann-Whitney-U test 
for non-normally distributed data. The MR multi-parametric measurements at 
different time-points and their alterations post-NCRT were evaluated against 
clinical data by means of one-way analysis of variance and chi-square or Fisher 
exact test plus Spearman rank correlation analysis, respectively.  
Subgroup analysis comparing difference in mean parametric values before and 
after treatment and clinicopathological markers was performed by Wilcoxon-
signed rank test. Statistical significance was taken at p <0.05. 
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Table 5.3: Statistical measures of spontaneous changes within-subject 
between paired measurements 
Statistical Measure Abbreviation Definition and Derivation 
Mean squared 
difference 
dSD Estimation of spontaneous change in a parameter between 
two measurement 
𝑑𝑆𝐷 = √
𝑑2
𝑛
 
95% Confidence 
Interval of dSD  
CI cohort Measures magnitude of spontaneous change in a 
parameter expected in a group. Any change in a group of 
‘n’ greater than this value would be significant at the 5% 
level. 
𝐶𝐼 = ± (1.96 ×
𝑑𝑆𝐷
√𝑛
) 
or, for natural log transformed data 
% 𝐶𝐼 =  
(100 × 𝑎𝑛𝑡𝑖𝑙𝑜𝑔 (𝑙𝑜𝑔10) 𝑚𝑒𝑎𝑛±𝐶𝐼
𝑚𝑒𝑎𝑛
  
Variance ratio F The ratio of between-patient variance to within-patient 
variance. It is a sensitive measure of reproducibility. 
Parameters with large F have small within-patient variance 
and large between-patient variance.  
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Table 5.4: Statistical measures of repeatability 
Statistical Measure Abbreviation Definition and Derivation 
Within-subject 
standard deviation 
wSD  It is the standard deviation of repeated measurements. The 
wSD measures the size of the measurement error [444].  
𝑤𝑆𝐷 =  √𝑤𝑖𝑡ℎ𝑖𝑛 𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒    
Repeatability 
Coefficient  
r  The difference between two measurements for the same 
subject is expected to be less than 2.77 (𝑤𝑆𝐷) for 95% of 
pairs of observations. The r is expressed at percentage. 
 𝑟 = √2 × 1.96(𝑤𝑆𝐷) =  2.77 (𝑤𝑆𝐷) 
or,  for transformed data 
%r = [100x antilog (log10 mean ± r)]/ mean 
Bland-Altman Limits 
of agreement 
LoA Gives an estimate of the range within which we expect 95% 
of future measurements between two observers / observers/ 
methods to lie. 
95% 𝐿𝑜𝐴 = 𝑚𝑒𝑎𝑛 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 ± 1.96 ×  𝑆𝐷 (𝑑𝑖𝑓𝑓𝑒𝑟𝑛𝑒𝑐𝑒) 
Note: the 1.96 was replaced with t-distribution score 
according to degree of freedom for current analysis 
(dependent on sample size) 
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Table 5.5: Statistical measures of reproducibility  
Statistical Measure Abbreviation Definition and Derivation 
Inter-class 
correlation 
coefficient 
ICC A measure of precision of parameters estimates. The 
proportion of total variance within the data that is explained 
by variance between observers; ICC = 1 means perfect 
agreement between observer; ICC = 0 means no agreement 
between observers.  
𝐼𝐶𝐶 =
𝑏𝑉𝐴𝑅
𝑏𝑉𝐴𝑅 + 𝑤𝑉𝐴𝑅
 
Variance 
components  
(within-subject and 
between-subject)  
wVAR and 
bVAR  
Measure variability of the results within patients (for 
example, within patients over two measurements: 1-2 days, 
1-2 observer) and between patients (for example, the same 
observer on day 1 or the same day different observer).  
Coefficient of 
variation  
(within-subject and 
between-subject)  
wCV and bCV Estimates the spread of measurements around the mean. 
The wCV estimates the degree of variation of 
measurements in an individual in relation to mean of the 
group. The bCV compares the degree of variation of 
measurements between groups. The value of > 0.5 is 
unreliable [445]. Expressed as percentage.  
𝐶𝑉 =
𝑆𝐷
𝑀𝑒𝑎𝑛
 
The wCV is estimated with the root mean squared 
approach. 
𝑤𝐶𝑉 = √𝑚𝑒𝑎𝑛 [(
𝑆𝐷
𝑚𝑒𝑎𝑛
)
2
𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑝𝑎𝑖𝑟𝑒𝑑 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡] 
or, for natural log transformed data  
𝑤𝐶𝑉 = 𝑎𝑛𝑡𝑖𝑙𝑜𝑔 (𝑤𝑆𝐷) −  1   
The bCV is estimated by the values of differences between 
repeated measurements 
𝑏𝐶𝑉 =  
𝑆𝐷 𝑜𝑓 𝑚𝑒𝑎𝑛 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒
𝑚𝑒𝑎𝑛 𝑜𝑓 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒
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5.3 Results 
5.3.1 Patient population, characteristics and clinical outcomes 
Please refer to chapter 4, sections 4.3.1, 4.3.2 and 4.3.3 (pages 121-125). 
5.3.2 Baseline measurement reproducibility and observer 
agreement of MR parameters in rectal cancers  
Multi-parametric MR data of 14 patients was suitable for reproducibility analysis 
as shown in the table 5.6. Overall, all the measured parameters had satisfactory 
reproducibility.  
Table 5.6: Baseline measurement reproducibility of MR parameters  
Parameter Mean 
Spontaneous Change Repeatability Reproducibility 
dSD 
CI cohort 
(as %) 
F r (as %) wSD wCV ICC LoA 
ADC (x10-3 
mm2/sec) 
1.35 0.07 
±0.039 
(±2.91%) 
35.1 
±0.14 
(±10.9%) 
0.05 0.03 0.94 ±0.15 
R2* 
(min-1) 
 
22.9 
(ln 3.12) 
0.09 
±0.04 (-
4.67 to 4.9 
%) 
6.7 
0.17 
(-16.38 to 
+19.6 %) 
0.06 0.06 0.74 
-0.16 to 
0.19 
Ktrans 
(min-1) 
0.17 0.04 
±0.02 
(±13.7%) 
4.3 
±0.09 
(±51.4%) 
0.03 0.18 0.60 
-0.06 to 
0.10 
ve 
(%) 
0.24 0.06 
±0.03 
(±14.1%) 
2.4 
±0.12 
(± 52.9%) 
0.04 0.19 0.38 
-011 to 
0.14 
kep 
(min-1) 
0.73 0.15 
± 0.08 
(±11.1%) 
4.9 
±0.3 
(±41.5%) 
0.1 0.15 0.64 
-0.23 to 
0.35 
IAUGC60 
(min-1) 
 
3.03 0.21 
±0.113 
(-10.7% to 
12.0 %) 
35.3 
0.42 
-34.6% to 
+52.9% 
0.15 0.16 0.94 
-0.33 to 
0.48 
dSD – mean squared differences, CI cohort – 95% confidence interval for the cohort, F – 
variance ratio, r – individual patient repeatability, wSD - within-patient standard deviation, wCV - 
within-patient coefficient of variation, , ICC – interclass correlation coefficient, LoA – Limits of 
agreement (Bland-Altman);   log transformed 
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For DW-MRI, ADC values showed minimal spontaneous change (CI cohort 
±2.91%, F 35.1) with excellent repeatability (r ±10.9%) and minimal observer 
introduced variability (wCV 3%, ICC 94%, LoA ±0.15) on paired measurements.  
Bar plots of paired mean ADC and corresponding Bland-Altman limits of 
agreement plots are shown in figure 5.5 and 5.6 respectively.  
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Figure 5.5: Baseline ADC reproducibility for individual patient data 
changes values to x10-3 
 
Figure 5.6: Bland-Altman plot for ADC measurement agreement changes 
values to x10-3 
 
Mean = 1.35 
Difference = 0.00 
95% Limits of 
agreement = ±0.153 
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For ISW-MRI, the difference between the mean R2* values from paired 
measurements was not normally distributed and, therefore, the data was natural 
log transformed for analysis. The R2* measurement showed minimal 
spontaneous changes (CI cohort -4.67 to +4.9%, F 6.7), better repeatability 
than dynamic parameters (r -16.3 to +19.6%) and minimal observer influence 
(ICC 74%, LoA -0.16 to +0.19) between readings.   
Bar plots of paired mean R2* value and corresponding Bland-Altman plots are 
shown in figure 5.7 and 5.8, respectively.  
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Figure 5.7: Baseline R2* reproducibility for individual patient data 
 
Figure 5.8: Bland-Altman plot for R2* measurement agreement 
 
Mean = 22.99 
Difference = 0.09 
95% Limits of 
agreement =  
- 0.16 to 0.19 
 
 
3.0 3.2 3.4
-0.4
-0.2
-0.0
0.2
0.4
R2*: Bland-Altman Measurement Agreement Plot
Mean of baseline measurement (R2*:s
-1
)
D
if
fe
re
n
c
e
 i
n
 b
a
s
e
li
n
e
 m
e
a
s
u
re
m
e
n
t
 CHAPTER 5: MRI – MULTIPARAMETRIC ANALYSIS 
 
203 
For DCE-MRI parameters, the reproducibility of cohort was better than an 
individual patient and non-model based measurements (IAUGC60) had best 
reproducibility. In summary, for paired measurements of model driven 
parameters: Ktrans and kep showed less spontaneous changes (CI cohort 
±13.7%, ±11.1% and F 4.3, 4.9, respectively) than ve (CI cohort ±14.1%, F 2.4); 
kep showed best repeatability (r ±41.5); the observer interference on readings 
was poor for ve (ICC 38%) and moderate for Ktrans and kep (ICC 60% and 64%, 
respectively). For non-model driven parameters, i.e. IAUGC60, the difference 
between the mean values from paired measurements was not normally 
distributed and, therefore, log transformed for analysis. For paired IAUGC60 
readings, there was minimal spontaneous change (CI cohort -10.75 to +12%, F 
35.3), better repeatability than model driven parameters (r -34.6% to +52.9%) 
and minimal observer influence (ICC 94%).  
Bar plots of paired mean Ktrans values and corresponding Bland-Altman plots 
are shown in figure 5.9 and 5.10, respectively. 
Bar plots of paired mean ve values and corresponding Bland-Altman plots are 
shown in figure 5.11 and 5.12, respectively. 
Bar plots of paired mean kep values and corresponding Bland-Altman plots are 
shown in figure 5.13 and 5.14, respectively. 
Bar plots of paired mean IAUGC60 values and corresponding Bland-Altman 
plots are shown in figure 5.15 and 5.16, respectively. 
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Figure 5.9: Baseline Ktrans reproducibility for individual patient data  
 
Figure 5.10: Bland-Altman plot for Ktrans measurement agreement 
 
Mean = 0.17 
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95% Limits of 
agreement =  
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Figure 5.11: Baseline ve reproducibility for individual patient data  
 
Figure 5.12: Bland-Altman plot for ve measurement agreement 
 
Mean = 0.24 
Difference = 0.01 
95% Limits of 
agreement =  
- 0.11 to 0.14 
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Figure 5.13: Baseline kep reproducibility for individual patient data  
 
Figure 5.14: Bland-Altman plot for kep measurement agreement 
 
Mean = 0.73 
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Figure 5.15: Baseline IAUGC60 reproducibility for individual patient data  
 
Figure 5.16: Bland-Altman plot for IAUGC60 measurement agreement 
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95% Limits of 
agreement =  
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5.3.3 Alterations in MR parameters in response to NCRT 
5.3.3.1 Estimation of significant changes in parametric measurements for 
cohort of patients  
The significance of therapy-induced changes on a cohort basis was gauged by 
the 95% confidence interval of cohort (CI cohort) of the baseline measurement 
reproducibility. Thus, significant changes during the interval between NCRT and 
TME surgery (T1-T3) were deemed to be present in study cohort if the 
percentage change of MR parameters increased or decreased beyond the 
upper or lower limits of ‘cohort 95% CI’, respectively. The alterations in absolute 
and percentage values of MR parameters are shown in tables 5.7-5.8 and 
figure 5.17, respectively.  
5.3.3.1.1 DW-MRI - ADC measurement alteration by cohort analysis 
For ADC measurement alterations by cohort, there was significant increase in 
ADC measurement between the interval after NCRT and TME surgery. The 
pattern of ADC increase was as follows: a relative percentage increase by 
+23.83% at T1 followed by lower percentage increase by +21.53% at T2 and 
then a maximum percentage increase by +27.06% at T3 from baseline.  
5.3.3.1.2 ISW-MRI – R2* measurement alteration by cohort analysis 
For R2* measurement alterations by cohort, there was an increase in R2* by 
+4.76% at T1 followed by a significant increase by + 9.91% at T2 reducing to 
+3.6% at T3 from baseline. 
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5.3.3.1.3 DCE-MRI – Ktrans measurement alteration by cohort analysis 
For Ktrans measurement alterations by cohort, there was consistent significant 
percentage decrease from baseline during the interval between completion of 
NCRT and TME surgery. The Ktrans levels fell by -19% at T1 followed by further 
decline by -32.1% at T2 and finally falling down by -46.5% at T3 from baseline.  
5.3.3.1.4 DCE-MRI – ve measurement alteration by cohort analysis 
For ve measurement alterations by cohort basis, there was significant increase 
in ve by +13.3% at T1, followed by a relatively lower but significant increase by 
8.57% at T2 and finally a non-significant increase by 1.69% at T3 from baseline. 
5.3.3.1.5 DCE-MRI – kep measurement alteration by cohort analysis 
For kep measurements by cohort analysis, there was a persistent significant 
decrease from T1 – T3. The kep decreased to -29.32% at T1, followed by further 
decline by -49.37% at T2 and then down by -50.09% at T3 from baseline.  
5.3.3.1.6 DCE-MRI – IAUGC60 measurement alteration by cohort analysis  
For IAUGC60 measurements by cohort analysis, there was a persistent 
significant decrease from T1 – T3. The IAUGC60 decreased by a non-significant -
5.28% at T1, followed by further decline by -22.31% at T2 and by -28.12% at T3 
from baseline. 
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Table 5.7: MRI multi-parametric alterations after NCRT by absolute mean 
values 
Parameter n 
T0  T1 
p n 
T0 T2 
p n 
T0 T3 
P 
(mean) (mean) (mean) 
ADC  
(x10-3 
mm2/s) 
14 1.31 1.6 0.000 12 1.36 1.57 0.01 11 1.33 1.65 0.003 
R2* (s-1) 13 23.27 24.1 0.60 11 23.6 25.8 0.11 10 23.7 24.23 0.69 
Ktrans 
(min-1) 
15 0.180 0.141 0.03 13 0.171 0.114 0.01 11 0.178 0.089 0.001 
ve (%) 15 0.247 0.269 0.375 13 0.237 0.244 0.82 11 0.237 0.205 0.344 
kep 
(min-1) 
15 0.748 0.496 0.002 13 0.741 0.415 <0.001 11 0.748 0.311 <0.001 
IAUGC60 
(mmol.s) 
15 16.27 15.04 0.36 13 15.47 11.75 0.03 11 15.88 11.25 0.003 
Bold – significant changes; Statistical test – paired sample T-test 
Table 5.8: MRI multi-parametric alterations after NCRT by percentage 
change  
Parameter 
% Change at T1  
[Cohort CI for ‘n’] 
% Change at T2 
[Cohort CI for ‘n’] 
% Change at T3 
[Cohort CI for ‘n’] 
ADC 
(mm2/s) 
23.83% 
[±3 (n=13)] 
21.53% 
[±3.2 (n=11)] 
27.06% 
[±3.2 (n=11)] 
R2* (s-1) 
4.76% 
[-5.2 to +5.5% (n=11)] 
9.91% 
[-5.5 to +5.8% (n=10)]  
3.60% 
[-6.1 to +6.5 (n=8)] 
Ktrans (min-1) 
-19.01% 
[±5.9% (n=15)] 
-32.1% 
[±6.3% (n=13)] 
-46.52% 
[±6.9% (n=11)] 
ve (%) 
13.43% 
[±6.9% (n=15)] 
8.57% 
[±7.4% (n=13)] 
1.69% 
[±8% (n=11)] 
kep (min-1) 
-29.32% 
[±5.4% (n=15)] 
-41.37% 
[±5.8% (n=13)] 
-50.09% 
[6.4% (n=11)] 
IAUGC60 
(mmol.s) 
-5.28% 
[-6.9 to +7.4% (n=15)] 
-22.31% 
[-7.4 to +7.9% (n=13)] 
-28.12% 
[-8 to +8.7% (n=11)] 
Bold – significant changes; Statistical test – cohort analysis  
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Figure 5.17: MRI multi-parametric alterations after NCRT by percentage 
change (cohort) 
 
5.3.3.2 Estimation of significant changes in parametric measurements for 
an individual patient  
The significance of therapy-induced changes on an individual basis was gauged 
by the percentage coefficient of repeatability (% r) derived from Bland-Altman 
analysis of baseline measurement. Thus, significant changes during the interval 
between NCRT and TME surgery (T1-T3) were deemed to be present in an 
individual if the percentage change of MR parameters increased or decreased 
beyond the upper or lower limits of ‘% r’. 
5.3.3.2.1 DW-MRI - ADC measurement alteration for individual patients  
Post-NCRT ADC measurement were available from the following time-points: T1 
to T3 from 11/14 patients; T1 to T2 from 1/14 patient; T1 only from 2/14 patient. 
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For ADC measurement alterations by individual basis, 12/14 (85%) patients 
showed significant percentage increase from baseline to final measurements 
(see figure 5.19 and 5.20). The remaining two patients showed a decrease in 
ADC values with time, one patient (code: 7 AF) had an isolated significant 
percentage decrease in ADC measurement at T2 measurements (-22.3%), 
whilst the other patient (code: 17 JT) had a non-significant percentage decrease 
from baseline from T1-T3. 
The following patterns of ADC changes were observed in patients who had T1 
to T3 measurements available and showed significant increase in ADC values: 
4/10 rectal tumours the ADC values showed relatively high positive percentage 
change at T1 followed by lower positive percentage change at T2 and then 
another high positive percentage change at T3 from baseline; 2/10 rectal 
tumours showed a relatively modest positive percentage change in ADC at T1 
followed by maximum positive percentage change at T2 then a low positive 
percentage change at T3 from baseline; 2/10 showed a gradual linear 
percentage increase in ADC values from T1 to T3.    
The actual DW-MRI images are presented in figure 5.18. The alterations in ADC 
values and pattern of changes are shown in table 5.9 and figure 5.19 and 5.20 
respectively.  
  
 CHAPTER 5: MRI – MULTIPARAMETRIC ANALYSIS 
 
213 
Figure 5.18: Serial DW-MRI images with ROIs  
The actual DW-MRI images of patient number 5 (KB) are presented below:  
  
  
 
 
 
Baseline Day 1 (T0(1))  Baseline Day 2 (T0(2)) 
2 weeks Post-NCRT (T1) 6 weeks Post-NCRT (T2) 
) 
) 
Pre-operative (T3) 
 CHAPTER 5: MRI – MULTIPARAMETRIC ANALYSIS 
 
214 
Table 5.9: ADC values and percentage changes after NCRT by individual 
basis (%r ±10.86%)  
Code 
Baseline Post-NCRT 
T0 (mean) T1 (% change) T2 (% change) T3 (% change) 
1 RY 1.00 x 10-3 1.81 x 10-3 (81%) 1.74 x 10-3 (73.4%) 1.85 x 10-3 (84.3%) 
2 DG 1.28 x 10-3 1.55 x 10-3 (21%) 1.59 x 10-3 (24.6%) 1.50 x 10-3 (17%) 
4 AH 1.64 x 10-3 1.94 x 10-3 (18.7%) 1.83 x 10-3 (11.6%) 1.90 x 10-3 (16%) 
5 KB 1.27 x 10-3 1.62 x 10-3 (26.9%) 1.57 x 10-3 (23.1%) 1.75 x 10-3 (37.3%) 
6 ED 1.31 x 10-3 1.51 x 10-3 (15.1%) 1.59 x 10-3 (21 %) - 
7 AF 1.64 x 10-3 1.61 x 10-3 (-2.1%) 1.28 x 10-3 (-22.3%) 1.56 x 10-3 (-4.9%) 
8 JN 1.28 x 10-3 1.38 x 10-3 (7.6%) 1.56 x 10-3 (21.8%) 1.46 x 10-3 (13.8%) 
9 SD 1.18 x 10-3 1.42 x 10-3 (20.2%) - - 
10 JH 1.52 x 10-3 1.71 x 10-3 (12.3%) 1.76 x 10-3 (15.4%) 1.88 x 10-3 (23.5%) 
11 DP 1.31 x 10-3 1.76 x 10-3 (33.6%) - - 
12 GA 1.40 x 10-3 1.75 x 10-3 (24.7%) 1.60 x 10-3 (14.1%) 1.88 x 10-3 (33.9%) 
15 RC1 0.97 x 10-3 1.60 x 10-3 (64.2%) 1.63 x 10-3 (67%) 1.58 x 10-3 (62.5%) 
16 RC2 1.24 x 10-3 1.29 x 10-3 (4.3%) 1.31 x 10-3 (5.8%) 1.46 x 10-3 (17.8%) 
17 JT 1.34 x 10-3 1.42 x 10-3 (6.2%) 1.37 x 10-3 (2.9%) 1.29 x 10-3 (-3.4%) 
Bold – significant changes; Statistical test – individual patient analysis  
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Figure 5.19: Absolute ADC values changes after NCRT (individual 
patients) 
 
Figure 5.20: Percentage ADC changes after NCRT (individual patients) 
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5.3.3.2.2 ISW-MRI – R2* measurement alteration by individual patients 
Post-NCRT R2* measurement were available from the following time-points: T1 
to T3 from 10/13 patients; T1 to T2 from 1/13 patient; T1 only from 2/13 patient. 
There was heterogeneous pattern of alteration in R2* measurement by 
individual basis. There were only non-significant alterations in R2* 
measurements in 6/13 (46.1%) patients: 4 patients showed percentage 
increases from baseline, whereas, 2 patients showed negative percentages 
change from baseline. In another 2 patients, there was significant percentage 
increase in R2* and in 2 patients there was significant negative percentage 
change in R2* from baseline on final measurements. One patient showed 
significant positive percentage change at T1 stage followed by non-significant 
positive percentage change at T2 stage from baseline and one patient had an 
isolated significant positive percentage change at T2 followed by non-significant 
positive percentage change from baseline at T3 stage. One patient had 
significant negative percentage change at T1 stage followed by non-significant 
negative percentage change from baseline at T2 and T3 stages.   
The actual ISW-MRI images are presented in figure 5.21. The alterations in R2* 
values and pattern of changes are shown in table 5.10 and figure 5.22 and 5.23 
respectively.  
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Figure 5.21: Serial ISW-MRI images with ROIs  
The actual ISW-MRI images of patient number 3 are presented below: the ROI 
showing R2* (scale 0-100s-1) 
  
  
 
 
Baseline Day 1 (T0(1)) 
2 weeks Post-NCRT (T1) 6 weeks Post-NCRT (T2) 
) 
) 
Pre-operative (T3) 
Baseline Day 1 (T0(2)) 
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Table 5.10: R2* values and percentage changes after NCRT (%r -16.38 – 
19.6%) 
Code Baseline Post-NCRT 
T0 T1 (% change) T2 (% change) T3 (% change) 
1 RY 23.68 24.72 (4.3%) 24.12 (1.8%) 27.44 (15.89%) 
2 DG 30.23 29.53 (-2.3%) 35.93 (18.8%) 24.99 (-17.35 %) 
4 AH 24.77 19.27 (-22.2%) 22.52 (-9 %) 23.92 (-3.47 %) 
5 KB 19.81 19.22 (-3 %) 19.77 (-0.19%) 19.78 (-0.15%) 
6 ED 22.64 38.46 (69.9%) 23.19 (2.4%) - 
7 AF 22.51 21.73 (-3.4%) 31.63 (40.5%) 28.64 (27.25%) 
8 JN 23.16 21.70 (-6.3%) 21.80 (-5.8%) 22.83 (-1.41%) 
9 SD 21.07 21.31 (1.1%) - - 
10 JH 27.54 19.82 (-28 %) 24.95 (-9.4%) 20.99 (-23.79%) 
11 DP 21.72 22.38 (3%) - - 
12 GA 23.55 23.62 (0.28%) 30.70 (30.3%) 24.83 (5.42%) 
15 RC1 20.17 26.89 (33.3%) 28.16 (39.6%) 23.41 (16.1%) 
17 JT 21.67 24.97 (15.21%) 21.67 (-0.04%) 25.49 (17.59%) 
Bold – significant changes; Statistical test – individual patient analysis  
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Figure 5.22: Absolute R2* values changes after NCRT (individual patients) 
 
Figure 5.23: Percentage R2* changes after NCRT (individual patients) 
 
%r =-16.38 – 19.6%  
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5.3.3.2.3 DCE-MRI – Ktrans measurement alteration by individual patients 
Post-NCRT Ktrans measurements were available from the following time-points: 
T1 to T3 from 11/15 patients; T1 to T2 from 2/15 patients and T1 only from 2/15 
patient.  
For Ktrans measurement alterations by individual basis, all patients showed a 
percentage decrease from baseline in Ktrans values after NCRT. There was 
significant percentage decrease on final measurements in 11/15 (73.3%) 
patients. The pattern of Ktrans alterations was as follows: 6 patients had 
crescendo negative percentage changes from T1 to T3 from baseline; maximum 
percentage decrease from baseline was seen at T2 in 2 patients and at T1 in 1 
patient. Another patient showed a significant positive percentage change at T2 
before a significant negative percentage change at T3 from baseline. Two 
patients had non-significant percentage decrease.  
The actual DCE-MRI images are presented in figures 5.24 and 5.25. The 
alterations in Ktrans values and pattern of changes are shown in table 5.11 and 
figures 5.26 and 5.27, respectively.  
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Figure 5.24: Alteration in MR parameters after NCRT 
The actual images of patient number 1 are presented below: columns show 
changes in transfer constant (color scale 0–1 min−1), leakage space (color scale 
0–100%) and normalized IAUGC60 (color scale 0–0.4 unit less). Note increases 
in transfer constant and leakage space consistent with tumor hyperemia at the 
end of radiation. 
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Figure 5.25: Alteration in MR parameters after NCRT 
Baseline day 1 (T0(1)) Baseline day 2 (T0(2)) 2 wks post-NCRT (T1) 6 wks post-NCRT (T2) Pre-Operative (T3) 
 CHAPTER 5: MRI – MULTIPARAMETRIC ANALYSIS 
 
223 
Table 5.11: Ktrans values and percentage changes after NCRT (%r = 
±22.95%) 
Code Baseline Post-NCRT 
T0 T1 (% change) T2 (% change) T3 (% change) 
1 RY 0.1933 0.09 (-52.4%) 0.062 (-67.6%) 0.05 (-69%) 
2 DG 0.17505 0.13 (-21.3%) 0.09 (-43.3%) 0.12 (-31%) 
4 AH 0.1751 0.18 (8 %) 0.12 (-26.3%) 0.09 (-48.4%) 
5 KB 0.207 0.18 (-8.7%) 0.26 (25.8%) 0.09 (-54.9%) 
6 ED 0.1131 0.13 (14.9%) 0.12 (12.1%) - 
7 AF 0.1459 0.15 (3.1%) 0 (-100%) 0.08 (-45%) 
8 JN 0.19675 0.23 (19.6%) 0.22 (14.2%) 0.19 (-1.8%) 
9 SD 0.26125 0.25 (-2.9%) - - 
10 JH 0.1171 0.10 (-11.4%) 0.08 (-28.6%) 0.09 (-22.8%) 
11 DP 0.20955 0.11 (-45.3%) - - 
12 GA 0.225375 0.10 (-52.5%) 0.07 (-65%) 0.07 (-65.2%) 
14 MM 0.15085 0 (-100%) 0.09 (-34.3%) - 
15 RC1 0.24345 0.10 (-55.2%) 0.1 (-55%) 0 (-100%) 
16 RC2 0.1425 0.18 (28.4%) 0.15 (5.7%) 0.09 (-36%) 
17 JT 0.1468 0.13 (-9.3%) 0.06 (-54.7%) 0.09 (-37.1%) 
Bold – significant changes; Statistical test – individual patient analysis  
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Figure 5.26: Absolute Ktrans values changes after NCRT (individual 
patients) 
 
Figure 5.27: Percentage Ktrans changes after NCRT (individual patients) 
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5.3.3.2.4 DCE-MRI – ve measurement alteration by individual patients 
Post-NCRT ve measurements were available from the following time-points: T1 
to T3 from 11/15 patients; T1 to T2 from 2/15 patients and T1 only from 2/15 
patient.  
For ve measurement alterations by individual basis, the percentages changes 
were heterogeneous between patients. Three patients had a significant positive 
percentage and one patient had negative percentage change from baseline on 
last examination. The pattern of percentage ve changes from T1-T3 (where 
available) were as follows: In 11/15 patients, there was initially a high positive 
percentage change at T1, thereafter, in 5 patients this was followed by relative 
percentage decrease at T2 (3 patient had negative percentage and 2 had lower 
positive percentage change) and finally a relative percentage increase at T3 
from baseline (2 remained altered by lower negative percentage change); in 3 
patients there was further higher positive percentage at T2 before decline at T4 
from baseline (in one patient ve altered by negative percentage change); in 2 
patients there was persistent relative percentage decrease at T2 followed by T3 
from baseline (one patient altered by negative percentage change). In 
remaining 4/15 patients, there was initial negative percentage change at T1, 
thereafter, in 2 patients this was followed by percentage increase in ve  (one still 
remained altered by negative percentage change) and in 1 patient there was 
crescendo negative percentage change in ve at T2 and T3 from base line.  
The actual DCE-MRI images are presented in figures 5.24 and 5.25. The 
alterations in ve values and pattern of changes are shown in table 5.12 and 
figure 5.28 and 5.29 respectively.  
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Table 5.12: ve values and percentage changes after NCRT (% r = ±26.77%) 
Bold – significant changes; Statistical test – individual patient analysis  
 
 
  
Code Baseline Post-NCRT 
T0 T1 (% change) T2 (% change) T3 (% change) 
1 RY 0.17385 0.2095 (20.5%) 0.2139 (23%) 0.1604 (-7.7%) 
2 DG 0.21475 0.2393 (11.4%) 0.1964 (-8.5%) 0.2391 (11.3%) 
4 AH 0.2456 0.3352 (36.5 %) 0.2614 (6.4%) 0.3038 (23.7 %) 
5 KB 0.18585 0.3244 (74.5%) 0.3297 (77.4%) 0.2775 (49.3 %) 
6 ED 0.1462 0.27 (84.7%) 0.2779 (90.1 %) - 
7 AF 0.25445 0.259 (1.8%) 0 (-100 %) 0.2468 (-3 %) 
8 JN 0.25745 0.3193 (24 %) 0.3162 (22.8%) 0.3162 (22.8 %) 
9 SD 0.26025 0.321 (23.3%) - - 
10 JH 0.22235 0.2141 (-3.7%) 0.21815 (-1.9%) 0.2222 (-0.1%) 
11 DP 0.3586 0.2998 (-16.4%) - - 
12 GA 0.3008 0.3123 (3.8 %) 0.2737 (-9 %) 0.29385 (-2.3%) 
14 MM 0.2403 0 (-100%) 0.3144 (30.8%)  
15 RC1 0.25995 0.2988 (14.9%) 0.2584 (-0.6 %) 0 (-100 %) 
16 RC2 0.3682 0.3269 (-11.2 %) 0.288 (-21.8 %) 0.2887 (-21.6 %) 
17 JT 0.2232 0.3062 (37.2 %) 0.229 (2.6%) 0.32625 (46.2 %) 
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Figure 5.28: Absolute ve values changes after NCRT (individual patients) 
 
Figure 5.29: Percentage ve changes after NCRT (individual patients) 
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5.3.3.2.5 DCE-MRI – kep measurement alteration by individual patients  
Post-NCRT kep measurements were available from the following time-points: T1 
to T3 from 11/15 patients; T1 to T2 from 2/15 patients and T1 only from 2/15 
patient.  
For kep measurement alterations by individual basis, all patients showed a 
decline in kep values between T1 and T3:10/15 patients had a significant 
decrease on the final examination. The pattern of changes were as follows: 
13/15 patients had negative percentage changes (10 significant high negative) 
at T1 from baseline, thereafter, 6 patients showed a further decline in kep at T2 
before a relative lower negative percentage change at T3 from baseline; 2 
patients had a decreasing kep percentage change from baseline. Two patients 
had positive percentage changes (1 significant high positive) at T1, thereafter; 
both patients had percentage decline in kep from baseline on subsequent 
measurements. 
The actual DCE-MRI images are presented in figures 5.24 and 5.25. The 
alterations in kep values and pattern of changes are shown in table 5.13 and 
figure 5.30 and 5.31 respectively.  
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Table 5.13: kep values and percentage changes after NCRT (%r = ±21.21%) 
Code 
Baseline Post-NCRT 
T0 T1 (% change) T2 (% change) T3 (% change) 
1 RY 1.07 0.45 (-57.6%) 0.26(-75.5%) 0.31(-71.2%) 
2 DG 0.81 0.57(-29.2 %) 0.46(-42.9 %) 0.50(-38.0%) 
4 AH 0.70 0.58(-16.5%) 0.51(-27.3%) 0.30(-57.0%) 
5 KB 1.07 0.61(-42.8%) 0.86(-20.2 %) 0.35(-67.5%) 
6 ED 0.72 0.49(-31.0%) 0.47(-34.5%) - 
7 AF 0.61 0.59(-3.4%) 0.00(-100.0 %) 0.34(-44.8%) 
8 JN 0.73 0.75(+2.9%) 0.61(-17.1 %) 0.61(-17.1%) 
9 SD 1.00 0.74(-25.7%) - - 
10 JH 0.53 0.51(-3.3%) 0.38(-28.9%) 0.43(-18.6%) 
11 DP 0.58 0.37(-36.3%) - - 
12 GA 0.75 0.36(-52.5%) 0.30(-60.1%) 0.29(-61.4%) 
14 MM 0.66 0.00(-100.0%) 0.32(-50.9%) - 
15 RC1 0.93 0.34(-63.6%) 0.42(-55.2%) 0.00(-100.0%) 
16 RC2 0.40 0.56(41.3%) 0.52(31.4%) 0.32(-19.6%) 
17 JT 0.66 0.52(-22.2%) 0.29(-56.7 %) 0.29(-55.8 %) 
Bold – significant changes; Statistical test – individual patient analysis  
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Figure 5.30: Absolute kep values changes after NCRT (individual patients) 
 
Figure 5.31: Percentage kep changes after NCRT (individual patients) 
 
%r = ±21.21% 
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5.3.3.2.6 DCE-MRI – IAUGC60 measurement alteration by individual 
patients 
Post-NCRT IAUGC60 measurements were available from the following time-
points: T1 to T3 from 11/15 patients; T1 to T2 from 2/15 patients and T1 only from 
2/15 patient.  
For IAUGC60 measurement alterations by individual basis, there was generally 
a decrease in IAUGC60 after NCRT. In 10/15 patients, there was negative 
percentage change (9 patients with significant changes) on the last 
examination. The pattern of changes from T1-T3 (where available) were as 
follows:  in 9/15 patients there was initial percentage decrease in IAUGC60 at T1, 
thereafter, in 5 patients there was further high negative percentage change at 
T2 before a relative lower negative percentage change at T3 in 4 patients and 
lower positive percentage change in IAUGC60 1 patient at T3 from baseline; in 
one patient, there was an increase at T2 before decline to high negative 
percentage at T3; in one patients there was crescendo negative percentage 
changes from T1-T3. In 6/15 patients, there was an initial percentage increase in 
IAUGC60 at T1 from baseline, thereafter, 2 patients had a high negative 
percentage change at T2 before a relatively lower negative percentage in one 
patient and a further higher negative percentage change in the other patients at 
T3 from baseline; in 2 patients, there was lower positive percentage change at 
T2 with one of these patients continued to have lower positive percentage 
change and the other developed a significantly high negative percentage 
change of IAUGC60 at T3 from baseline.  
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The actual DCE-MRI images are presented in figures 5.24 and 5.25.The 
alterations in IAUGC60 values and pattern of changes are shown in table 5.14 
and figure 5.32 and 5.33 respectively.  
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Table 5.14: IAUGC60 values and percentage changes after NCRT (%r = -
24.2 to 31.9%) 
Code 
Baseline Post NCRT 
T0 T1 (% change) T2 (% change) T3 (% change) 
1 RY 16.84 10.29 (-38.9%) 7.09 (-57.9%) 7.49 (-55.5%) 
2 DG 16.57 14.90 (-10.1%) 11.48 (-30.7%) 13.27 (-19.9%) 
4 AH 17.11 21.39 (25.0%) 12.55 (-26.7%) 8.46 (-50.6%) 
5 KB 16.71 15.57 (-6.8%) 20.84 (24.7%) 10.29 (-38.4%) 
6 ED 11.24 16.58 (47.5%) 13.97 (24.4%) - 
7 AF 13.81 14.80 (7.2%) 1.81 (-86.9%) 8.48 (-38.6%) 
8 JN 15.75 22.04 (40%) 20.56 (30.6%) 19.74 (25.4%) 
9 SD 22.10 24.27 (9.8%) - - 
10 JH 11.00 10.78 (-2 %) 9.36 (-14.9%) 11.36 (3.3%) 
11 DP 20.84 12.92 (-38%) - - 
12 GA 17.11 13.19 (-22.9%) 9.43 (-44.9 %) 8.79 (-48.6%) 
14 MM 15.16 5.56 (-63.3%) 10.28 (-32.2%) - 
15 RC1 19.94 12.57 (-36.9%) 11.13 (-44.2%) 15.92 (-20.1%) 
16 RC2 13.56 17.24 (27.1%) 16.15 (19%) 8.99 (-33.7%) 
17 JT 16.38 13.62 (-16.8%) 8.12 (-50.4%) 11 (-32.5%) 
 Bold – significant changes; Statistical test – individual patient analysis  
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Figure 5.32: Absolute IAUGC60 values changes after NCRT (individual 
patients) 
 
Figure 5.33: Percentage IAUGC60 changes after NCRT (individual patients) 
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5.3.4 Relationship between MR multi-parametric measurements and 
clinical markers 
5.3.4.1 Multiparametric analysis of tumour clinicopathological 
characteristics, response to therapy and long-term outcomes  
The summary of association between MR multiparametric measurements at 
different time-points and clinical markers is presented in tables 5.15 and 5.16. 
The correlation between MR parameters and clinical markers is presented in 
tables 5.17 to 5.22. The association between mean values of MR parameters 
and clinical markers is presented in tables 5.23 to 5.25. 
At pre-treatment stage, hypoxic tumours showed nodal involvement, resisted 
tumour downstaging and recurred distally; large tumours had higher perfusion 
and tumour with higher interstitial space showed T-downstaging resulting in 
lower pathological T-stage.   
Immediately after NCRT, hypoxic tumours decreased in size; higher staged 
tumours maintained better perfusion, whilst tumours with decline in perfusion 
and interstitial space showed nodal downstaging.  
Six weeks after NCRT, tumours with T-downstaging had decreased cellularity 
with increasing interstitial space.  
Pre-operatively, tumours that remained or developed hypoxia (after NCRT) 
decreased in size, but showed nodal involvement, poor nodal downstaging with 
distant metastasis and shortened survival; large size tumours had decreased 
cell density, increased interstitial space and relatively less hypoxia; tumours 
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remaining perfused or re-developing perfusion (after NCRT) showed better 
nodal downstaging but higher recurrence and poor survival, whilst tumours 
developing increased transit of contrast within interstitium showed nodal 
involvement and poor nodal downstaging and higher distant metastasis rates. 
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Table 5.15: Summary of correlation between MR multi-parametric measurements and clinical markers during treatment timeline 
 
Clinicopathological Features Response to NCRT Long-term Outcomes 
cT cN pT pN cL nL pL T N pCR nRECIST LR DM OS 
T0 
- - - 
+ R2* 
- - 
+IAUGC60 + ve - 
- 
- 
- 
+R2* 
- 
T1 
- +ve, 
+IAUGC60 
- - - - - 
- - 
- 
+R2* 
- 
- 
- 
T2 
- 
 -ve 
- - 
+ADC - +ve - 
- 
- 
- 
- 
- 
T3 
- 
+ve - 
+ΔR2* 
-Δkep, 
- +ADC -  
-ΔR2* 
+Δkep, 
+ΔIAUGC60 
- 
+R2* 
- +ΔR2*, 
-Δkep, 
-ΔIAUGC60 
+ΔR2*, 
-ΔIAUGC60 
‘+’ positive correlation; ‘-’  negative correlation; prefix ‘c’ –Clinical; prefix ‘p’ – pathological;  suffix ‘’ – downstage; CR – pathological complete response; LR – local 
recurrence; DM – Distant metastasis; OS – overall survival
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Table 5.16: Summary of association between mean multiparametric measurements and clinical markers during treatment 
timeline 
 
Clinicopathological Features Response to NCRT Long-term Outcomes 
cT cN pT pN cL nL pL T N pCR nRECIST LR DM OS 
T0 - - ve R2* - - - R2* R2* - - - - - 
T1 
Ktrans, 
ve, kep 
ve, 
IAUGC60 
R2* - - - - - - - R2* - - - 
T2 - - - - - - - - - - - - - - 
T3 - - - - - - - - - - ADC, R2* 
Ktrans, 
IAUGC60 
- - 
‘+’ positive correlation; ‘-’  negative correlation; prefix ‘c’ –Clinical; prefix ‘p’ – pathological;  suffix ‘’ – downstage; CR – pathological complete response; LR – local 
recurrence; DM – Distant metastasis; OS – overall survival 
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Table 5.17: Correlation between ADC measurement and clinical markers 
ADC 
Clinicopathological Features Response to NCRT Long-term Outcomes 
cT cN pT pN cL nL pL T N pCR nRECIST LR DM Death 
T0 
ρ / r -0.24 0.16 0 0.17 -0.30* -0.13* -0.10* 0 0.06 0 -0.16 -0.03 0.15 -0.15 
p 0.40 0.56  0.57 0.29 0.66 0.72  0.82  0.57 0.90 0.60 0.59 
T1 
ρ / r -0.24 0.08 0.17 0.22 -0.004* 0.32* 0.12* -0.11 0.15 -0.15 -0.38 -0.37 0.05 -0.07 
p 0.40 0.77 0.55 0.45 0.98 0.27 0.67 0.68 0.60 0.60 0.17 0.18 0.86 0.79 
T2 
ρ / r -0.13 0.03 0.27 0.38 -0.21* 0.63* 0.20* -0.25 -0.32 -0.19 -0.47 -0.21 0.32 0.19 
p 0.68 0.90 0.38 0.21 0.49 0.02 0.52 0.42 0.30 0.54 0.12 0.49 0.30 0.54 
T3 
ρ / r -0.40 0.13 -0.12 0.22 0.10* 0.68* -0.27* 0.12 -0.07 0.07 -0.58 -0.40 0.07 0.12 
p .022 0.68 0.72 0.50 0.75 0.02 0.41 0.72 0.82 0.82 0.06 0.22 0.82 0.70 
‘+’ positive correlation; ‘-’  negative correlation; prefix ‘c’ –Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; suffix ‘’ – downstage; T – TNM 
T-stage; N – TNM N-stage; L – craniocaudal tumour length; RECIST – response evaluation criteria in solid tumours; CR – complete response; LR – 
local recurrence; DM – Distant metastasis; Statistical test – Shapiro-Wilk test  and Q-Q plots for normality, Spearman rho correlation analysis (ρ) for 
non-parametric data, *Pearson Correlation (r) for parametric data 
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Table 5.18: Correlation between R2* measurements and clinical markers 
R2*   
Clinicopathological Features Response to NCRT Long-term Outcomes 
cT cN pT pN cL nL pL T N pCR nRECIST LR DM Death 
T0 
ρ / r -0.15 0.11 0.30 0.58 -0.04 0.18 -0.18 -0.49 -0.34 0.15 0.12 0.07 0.627 0.04 
p 0.61 0.70 0.33 0.04 0.87 0.57 0.57 0.08 0.25 0.61 0.68 0.80 0.02 0.88 
T1 
ρ / r -0.07 -0.10 0.02 0 -0.04 -0.55 -0.08 -0.26 -0.09 0.077 0.76 -0.15 0.05 -0.35 
p 0.80 0.72 0.93  0.88 0.06 0.80 0.37 0.75 0.802 0.003 0.61 0.85 0.23 
T2 
ρ / r -0.30 -0.14 0 0.22 0.27* -0.25* -0.25* -0.12 -0.44 0.3 0.38 -0.30 0.44 0.06 
p 0.37 0.66  0.50 0.41 0.45 0.44 0.72 0.16 0.37 0.23 0.37 0.16 0.85 
T3 
ρ / r -0.05 0.01 0.22 0.08 0.37* -0.56* -0.22* -0.28 0.17 0.058 0.64 -0.29 -0.17 -0.49 
p 0.87 0.97 0.53 0.81 0.28 0.09 0.53 0.42 0.63 0.87 0.04 0.41 0.63 0.14 
‘+’ positive correlation; ‘-’  negative correlation; prefix ‘c’ –Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; suffix ‘’ – downstage; T – TNM 
T-stage; N – TNM N-stage; L – craniocaudal tumour length; RECIST – response evaluation criteria in solid tumours; CR – complete response; LR – 
local recurrence; DM – Distant metastasis; Statistical test – Shapiro-Wilk test for normality; Spearman rho correlation analysis (ρ) (non-parametric 
data), *Pearson Correlation (r) (for parametric data) 
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Table 5.19: Correlation between Ktrans measurement and clinical markers 
Ktrans   
Clinicopathological Features Response to NCRT Long-term Outcomes 
cT cN pT pN cL nL pL T N pCR nRECIST LR DM Death 
T0 
ρ / r -0.29 0.40 -0.04 0 0.16* 0.26* 0.32* 0.31 0.30 -0.07 -0.18 0.12 -0.31 0.10 
p 0.28 0.13 0.88  0.56 0.36 0.25 0.25 0.29 0.78 0.50 0.66 0.24 0.71 
T1 
ρ / r -0.12 0.50 -0.01 0.35 0.07* 0.06* 0.35* 0.34 0.15 -0.3 -0.06 0.37 -0.18 0.24 
p 0.65 0.05 0.96 0.21 0.79 0.82 0.21 0.20 0.60 0.26 0.82 0.17 0.51 0.38 
T2 
ρ / r 0.10 0.26 -0.32 0.17 -0.19* 0.23* 0.41* 0.49 0.11 0 -0.26 0.38 -0.11 0.19 
p 0.73 0.37 0.28 0.57 0.51 0.44 0.16 0.08 0.71  0.37 0.19 0.71 0.52 
T3 
ρ / r 0.30 0.05 0.15 0.22 -0.23* 0.03* 0.41* -0.12 -0.29 -0.14 -0.12 0.50 0.29 0.45 
p 0.37 0.87 0.64 0.50 0.48 0.91 0.20 0.72 0.37 0.66 0.07 0.11 0.37 0.16 
‘+’ positive correlation; ‘-’  negative correlation; prefix ‘c’ –Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; suffix ‘’ – downstage; T – TNM 
T-stage; N – TNM N-stage; L – craniocaudal tumour length; RECIST – response evaluation criteria in solid tumours; CR – complete response; LR – 
local recurrence; DM – Distant metastasis; Statistical test – Shapiro-Wilk test for normality; Spearman rho correlation analysis (ρ) (non-parametric 
data), *Pearson Correlation (r) (for parametric data) 
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Table 5.20: Correlation between ve measurement and clinical markers 
ve**    
Clinicopathological Features Response to NCRT Long-term Outcomes 
cT cN pT pN cL nL pL T N pCR nRECIST LR DM Death 
T0 
ρ / r -0.25 0.29 -0.46 -0.15 0.29 0.02 -0.14 .523 .304 0.42 -0.03 0.12 -0.31 -0.27 
p 0.36 0.28 0.09 0.60 0.28 0.94 0.62 .045 .291 0.11 0.91 0.66 0.24 0.31 
T1 
ρ / r -.038 0.64 -0.29 0.15 -0.20 0.08 0.24 .489 .405 0.03 -0.12 0.18 -0.40 0 
p 0.16 0.01 0.30 0.60 0.46 0.78 0.39 .065 .151 0.89 0.65 0.50 0.13  
T2 
ρ / r 0.15 0.17 -0.62 -0.28 -0.28 0.23 0.02 .624 .456 0.39 -0.31 0.38 -0.45 -0.09 
p 0.60 0.56 0.021 0.34 0.34 0.43 0.92 .023 .117 0.18 0.30 0.19 0.11 0.75 
T3 
ρ / r -0.42 .642 0.08 0.17 -0.23 0.03 0.33 0 .172 0 0.09 0.38 -0.17 -0.09 
p 0.15 .018 0.77 0.57 0.43 0.90 0.26  .574  0.77 0.19 0.57 0.75 
‘+’ positive correlation; ‘-’  negative correlation; prefix ‘c’ –Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; suffix ‘’ – downstage; T – TNM 
T-stage; N – TNM N-stage; L – craniocaudal tumour length; RECIST – response evaluation criteria in solid tumours; CR – complete response; LR – 
local recurrence; DM – Distant metastasis; Statistical test – Shapiro-Wilk test for normality; Spearman rho correlation analysis (ρ) (non-parametric 
data), *Pearson Correlation (r) (for parametric data); ** ve not normal distribution  
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Table 5.21: Correlation between kep measurement and clinical markers 
kep    
Clinicopathological Features Response to NCRT Long-term Outcomes 
cT cN pT pN cL nL pL T N pCR nRECIST LR DM Death 
T0 
ρ / r -0.19 0.27 0.19 0.15 0.06* 0.23 0.21 -.035 0.10 -0.29 0.09 .006 -0.13 .297 
p 0.49 0.32 0.51 0.60 0.82 0.42 0.45 0.90 0.73 0.29 0.73 0.82 0.62 .282 
T1 
ρ / r -0.08 0.34 0.26 0.30 0.17* 0.11* 0.34* 0.07 -0.10 -0.42 -0.06 0.43 0.04 .419 
p 0.76 0.20 0.35 0.29 0.53 0.70 0.22 0.80 0.73 0.11 0.82 0.10 0.87 .120 
T2 
ρ / r 0.05 0.26 -0.23 0.22 -0.27* 0.26* 0.43* 0.40 0 -0.04 -0.26 0.38 0 .293 
p 0.86 0.37 0.43 0.45 0.37 0.38 0.13 0.17  0.87 0.37 0.19  .332 
T3 
ρ / r 0.26 -0.08 0.34 0.19 0.15* 0.34* 0.29* -0.23 -0.52 -0.16 -0.25 0.48 0.52 .587 
p 0.40 0.78 0.27 0.54 0.63 0.27 0.35 0.47 0.08 0.61 0.43 0.11 0.08 .045 
‘+’ positive correlation; ‘-’  negative correlation; prefix ‘c’ –Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; suffix ‘’ – downstage; T – TNM 
T-stage; N – TNM N-stage; L – craniocaudal tumour length; RECIST – response evaluation criteria in solid tumours; CR – complete response; LR – 
local recurrence; DM – Distant metastasis; Statistical test – Shapiro-Wilk test for normality; Spearman rho correlation analysis (ρ) (non-parametric 
data), *Pearson Correlation (r) (for parametric data) 
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Table 5.22: Correlation between IAUGC60 measurement and clinical markers 
IAUGC60    
Clinicopathological Features Response to NCRT Long-term Outcomes 
cT cN pT pN cL nL pL T N pCR nRECIST LR DM Death 
T0 
ρ / r -0.27 0.39 0.07 0.22 0.01* 0.07* 0.53* 0.21 0.30 -0.17 -0.23 -0.12 -0.31 0.03 
p 0.32 0.14 0.80 0.43 0.95 0.78 0.05 0.45 0.29 0.53 0.39 0.66 0.24 0.90 
T1 
ρ / r -0.21 0.55 -0.17 0.35 -0.09* -0.03* 0.31* 0.38 0.15 -0.19 0.03 0.37 -0.18 0.17 
p 0.45 0.00 0.54 0.21 0.73 0.92 0.26 0.15 0.60 0.49 0.91 0.17 0.51 0.53 
T2 
ρ / r 0.05 0.30 -0.36 0.17 -0.22* 0.19* 0.36* 0.49 0.11 0.04 -0.17 0.38 -0.11 0.19 
p 0.86 0.31 0.21 0.57 0.46 0.53 0.22 0.08 0.71 0.87 0.56 0.19 0.71 0.52 
T3 
ρ / r 0.20 -0.13 0.14 -0.07 -0.21 0.005 0.42 -0.06 -0.37 -0.22 0.12 0.50 0.37 0.32 
p 0.55 0.68 0.66 0.82 0.52 0.98 0.19 0.86 0.25 0.5 0.70 0.11 0.25 0.33 
‘+’ positive correlation; ‘-’  negative correlation; prefix ‘c’ –Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; suffix ‘’ – downstage; T – TNM 
T-stage; N – TNM N-stage; L – craniocaudal tumour length; RECIST – response evaluation criteria in solid tumours; CR – complete response; LR – 
local recurrence; DM – Distant metastasis; Statistical test – Shapiro-Wilk test for normality; Spearman rho correlation analysis (ρ) (non-parametric 
data), *Pearson Correlation (r) (for parametric data) 
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Table 5.23: Difference in mean multiparametric values according to clinical features 
Parameter 
cT cN pT pN 
cT2 cT3 cT4 p cN0 cN1 cN2 p pT0 pT1 pT2 pT3 p pN0 pN1 p 
ADC 
T0 1.40 1.31 - 0.65 1.52 1.25 1.44 0.20 1.32 1.31 1.35 1.28 0.97 1.30 1.46 0.32 
T1 1.75 1.59 - 0.40 1.71 1.56 1.69 0.49 1.52 1.51 1.65 1.62 0.83 1.59 1.74 0.28 
T2 1.60 1.57 - 0.84 1.76 1.51 1.66 0.23 1.46 1.59 1.57 1.61 0.81 1.54 1.71 0.21 
T3 1.88 1.62 - 0.26 1.88 1.57 1.75 0.27 1.67 - 1.65 1.63 0.97 1.63 1.70 0.72 
 
R2* 
T0 23.5 23.24 - 0.92 27.5 22.6 23.8 0.27 23.5 22.6 22.0 25.7 0.28 22.6 27.5 0.02 
T1 23.6 23.1 - 0.92 19.8 25.4 21.5 0.40 23.6 38.4 21.8 24.7 0.01 24.3 24.4 0.99 
T2 30.7 25.3 - 0.34 24.9 26.3 25.0 0.92 30.7 23.1 24.7 26.6 0.74 25.1 29.2 0.32 
T3 24.8 24.1 - 0.83 20.9 24.9 23.8 0.42 24.8 - 23.7 24.7 0.86 24.1 24.4 0.90 
 
Ktrans 
T0 0.22 0.17 0.15 0.51 0.13 0.18 0.19 0.26 0.17 0.11 0.19 0.15 0.18 0.17 0.17 0.98 
T1 0.10 0.15 0.00 0.03 0.05 0.14 0.17 0.06 0.09 0.13 0.16 0.11 0.35 0.12 0.16 0.44 
T2 0.07 0.11 0.09 0.85 0.09 0.10 0.14 0.69 0.10 0.12 0.14 0.07 0.59 0.11 0.11 0.99 
T3 0.07 0.09 - 0.80 0.09 0.07 0.12 0.42 0.08 - 0.09 0.09 0.98 0.08 0.10 0.62 
 
ve* 
T0 0.30 0.24 0.24 0.50* 0.23 0.24 0.26 0.53* 0.30 0.14 0.26 0.20 0.05* 0.24 0.23 0.58* 
T1 0.31 0.28 0.00 0.25* 0.10 0.28 0.32 0.50* 0.21 0.27 0.20 0.24 0.30* 0.26 0.28 0.58* 
T2 0.27 0.23 0.31 0.53* 0.26 0.22 0.28 0.54* 0.29 0.27 0.23 0.21 0.16* 0.24 0.19 0.32* 
T3 0.29 0.21 0.00 0.31* 0.11 0.19 0.30 0.08* 0.19 0.00 0.22 0.23 0.57* 0.19 0.27 0.55* 
 
kep 
T0 0.75 0.75 0.66 0.91 0.59 0.78 0.72 0.48 0.60 0.72 0.77 0.76 0.68 0.72 0.75 0.85 
T1 0.36 0.54 0.00 0.003 0.25 0.52 0.56 0.12 0.30 0.49 0.54 0.51 0.31 0.46 0.57 0.41 
T2 0.30 0.43 0.29 0.76 0.35 0.41 0.47 0.82 0.38 0.47 0.48 0.34 0.82 0.40 0.48 0.62 
T3 0.29 0.31 - 0.90 0.43 0.26 0.40 0.44 0.30 0.00 0.32 0.38 0.30 0.29 0.40 0.46 
 
IAUGC60 
T0 17.1 16.2 15.1 0.91 13.0 16.7 16.6 0.32 15.2 11.2 17.3 15.1 0.18 15.6 16.8 0.61 
T1 13.1 15.9 5.5 0.10 8.17 15.2 18.8 0.03 11.9 16.5 16.5 12.3 0.33 13.7 18.1 0.19 
T2 9.4 12.0 10.2 0.87 9.82 11.3 14.1 0.65 11.9 13.9 13.3 9.01 0.68 11.7 12.0 0.94 
T3 8.7 11.5 0 0.51 11.3 10.7 12.3 0.86 8.89 - 12.5 10.7 0.52 11.3 10.8 0.87 
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‘+’ positive correlation; ‘-’  negative correlation; prefix ‘c’ –Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; T –TNM T-stage; N – TNM N-stage; 
L – craniocaudal tumour length; RECIST – response evaluation criteria in solid tumours; CR – complete response; LR – local recurrence; DM – Distant 
metastasis; Statistical test – Shapiro-Wilk test and Q-Q plots for normality; Spearman rho correlation analysis (ρ) (non-parametric data), *Pearson 
Correlation (r) (for parametric data); Means compared with ANOVA (for normally distributed data) and Kruskal-Wallis test or Mann-Whitney-U test for 
non-normal distribution; * ve not normally distributed. 
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Table 5.24: Difference in mean multiparametric values according to response to NCRT 
Parameter 
T- downstaging N-downstaging Post NCRT RECIST Post-Operative NCRT 
‘+’ positive correlation; ‘-’  
negative correlation; prefix ‘c’ –
Clinical; prefix ‘p’ – pathological; 
prefix ‘n’ – post-NCRT; suffix ‘’ 
– downstage; T – TNM T-stage; 
N – TNM N-stage; L – 
craniocaudal tumour length; 
RECIST – response evaluation 
criteria in solid tumours; CR – 
complete response; LR – local 
recurrence; DM – Distant 
metastasis; Statistical test – 
Shapiro-Wilk test and Q-Q plots 
for normality; Spearman rho 
correlation analysis (ρ) (non-
parametric data), *Pearson 
Correlation (r) (for parametric 
data); Means compared with 
ANOVA (for normally distributed 
data) and Kruskal-Wallis test or 
Mann-Whitney-U test for non-
normal distribution; * ve not 
normally distributed 
T T p N N p PR SD p CR PR SD p 
ADC 
T0 1.33 1.28 0.79 1.31 1.32 0.91 1.27 1.39 0.33 1.32 1.29 1.42 0.70 
T1 1.59 1.62 0.77 1.61 1.56 0.68 1.55 1.69 0.17 1.52 1.61 1.64 0.82 
T2 1.55 1.61 0.53 1.55 1.67 0.36 1.52 1.72 0.08 1.46 1.59 1.60 0.64 
T3 1.66 1.63 0.83 1.64 1.69 0.78 1.57 1.84 0.05 1.67 1.68 1.56 0.76 
 
R2* 
T0 22.1 25.7 0.03 22.3 26.2 0.03 23.4 22.9 0.79 23.5 22.7 25.5 0.46 
T1 23.8 24.7 0.78 24.2 23.5 0.84 26.4 20.4 0.03 23.6 24.6 24.5 0.98 
T2 25.3 26.6 0.71 24.8 30.4 0.16 27.1 22.4 0.17 30.7 24.8 26.7 0.57 
T3 23.9 24.7 0.66 24.5 22.9 0.49 25.3 21.5 0.02 24.8 23.8 24.8 0.88 
 
Ktrans 
T0 0.18 0.15 0.26 0.17 0.18 0.86 0.17 0.18 0.65 0.17 0.17 0.16 0.96 
T1 0.15 0.11 0.36 0.13 0.16 0.49 0.14 0.14 0.99 0.09 0.14 0.15 0.45 
T2 0.13 0.07 0.30 0.11 0.09 0.62 0.10 0.14 0.34 0.10 0.12 0.09 0.87 
T3 0.08 0.09 0.96 0.08 0.10 0.61 0.08 0.09 0.95 0.08 0.08 0.10 0.90 
 
ve* 
T0 0.26 0.20 0.05 0.25 0.23 0.73 0.24 0.25 0.95 0.30 0.21 0.26 0.20 
T1 0.27 0.24 0.06 0.27 0.25 0.53 0.28 0.24 0.68 0.21 0.27 0.29 0.68 
T2 0.25 0.21 0.03 0.25 0.20 0.15 0.22 0.28 0.33 0.22 0.23 0.22 0.28 
T3 0.19 0.23 1.0 0.20 0.23 0.64 0.20 0.20 0.82 0.19 0.17 0.28 0.27 
 
kep 
T0 0.74 0.76 0.82 0.74 0.78 0.76 0.74 0.75 0.89 0.60 0.80 0.68 0.27 
T1 0.49 0.51 0.43 0.46 0.60 0.25 0.51 0.46 0.65 0.30 0.53 0.51 0.16 
T2 0.44 0.34 0.44 0.41 0.42 0.97 0.37 0.51 0.24 0.38 0.42 0.42 0.95 
T3 0.38 0.27 0.34 0.28 0.26 0.18 0.29 0.36 0.60 0.30 0.29 0.36 0.86 
 
IAUGC60 
T0 16.6 15.1 0.44 16.2 16.5 0.86 15.6 17.1 0.39 15.2 15.0 17.7 0.30 
T1 16.0 12.3 0.21 14.6 16.6 0.52 15.0 15.0 0.98 11.9 14.6 15.7 0.54 
T2 12.9 9.01 0.22 11.9 10.4 0.71 11.0 13.2 0.51 11.9 12.1 10.7 0.93 
T3 11.5 10.7 0.77 11.0 12.3 0.68 11.7 10.0 0.53 8.89 12.2 10.9 0.59 
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Table 5.25: Difference in mean multiparametric values according to long-term outcomes 
Parameter 
Local Recurrence Distant Metastasis Survival 
‘+’ positive correlation; ‘-’  negative correlation; prefix ‘c’ –
Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; T – 
TNM T-stage; N – TNM N-stage; L – craniocaudal tumour 
length; RECIST – response evaluation criteria in solid tumours; 
CR – complete response; LR – local recurrence; DM – Distant 
metastasis; Statistical test – Shapiro-Wilk test and Q-Q plots 
for normality; Spearman rho correlation analysis (ρ) (non-
parametric data), *Pearson Correlation (r) (for parametric 
data); Means compared with ANOVA (for normally distributed 
data) and Kruskal-Wallis test or Mann-Whitney-U test for non-
normal distribution; * ve not normally distributed   
Yes No p Yes No p Yes No p 
ADC 
T0 1.28 1.32 0.87 1.40 1.30 0.53 1.31 1.31 0.98 
T1 1.38 1.61 0.23 1.63 1.59 0.82 1.61 1.57 0.76 
T2 1.56 1.57 0.96 1.67 1.55 0.36 1.54 1.64 0.43 
T3 1.46 1.66 0.38 1.69 1.64 0.78 1.62 1.71 0.58 
 
R2* 
T0 23.1 23.2 0.97 28.8 22.2 <0.001 22.6 24.6 0.26 
T1 21.7 24.3 0.65 24.6 24.0 0.88 24.6 22.4 0.47 
T2 21.8 26.2 0.43 30.4 24.8 0.16 25.4 26.8 0.70 
T3 22.8 24.3 0.61 22.9 24.5 0.49 25.2 21.9 0.07 
 
Ktrans 
T0 0.19 0.17 0.71 0.14 0.18 0.25 0.17 0.19 0.62 
T1 0.23 0.13 0.12 0.12 0.14 0.62 0.13 0.17 0.29 
T2 0.22 0.10 0.09 0.09 0.11 0.62 0.10 0.14 0.36 
T3 0.19 0.07 0.008 0.10 0.08 0.61 0.08 0.10 0.63 
 
ve* 
T0 0.25 0.24 0.64 0.21 0.25 0.23 0.25 0.22 0.29 
T1 0.31 0.26 0.48 0.22 0.27 0.12 0.26 0.27 1 
T2 0.31 0.23 0.18 0.20 0.25 0.11 0.24 0.24 0.73 
T3 0.31 0.19 0.17 0.23 0.20 0.55 0.19 0.24 0.73 
 
kep 
T0 0.73 0.74 0.92 0.67 0.76 0.56 0.71 0.85 0.22 
T1 0.75 0.47 0.15 0.54 0.48 0.72 0.45 0.60 0.16 
T2 0.61 0.39 0.34 0.42 0.41 0.97 0.37 0.56 0.14 
T3 0.61 0.28 0.07 0.46 0.28 0.18 0.27 0.42 0.20 
 
IAUGC60 
T0 15.7 16.3 0.87 13.7 16.6 0.24 16.1 16.5 0.82 
T1 22.0 14.5 0.14 12.8 15.3 0.50 14.5 16.3 0.54 
T2 20.5 11.0 0.08 10.4 11.9 0.71 11.1 13.8 0.44 
T3 19.7 10.4 0.008 12.3 11.0 0.68 11.1 11.6 0.84 
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5.3.4.2 Association between MRI multiparametric alteration after NCRT 
and clinicopathological characteristics, response to therapy and 
long-term outcomes 
The binary alteration pattern in parametric measurements (increase or 
decrease) were analysed against clinicopathological characteristics, response 
to therapy and long-term outcomes. The relation between alterations in MR 
multi-parametric measurements and clinical data was investigated by Chi-
Square or Fisher exact tests and Spearman rho correlation analysis. The results 
are presented in table 5.26 to 5.28. 
During the interval between completion of NCRT and surgery (see table 5.27), 
tumours that remained large in size had low cell density (low ADC) with large 
interstitial space (high ve); tumours that remained (or became) hypoxic (high 
R2*) showed localised nodal metastasis, poor nodal downstaging with distant 
metastasis and shortened survival; tumours remaining perfused or re-
developing perfusion showed increased nodal downstaging, decreased distant 
metastasis and survival, whilst tumours developing increased transit of contrast 
within interstitium (high kep) showed poor nodal involvement, good nodal 
downstaging and low distant metastasis. 
None of the MR parameters changes showed any association with clinical 
markers based on chi-square or Fisher exact tests.
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Table 5.26: MR multi-parametric alterations after NCRT and clinical outcomes.  
 
* Statistically significant; PCR – pathological complete response; RCR – radiological complete response 
Code 
Sex Age cTNM Δ ADC Δ R2* Δ Ktrans Δ ve Δ kep Δ IUAGC60 
Post NCRT 
TNM (yp or r) 
Local 
Recurrence 
Distant 
Recurrence 
Death 
1 RY M 59 T3N1M0 *  *  * * T3N0    
2 DG* M 52 T3N1M0 * * *  *  T3N1  ✓: Lung ✓ 
3 DJ M 72 T3N1M2 - - - - - - - - ✓: Liver ✓ 
4 AH M 74 T3N2M0 *  *  * * T2N1    
5 KB M 78 T3N1M0 *  * * * * T2N0   ✓ 
6 ED F 72 T3N1M0 *  * * *  T1N0    
7 AF F 60 T3N1M0  * *  * * T2N0    
8 JN M 79 T3N2M0 *      T2N0 ✓   
9 SD** M 71 T3N1M0 *    *  T2N0   ✓ 
10 JH M 67 T3N0M0 * *     T3N0  ✓: Pancreas ✓ 
11 DP M 58 T3N1M0 *  *  * * T2N0    
12 GA*** M 53 T2N2M0 *  *  * * RCR    
13 PO F 59 T3N2M0 - - - - - - T3N2  ✓: Liver  
14 MM*** F 78 T4N0M0 - - * * * * RCR    
15 RC1 M 76 T3N1M0 * * * * * * T2N0    
16 RC2 M 56 T3N1M0 * - *    PCR    
17 JT F 79 T3N1M0   * * * * T3N0    
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Table 5.27: Correlation between MR multi-parametric alteration trends after NCRT and clinical markers 
Parameter Clinicopathological Features Response to NCRT Long-term outcomes 
cT cN pT pN cL nL pL T N CR nRECIST LR DM Death 
Δ ADC 
ρ 0.11 -0.12 0.24 -0.18 -0.02 - 0.60 -0.08 -0.19 0.18 -0.16 0.30 -0.11 -0.16 -0.25 
p 0.7 0.6 0.4 0.5 0.93 0.03 0.78 0.5 0.5 0.56 0.29 0.7 0.5 0.3 
Δ R2* 
ρ 0.2 0.11 0.33 0.53 -0.33 0.33 0.40 -0.18 -0.53 -0.30 -0.21 0.37 0.54 0.51 
p 0.4 0.6 0.2 0.05 0.24 0.25 0.17 0.5 0.05 0.29 0.43 0.1 0.04 0.05 
Δ Ktrans 
ρ 0 0.03 0.25 0.11 0.27 0.34 0.03 -0.16 -0.11 0.13 -0.21 0.07 0.1 0.16 
p  0.8 0.3 0.7 0.31 0.22 0.90 0.5 0.7 0.63 0.43 0.8 0.7 0.5 
Δ ve 
ρ -0.36 -0.13 -0.03 -0.4 0.80 0.32 -0.41 0.04 0 0.13 0.05 -0.28 -0.02 -0.04 
p 0.1 0.6 0.8 0.1 <0.001 0.26 0.14 0.8  0.63 0.84 0.3 0.9 0.88 
Δ kep 
ρ 0 0.03 -0.36 -0.67 0.18 0.24 -0.31 0.44 0.67 0.13 -0.21 0.07 -0.68 -0.44 
p  0.8 0.2 0.008 0.50 0.40 0.27 0.09 0.008 0.63 0.43 0.8 0.005 0.09 
Δ IAUGC60 
ρ 0 0.07 -0.27 -0.19 0.115 -0.20 -0.23 0.21 0.64 0.35 0 -0.37 -0.55 -0.53 
p  0.7 0.3 0.5 0.68 0.48 0.41 0.4 0.01 0.19  0.1 0.03 0.04 
‘+’ positive correlation; ‘-’  negative correlation; prefix ‘c’ –Clinical; prefix ‘p’ – pathological;  suffix ‘’ – downstage; CR – pathological complete 
response; LR – local recurrence; DM – Distant metastasis; Statistical test – Spearman rho correlation analysis. (ρ - rho, p-significance value) 
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Table 5.28: Association between MR multi-parametric changes after NCRT and clinical markers  
Parameters Clinicopathological Features Response to NCRT Long-term Outcomes 
cT cN pT pN T N CR nRECIST LR DM Death 
Δ ADC 0.87* 0.47 0.73 0.7* 0.5* 0.7* 0.72* 0.39* 0.8* 0.7* 0.4* 
Δ R2*   0.64* 0.11 0.32 0.12* 0.45* 0.12* 0.39* 0.20* 0.35* 0.11* 0.09* 
Δ Ktrans  0.86 0.65 0.06 0.85* 0.73* 0.85* 0.8* 0.60* 0.93* 0.86* 0.73* 
Δ ve 0.24 0.71 0.63 0.23* 0.66* 0.76* 0.55* 0.62* 0.46* 0.73* 0.66* 
Δ kep  0.86 0.65 0.43 0.14* 0.26* 0.14* 0.8* 0.60* 0.93* 0.13* 0.26 
Δ IAUGC60 0.41 0.86 0.12 0.5* 0.4* 0.06* 0.26* 0.71* 0.33* 0.09* 0.07* 
Prefix ‘c’ –Clinical; prefix ‘p’ – pathological;  suffix ‘’ – downstage; CR – pathological complete response; LR – local 
recurrence; DM – Distant metastasis; Statistical tests - Chi-Square; *Fisher exact test 
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5.3.5 Role of MRI Multiparametric analysis in predicting response to 
NCRT and long-term prognosis 
The difference in parameters values and statistical significance between 
baseline and each time point for response and long-terms outcomes is given in 
tables 5.29–5.31. 
In summary, increase in ADC from baseline was statistically significant in 
responders and patients without recurrence. However, ADC significantly 
increased in both survived and diseased groups, hence ADC was of value in 
predicting response and recurrence but not survival.  On the other hand, 
patients with hypoxic tumour at pre-operative stage (significantly increased R2*  
at T3) showed N-downstaging and were alive at the end of study. Amongst DCE 
parameters: patient with T-downstaging showed a significant decrease in kep at 
all time-points, preoperative Ktrans and IAUGC60 at T3; patients with N-
downstaging showed significant decrease in Ktrans and kep at all time-points and 
IAUGC60 at T3; patients without recurrence and who remained alive at the end 
of the study showed decline in Ktrans (T1-T3), kep (T2-T3) and IAUGC60 (T2-T3).  
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Table 5.29: Difference in mean parametric values after NCRT between 
patient with and without TNM downstaging 
Parameter T0 vs. T1 
(mean) 
p 
T0 vs. T2 
(mean) 
p 
T0 vs. T3 
(mean) 
p 
T 
 
ADC 1.33 1.59 0.002 1.35 1.55 0.08 1.35 1.66 0.01 
R2* 22.4 23.4 0.43 22.3 25.3 0.31* 22.3 23.9 0.20 
Ktrans 0.18 0.15 0.11 0.17 0.13 0.11 0.19 0.08 0.01 
ve 0.26 0.27 0.24* 0.25 0.25 0.67* 0.25 0.19 0.21 
kep 0.74 0.49 0.01* 0.73 0.44 0.005 0.73 0.27 0.004 
IAUGC60 16.6 16.0 0.71 15.5 12.9 0.24 16.2 11.5 0.02* 
 
T 
 
ADC 1.28 1.62 0.12 1.28 1.61 0.10 1.28 1.63 0.16 
R2* 25.7 24.7 0.69 25.7 26.6 0.59* 25.7 24.7 0.73 
Ktrans 0.15 0.11 0.14 0.15 0.07 0.02 0.15 0.09 0.06 
ve 0.20 0.24 0.14* 0.20 0.21 0.71* 0.20 0.23 0.35 
kep 0.76 0.51 0.06* 0.76 0.34 0.05 0.76 0.38 0.06 
IAUGC60 15.1 12.3 0.13 15.1 9.0 0.04 15.1 10.7 0.14* 
 
N 
 
ADC 1.31 1.61 0.003 1.31 1.54 0.03 1.31 1.64 0.01 
R2* 22.3 24.2 0.32 22.4 24.8 0.26* 22.4 24.5 0.04 
Ktrans 0.17 0.13 0.06 0.17 0.11 0.03 0.18 0.08 0.003 
ve 0.25 0.27 0.20* 0.24 0.25 0.42* 0.24 0.20 0.31 
kep 0.74 0.46 0.01* 0.75 0.41 0.001 0.76 0.28 <0.001 
IAUGC60 16.2 14.6 0.35 15.7 11.9 0.70 16.3 11.0 0.01* 
 
N 
 
ADC 1.32 1.56 0.01 1.40 1.67 0.09 1.40 1.69 0.15 
R2* 26.2 23.5 0.39 28.8 30.4 0.65* 28.8 22.9 0.07 
Ktrans 0.18 0.16 0.16 0.14 0.09 0.23 0.14 0.10 0.20 
ve 0.23 0.25 0.28* 0.21 0.20 0.18* 0.21 0.23 0.50 
kep 0.78 0.60 0.10* 0.67 0.42 0.24 0.67 0.46 0.30 
IAUGC60 16.5 16.6 0.94 13.7 10.4 0.30 13.7 12.3 0.65* 
Statistical Test: Paired sample T-test; *Wilcoxon Signed ranked test 
Note: Complete response not assessed as few small sample size 
‘’ denotes downstaging; ‘’ denotes no change 
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Table 5.30: Difference in mean parametric values after NCRT between 
patient with and without RECIST downstaging 
Parameter T0 vs. T1 
(mean) 
p 
T0 vs. T2 
(mean) 
p 
T0 vs. T3 
(mean) 
p 
nRECIST 
 
ADC 1.27 1.55 0.02 1.27 1.52 0.05 1.27 1.57 0.03 
R2* 23.4 26.4 0.18 23.4 27.1 0.04 23.5 25.3 0.24 
Ktrans 0.17 0.14 0.17 0.17 0.10 0.01 0.18 0.08 0.01 
*ve 0.24 0.28 0.05 0.24 0.22 0.85 0.24 0.20 0.44 
kep 0.74 0.51 0.03 0.74 0.37 0.003 0.74 0.29 0.002 
IAUGC60 15.6 15.0 0.70 15.6 11.0 0.05 16.2 11.7 0.01 
 
nRECIST 
 
ADC 1.39 1.69 0.002 1.48 1.72 0.01 1.48 1.84 0.02 
R2* 22.9 20.4 0.20 24.0 22.4 0.17 24.0 21.5 0.35 
Ktrans 0.18 0.14 0.14 0.16 0.14 0.48 0.16 0.09 0.09 
*ve 0.25 0.24 0.75 0.22 0.28 0.14 0.22 0.20 1 
kep 0.75 0.46 0.03 0.74 0.51 0.01 0.76 0.36 0.15 
IAUGC60 17.1 15.0 0.40 14.9 13.2 0.46 14.9 10.0 0.21 
prefix ‘n’ – post NCRT; Prefix ‘p’ – pathological; Suffix ‘’ denotes downstaging; Suffix ‘’ 
denotes no change: Statistical Test: Paired sample T-test ; *Wilcoxon Signed ranked test 
Note: Complete response not assessed as few small sample size 
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Table 5.31: Changes after NCRT and long-term outcomes 
 T0 vs. T1 
(mean) 
p 
T0 vs. T2 
(mean) 
p 
T0 vs. T3 
(mean) 
p 
No 
Recurrence 
(local or 
distant) 
 
ADC 1.30 1.61 0.002 1.31 1.55 0.06 1.31 1.66 0.01 
R2* 22.3 24.2 0.27 22.3 25.2 0.12* 22.6 24.7 0.03 
Ktrans 0.18 0.13 0.03 0.17 0.10 0.03 0.18 0.07 0.002 
ve 0.25 0.27 0.2* 0.23 0.24 0.57* 0.23 0.18 0.25 
kep 0.76 0.46 0.006* 0.75 0.39 0.002 0.76 0.24 <0.001 
IAUGC60 16.7 14.8 0.23 15.7 11.1 0.03 16.4 9.9 0.01* 
 
Recurrence 
(local or 
distant) 
 
ADC 1.36 1.54 0.10 1.36 1.64 0.10 1.36 1.61 0.10 
R2* 26.9 23.6 0.10 26.9 27.5 -* 26.9 22.9 0.10 
Ktrans 0.16 0.15 0.87 0.16 0.13 0.46 0.16 0.13 0.19 
ve 0.23 0.25 0.28* 0.23 0.24 -* 0.23 0.25 0.24 
kep 0.69 0.61 0.41* 0.69 0.48 0.10 0.69 0.51 0.11 
IAUGC60 14.4 15.9 0.61 14.4 13.8 0.84 14.4 14.7 0.59* 
 
Alive 
 
ADC 1.31 1.61 0.008 1.31 1.54 0.06 1.31 1.62 0.03 
R2* 22.6 24.8 0.30 22.7 25.4 0.23* 22.7 25.2 0.04 
Ktrans 0.17 0.13 0.07 0.17 0.10 0.01 0.18 0.08 0.008 
ve 0.25 0.26 0.32* 0.24 0.24 0.64* 0.24 0.19 0.21 
kep 0.71 0.45 0.01* 0.72 0.37 0.002 0.73 0.27 0.002 
IAUGC60 16.1 14.5 0.39 15.6 11.1 0.03 16.3 11.1 0.01* 
 
Diseased 
 
ADC 1.31 1.57 0.06 1.36 1.64 0.007 1.36 1.71 0.04 
R2* 24.6 22.4 0.32 25.8 26.8 -* 25.8 21.9 0.18 
Ktrans 0.19 0.17 0.05 0.16 0.14 0.67 0.16 0.10 0.12 
ve 0.22 0.27 0.14* 0.20 0.24 -* 0.20 0.24 0.29 
kep 0.85 0.60 0.06* 0.80 0.56 0.05 0.80 0.42 0.17 
IAUGC60 16.5 16.3 0.81 14.7 13.8 0.77 14.7 11.6 0.28* 
Statistical Test: Paired sample T-test; *Wilcoxon Signed ranked test 
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5.4 Discussion 
The role of standard MRI in clinical staging of locally advanced rectal cancers is 
well established and this imaging modality is part of standard work up in many 
countries.  However, post-NCRT staging of rectal cancer is limited by that fact 
that T2-weighted MRI is unable to exclude active disease within areas of 
fibrosis. A pre-requisite for the current trends towards individualised therapy for 
patients with rectal cancers demands perceptive markers of rectal cancer 
biology. MR multi-parametric analysis can provide in depth analysis of rectal 
cancer pathophysiology. As demonstrated in the current study, MR multi-
parametric analysis enabled valuable insight into locally advance rectal tumour 
pathophysiology during the interval between NCRT and surgery. In general, the 
results of analysis were consistent with theoretical expectations; for example, 
rise in ADC values and increase in extracellular volume (ve) during the interval 
represents a reduction in tumour cell density with necrosis, whilst, decreasing 
Ktrans, kep, IAUGC60 and higher R2* corresponds to progressive tumour 
devascularisation an hypoxia. Statistically significant clinical correlation were 
seen with all parameters.  
The unique quality of DW-MRI to produce enhanced signals from regions of 
restricted proton diffusion, such as disorganised cellular architecture in tumours, 
that accentuates any neoplastic disease process especially residual tumour 
after neoadjuvant treatments has generated interest in the application of DW-
MRI sequence with T2-weighted images in staging/re-staging post-NCRT and 
management of patients with locally advance rectal cancer [446]. In the current 
experiment, mean ADC values from pre-treatment paired samples were similar 
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to that reported earlier and showed best reproducibility and inter-observer 
agreement amongst all parameters measured [447, 448]. The pre-operative 
ADC significantly increased from baseline in 85.7% of patients. The relative 
higher increase at immediately after NCRT may represent tissue oedema due to 
radiotherapy. Further increase in ADC values later during the interval 
represents loss of membrane integrity and cell necrosis with increased water 
diffusion. The negative correlation between ADC and DCE parameters (Ktrans 
and kep at baseline and IAUGC60 immediately after NCRT) shows that LARC 
have several foci of cellular necrosis and poor microvascular circulation that 
increases after NCRT. In recent years, DWI-MRI has shown the potential to 
enhance diagnostic/staging accuracy when added to standard T2-weighted 
images. For example, DW-MRI enhances the characterising of rectal cancers 
[449-451] and the nodal status [452-454]; delineates involvement of mesorectal 
resection margin [449, 455]; improves response assessment [456, 457] and 
prediction of response to NCRT [458]. Most studies have reported a distinct link 
between ADC values at either baseline [457, 458] and/or post-NCRT [459] 
and/or percentage changes after NCRT [460, 461] with tumour downstaging 
after NCRT. In the current study, a rise in ADC was apparent before changes in 
craniocaudal tumour length demonstrating intra-tumoural changes (cell 
destruction) earlier than conventional methods based on RECIST criteria. Whilst 
some studies reported that tumours with lower mean ADC values at pre-
treatment have consistent ‘T’ downstaging and pCR [460, 462]; other 
investigators reported lower pre-treatment ADC values to be related with poor 
response and predicted early local recurrence [463]. In addition, studies 
comparing ADC with tumour histopathology have reported low ADC in rectal 
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cancers that are poorly differentiated, spread to lymph nodes and invade CRM 
[449, 451]. In the current study, patients with lower baseline mean ADC values 
also showed poor T-downstaging (see table 5.31, page 260). In other studies, 
patients with higher ADC value post-NCRT showed complete response [459, 
464, 465] and also increased diagnostic accuracy of active tumour when DW 
sequence was added to post-NCRT conventional MRI [466]. A number of 
studies have also reported that tumours with significant percentage increase in 
ADC during NCRT tended to downstage [460, 467] and show pCR [461, 462]. 
Similarly, in the current cohort, there was a significant rise in ADC values after 
NCRT in patients who had T- and N-downstaging and survived without 
recurrence during the follow-up period (see table 5.31, page 260). However, on 
comparison of mean ADC values with clinical parameters, there was neither 
correlation nor significant variation in the mean ADC at different time-points and 
clinical markers (tables 5.17, page 243 and tables 5.23–5.25, page 249-252).  
Similar non-association of ADC with clinical parameters have been reported in 
previous studies [468-471]. For example, DeVries et al [468] reported no 
difference in the mean ADC values between responders and non-responders, 
however when they investigated the distribution of any single voxel ADC value 
in a tumour region in a histogram-like fashion, ADC histogram showed a higher 
relative fraction of high ADC in the therapy non-responder group compared with 
the therapy responder group. The ADC values and/or changes after NCRT were 
not useful in distinguishing between worse outcomes with regards to recurrence 
and survival. Such discrepancies in the results amongst aforementioned studies 
including current experiment are not only due to variation in techniques (MRI 
protocol and software for data analysis) but also small sample size, variability in 
 CHAPTER 5: MRI – MULTIPARAMETRIC ANALYSIS 
 
260 
patient selection criteria, variations in timing of image acquisition during 
treatment timeline, ADC measurement errors (subtle variations in regions of 
interest positioning between observers may result in substantial variation in 
ADC [472]), inter-observer variability especially after NCRT and the inconsistent 
definition of ‘response to NCRT’ between studies (some authors use tumour 
size, whilst others use histopathological T stage and/or pCR).  
Tissue hypoxia is a common feature of most advanced solid tumours. ISW-MR 
assessment of tumour hypoxia has been applied in cancers of prostate [337, 
473], brain [327], breast [338, 474] and cervix [339]. In rectal cancers, tissue 
hypoxia may have a heterogeneous distribution within the same tumour and 
even within neighbouring micro-areas of the tissue [475]. Hypoxic rectal cancers 
are not only resistant to radiotherapy, but also release active proteins that 
promote tumour growth and spread, for example release of hypoxia-induced 
factor (HIF-1 Alpha) that triggers angiogenesis by activation of VEGF gene. In 
vivo assessment of rectal tumour hypoxia has been performed successfully by 
means of PET with hypoxia-detecting agents [476, 477]. In our study the mean 
baseline R2* was 22.9 (±2.9) sec-1 between paired analysis which is in the range 
of R2* values reported for pelvic malignancies (20.8 ±1.6 sec-1) [347], cervical 
cancers (21.1±6.7 sec-1) [339] and pelvic muscles (25.01 sec-1) [473]. The 
reproducibility of R2* was extremely good and better than mentioned studies. 
These findings suggest that rectal cancer are less hypoxic than other pelvic 
malignancies, however, given the rich blood supply of rectum, these tumours 
may still be relatively hypoxic compared to surrounding bowel tissue. After 
NCRT, the R2* measurements gradually increased to a maximum value at sixth 
weeks (see table 5.8, page 214), which may represent the maximum vascular 
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and cellular disruption caused by NCRT. Another notable observation is the 
negative correlation between R2* and ve that gradually increases after NCRT 
until significant levels at sixth week (-0.67, p 0.02). As R2* represents hypoxia 
immediately in the vicinity of vessels and ve represents extracellular space, it 
may be hypothesised that: after NCRT, the surviving tumour cells may locate 
and concentrate near blood vessels resulting in low ve and high R2*; a further 
loss of the tumour cell load (probably most hypoxic cells) after sixth weeks 
reduces the burden of cells sharing nutrients, and therefore results in further 
decline in ve, but also a paradoxical decline in R2* suggesting a relatively 
improved oxygenation for the remaining tumour cells. Such cells can survive 
and may develop aggressive traits (see below). The R2* measurements were 
associated with several clinical markers. Tumours with high baseline R2* 
measurements were associated with nodal involvement (mean 27.5 sec-1), 
inhibited T (mean 25.7 sec-1) or N (mean 28.8 sec-1) down-staging and distant 
metastasis (mean 28.8 sec-1). Hence, these finding supports the theory that 
intra-tumoural hypoxia is marker of aggressive biological behaviour. 
Pathological advanced tumours showed significant hypoxia (high R2*) 
immediately after NCRT. The pattern of R2* alteration (Δ R2*) during the interval 
between NCRT and surgery showed significant positive correlation with 
pathological nodal disease, distant metastasis and numbers alive at the end of 
the study, whilst significant negative correlation with nodal downstaging. These 
findings not only provide vital insight that hypoxic tumour metastasize early with 
impact on future outcomes but are also in keeping with previous studies. For 
example, retrospective studies investigating immunohistochemical markers of 
hypoxia in rectal cancer specimen have shown poor response to NCRT and 
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adverse prognosis in patients with hypoxic tumours [181, 478, 479]. PET 
assessment of rectal tumour with hypoxia-detecting agents has also shown 
poor downstaging after NCRT and worst survival in patients with hypoxic 
cancers [476, 477]. The association between R2* and nodal disease also 
highlights the potential role of R2* in predicting nodal involvement in patients 
with high suspicion but node-negative disease (especially after NCRT) on 
standard T2-weighted MRI images.  In subgroup analysis, there was no role of 
R2* measurements or changes after NCRT in differentiating long-term 
outcomes. There are some limitations associated with R2*calculation in rectum, 
these include susceptibility artefact at air-tissue boundaries, motion artefact due 
to bowel peristalsis and bladder filling, changes in tumour position between 
sequences and changes in tumour size with treatment.  
Amongst DCE parameters, the baseline values and 95% CI for cohort were 
consistent with previously published reports but the magnitudes of spontaneous 
changes in an individual patient were very high [347]. Such findings are 
acceptable given tissue perfusion is a dynamic process with wide variation 
depending on several factors including cell activity, inflammatory response, 
stress and cardiac output. With regards to reproducibility, semi-quantitative 
parameter IAUGC60 was most reproducible with minimal spontaneous changes 
(CI cohort -10.75% to +12%, F 35.5), better repeatability than model driven 
parameters (r -34.6% to +52.9%) and minimal observer influence (ICC 94%). 
These findings are in keeping with published studies [414].  In model-based 
parameters, Ktrans and kep showed less spontaneous changes (CI cohort 
±13.7%, ±11.1% and F 4.3, 4.9, respectively) than ve (CI cohort ±14.1%, F 2.4); 
kep showed best repeatability (r ±41.5); the observer interference on readings 
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was poor for ve (ICC 38%) and moderate for Ktrans and kep (ICC 60% and 64%, 
respectively). In advanced tumours, vascular networks and circulation are poor 
partly due to abnormal development and partly due to greater rates of cellular 
necrosis; hence one would expect lower values of perfusion parameters. In the 
current study, a low value for all DCE parameters was seen in clinically 
advanced tumour but the differences were not statistically significant. Low levels 
of baseline and six weeks post-NCRT ve were associated with pathologically 
advanced tumours and alteration pattern in Δkep correlated negatively with 
pathological nodal disease. As ve is also related to endothelial cell integrity and 
membrane permeability, these finding may suggest that intact vascular 
endothelial lining in tumours may be a biological aggressive trait. In contrast, in 
another study, a higher level of ve equivalent (amplitude A: %; Brix model), was 
seen in patients with pathological lymph node metastases [480]. Previously, a 
low Ktrans equivalent (Plasma flow (PF): ml/100ml/min) and kep has been 
reported in clinically and pathologically advanced staged rectal tumours, 
respectively [471, 481], whereas no correlation between any DCE parameters 
and tumour stage was seen in another study [190]. Microvascular disruption as 
a result of NCRT also plays a role in tumour downstaging and reflected by 
changes in DCE parameters. After NCRT, there was a progressive significant 
percentage decrease in Ktrans, kep and IAUGC60, whilst ve values had maximum 
increase immediately after NCRT followed by lower percentage increases from 
baseline. The increase in ve immediately after NCRT may reflect tissue oedema 
following radiotherapy (as also seen by transient decrease in ADC). These 
finding suggest a continuing involution of the tumour vascular network during 
the interval between NCRT and surgery. Hence DCE parameters displayed 
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detailed insight into tumour pathophysiological processes after NCRT despite 
modest change in tumour size. Similar patterns of DCE parameters alterations 
after NCRT have been reported previous studies [482]. Earlier investigators 
have shown a link between high pre-treatment Ktrans and IAUGC60 (or their 
equivalent from other models) and poor downstaging [468, 480, 483]. In the 
current cohort, however, pre-treatment Ktrans and IAUGC60 of responders were 
higher at each time-points but this was not statistically significant (see tables 
5.29–5.30). These findings are still consistent with earlier results [351, 482, 
484]. Gollub et al [485] reported high Ktrans post-chemotherapy in patients not 
achieving pCR, however, in their study patients received non-standard 
neoadjuvant chemotherapy only (no irradiation). In the current cohort, a high 
baseline and post-NCRT ve and a low post-NCRT kep were associated with 
downstaging and complete response, respectively. The patients with T 
downstaging had a statistically significant drop in pre-operative Ktrans and 
IAUGC60 but not before that, whilst a significant drop in kep at all time-points. 
The patients with N- downstaging had statically significant drop in Ktrans and kep 
at all time-points and pre-operative IAUGC60. Similarly Kim et al [486] showed a 
significant decrease in absolute and percentage values of Ktrans after NCRT in 
patients with tumour downstaging. In another study by Dinter et al [487], a 
decrease in IAUGC60 equivalent measure (slope of contrast media 
enhancement curve) was significantly higher in patients with tumour 
downstaging after NCRT. Also, the alteration in Δkep and ΔIAUGC60 correlated 
positively with N downstaging.  These findings simply suggest that patients with 
continuous tumour vascular decline and cell destruction after NCRT are likely to 
downstage in size with nodal sterilization. Such response to NCRT will surely 
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benefit long-term outcomes and in fact, patients who showed significant 
decrease in Ktrans, IAUGC60 and kep were alive without any recurrence until the 
end of the follow-up period for this study. In contrast to a previous reports, 
where pre-treatment Ktrans equivalent (k21: min-1; Brix Model) was higher in 
patients with distant metastasis [480], in the current sample, the pre-treatment 
Ktrans was higher in patients without any recurrence. However, a preoperative 
high Ktrans and IAUGC60 value was associated with local recurrence. These 
findings indicate the return of angiogenesis and tumour revival with potential 
enhanced aggressive behaviour prior to surgery that possibly impedes local 
control. On the other hand, alteration in Δkep and ΔIAUGC60 negatively 
correlated with distant metastasis, whilst, ΔIAUGC60 also negatively correlated 
with survival. These findings together with ΔR2* association with long-term 
outcomes mentioned earlier, shows that after NCRT rectal cancers cells 
remaining viable in an environment with poor circulation and hypoxia represent 
a subset of tumour cell population that not only resists effects of irradiation but 
also develop aggressive traits prone to impedes distant disease control with 
impact on survival. Such findings also provide vital clues about time span of 
NCRT effects and optimal timing of surgery. In addition to similar limitation as 
for ADC and R2*, investigators of DCE-MRI have used different semi-
quantitative parameters, pharmacokinetic models to derive quantitative 
measures and contrast agents.  Such inhomogeneity in study designs and 
methodology makes comparison between results challenging.  
There are several limitations to this experiment. In addition to limitation in 
sample size, multiple visits for scans and simultaneous rectal biopsy deterred 
patients and also lead to loss of compliance after NCRT. This was further 
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reduced by technical or operator failures. Since MR multi-parametric analysis is 
still a developing technique, sample size reductions due to technical errors is 
not uncommon in published literature [471, 481]. The mean of all parameters 
values was used for analysis, which can result loss of specific data, for example 
tumour vascular heterogeneity, but such analysis are time efficient and 
reproducible at other units.  
In summary, MR multi-parametric analyses were reproducible and provided vital 
information about rectal cancer pathophysiology before and after NCRT, clinical 
staging and long-term outcomes. With regards to tumour pathophysiology: at 
baseline, LARC showed high cellularity (low ADC), adequate oxygenation (low 
R2*), minimal extracellular space (low ve) and near normal perfusion (Ktrans, kep, 
IAUGC60). After NCRT, there were a mixture of changes: in the first 6 weeks, 
there was gradual decline in tumour cellularity (increasing ADC and high ve) and 
functional vascularity (decreasing Ktrans, kep and IAUGC60), with maximal 
increase in intra-tumoural hypoxic foci (increase in R2*); after 6 weeks, the R2* 
and ve measurements were closer to baseline, which indicates decrease in 
extracellular-extravascular space and improvement in tumour hypoxia. It may 
be deduced from these findings that declining tumour cell burden had improved 
relative oxygenation at pre-operative stage and these cells may attain 
aggressive traits (tumours with low preoperative kep, IAUGC60 and high R2* has 
poor prognosis). With regards to clinical staging and outcomes, R2* and DCE 
parameters provided vitals clues about tumour behaviours and aggressiveness: 
a pre-operative return of angiogenesis indicates higher potential for local 
recurrence, whereas pre-operative tumour cell hypoxia indicates higher 
potential for distant metastasis and survival. However, the clinical correlation 
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showed be interpreted with caution due to the small sample size of current 
study.  
The current study has clearly demonstrated a potential role of MR- 
multiparametric analysis of rectal cancer in tumour staging, prediction of 
response to NCRT and long-term outcomes. Therefore further studies 
addressing the shortcomings of current and previous studies and designed as 
prospective multicentre study, standardization of parameters acquisition and 
modelling techniques on a larger sample size, would enable validation of our 
results.  
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6 CHAPTER 6: DYNAMIC CONTRAST ENHANCED 
COMPUTED TOMOGRAPHY  
Assessment of rectal cancer microcirculation  
6.1 Introduction 
Dynamic contrast enhanced CT is a validated technique to assess tumour 
angiogenesis non-invasively and has been utilised effectively in phase I/II trials 
for the development of anti-angiogenic drugs [488, 489] and monitoring disease 
control after locoregional therapy [490, 491]. Alterations in DCE-CT parameters 
may occur before any morphological changes in response to therapy, making 
perfusion CT a potential surrogate marker of response. In oncology, limited 
studies have shown its value in characterising lesions including biological 
behaviour, enhancing tumour staging, and as biomarkers of therapy response 
and long term prognosis. In terms of clinical integration, DCE-CT offers practical 
advantages over other imaging modalities including widespread availability of 
CT, protocols that are readily integrated into clinical coverage, short coverage 
periods and patient compliance.  
Some authors have investigated the correlation between DCE-CT parameters 
and histopathological markers of angiogenesis in colorectal cancer: such 
reports are mostly conflicting [381, 382, 384]. One reason for such variable 
results may be the presence of temporal and spatial functional vascular 
heterogeneity that is known to exist in most solid tumours [492]. In the last few 
years, migration of CT coverage from a limited ‘central core’ to a whole tumour 
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volume using either wide detector MDCT, shuttle or helical perfusion CT 
techniques has been seen as an advantage [493, 494], particularly for large 
solid tumours that may contain central areas of necrosis, demonstrating spatial 
variation in vascularization. Studies on lung [493] and renal cancers [495] using 
volumetric helical coverage techniques have reported improved reproducibility 
with whole tumour coverage. The evidence outside of this scenario has been 
less convincing. It is uncertain, for example, whether this applies readily to 
primary gastrointestinal cancers. An earlier study of colorectal cancer, for 
example, has suggested no difference in measurements, though this 
preliminary study only compared a 5mm and 20mm tumour volume, which is 
restricted compared with that achievable currently [496].  
The correlations between DCE-CT parameters and clinicopathological markers, 
response to NCRT and long-term outcomes of locally advanced rectal cancers 
have not been reported in literature to date. Few studies have also shown a 
difference in baseline DCE-CT parameters between responder and non-
responder to NCRT [47, 152, 265], hence indicating a potential role of perfusion 
CT in tailored treatment regimes.   
The current chapter presents a study of the application of DCE-CT using a 
volumetric coverage technique in patients with locally advanced rectal cancers. 
The aim of this experiment was to investigate: (1) The effects of volume 
coverage (2-D versus 3-D whole tumour volume coverage) on baseline day-to-
day reproducibility of DCE-CT parameters and observer agreement at baseline; 
(2) alteration in DCE-CT parameters in response to NCRT, and (3) role of DCE-
CT parameters in characterising rectal cancer angiogenesis and their 
 CHAPTER 6: DCE-CT: MICROCIRCULATION ANALYSIS  
 
271 
correlation with clinicopathological markers, response to treatment and long 
term prognosis.   
6.2 Methods 
6.2.1 Patient population 
See chapter 3 for detail of the patient population. Additional exclusion criteria 
included standard contraindications to CT iodinated contrast agent i.e. previous 
hypersensitivity reaction (n=0), impaired renal function (n=0); and the presence 
of metastatic disease at staging (n=1: metastatic liver disease).  
6.2.2 Patient Compliance and Exclusions 
Thirty-two patients were screened; 17 patients consented to participate in the 
study. Thirteen patients completed two scans and four patients completed one 
scan prior to NCRT. Fourteen patients completed immediate post-NCRT scan 
and 12 patients completed scans for 6 and 11 weeks post NCRT.  One patient 
was excluded after paired baseline scans due to finding of metastatic disease. 
After NCRT, one patient died due to a cause unrelated to rectal cancer or 
treatment, one more patient declined further participation in the study. At the 
post processing stage, one more patient was excluded due to mucinous 
histopathology and inconsistent parametric measurements. Patient and data 
available for analysis is presented in table 6.1 and figure 6.1 below:   
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Table 6.1: Patient compliance and exclusions during scan coverage and 
post processing stage 
Code T0 (1) T0 (2) T1 T2 T3 Reason for exclusion 
1 RY ✓ ✓ ✓ ✓ ✓  
2 DG ✓ ✓ ✓ ✓ ✓  
3 DJ ✓ ✓ X X X Metastasis 
4 AH ✓ ✓ ✓ ✓ ✓  
5 KB ✓ ✓ ✓ ✓ ✓  
6 ED ✓ ✓ ✓ X ✓ DNA T2 
7 AF ✓ X ✓ ✓ ✓  
8 JN ✓ ✓ ✓ ✓ ✓  
9 SD ✓ ✓ X X X 
T1: technical failure 
Died after NCRT 
10 JH ✓ ✓ ✓ ✓ ✓  
11 DP ✓ ✓ ✓ X X Declined participation 
12 GA ✓ ✓ ✓ ✓ X  
13 PO ✓ X ✓ ✓ ✓ DNA T0 day 2 
14 MM ✓ X ✓ ✓ ✓ DNA T0 day 2 
15 RC1 ✓ ✓ ✓ ✓ ✓  
16 RC2 ✓ X ✓ ✓ ✓ DNA T0 day 2 
17 JT ✓ ✓ ✓ ✓ ✓  
Scans Completed 17 13 15 13 13  
Included in Study 16 13 14 12 12 PO excluded 
‘✓ ’ Completed scan and included in analysis; ‘✓’ Completed scan but not included in analysis;’ 
X’ Did not complete scan; DNA- did not attend 
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6.2.3 Volumetric helical perfusion CT 
At baseline, two examinations were performed within 14 days to allow 
reproducibility analysis. The examination schedule is shown in figure 6.1. 
Figure 6.1: Schedule of DCE-CT  
 
where, T (subscript) represent timing of the examination along the treatment 
line: T0 (1) and T0 (2) were paired baseline examination on day-1 and day-2, 
respectively; T1, T2 and T3 were post-NCRT examination at second week, sixth 
week and eleventh week, respectively. The ‘n’ denotes number of patients 
completing examination.   
6.2.4 Image coverage 
All subjects underwent volumetric helical perfusion CT using a ‘4D-adaptive 
spiral mode’ (Dual Source CT, Somatom Definition, Siemens Healthcare, 
Forchheim, Germany). The patient examination consisted of a ‘topogram’, a 
targeted low-dose unenhanced helical coverage to locate the known tumour 
T0
(1) T1 T2 T3 
NCRT  Interval to TME surgery 
6 weeks 2 weeks 11 weeks 
Baseline 
n = 9 
n= 1 
n= 1 
n=2 
N = 4 
Successfully 
completed 
study Unable to complete last 
examination 
One patient declined further participation 
Patient diagnosed with metastatic disease; 
One patient died after NCRT  
Unable to complete 
paired baseline 
examination 
0 - 2 weeks 
 5  weeks 12 weeks 
Treatment Timeline 
Diagnosis Surgery 
T0
(2) 
DCE-CT Examination Schedule 
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(100kV, effective mAs 70, rotation time 0.5s, detectors 24x1.2mm, pitch 1.2, 
slice collimation 5mm, SFOV 300-450mm, matrix 512mm), and a volumetric 
helical dynamic contrast-enhanced coverage following intravenous 
administration of 50mL of iodinated contrast agent (Ioversol 350 mg/mL iodine; 
Optiray, Covidien, Mansfield, MA, USA) at 6mL/s using a dual headed pump 
injector, followed by a 50ml saline chaser at the same rate. 
After a delay of 10 s from the start of injection, a volumetric perfusion CT 
coverage consisting of successive craniocaudal and caudocranial coverages 
was obtained (100 kV, 110mAs, 4D adaptive spiral with a variable pitch - 
consisting of a pitch of 1 at the central point of table travel and <1 in the 
accelerating and decelerating portions, thereby guaranteeing a full rotation was 
always available for reconstruction), cycle time of 1.5s for the first 30s, 
decreased to a cycle time of 3.0s between helical coverages after 30s for the 
remaining 20s;  z-axis coverage 11.4 cm; reconstructed slice thickness 5 mm, 
increment 3 mm; CTDI vol 116.04mGy; figure 6.2). Patients returned within 2 
weeks of the initial examination for a second CT examination, with identical 
parameters, to assess measurement reproducibility.  
Figure 6.2: DCE-CT Image Coverage 
 First Phase = 30 sec   Second Phase = 20 sec   
Bolus of IV 
Contrast  
Planning 
Acquisition 
1.5 sec interval  3 sec interval 
Dynamic contrast enhanced acquisition 
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6.2.5 Image Analysis 
Image analysis was performed using validated commercially available software 
(Deconvolution algorithm, vPCT; Siemens Healthcare, Forchheim, Germany). 
Initial post-processing steps within the software platform included motion 
correction and application of a noise reduction filter. Motion correction was 
based on a non-rigid deformable registration technique. The arterial time-
attenuation curve was defined by placing a region of interest (ROI) within the 
common femoral or external iliac artery visible on the images. Parametric maps 
of regional blood flow (BF; units: mL/min/100 mL), blood volume (BV; units: 
mL/100 mL), and permeability surface product (PS; units: mL/min/100mL), were 
then generated in axial, coronal and sagittal planes.  
The DCE-CT images (see figure 6.3) were reviewed by two observers using two 
different image coverage techniques (2D and 3D), hence each individual study 
produced 4 measurements for an individual patient. The ROIs were drawn 
freehand using an electronic cursor and mouse outlining the margin of the 
entire tumour in axial plane. This was placed for two different z-axis coverage: 
a) a central tumour core of 30mm (consisting of 6 contiguous 5 mm thick axial 
slices; mean area/slice=15.3 cm2 for Observer 1 and 15.1 cm2 for Observer 2; 
and, b) the entire tumour volume (mean volume= 62.3cm3 for Observer 1 and 
73.0cm3 for Observer 2). Analysis was performed for all CTs and also repeated 
by each observer with >4 weeks between readings.  
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Figure 6.3: CT and DCE-CT images  
 
CT MIP (A) images showing a T3N1 rectal cancer and corresponding blood flow 
parametric maps in the axial (B), coronal (C) and sagittal (D) planes.  
6.2.6 Statistical Analysis  
A detailed account on statistical methods used are as given in Chapter 5 (see 
section 5.2.6, page 196). The only difference was as follows: the Wilcoxon 
signed-rank test was applied to ascertain if there were any differences between 
paired observations for the different tumour volumes, with statistical significance 
at 0.0056, after correcting for multiple comparisons.  
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6.3 Results 
The results are presented in the following order 
1. Patients characteristics and their outcomes (section 6.3.1) 
2. Baseline Day-1:Day-2 reproducibility (section 6.3.2 for 2-D and section 
6.3.3 for 3-D image coverage) 
3. Inter-observer agreement for Day 1 measurements (section 6.3.2 for 2-D 
and section 6.3.3 for 3-D image coverage) 
4. Alterations in DCE-CT parameters (3-D image coverage) after 
chemoradiotherapy (section 6.3.7) 
5. Association between ‘measured DCE-CT parameters (3-D image 
coverage)’ and ‘clinicopathological markers’ (section 6.3.8) 
6. Association between ‘alteration of DCE-CT parameters before and after 
chemoradiotherapy (3-D image coverage)’ and ‘clinical outcomes’ (section 
6.3.9) 
6.3.1  Patient population, characteristics and clinical outcomes 
Please refer to chapter 4, sections 4.3.1, 4.3.2 and 4.3.3 (pages 121-125). 
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6.3.2 Baseline Day-1:Day-2 reproducibility and inter-observer 
agreement of DCE-CT parametric measurements obtained 
from 2-D image coverage of rectal cancers  
The DCE-CT parameter actual measurements obtained by 2-D coverage are 
shown in table 6.2 and figure 6.4. The baseline Day1:Day2 reproducibility 
analysis is shown in table 6.3 and figure 6.5.  The inter-observer agreement for 
day 1 measurements is shown in table 6.4 and figure 6.6.  
6.3.2.1 Summary of results  
All statistical analysis of BV measurements for observer 1 were affected by 
outlier data (observer 1 measurement of BV for patient 8 on T0 (2) = 
32.35mL/100mL) 
For the day-1:day-2 reproducibility analysis (see table 6.3):  
 The mean differences between day-1:day-2 measurement was greatest for 
BF measurements and least for BV measurements for both observers.  
 The sensitivity to spontaneous changes was seen in BF and PS 
measurements as evidenced by narrow range of 95% group CI and high 
variance ratio. The sensitivity to spontaneous changes was poor for BV 
measurements: data obtained from observer 1 may have been affected by 
outliers values (see table 6.2) and data obtained from observer 2 does 
show a narrow 95% group CI of BV= ±1.25 (12.5%) mL/100mL, however, 
there was low variance ratio for both observers (F=1.26 and 2.9 for 
observer 1 and observer 2, respectively) 
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 For repeatability analysis, the mean difference lie well within the range 
predicted by repeatability coefficient for all parameters. In general, the 
Bland-Altman LoA for BF and BV were better than PF. More specifically, 
Bland-Altman LoA for BF and BV were better for observer 1.  
 There was probably acceptable day-1:day-2 reproducibility of all parametric 
measurements for each observers. The BF and PS analysis for both 
observers and the BV analysis for observer 2 only showed low wCV, high 
ICC and greater between/within-subject variance components. The poor 
results of BV for observer are attributable to outlier value.  
For the inter-observer analysis (see table 6.4 and figure 6.6): 
 The measurements between observers for all parameters were similar with 
small mean differences at each time point (T0 (1) and T0 (2)).  
 The mean difference between parametric measurements is well below the 
values defined by repeatability co-efficient. There was narrow Bland-Altman 
LoA for BV and BF, but slightly wider for PS measurements.  
 There was excellent inter-observer reproducibility for BF and PS 
measurements (low wCV≤ 0.10, ICC >90% and high between/within-subject 
variance components) and good for BV measurement.
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Table 6.2: The actual Day-1:Day-2 DCE-CT parametric measurements obtained from 2-D image coverage 
Code 
Blood Flow 
(mL/min/100mL) 
Blood Volume 
(mL/100mL) 
Permeability Surface 
(mL/min/100mL) 
Observer 1 Observer 2 Observer 1 Observer 2 Observer 1 Observer 2 
T0(1) T0(2) T0(1) T0(2) T0(1) T0(2) T0(1) T0(2) T0(1) T0(2) T0(1) T0(2) 
1 RY 94.61 157.22 137.22 137.63 12.35 12.59 14.02 11.53 18.60 19.59 17.10 18.59 
2 DG 66.83 72.03 68.63 71.08 11.38 11.22 10.89 11.20 17.92 30.42 17.44 24.63 
3 DJ 50.33 67.67 50.09 70.45 8.65 9.14 8.80 8.99 11.86 13.07 12.25 13.33 
4 AH 58.77 66.85 53.86 61.51 9.82 12.01 9.76 11.41 21.40 18.87 20.02 17.04 
5 KB 43.74 54.20 52.57 60.53 9.27 9.08 11.13 10.21 15.75 16.86 18.43 18.21 
6 ED 45.30 65.50 46.28 64.20 7.77 8.52 8.11 8.18 12.73 12.28 13.21 12.35 
8 JN 56.33 74.54 49.52 58.83 9.09 32.35 8.10 10.25 15.47 24.84 13.71 24.89 
9 SD 59.82 65.10 63.04 65.43 10.0 11.34 10.60 11.48 36.13 41.86 38.52 42.17 
10 JH 22.15 33.27 24.49 35.81 5.12 8.49 5.35 9.01 9.77 11.50 10.21 13.86 
11 DP 74.01 65.92 71.41 58.26 11.54 10.41 11.22 10.04 21.51 21.51 20.80 20.26 
12 GA 81.44 87.33 71.51 79.46 10.68 16.16 9.94 14.93 23.84 32.67 20.41 27.00 
15 RC1 74.22 85.13 88.72 91.50 11.16 6.22 7.71 6.80 22.04 15.58 18.70 15.71 
17 JT 77.26 77.10 87.59 77.81 9.00 9.46 10.15 9.69 15.65 15.66 17.45 16.81 
Bold and italic – outlier value;  T0(1)- Day 1 scan;  T0(2)- Day 2 scan 
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Figure 6.4: Baseline DCE-CT parameter measurement reproducibility 
obtained from 2-D image coverage 
A - Observer 1  
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B - Observer 2 
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Table 6.3: Day-1:Day-2 reproducibility analysis of DCE-CT parameters 
obtained from 2-D image coverage for each observer 
 
Blood Flow 
(mL/min/100mL) 
Blood Volume 
(mL/100mL) 
Permeability Surface 
(mL/min/100mL) 
Observer 1 2 1 2 1 2 
Measurements       
T0(1); T0(2) 
(mean) 
60.9; 74.7 64.3; 71.7 9.37; 12.08 9.65; 10.2 18.02; 21.1 18.08; 20.3 
Mean (Total) 68.33 69.13 10.88 9.98 19.90 18.91 
Mean 
Difference 
-12.85 -5.20 -2.4 -0.61 -2.47 -2.04 
Wilcoxon test 0.007 0.07 0.08 0.5 0.099 0.15 
Spontaneous Changes      
95% Group CI 
for mean 
difference 
-10.38, -
14.11 
(-19.2%, 
9.82%) 
-4.34, -5.51 
(-16.45%, 
6.02%) 
-2.93, -1.73 
(-27.66%, 
22.41%) 
±1.25 
(12.5%) 
±3.39 
(17%) 
±2.75 
(14.5%) 
F 7.4** 19.1** 1.26 2.9 7.2** 9.9** 
Repeatability       
wSD  
(95% CI) 
0.179  
(0.11, 0.24) 
0.139  
(0.07, 0.19) 
0.307  
(0.17, 0.43) 
1.46  
(1.09, 2.52) 
3.97  
(2.96, 6.82) 
3.21  
(2.4, 5.53) 
r  
(95% CI) 
0.49* 
(-42.7%, 
54.9%) 
0.38* 
(-36%, 
38.4%) 
0.85* 
(-59.8%, 
120.6%) 
4.06  
(3.03, 6.98) 
11.0  
(8.21, 18.90) 
8.91  
(6.65, 15.32) 
95% LoA  
(Precision 
limits) 
*-0.54  
(-0.72, -
0.35);  
0.16 (-
0.017, 0.34) 
*-0.45  
(-0.63,-
0.27);  
0.23  
(0.06, 0.41) 
*-1.0 
(-1.43, -
0.56); 0.69 
(0.25, 1.12) 
-4.74  
(-6.87, -2.6); 
3.51  
(1.38, 5.65) 
-12.97  
(-18.4, -
7.54);  
8.04 (2.61, 
13.47) 
-10.51  
(-14.8,-
6.13);  
6.42  
(2.04, 10.79) 
Reproducibility      
ICC  
(95% CI) 
0.75  
(0.37, 0.91) 
0.93  
(0.79, 0.97) 
0.031  
(-0.50, 0.55) 
0.49  
(-0.05, 0.81) 
0.78  
(0.43, 0.92) 
0.84  
(0.55, 0.94) 
wCV  
(95% CI) 
0.19  
(0.11, 0.28) 
0.14  
(0.08, 0.22) 
0.36  
(0.19, 0.55) 
0.14  
(0.12, 0.17) 
0.17  
(0.14, 0.19) 
0.16  
(0.13, 0.19) 
Between- / 
within-subject 
variance 
components 
440.8; 141.0 595.4; 48.96 0.76; 22.5 0.97; 3.18 50.1; 13.78 44.93; 12.18 
CI – confidence interval  (as % for log transformed data); F – variance ratio; wSD – within-
subject standard deviation; wCV – within-subject coefficient of variation; r – repeatability 
coefficient; LoA – Limits of agreement; ICC – Inter-class coefficient; *Natural Log transformed 
data; ** p<0.05 
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Figure 6.5: Bland-Altman plots of Day-1:Day-2 reproducibility of 
parametric measurements obtained from 2-D image coverage 
Observer 1 Observer 2 
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Table 6.4: Inter-observer agreement of DCE-CT parametric measurements 
on Day 1 obtained from 2-D image coverage 
 
Blood Flow 
(mL/min/100mL) 
Blood Volume 
(mL/100mL) 
Permeability 
Surface 
(mL/min/100mL) 
Measurements       
Observer 1; 2  
(mean) 
60.9; 64.3 9.37; 9.65 18.02; 18.08 
Mean (Total) 62.62 9.51 18.05 
Mean Difference -3.42 -0.28 -0.05 
Wilcoxon test 0.40 0.37 0.87 
Repeatability       
wSD  
(95% CI) 
0.095 
(0.05, 0.13) 
1.08 
(0.83, 1.74) 
1.55 
(1.18, 2.49) 
r  
(95% CI) 
0.26* 
(-28.2%, 21.8%) 
3.015 
(2.3, 4.82) 
4.31 
(3.29, 6.89) 
95% LoA  
(Precision limits) 
*-0.30 (-0.43,-0.18); 
0.22 (0.10, 0.35) 
-3.4 (-4.8, -1.9); 
2.85 (1.42, 4.27) 
-4.60 (-6.6, -2.5); 
4.49 (2.4, 6.5) 
Reproducibility      
ICC  
(95% CI) 
0.92 
(0.78, 0.97) 
0.84 
(0.56, 0.94) 
0.97 
(0.91, 0.99) 
wCV  
(95% CI) 
0.10 
(0.06, 0.14) 
0.112 
(0.09, 0.12) 
0.077 
(0.072, 0.08) 
Between-/ within-subject 
variance components 
469.3; 67.8 4.174, 0.302 44.9; 5.38 
CI – confidence interval  (as %of the mean for log transformed data); F – variance ratio; wSD – 
within-subject standard deviation; wCV – within-subject coefficient of variation; r – repeatability 
coefficient; LoA – Limits of agreement; ICC – Inter-class coefficient; *Natural Log transformed 
data; ** p<0.05 
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Figure 6.6: Bland-Altman plots of Inter-observer agreement of DCE-CT 
parametric measurements on Day 1 obtained from 2-D image coverage 
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6.3.3 Baseline Day-1:Day-2 reproducibility and observer agreement 
of baseline DCE-CT parametric measurements obtained by 3-
D image coverage of rectal cancers  
The actual DCE-CT parameter measurements obtained by 3-D coverage are 
shown in table 6.5 and figure 6.7.The baseline Day1:Day2 reproducibility is 
shown in table 6.6 and figure 6.8.  The inter-observer agreement for day 1 
measurements is shown in table 6.7 and figure 6.9.  
6.3.3.1 Summary of results 
For day-1:day-2 reproducibility: 
 The mean difference was least for BV and most for BF measurements for 
both observers 
 The BV measurements were most sensitive to spontaneous change 
followed by PS measurements. This analysis was more pronounced for 
observer 2 (variance ration >8 for both BV and PS).  
 The mean difference of all parametric values between observers fell below 
the values defined by repeatability coefficient. The Bland-Altman LoA were 
small for PS measurements for both observers and for BV measurements 
for observer 2. The Bland-Altman LoA were extremely wide for BV 
measurements for both observers.  
 The variation in measurements between day-1:day-2 was most for BF (low 
wCV; low ICC and between/within-subject variance components) and least 
for BV. The PS measurement were also varied between two days as seen 
by high wCV and between/within-subject variance components for both 
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observers, however, observer dependent variance was least for observer 2 
only (ICC=0.80).  
For inter-observer analysis: 
 In general, the mean difference was least for BV measurements. The 
maximum mean difference was seen in BF. 
 The repeatability coefficient values were above the mean difference for all 
parametric values. The Bland-Altman LoA was narrow for BV measurement 
and PS measurements. In contrast, the BV measurement showed wide 
Bland-Altman LoA.  
 The wCV was low for all parameters with corresponding high ICC and 
between/within-subject variance for BF and PS. The BV measurement 
showed relatively poor reproducibility between observers (wCV=0.244, 
ICC=0.50, between/within-subject variance=4.03; 2.49)
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Table 6.5: The actual Day-1:Day-2 DCE-CT parametric measurements obtained from 3-D image coverage 
 
 
 
 
 
 
 
 
Code 
Blood Flow 
(mL/min/100mL) 
Blood Volume 
(mL/100mL) 
Permeability Surface 
(mL/min/100mL) 
Observer 1 Observer 2 Observer 1 Observer 2 Observer 1 Observer 2 
T0(1) T0(2) T0(1) T0(2) T0(1) T0(2) T0(1) T0(2) T0(1) T0(2) T0(1) T0(2) 
1 RY 106.1 167.71 106.39 153.08 13.38 14.22 13.24 13.26 19.36 19.25 20.06 19.35 
2 DG 68.88 75.04 72.88 79.65 12.31 12.03 12.28 12.34 17.53 24.35 18.23 27.41 
3 DJ 73.36 86.3 75.7 84.52 12.81 12.82 13.16 12.39 22.89 22.09 22.94 20.74 
4 AH 60.53 96.16 69.39 89.56 9.85 11.35 11.78 11.22 14.66 14.25 16.55 13.45 
5 KB 55.18 69.01 57.69 62.51 10.44 11.86 10.98 11.81 18.06 21.75 18.7 20.27 
6 ED 73.14 69.61 64.01 71.06 11.67 10.58 10.01 10.2 19.3 16.59 17.89 16.84 
8 JN 66.84 65.94 69.76 72.08 11.46 11.17 11.62 12.46 38.77 40.78 41.28 44.67 
9 SD 53.45 62.25 57.86 63.69 8.95 10.82 9.73 11.04 14.56 25.83 15.73 26.96 
10 JH 68.53 64.48 69.47 75.56 9.96 11.1 10.36 12.94 15.37 16.7 16.94 21.24 
11 DP 94.68 72.28 84.61 65.1 14.1 11.98 12.85 11.21 22.09 21.04 21.71 18.84 
12 GA 80.28 98.95 96.48 96.1 10.12 15.74 13.26 15.32 21.09 29.09 27.31 24.95 
15 RC1 33.83 103.78 40.89 106.08 5.46 7.22 5.99 7.45 11.21 46.68 12.91 17.43 
17 JT 72.19 70.45 90.47 83.28 9.37 9.21 11.21 10.38 15.42 16.28 18.35 18.34 
Bold and italic – outlier value;  T0(1)- Day 1 scan;  T0(2)- Day 2 scan 
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Figure 6.7: Baseline DCE-CT parameter measurement reproducibility 
obtained from 2-D image coverage 
A - Observer 1  
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B - Observer 2 
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Table 6.6: Day-1:Day-2 reproducibility analysis of DCE-CT parameters 
obtained from 3-D image coverage for each observer 
 
Blood Flow 
(mL/min/100mL) 
Blood Volume 
(mL/100mL) 
Permeability Surface 
(mL/min/100mL) 
Observer 1 2 1 2 1 2 
Measurements       
T0(1); T0(2)  
(mean) 
65.3; 84.77 71.1; 84.79 
10.06; 
11.55 
10.96; 11.69 19.25; 24.2 19.92; 22.35 
Mean (Total) 77.27 79.15 11.15 11.48 21.73 21.5 
Mean 
Difference 
-14.9 -11.28 -0.79 -0.43 4.95 -1.68 
Wilcoxon 0.075 0.06 0.19 0.85 0.06 0.34 
Spontaneous Changes      
95% Group CI 
for mean 
difference 
±17.82 
(23%) 
±14.55 
(18.3%) 
±1.189 
(10.6%) 
±0.758 
(6.6%) 
-3.55, -6.12 
(-28.3%, 
23.6%) 
-1.40, -1.85 
(-16.8%, 
10.03%) 
F 1.82 2.25 4.0 8.52** 1.52 8.9** 
Repeatability       
wSD  
(95% CI) 
20.85  
(15.5, 35.8) 
17.03  
(12.7, 29.2) 
1.39  
(1.03, 2.39) 
0.88  
(0.66, 1.52) 
0.319  
(0.18, 0.45) 
0.163  
(0.09, 0.23) 
r  
(95% CI) 
57.75 
(43.1, 99.2) 
47.1  
(35.1, 81.0) 
3.85 
(2.87, 6.62) 
2.45  
(1.83, 4.22) 
0.88* (-61%, 
127.9%) 
0.45* (-39%, 
50.5%) 
95% LoA  
(Precision 
limits) 
-67.85  
(-95.1, -
40.5);  
37.8  
(10.55, 
65.1) 
-55.5  
(-78.4, -32.6) 
33.01  
(10.12, 55.9) 
-4.54  
(-
6.48,2.60);  
2.96  
(1.02, 4.90) 
-2.88  
(-4.14, -1.61); 
2.02  
(0.76, 3.29) 
*-1.04  
(-1.47, -
0.61); 0.61  
(0.18, 1.04) 
*-0.53  
(-0.76, -
0.29); 0.37  
(0.14, 0.61 
Reproducibility      
ICC  
(95% CI) 
0.39  
(-0.18, 0.76) 
0.45  
(-0.10, 0.79) 
0.62  
(0.14, 0.87) 
0.79  
(0.46, 0.93) 
0.28 
(-0.29, 0.70) 
0.80  
(0.48, 0.93) 
wCV 
(95% CI) 
0.253  
(0.17, 0.33) 
0.206  
(0.14, 0.26) 
0.122 
(0.107, 
2.39) 
0.081 (0.076, 
0.086) 
0.376  
(0.20, 0.57) 
0.177  
(0.09, 0.26) 
Between / 
within-subject 
variance 
components 
233.0; 349.2 203.9; 245.3 2.99; 1.76 2.97; 0.75 19.53; 50.26 0.098; 0.263 
CI – confidence interval  (as % of the mean for log transformed data); F – variance ratio; wSD – 
within-subject standard deviation; wCV – within-subject coefficient of variation; r – repeatability 
coefficient; LoA – Limits of agreement; ICC – Inter-class coefficient; *Natural Log transformed data; 
** p<0.05 
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Figure 6.8: Bland-Altman plots of Day-1:Day-2 reproducibility of 
parametric measurements obtained from 3-D image coverage 
Observer 1 Observer 2 
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Table 6.7: Inter-observer agreement of DCE-CT parametric measurements 
on Day 1 obtained from 3-D image coverage 
 
Blood Flow 
(mL/min/100mL) 
Blood Volume 
(mL/100mL) 
Permeability 
Surface 
(mL/min/100mL) 
Measurements       
Observer 1; 2  
(mean) 
65.3; 71.1 10.06; 10.96 17.9; 19.9 
Mean (Total) 68.22 10.5 18.9 
Mean Difference -5.77 -0.91 -1.93 
Wilcoxon test 0.12 0.17 0.06 
Repeatability       
wSD (95% CI) 
9.27 
(7.07, 14.8) 
1.65  
(1.26, 2.64) 
0.27  
(0.16, 0.37) 
r (95% CI) 
25.6 
(19.6, 41.07) 
4.59  
(3.5, 7.3) 
0.75* 
(-56.02%, 97.90%) 
95% LoA  
(Precision limits) 
-30.1(-41.1, -19); 
18.57 (7.48, 29.6) 
-5.37 (-7.4, -3.33);  
3.55 (1.52, 5.58) 
*-0.96 (-1.33, -0.59); 
0.66 (0.29, 1.03) 
Reproducibility      
ICC  
(95% CI) 
0.71 
(0.22, 0.89) 
0.50  
(0.35, 0.82) 
0.86 
(0.61, 0.95) 
wCV  
(95% CI) 
0.24  
(0.13, 0.35) 
0.244  
(0.13, 0.35) 
0.311 
(0.18, 0.45) 
Between- / within-subject 
variance components 
323.7; 74.06 4.03; 2.49 44.92; 5.38 
CI – confidence interval  (as % of the mean for log transformed data); F – variance ratio; wSD 
– within-subject standard deviation; wCV – within-subject coefficient of variation; r – 
repeatability coefficient; LoA – Limits of agreement; ICC – Inter-class coefficient; *Natural Log 
transformed data; ** p<0.05 
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Figure 6.9: Bland-Altman plots of Inter-observer agreement of DCE-CT 
parametric measurements on Day 1 obtained from 3-D image coverage 
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6.3.4 Alterations in DCE-CT parameters (3-D image coverage) in 
response to NCRT 
6.3.4.1 Estimation of significant changes in parametric measurements for 
a cohort of patients  
The mean values of all the measured DCE-CT parameters show a statistically 
significant decline during the interval after NCRT and surgery as shown in 
tables 6.8 - 6.9 and figure 6.10. The BF measurement show similar decline at 6 
weeks post-NCRT (T2) and pre-operative stage (T3) (-41.01% and -41.08%, 
respectively, see table 6.9 and figure 6.10), whilst BV and PS show a 
continuous steady decline. 
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Table 6.8: Mean parametric alterations after NCRT  
Parameter n 
T0  T1 
p n 
T0 T2 
p n 
T0 T3 
p 
(mean) (mean) (mean) 
BF 
(mL/min/
100mL) 
14 75.75 56.07 0.013 12 76.51 42.70 0.002 12 74.12 40.77 0.002 
BV 
(mL/ 
100mL) 
14 11.04 8.53 0.016 12 11.04 7.75 0.005 12 10.69 6.82 0.002 
PS 
(mL/min/
100mL) 
14 19.41 15.75 0.035 12 19.50 13.42 0.003 12 18.77 10.96 0.002 
Bold – significant changes; Statistical test – Shapiro-Wilk and Q-Q plots distribution test; Wilcoxon 
signed rank test 
 
Table 6.9: Percentage parametric alterations after NCRT 
Parameter 
% Change at T1  
(Cohort CI for ‘n’) 
% Change at T2 
(Cohort CI for ‘n’) 
% Change at T3 
(Cohort CI for ‘n’) 
BF 
(mL/min/100
mL) 
-23.44% 
(-18.19%, 22.23%; n=14) 
-42.01% 
(-16.01%,19.06%;n=12) 
-42.08% 
(-16.01%,19.06%;n=12) 
BV 
(mL/ 100mL) 
-19.77% 
(-5.89%, 6.26%; n=14) 
-27.87% 
(-6.35%, 6.78%; n=12) 
-35.56% 
(-6.35%, 6.78%; n=12) 
PS 
(mL/min/100
mL) 
-17.04% 
[-11.42%, 12.89%; n=14) 
-32.68% 
(-12.27%, 13.99%; n=12) 
-42.30% 
(-12.27%, 13.99%; n=12) 
Bold – significant changes; Statistical test – Shapiro-Wilk and Q-Q plots distribution test; Wilcoxon 
signed rank test; Cohort CI – represent the confidence interval of spontaneous change in a group 
of ‘n’ patients.  
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Figure 6.10: DCE-CT parameter alteration after NCRT by percentage 
change 
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6.3.4.2 Estimation of significant changes in parametric measurements for 
individual patient  
The parametric measurements and their percentage change from the mean of 
paired baseline measurements for each patient during the interval after NCRT 
and surgery is given in table 6.10 - 6.13 and figures 6.11 - 6.13.  
In general, there was numerical decline in measurements for all parameters 
with statistical significance commonly seen in BV measurements for most 
patients. The most significant decline from baseline was seen on pre-operative 
stage (T3) for all parameters indicating continual tumour devascularisation. 
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Table 6.10: Post-NCRT measurement of DCE parameter obtained from 3-D 
image coverage 
Code 
Blood Flow 
(mL/min/100mL) 
Blood Volume 
(mL/100mL) 
Permeability Surface 
(mL/min/100mL) 
T1 T2 T3 T1 T2 T3 T1 T2 T3 
1 RY 55.65 52.13 36.09 8.52 8.79 6.39 15.44 14.33 10.03 
2 DG 52.53 48.81 50.27 10.59 8.91 9.52 19.7 15.17 11.99 
3 AH 89.93 48.57 49.68 11.29 9.73 9.6 25.54 16.79 11.86 
5 KB 54.15 54.69 42.18 11.54 11.94 7.1 18.01 19.66 13.97 
6 ED 51.16 - 42.62 8.86 - 4.7 16.41 - 9.7 
7 AF 35.2 18.72 21.97 6.03 4.98 4.92 5.9 10.16 9.89 
8 JN 59.47 53.23 54.92 12.81 9.42 10.07 19.27 16.29 17.17 
10 JH 33.78 37.02 31.18 6.01 7.23 6.68 12.76 15.47 10.68 
11 DP 46.44 - - 7.98 - - 11.61 - - 
12 GA 52.09 48.5 - 7.39 5.7 - 11.88 13.71 - 
14 MM 38.56 32.64 37.24 5.9 7.83 5.29 13.49 0.71 4.88 
15 RC1 110.57 41.48 54.34 10.39 5.86 5.43 18.97 13.21 7.85 
16 RC2 59.34 54.1 41.19 6.21 8.19 7.38 14.39 16.27 13.15 
17 JT 46.2 22.54 27.6 6.03 4.46 4.84 17.17 9.33 10.38 
Bold italic – outlier value; T1- Day 3 scan;  T2- Day 4 scan; T3- Day 5 scan 
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Table 6.11: Blood flow measurements (mL/min/100mL) and percentage 
changes after NCRT (r = -45.3% to 83%) 
Code T0 (mean) T1 T2 T3 
1 RY 129.74 55.65 (-57%) 52.13 (-60%) 36.09 (-72%) 
2 DG 76.27 52.53 (-31%) 48.81 (-36%) 50.27 (-34%) 
4 AH 80.11 89.93 (12%) 48.57 (39%) 49.68 (38%) 
5 KB 60.10 54.15 (-10%) 54.69 (-9%) 42.18 (-30%) 
6 ED 67.54 51.16 (-24%) - 42.62 (-37%) 
7 AF 53.32 35.2 (-34%) 18.72 (-65%) 21.97 (59%) 
8 JN 60.78 59.47 (-2%) 53.23 (-12%) 54.92 (-10%) 
10 JH 72.52 33.78 (-53%) 37.02 (-49%) 31.18 (-57%) 
11 DP 74.8 46.44 (-38%)   
12 GA 96.29 52.09 (-46%) 48.5 (-50%) - 
14 MM 51.45 38.56 (-25%) 32.64 (-37%) 37.24 (28%) 
15 RC1 73.49 110.57 (50%) 41.48 (-44%) 54.34 (-26%) 
16 RC2 77.27 59.34 (-23%) 54.1 (-30%) 41.19 (-47%) 
17 JT 86.88 46.2 (-47%) 22.54 (-74%) 27.6 (-68%) 
r – repeatability coefficient expressed at %; BOLD – significant changes; prefix 
‘+ / -’ indicates positive  or negative change; T1- Day 3 scan;  T2- Day 4 scan; T3- 
Day 5 scan 
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Figure 6.11 Absolute and percentage ‘BF’ value changes after NCRT 
(individual patients) 
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Table 6.12 Blood volume measurements (mL/100mL) and percentage 
changes after NCRT (r = -20.3% to 25.5%) 
 
 
 
Code T0 (mean) T1 T2 T3 
1 RY 13.25 8.52 (-38%) 8.79 (-34%) 6.39 (-52%) 
2 DG 12.31 10.59 (-14%) 8.91 (-28%) 9.52 (-23%) 
4 AH 12.78 11.29 (-12%) 9.73 (-24%) 9.6 (-25%) 
5 KB 11.40 11.54 (1%) 11.94 (5%) 7.1 (-38%) 
6 ED 10.11 8.86 (-12%) - 4.7 (-53%) 
7 AF 10.16 6.03 (-41%) 4.98 (-51%) 4.92 (-52%) 
8 JN 10.39 12.81 (23%) 9.42 (-9%) 10.07 (-3%) 
10 JH 11.65 6.01 (-48%) 7.23 (-38%) 6.68 (-43%) 
11 DP 12.03 7.98 (-34%) - - 
12 GA 14.29 7.39 (-48%) 5.7 (60%) - 
14 MM 7.68 5.9 (-23%) 7.83 (2%) 5.29 (-31%) 
15 RC1 6.72 10.39 (55%) 5.86 (-13%) 5.43 (-19%) 
16 RC2 11.11 6.21 (-44%) 8.19 (-26%) 7.38 (-34%) 
17 JT 10.80 6.03 (-44%) 4.46 (-59%) 4.84 (-55%) 
r – repeatability coefficient expressed at %; BOLD – significant changes; prefix ‘+ 
/ -’ indicates positive  or negative change;  T1- Day 3 scan;  T2- Day 4 scan; T3- 
Day 5 scan 
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Figure 6.12 Absolute and percentage ‘BV’ value changes after NCRT 
(individual patients) 
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Table 6.13: Permeability surface (mL/min/100mL) and percentage changes 
after NCRT (r = -36.5% to 57.4%) 
Code T0 (mean) T1 T2 T3 
1 RY 19.71 15.44 (-22%) 14.33 (-27%) 10.03 (-49%) 
2 DG 22.82 19.7 (-14%) 15.17 (-33%) 11.99 (-47%) 
4 AH 21.84 25.54 (17%) 16.79 (-23%) 11.86 (-46%) 
5 KB 19.49 18.01 (-8%) 19.66 (0.9%) 13.97 (-28%) 
6 ED 17.37 16.41 (-5%) - 9.7 (-44%) 
7 AF 15.72 5.9 (-62%) 10.16 (-35%) 9.89 (-35%) 
8 JN 21.35 19.27 (-10%) 16.29 (-24%) 17.17 (-20%) 
10 JH 19.09 12.76 (-33%) 15.47 (-19%) 10.68 (-44%) 
11 DP 20.28 11.61 (-43%) - - 
12 GA 26.13 11.88 (-55%) 13.71 (-47%) - 
14 MM 11.96 13.49 (13%) 0.71 (-94%) 4.88 (-59%) 
15 RC1 15.17 18.97 (25%) 13.21 (-13%) 7.85 (-48%) 
16 RC2 22.46 14.39 (-36%) 16.27 (-28%) 13.15 (-41%) 
17 JT 18.35 17.17 (-6%) 9.33 (-49%) 10.38 (-42%) 
r – repeatability coefficient expressed at %; BOLD – significant changes; prefix ‘+ 
/ -’ indicates positive  or negative change; T1- Day 3 scan;  T2- Day 4 scan; T3- 
Day 5 scan 
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Figure 6.13 Absolute and percentage ‘PS’ value changes after NCRT 
(individual patients) 
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6.3.5 Relationship between DCE-CT parametric measurements (3-D 
image coverage) and clinicopathological markers 
The correlation between DCE-CT parameters and clinical markers is shown in 
tables 6.14 (A-C). The difference in mean parametric values between clinical 
markers is given in tables 6.15. There was no difference in mean DCE-CT 
parametric measurements in response to NCRT (see in table 6.16) and long-
term outcomes (6.17).  
Summary of results: 
 At the pre-treatment stage, a low BF was associated with higher clinical T-
stage (ρ -0.53, p 0.03); a higher PS was associated with lower clinical T- 
and higher N-stage (ρ -0.53, p 0.03 and ρ 0.52, p 0.03, respectively); whilst, 
BV did not show any correlation with clinical markers. The results indicate 
poor perfusion in larger tumours with higher PS in tumours with metastatic 
potential  
 Two weeks after NCRT, node positive tumours showed strong positive 
correlation with BF and BV (ρ 0.63, p 0.01 for both parameters). Tumours 
with high BV and PS at this stage also showed higher tumour length (ρ 
0.68, p 0.007) and nodal involvement on histopathology (ρ 0.60, p 0.02; 
mean PS = 14.6 mL/min/100mL for pN0 vs 22.6 mL/min/100mL for pN1, p 
0.01), respectively. The results indicate active angiogenesis in tumours with 
metastatic nodes after NCRT.  
 Six weeks post-NCRT, there was no correlation between DCT-CT 
parameters and clinical markers.  
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 Pre-operatively, there was strong positive correlation between PS and 
tumour length on histopathology (ρ 0.58, p 0.04). Higher mean PS 
measurements were also seen in cT3 than cT4 tumours (11.51 
mL/min/100mL vs 4.88 mL/min/100mL, p 0.03), indicating that tumors that 
remained large after NCRT had increased vascular leakage.  
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Table 6.14: Correlation between DCE-CT parameters and clinicopathological markers 
Table 6.14 A: Blood Flow (mL/min/100mL)  
BF 
Clinicopathological Features Response to NCRT Long-term Outcomes 
cT cN pT pN cL nL pL T N pCR RECIST LR DM Death 
T0 
ρ / r -0.53 0.35 0.27 0.40 0 0.49 0.131 -0.30 -0.31 -0.017 -0.15 -0.18 0.22 0.27 
p 0.03 0.17 0.35 0.15  0.07 0.65 0.24 0.23 0.94 0.57 0.50 0.41 0.29 
T1 
ρ / r -0.23 0.63 0.11 0.40 -0.155 0.12 0.52 0.21 0.101 -0.45 0.093 0.44 -0.10 0.15 
p 0.41 0.01 0.69 0.15 0.59 0.68 0.05 0.45 0.73 0.10 0.75 0.10 0.73 0.60 
T2 
ρ / r 0.177 0.248 0.004 0.45 -0.052 0.37 0.42 0.15 -0.06 -0.195 -0.41 0.30 0.06 0.36 
p 0.58 0.43 0.99 0.13 0.87 0.22 0.16 0.63 0.84 0.54 0.18 0.33 0.84 0.24 
T3 
ρ / r -0.21 0.502 0.089 0.51 -0.40 0.31 0.49 0.051 -0.25 0 -0.20 0.48 0.25 0.30 
p 0.49 0.09 0.78 0.08 0.90 0.31 0.09 0.87 0.41  0.52 0.11 0.41 0.33 
‘+’ positive correlation; ‘-’  negative correlation; prefix ‘c’ –Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; suffix ‘’ – downstage; T – TNM 
T-stage; N – TNM N-stage; L – craniocaudal tumour length; RECIST – response evaluation criteria in solid tumours; CR – complete response; LR 
– local recurrence; DM – Distant metastasis; Statistical test – Shapiro-Wilk test for normality; Spearman rho correlation analysis (ρ) non-parametric 
data, Pearson correlation (r) for parametric data, p – significant value at 0.05 
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Table 6.14 B: Blood Volume (mL/100mL)  
BV 
Clinicopathological Features Response to NCRT Long-term Outcomes 
cT cN pT pN cL nL pL T N pCR nRECIST LR DM Death 
T0 
ρ / r -0.53 0.35 0.27 0.40 0 0.49 0.13 -0.30 -0.31 -0.17 -0.157 -0.18 0.227 0.278 
p 0.03 0.17 0.35 0.15  0.07 0.65 0.24 0.24 0.94 0.57 0.50 0.41 0.29 
T1 
ρ / r -0.23 0.63 0.11 0.40 -0.14 0.25 0.68 0.21 0.10 -0.45 0.093 0.44 -0.10 0.151 
p 0.41 0.01 0.69 0.15 0.63 0.40 0.007 0.45 0.73 0.10 0.103 0.10 0.73 0.60 
T2 
ρ / r 0.177 0.24 0.004 0.45 -0.161 0.45 0.45 0.15 -0.06 -0.19 -0.41 0.306 0.065 0.36 
p 0.58 0.43 0.99 0.13 0.61 0.14 0.14 0.63 0.84 0.54 0.18 0.33 0.84 0.24 
T3 
ρ / r -0.21 0.50 0.08 0.51 0.05 0.54 0.43 0.051 -0.25 0 -0.205 0.48 0.259 0.307 
p 0.49 0.09 0.78 0.08 0.86 0.06 0.15 0.87 0.41  0.52 0.11 0.41 0.33 
‘+’ positive correlation; ‘-’  negative correlation; prefix ‘c’ –Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; suffix ‘’ – downstage; T – TNM 
T-stage; N – TNM N-stage; L – craniocaudal tumour length; RECIST – response evaluation criteria in solid tumours; CR – complete response; LR 
– local recurrence; DM – Distant metastasis; Statistical test – Shapiro-Wilk test for normality; Spearman rho correlation analysis (ρ) non-parametric 
data, Pearson correlation (r) for parametric data, p – significant value at 0.05 
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Table 6.14 C: Permeability Surface (mL/min/100mL)  
PS 
Clinicopathological Features Response to NCRT Long-term Outcomes 
cT cN pT pN cL nL pL T N pCR nRECIST LR DM Death 
T0 
ρ / r -0.53 0.52 -0.012 0.45 -0.02 0.38 0.19 0.13 -0.15 0.122 -0.03 0.12 0.13 0.13 
p 0.03 0.03 0.96 0.10 0.94 0.17 0.49 0.62 0.56 0.65 0.91 0.66 0.62 0.62 
T1 
ρ / r 0.094 0.37 0.27 0.60 -0.49 0.05 0.25 -0.11 -0.10 -0.36 0.092 0.31 0.101 0.19 
p 0.75 0.19 0.33 0.02 0.07 0.85 0.37 0.68 0.73 0.197 0.75 0.28 0.73 0.50 
T2 
ρ / r -0.23 0.39 0.03 0.32 -0.01 0.54 0.44 0.15 -0.13 -0.251 -0.307 0.30 0.13 0.41 
p 0.45 0.20 0.91 0.30 0.97 0.06 0.15 0.63 0.68 0.43 0.33 0.33 0.68 0.17 
T3 
ρ / r -0.48 0.50 0.17 0.25 0.157 0.21 0.58 -0.05 -0.19 -0.13 -0.051 0.48 0.19 0.41 
p 0.11 0.09 0.58 0.41 0.62 0.49 0.04 0.87 0.54 0.68 0.87 0.11 0.54 0.17 
‘+’ positive correlation; ‘-’  negative correlation; prefix ‘c’ –Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; suffix ‘’ – downstage; T – TNM 
T-stage; N – TNM N-stage; L – craniocaudal tumour length; RECIST – response evaluation criteria in solid tumours; CR – complete response; LR 
– local recurrence; DM – Distant metastasis; Statistical test – Shapiro-Wilk test for normality; Spearman rho correlation analysis (ρ) non-parametric 
data, Pearson correlation (r) for parametric data, p – significant value at 0.05 
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Table 6.15: Difference in mean parametric values according to clinicopathological features 
Parameter cT cN pT pN 
cT2 cT3 cT4 p cN0 cN1 cN2 p pT0 pT1 pT2 pT3 p pN0 pN1 p 
BF 
(mL/min/1
00mL) 
T0 96.29 75.94 51.45 0.11 61.98 77.26 79.06 0.29 75.00 67.54 67.11 91.35 0.37 75.35 78.19 0.36 
T1 52.09 57.86 38.56 0.52 36.17 56.80 67.16 0.07 49.99 51.16 65.96 47.04 0.61 53.55 71.23 0.27 
T2 48.50 43.12 32.64 0.58 34.83 41.78 50.10 0.41 45.08 - 43.33 40.12 0.87 41.50 48.69 0.66 
T3 - 41.09 37.2 0.74 34.21 39.53 52.30 0.20 39.21 42.62 44.61 36.28 0.74 38.93 49.97 0.18 
 
BV 
(mL/ 
100mL) 
T0 14.29 11.16 7.68 0.11 9.66 11.03 12.48 0.37 11.02 10.11 10.58 12.00 0.46 10.79 12.54 0.14 
T1 7.39 8.85 5.90 0.24 5.95 8.46 10.49 0.053 6.50 8.86 10.0 7.78 0.19 8.13 10.94 0.14 
T2 5.70 7.95 7.83 0.58 7.53 7.59 8.28 0.69 7.24 - 8.38 7.34 0.56 7.44 9.32 0.13 
T3 - 6.96 5.29 0.46 5.98 6.28 9.83 0.09 6.33 4.70 7.42 6.85 0.39 6.28 9.56 0.08 
 
PS 
(mL/min/1
00mL) 
T0 26.13 20.83 11.96 0.11 15.52 20.85 23.10 0.12 20.18 17.37 18.97 19.99 0.74 18.92 22.33 0.10 
T1 11.88 16.26 13.49 0.62 13.12 15.28 18.89 0.38 13.25 16.41 16.55 16.26 0.82 14.60 22.62 0.018 
T2 13.71 14.66 0.71 0.23 8.09 14.01 15.59 0.41 10.20 - 15.22 13.57 0.45 12.91 15.98 0.28 
T3 - 11.51 4.88 0.03 7.78 10.87 14.51 0.07 9.01 9.70 12.14 10.77 0.69 10.77 11.92 0.65 
Prefix ‘c’ –Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; suffix ‘’ – downstage; T – TNM T-stage; N – TNM N-stage; L – craniocaudal 
tumour length; RECIST – response evaluation criteria in solid tumours; CR – complete response; LR – local recurrence; DM – Distant metastasis; 
TX – Time-point of measure; BV – blood volume; BF – blood flow; PS – permeability surface; Statistical test – Shapiro-Wilk test and Q-Q plots for 
normality; Spearman rho correlation analysis (ρ) (non-parametric data), *Pearson Correlation (r) (for parametric data); Means compared with 
ANOVA (for normally distributed data), Kruskal-Wallis test or Mann-Whitney-U test for non-normal distribution; Bold – significance <0.05  
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Table 6.16: Difference in mean multiparametric values according to response to NCRT 
Parameter T- downstaging N-downstaging Post NCRT RECIST Post Operative NCRT 
T T p N N p PR SD p CR PR SD p 
BF 
(mL/min/
100mL) 
T0 69.64 88.97 0.06 75.98 74.79 0.90 80.17 68.32 0.23 75.00 73.92 81.08 0.33 
T1 59.69 47.04 0.32 58.23 43.15 0.27 58.02 52.57 0.38 49.99 57.14 62.88 0.91 
T2 40.12 43.99 0.61 42.66 42.91 0.83 42.43 43.23 1.0 45.08 42.87 39.97 0.89 
T3 43.01 36.28 0.23 40.78 40.72 1.0 41.12 40.07 0.73 39.21 40.47 42.51 0.94 
 
BV 
(mL/ 
100mL) 
T0 10.79 11.90 0.23 10.89 11.87 0.22 11.01 11.26 0.55 11.02 10.52 11.96 0.52 
T1 8.84 7.78 0.43 8.57 8.30 0.71 8.53 8.54 0.73 6.50 9.16 9.30 0.31 
T2 7.95 7.34 0.61 7.69 8.07 0.83 7.03 9.18 0.17 7.24 8.03 7.70 0.80 
T3 6.81 6.85 0.86 6.57 8.10 0.39 6.65 7.16 0.49 6.33 6.47 7.98 0.79 
 
PS 
(mL/min/
100mL) 
T0 21.34 18.99 0.61 19.15 24.97 0.54 19.89 22.60 0.90 20.18 18.27 21.00 0.35 
T1 15.54 16.26 0.67 15.67 16.23 0.71 15.45 16.28 0.73 13.25 15.25 20.80 0.11 
T2 13.35 13.57 0.61 13.04 15.32 0.66 13.55 13.15 0.30 10.23 14.85 13.76 0.69 
T3 11.05 10.77 0.86 10.88 11.33 0.51 11.27 10.34 0.86 11.32 11.32 11.41 0.66 
Prefix ‘c’ –Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; suffix ‘’ – downstage; T – TNM T-stage; N – TNM N-stage; L – 
craniocaudal tumour length; RECIST – response evaluation criteria in solid tumours; CR – complete response; LR – local recurrence; 
DM – Distant metastasis; TX – Time-point of measure; BV – blood volume; BF – blood flow; PS – permeability surface; Statistical test – 
Shapiro-Wilk test and Q-Q plots for normality; Spearman rho correlation analysis (ρ) (non-parametric data), *Pearson Correlation (r) 
(for parametric data); Means compared with ANOVA (for normally distributed data), Kruskal-Wallis test or Mann-Whitney-U test for 
non-normal distribution; Bold – significance <0.05  
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Table 6.17: Difference in mean multiparametric values according to long-term outcomes 
Parameter Local Recurrence Distant Metastasis Any recurrence Survival 
Yes No p Yes No p Yes No p Yes No p 
BF 
(mL/min/
100mL) 
T0 60.78 76.48 0.35 74.39 75.59 0.86 72.26 76.83 0.90 77.43 71.85 0.61 
T1 59.47 55.81 0.26 43.15 58.23 0.27 48.59 58.11 0.81 58.60 46.82 0.48 
T2 41.74 53.23 0.311 42.91 42.66 0.83 46.35 41.48 0.64 41.23 46.84 0.40 
T3 54.92 39.48 0.11 40.72 40.78 1.0 45.45 39.21 0.30 40.62 41.21 0.92 
 
BV 
(mL/ 
100mL) 
T0 10.39 11.16 0.48 11.98 10.98 0.39 11.46 11.03 0.71 10.84 11.78 0.28 
T1 12.81 8.21 0.10 8.30 8.57 0.71 9.80 8.19 0.48 8.31 9.38 0.28 
T2 9.42 7.60 0.31 8.07 7.69 0.83 8.52 7.49 0.40 7.21 9.36 0.22 
T3 10.07 6.53 0.11 8.10 6.57 0.39 8.75 6.18 0.07 6.51 7.76 0.30 
 
PS 
(mL/min/
100mL) 
T0 21.35 20.95 0.64 20.95 20.98 0.61 19.56 20.95 1.0 19.12 23.87 0.61 
T1 19.27 15.48 0.26 16.23 15.67 0.71 17.24 15.34 0.31 15.46 16.82 0.48 
T2 16.29 13.16 0.31 15.32 13.04 0.66 15.64 12.68 0.30 12.31 16.76 0.16 
T3 17.17 10.39 0.11 11.33 10.88 0.51 13.28 10.19 0.11 10.54 12.21 0.16 
Prefix ‘c’ –Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; suffix ‘’ – downstage; T – TNM T-stage; N – TNM N-stage; 
L – craniocaudal tumour length; RECIST – response evaluation criteria in solid tumours; CR – complete response; LR – local 
recurrence; DM – Distant metastasis; TX – Time-point of measure; BV – blood volume; BF – blood flow; PS – permeability 
surface; Statistical test – Shapiro-Wilk test and Q-Q plots for normality; Spearman rho correlation analysis (ρ) (non-parametric 
data), *Pearson Correlation (r) (for parametric data); Means compared with ANOVA (for normally distributed data), Kruskal-
Wallis test or Mann-Whitney-U test for non-normal distribution; Bold – significance <0.05  
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6.3.6 Association between DCE-CT parametric alteration after 
NCRT (3-D image coverage) and response to therapy and 
long-term outcomes 
The alterations trends in DCE-CT parametric measurements post-NCRT for 
each patient are given in table 6.18. The changes in the DCE-CT mean 
parametric values pre- and post NCRT for patients with and without TNM and 
RECIST downstaging and long-term outcome is showed in in tables 6.19 to 
6.21.  
Summary of results: 
 In general, there was a decline in DCE-CT parametric measurements after 
NCRT in all patients. Significant decline was commonly seen for PS 
measurements.  
 In tumour that showed T and N- downstaging, there was statistically 
significant decline in all mean parametric values at six week post-NCRT (T2) 
and pre-operative stage (T3) only. In tumour that showed N-downstaging, 
there was statistically significant decline in mean BF and BV values at all 
time-point. 
 In tumours that showed downstaging by RECIST criteria, there was 
statistically significant decline in mean BF and BV parametric values at six 
week post-NCRT (T2) and pre-operative stage (T3) only, whilst mean PS 
measurements significantly declined at all time-points.  
 In patients without disease recurrences and in patients who survived the 
study observation periods (with or without recurrence) , there was 
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statistically significant decline in mean BF and BV parametric values at all 
time-points and in mean PS measurements at six week post-NCRT (T2) and 
pre-operative stage (T3) only.  
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Table 6.18: DCE- CT parametric alterations after NCRT and clinical outcomes 
Code Sex Age cTNM 
3-D Coverage 
Post NCRT 
TNM (yp or r) 
Local 
Recurrence 
Distant 
Recurrence 
Death 
Δ BF 
(mL/min
/100mL) 
Δ BV 
(mL 
/100mL) 
Δ PS 
(mL/min
/100mL) 
1 RY M 59 T3N1M0 * * * T3N0    
2 DG* M 52 T3N1M0  * * T3N1  ✓: Lung ✓ 
3 DJ M 72 T3N1M2 - - - - - ✓: Liver ✓ 
4 AH M 74 T3N2M0  * * T2N1    
5 KB M 78 T3N1M0  *  T2N0   ✓ 
6 ED F 72 T3N1M0  * * T1N0    
7 AF F 60 T3N1M0    T2N0    
8 JN M 79 T3N2M0    T2N0 ✓   
9 SD** M 71 T3N1M0 - - - -   ✓ 
10 JH M 67 T3N0M0 * * * T3N0  ✓: Pancreas ✓ 
11 DP M 58 T3N1M0  * * T2N0    
12 GA*** M 53 T2N2M0 * * * RCR    
13 PO F 59 T3N2M0 - - - T3N2  ✓: Liver  
14 MM*** F 78 T4N0M0   * RCR    
15 RC1 M 76 T3N1M0 *  * T2N0    
16 RC2 M 56 T3N1M0   * PCR    
17 JT F 79 T3N1M0 * * * T3N0    
Prefix ‘c’ –Clinical; prefix ‘p’ – pathological; prefix ‘n’ – post-NCRT; T – TNM T-stage; N – TNM N-stage; BV – blood volume; BF – blood flow; 
PS – permeability surface;  symbol ‘’ – downstage; * - significant changes 
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Table 6.19: Difference in mean parametric values after NCRT between 
patient with and without TNM downstaging 
Parameter T0 vs. T1 
(mean) 
p 
T0 vs. T2 
(mean) 
p 
T0 vs. T3 
(mean) 
p 
T 
 
BF 69.52 59.69 0.114 69.10 43.99 0.012 65.50 43.01 0.012 
BV 10.66 8.84 0.114 10.56 7.95 0.036 10.04 6.81 0.012 
PS 19.17 15.54 0.169 19.26 13.35 0.017 18.17 11.05 0.012 
T 
 
BF 91.35 47.04 0.068 91.35 40.12 0.068 91.35 36.28 0.068 
BV 12.00 7.78 0.068 12.00 7.34 0.068 12.00 6.85 0.068 
PS 19.99 16.26 0.068 19.99 13.57 0.068 19.99 10.77 0.068 
N 
 
BF 74.98 58.23 0.034 76.94 42.66 0.005 74.06 40.78 0.005 
BV 10.85 8.57 0.034 10.44 7.69 0.013 10.44 6.57 0.005 
PS 19.15 15.67 0.084 19.21 13.04 0.007 18.34 10.88 0.005 
N 
 
BF 74.39 43.15 0.18 74.39 42.91 0.18 74.39 40.72 0.18 
BV 11.98 8.30 0.18 11.98 8.07 0.18 11.98 8.10 0.18 
PS 20.95 16.23 0.18 20.95 15.32 0.18 20.95 11.33 0.18 
‘’ denotes downstaging; ‘’ denotes no change Statistical Test: Paired sample T-test; 
*Wilcoxon Signed ranked test; Units: BF – mL/min/100mL, BV – mL/100mL, PS – 
mL/min/100mL 
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Table 6.20: Difference in mean parametric values after NCRT between 
patient with and without RECIST downstaging 
Parameter T0 vs. T1 
(mean) 
p 
T0 vs. T2 
(mean) 
p 
T0 vs. T3 
(mean) 
p 
R
E
C
IS
T

 BF 80.17 58.02 0.051 81.75 42.43 0.012 78.16 41.12 0.012 
BV 11.01 8.53 0.066 11.12 7.03 0.012 10.60 6.65 0.012 
PS 19.89 15.45 0.038 20.21 13.55 0.012 19.11 11.27 0.012 
R
E
C
IS
T

 BF 67.80 52.57 0.13 66.04 43.23 0.068 66.04 40.07 0.068 
BV 11.10 8.54 0.08 10.87 9.18 0.465 10.87 7.16 0.068 
PS 18.53 16.28 0.50 18.09 13.15 0.14 18.09 10.34 0.068 
‘’ denotes downstaging; ‘’ denotes no change Statistical Test: Paired sample T-test; 
*Wilcoxon Signed ranked test; Units: BF – mL/min/100mL, BV – mL/100mL, PS – 
mL/min/100mL 
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Table 6.21: Changes after NCRT and long-term outcomes 
Outcomes 
T0 vs. T1 
(mean) 
p 
T0 vs. T2 
(mean) 
p 
T0 vs. T3 
(mean) 
p 
Recurrence 
(local or 
distant) 
BF 69.85 48.59 0.10 69.85 46.35 0.10 69.85 45.45 0.10 
BV 11.45 9.80 0.59 11.45 8.52 0.10 11.45 8.75 0.10 
PS 21.08 17.24 0.10 21.08 15.64 0.10 21.08 13.28 0.10 
No 
Recurrence 
(local or 
distant) 
 
BF 77.36 58.11 0.041 78.73 41.48 0.008 75.54 39.21 0.008 
BV 10.93 8.19 0.016 10.91 7.49 0.021 10.44 6.18 0.008 
PS 18.95 15.34 0.110 18.98 12.68 0.011 18.00 10.19 0.008 
Alive 
BF 77.43 58.60 0.041 78.81 41.32 0.008 75.62 40.62 0.008 
BV 10.84 8.31 0.033 10.79 7.21 0.011 10.33 6.51 0.008 
PS 19.12 15.46 0.091 19.18 12.31 0.008 18.21 10.54 0.008 
Diseased 
BF 69.63 46.82 0.109 69.63 46.84 0.109 69.63 41.21 0.109 
BV 11.78 9.38 0.285 11.78 9.36 0.285 11.78 7.76 0.109 
PS 20.46 16.82 0.109 20.46 16.76 0.285 20.46 12.21 0.109 
‘’ denotes downstaging; ‘’ denotes no change Statistical Test: Paired sample T-test; *Wilcoxon 
Signed ranked test; Units: BF – mL/min/100mL, BV – mL/100mL, PS – mL/min/100mL 
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6.4 Discussion 
The current experiment presents result on the application of DCE-CT using 
volumetric techniques in patients with locally advanced rectal cancers and its 
association with clinical parameters and long-term prognosis. Tumour hypoxia 
and neoangiogenesis contribute to radioresistance and chemoresistance and 
hence, the evaluation of functional vascular heterogeneity will prove to be of 
critical value in clinical practice [497]. The ability to map spatially the vascular 
heterogeneity across the whole tumour may be relevant to treatment targeting 
as well as monitoring response. 
6.4.1 Reproducibility analysis and influence of coverage volume 
An appreciation of the baseline reproducibility is important in the therapeutic 
response setting in order to estimate the effects of treatment on parameters 
over and above the day-to-day variation. The study shows difference in day-to-
day reproducibility of DCE-CT parameters, at baseline, between 2-D ROI and 3-
D VOI coverage and also the effects of observers. Unlike previous studies of 
solid tumours [493, 495] overall reproducibility was much more variable: the 
extent and direction of change appeared to be parameter-dependent, i.e., 
reproducibility did not necessarily improve with greater volume coverage. This 
reflects the greater spatial and temporal vascular heterogeneity of rectal 
tumour, and the challenges presented by the relative motility of the gut, due to 
peristalsis, respiration, and abdominal wall motion.  
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Regional blood flow represents the delivery rate of contrast agent to the tumour 
(blood flow per unit volume or mass of tissue). Given the physiological 
regulation of regional blood flow to the needs of the tissue, and the nature of the 
tumour vasculature, changes in regional blood flow are expected to be high 
from day 1 to day 2. This was reflected on both 2-D and 3-D analysis with large 
mean difference. The level of day1:day2 reproducibility in the current study for 
the 2-D ROI was similar to previously published colorectal cancer study of a 
similar limited tumour volume [386]: the BF measurements were sensitive to 
spontaneous changes, narrow B-A limits of agreement and minimal observer 
variance between readings. However the current study also revealed that BF 
worsened with increased tumour coverage (3-D analysis) for both observers, 
unlike previous studies on lung [493] and renal cancer [495]. For example, the 
repeatability coefficient decreased from -42.6% to 54.9% around the mean to 
57.7 absolute difference for observer 1, and from -36% to 38.4% around the 
mean to 47.1 absolute difference for observer 2 (see table 6.3). The observer 
variance also increased as seen by decrease in ICC from 0.75 to 0.39 for 
observer 1 and from 0.93 to 0.45 for observer 2. This effect of tumour volume 
indicates that the spatial variation in BF is considerable; this is also confirmed 
by poor wCV and variance component analysis.  
Regional tumour blood volume represents the functional vascular volume. For 
the BV measurements, there was good day-1:day-2 reproducibility analysis 
independent of volume coverage; however, sensitivity to spontaneous changes 
was much better on 3-D volume. The poor results for observer 1 were probably 
due to outlier values on day 2 with 2-D coverage (see table 6.2). Hence for day 
1, the inter-observer agreement was better for 2-D volumes, especially with low 
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observer variance (wCV 0.11 and ICC 0.84 for 2-D volume versus wCV 0.24 
and ICC 0.50 for 3-D volume, see tables 6.4 and 6.7). The difference between 
BV and BF suggests that for blood volume the spatial variation is less than for 
BF, and reflected by the wCV and variance component analysis. Given that 
blood volume provides a ‘snapshot’ of the functional vascular volume, this is not 
unexpected from physiology.  
The blood permeability surface product reflects the rate of transfer of the 
contrast agent from the intravascular to extravascular space. This is dependent 
both on the flow rate and flux of contrast agent into the interstitial space. With 
the haphazard anatomical and functional nature of the microvasculature, one 
might expect this to be highly variable. However, overall, the day-to-day 
reproducibility for the PS was consistently good for both observers with 2-D 
coverage and slightly worse on 3-D coverage. Between 2-D and 3-D coverage: 
the repeatability coefficient worsened from 11 absolute difference to -61% to 
127.9% around the mean for observer 1, and from 8.91 absolute difference to -
39% to 50.5% around the mean for observer 2, whilst the ICC declined from 
0.78 to 0.28 and 0.84 to 0.80 for observer 1 and 2 respectively. However, the 
obviously poor results for observer 1 with 3-D coverage may reflect the outlier 
value on day-1 (see table 6.5). Similarly, the inter-observer agreement was also 
better on 2-D coverage with identical measurement on day one for both 
observers.  
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6.4.2 Changes in DCE-CT parameters after neoadjuvant 
chemoradiotherapy 
During the interval between NCRT and surgery, there was a significant decline 
in absolute (and/or percentage) measurements for all DCE-CT parameters 
compared to baseline levels.  This is consistent with previous studies [403, 404] 
and the drop in post-NCRT parametric measurements relates to progressive 
tumour devascularisation. All parameters show most significant decline 
immediately post-NCRT, thereafter, the percentage decline in BF is lower, 
suggesting gradual recovery with time, whereas, BV and PS show marginal 
recovery at 6 weeks post-NCRT followed by a further decline at pre-operative 
stage (see figure 6.10). These variable changes in DCE-parameters reflect 
partial recovery of blood network with poor function. Such effect may be due to 
radiotherapy induced loss of the tumour volume and fibrosis that decreases the 
amount of blood entering the tumour microcirculation (BV) and the rate of 
contrast passing through these vessels (PS). Hence, the maximal 
devascularisation occurs immediately after NCRT with the overall tumour 
functional microcirculation remaining poor till surgery.   
6.4.3 The impact of DCE-CT parameters and clinical markers 
There were important correlations between DCE-CT perfusion parameters and 
clinical markers. The rectal tumours with higher T-stage were found to have 
lower measurements for perfusion parameters especially when obtain by 2-D 
volume coverage.  This correlation supports the theory that large tumours have 
poor functional vascularity with areas of hypoxia and collapsed vessels. In the 
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literature, authors have reported an association of low baseline perfusion 
parameters with poorly differentiated histopathology [382, 392] and potential to 
metastasize [498]. In contrast, tumours with higher blood volume and 
permeability surface showed nodal involvement. Such finding supports the 
pathophysiological aspect of tumour metastasis: tumours cells with readily 
available blood supply and leaky tumoural endothelium showed early 
metastasis [499]. Moreover, tumours with clinical nodal involvement showed 
persistent functional vascularity even after NCRT. Hence tumours with high 
angiogenic activity (independent of tumour size) were biologically aggressive at 
the time of diagnosis and also resisted vascular disruption by standard NCRT. 
These finding supports the theory that tumour size is not representative of its 
intrinsic biology and also supports the case for adding anti-vascular biological 
agents into NCRT regimes for locally advanced rectal cancers with nodal 
disease. Previously, authors have investigated the role of baseline DCE-CT 
parameters in predicting response to NCRT; the results are conflicting: whilst 
some authors have shown a low BF and high MTT in responders, others have 
shown lower BF in non-responders [403, 404, 500]. In the current study, there 
were numerical differences without statistical significance in baseline values 
between responders and non-responders: patients with T-downstaging showed 
a relatively lower baseline BF and higher PS than non-responders, whilst, 
patients with N-downstaging showed a relatively higher BF and lower PS than 
non-responder; both findings were independent of observer and coverage 
volume. Therefore it can be hypothesized that presence of leaky endothelium 
(high PS) within tumours enabled delivery of radical oxidant generated by 
NCRT to susceptible cancer cell load even at lower delivery rates (low BF) and, 
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at higher delivery rates and less leaky tumoural endothelium, the radical oxidant 
reached draining lymph node. There are several reasons for conflicting results 
on the role of baseline DCE-CT parameters in predicting response to NCRT in 
previous studies including different end-points to assess response, different 
patient selection criteria, difference in perfusion techniques and different 
mathematical models used to derive parameters [420, 500]. After NCRT, 
patients with significantly declining perfusion parameters showed tumour 
downstaging and remained alive without disease recurrence for the entire study 
period. Rectal tumour with significantly declining blood volume and permeability 
surface after NCRT achieved pathological complete response. In contrast, 
patients with persistently high blood volume and permeability surface (persistent 
angiogenic activity) after NCRT had tumour that remained large in size 
(according to RECIST criteria), had higher pathological T and N stage and 
suffered recurrence. The results of current study show an obvious distinction in 
DCE-CT parameters between patients with and without favourable prognosis 
and support the role of DCE-CT analysis to filter patients for tailored 
management regimes.  
6.4.4 Benefits and limitation of current experiment 
The current study adds to the literature by showing that reproducibility may vary 
additional due to spatial heterogeneity of vasculature; reproducibility results 
from a more limited coverage may not necessarily be translatable to the whole 
tumour; nor may whole tumour coverage improve reproducibility in all tumour 
types. Given the relative good inter-observer agreement, the effect of observers 
on reproducibility is less relevant than the spatial and temporal fluctuations in 
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regional perfusion. The baseline DCE-CT parameters provide an insight into 
tumour biology and supports previous evidence [499]. After NCRT, responsive 
tumours show an obvious decline is perfusion parameters, whilst aggressive 
tumours maintain good functional vasculature. Such finding can be utilized in 
clinical setting to help tailor management of rectal cancers.  
There are some limitations to the current study: the sample size is small (though 
comparable to previous studies on reproducibility), reflecting challenges in 
recruiting patients for a second study that they perceive confers no additional 
benefit. About 50% of the patients who were originally screened to take part in 
the study declined due to the different components of the study, which they 
perceived as invasive (serial biopsies and blood sampling). On the other hand, 
the current experiment is the first study in literature to provide a comprehensive 
assessment on reproducibility of DCE-CT perfusion parameters with two 
different volumes in rectal cancers at baseline also provide an insight into 
association of these parameters with clinical markers and long-term prognosis.   
6.4.5 Conclusion 
The current study shows that coverage volume influences the reproducibility of 
DCE-CT parameters due to spatial and temporal fluctuation in vascular 
parameters. Whole tumour analysis may provide assessment of vascular 
heterogeneity in rectal cancers but may not necessarily improve reproducibility 
over and above smaller volume coverage. The DCE-CT parameters decline 
after NCRT in responsive tumours, whilst persistent BV and PS (angiogenic 
activity) after NCRT correlate with biologically aggressive tumours with early 
nodal disease and recurrence.
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7 CHAPTER 7: CONCLUSIONS 
The current work presented in this thesis demonstrates the first prospective 
report on the biological behaviour of rectal cancers to standard therapy. The 
experiments showed alteration in the DNA repair profiles, tumour cellularity, 
tumour hypoxic blood volumes, and functional vascularity in locally advance 
rectal cancer during the interval between neoadjuvant chemoradiotherapy and 
curative surgery with notable clinical correlations.  
7.1 Hypothesis and results 
“We believe that effects of NCRT are time-limited and aggressive rectal 
cancers can overcome the effects of NCRT after certain time by repairing 
their DNA and re-generating functional vascularity” 
The primary mechanism of NCRT is cell death by DNA damage. The DNA 
repair analysis confirmed the effects of NCRT to be time-limited: comet assay 
analysis of rectal cancers showed that the DNA demonstrates poor repair 
profiles until six weeks post-NCRT, thereafter, the residual tumour load at pre-
operative stage had comparable DNA repair properties to the baseline samples 
(see figure 4.4). Interestingly, all viable tumour cells harvested at different time 
points showed a tendency towards repair however impaired on timed-comet 
assay analysis (see figure 4.11). Hence, at the time of surgery, the residual 
tumour load had cells with intact DNA repair mechanism. These tumour cells 
may either represent radioresistent fraction within original tumour or a new 
populations of cells with enhanced DNA repair.   
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The oxygen radicals generated by NCRT may also disrupts tumour 
microvasculature. Functional imaging did not show regeneration of functional 
vascularity. There seems to be a steady decline in microcirculation until surgery, 
however, the findings do indicate rearrangement of cells around available blood 
supply to improve oxygenation (see below). 
“We believe that after NCRT, there are functional changes in rectal cancer 
tissues, such as cellularity, hypoxic foci and functional vascularity, which 
may be detectable with functional imaging techniques.”  
There were many relevant changes detectable on functional imaging that 
appeared before morphological changes seen on conventional imaging 
techniques. Immediately after NCRT, there was an acute drop in blood reaching 
tumour cells (decreased BF) affecting the volume of blood within tumour tissue 
(decreased BV) and exchange of nutrients at endothelial level (drop in PS, 
Ktrans/IAUGC60 and kep), indicating vascular disruption. There were 
corresponding rise in ADC and ve suggesting cell destruction and increased 
extracellular extravascular space. The acute increase in ADC and ve may also 
represent tissue oedema after NCRT. Interestingly, there was only modest rise 
in tissue hypoxia (increase R2*), indicating tumour cells around blood vessels 
are able to maintain oxygenation despite sharp changes in microcirculation. At 
sixth-week post-NCRT, the microcirculatory changes were incoherent: whilst the 
BF improved, there was only modest improvement in BV and PS and continued 
drop in Ktrans/IAUGC60 and kep, indicating that despite improvements in the 
amount of blood reaching the tumour tissue, there is poor exchange of nutrients 
at endothelial levels. This is further demonstrated by a rise in hypoxia levels 
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(increasing R2*). The drop in ADC and ve may at sixth-week post-NCRT may 
represented true level of cell destruction as tissue oedema subsides. At the pre-
operative stage, the BF continues to recover, however, both BV and PS show 
decline similar to worsening Ktrans/IAUGC60 and kep, suggesting continual 
tumour devascularisation until surgery and formation of fibrosis. The rise is ADC 
also suggests further cell destruction. Interestingly, there is decline in ve and 
improvement in the level of tumour hypoxia (R2*), which may indicate 
concentration of residual tumour cells near blood vessels to improve survival. 
The improved hypoxia also indicate that surviving tumour cells are not entirely 
dependent on their own micro-environment.  
“We believe that baseline and changes after NCRT in DNA repair 
properties, cellularity, hypoxic foci and functional vascularity may affect 
clinical outcomes” 
The limited sample size means all clinical correlation present must be 
considered with caution. The experiments revealed interesting clinical 
correlations: the DNA repair analysis showed that rectal cancers with intact 
DNA repair on biopsy specimen also showed clinical downstaging or vice versa, 
hence the sample biopsied may not be representative of majority of tumour cell 
population, indicating tumour composition of cell populations with 
heterogeneous radiosensitivities. The R2* and MRI-DCE parameter 
measurements provided vitals clues about tumour behaviours and 
aggressiveness: a pre-operative return of angiogenesis indicated higher 
potential for local recurrence, whereas pre-operative tumour cell hypoxia 
indicates higher potential for distant metastasis. The DCE-CT parameters 
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decline after NCRT in responsive tumours, whilst persistent angiogenic activity 
(stable BV and PS) after NCRT correlates with biologically aggressive tumours 
with early nodal disease and recurrence. 
7.2 The optimal time to surgery 
Based on the DNA repair analysis, the optimal time for surgery should fall 
between six-to-twelve weeks from completion of NCRT. This is based on the 
fact that NCRT mechanism of action is cell death by DNA damage with 
secondary disruption of microcirculation. Since the DNA repair profiles of rectal 
cancer show obvious impairment until six weeks after NCRT and thereafter 
imitates baselines values, surgical resection of tumour after six weeks would 
enable successful treatment.  
The microcirculatory decline continues at pre-operative stage despite tumour 
cell regaining DNA repair mechanisms. Such observation indicate that tumour 
cell survival is not entirely dependent on its own micro-environment. Hence, the 
effect of NCRT continues on tumour microenvironment well after six weeks, but 
this observation would not affect timing of surgery. In theory, surviving cell 
fraction can potentiate tumour regrowth and re-establish their circulation with 
time. This is supported by studies showing higher risk of local recurrence in 
patients achieving pCR after NCRT who did not undergo curative surgery [501].  
The microcirculatory changes do however provide vital insight into tumour 
biology and holds potential for future tumour staging and response assessment 
of novel therapeutics. 
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II Mathematical principals of ISW-MRI: 
The deoxygenated haemoglobin increases the transverse relaxation rate (R2*) 
of water in blood and in the tissue surrounding blood vessels, represented as:  
𝑅2
∗ =
1
𝑇2
∗ 
Thus ISW-MRI is sensitive to pO2 within and in tissues adjacent to perfused 
vessels [502]. It has been suggested that fast R2* rate may be directly 
indicative of tumour hypoxia (extensive deoxyhaemoglobin) [503]. However 
R2* is also highly dependent on intrinsic tissue properties which can have 
static and dynamic component. The static components includes tissue iron 
content  (for example, myoglobin found in muscle), presence of fibrous 
structure or ligamentous structures, calcification, vascular structure and/or 
quantity (blood volume) and dynamic components include the velocity of 
blood circulation (blood flow), local haematocrit, haemorrhage or red blood 
cells in the tissue [504]. Other factors affecting R2* include B0 field 
inhomogeneity at tissue interfaces [504-506]. Also, the amount of 
deoxyhaemoglobin at a particular region of the tumour is not only dependent 
on blood oxygenation but also tumour blood flow. A high tumour blood flow 
reduces the extraction of oxygen from blood, thereby decreasing 
deoxyhaemoglobin levels. In order to separate the effects of flow from 
deoxyhaemoglobin and static components it is necessary to measure the T2* 
relaxation rates. Gradient-recalled-echo (GRE) sequence with increasing 
echo times (TE; usually spanning 5–65 ms) are used to display T2* effects 
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[321]; the series of images obtained have T2*  susceptibility effects with 
increasing TE. The rate of signal intensity decay is dependent on intrinsic T2* 
relaxation (local structures), deoxyhaemoglobin and local blood flow as 
mentioned above. Synthetic R2* images are created by plotting the natural 
logarithm (ln) of the signal intensity against the TE.  R2* map reflects on the 
structure of the tissues and local deoxyhaemoglobin but inflow effects are 
minimised; however, R2* maps retain sensitivity to pO2 changes caused by 
alterations in blood flow [504]. The contribution of blood deoxyhaemoglobin to 
R2* relaxation rate of the surrounding tissue can be written as: 
 𝑅2
∗ = 𝑅2 𝑡𝑖𝑠𝑠𝑢𝑒
∗ + 𝑅2 𝑏𝑙𝑜𝑜𝑑
∗   
where, R2*tissue is assumed to be the static component, R2*blood is related to 
blood volume and tumour blood oxygenation saturation and can be expressed 
as:  
𝑅2 𝑏𝑙𝑜𝑜𝑑
∗ = 𝑘. 𝑉 (1 − 𝑌) 
where, k is constant, V is the blood volume, and Y is the tumour blood 
oxygenation saturation, or  
𝑅2 𝑏𝑙𝑜𝑜𝑑
∗ = 𝑘′[𝑑𝐻𝑏] 
where, [dHb] is the concentration of deoxyhaemoglobin in the tissue, therefore 
𝑅2 
∗ = 𝑅2 𝑡𝑖𝑠𝑠𝑢𝑒
∗ + 𝑘′[𝑑𝐻𝑏] 
Thus R2* contains a component that depends on the tumour tissue 
deoxyhaemoglobin content [dHb], which is a function of the vascular volume 
of the tumour actively perfused by erythrocytes.  
APPENDIX II 
 
370 
So it can be deduced that ISW-MRI images are more likely to reflect on acute 
tissue hypoxia as hypoxic areas extend to the level of the blood vessels 
(whereas, in chronic hypoxia the red cells in the vessels are too distant from 
area of hypoxia) and red blood cells have to be delivered to the tissue in order 
to assess its oxygenation status. It should also be noted that perfusion in 
tumour tissue is heterogeneous, the red cell perfusion is not simply related to 
the absence/presence of vessels; plenty of tumour vessels may be present 
but perfusion by red cell may not occur [332]. Hence R2* does not measure 
tissue pO2 directly and therefore, the distribution of blood volume in tissue has 
to be determined in order to be able to correctly interpret R2* images in order 
to infer oxygenation status [504]; this hypothesis is supported by preclinical 
and clinical data [341] 
Many studies have reported that changes in R2* are temporally correlated with 
changes in tissue pO2 in response to vasomodulation with hyperoxic gas 
challenge, for example carbogen (95%CO2: 2% O2) inhalation. The changes 
in tumour vascular oxygenation as revealed by changes in R2* are 
represented as: 
∆𝑅2
∗ =  ∆𝑅2 𝑡𝑖𝑠𝑠𝑢𝑒
∗ + ∆𝑅2 𝑏𝑙𝑜𝑜𝑑
∗ = 𝑘′∆[𝑑𝐻𝑏]  
where, Δ [dHb] is the change is tissue deoxyhaemoglobin concentration 
caused by challenge with carbogen. Thus ΔR2* is sensitive to blood volume, 
haematocrit, and oxygenation. Hence ΔR2* can provide vital information about 
the potential to enhance oxygen delivery to the tumour [333]. 
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III Mathematical principals of Dynamic Contrast 
Enhanced Imaging (CT and MRI) 
Dynamic contrast enhanced imaging (DCEI) offer measurement of tissue 
microcirculation including details on capillary networks, exchanges between 
blood and extravascular space, and vascular permeability. DCEI provides vital 
insight in to tumour pathophysiology before morphological changes are 
obvious. Advancements in both CT and MRI technology and availability of 
commercial software has made it possible to obtain high temporal and spatial 
resolution images and enabled imaging of microcirculation with morphological 
imaging. The most popular method of analysing microcirculation by cross-
sectional imaging is the analysis of the kinetics of passage of contrast agent 
through the tissue after a bolus intravenous injection.     
Physiological parameters of microcirculation 
Microcirculatory parameters are generally expressed for a given mass or 
volume of tissue so that different tissues can be compared. As in cross-
sectional imaging voxel represents one volume element of tissue, the 
parameters of the microcirculation are expressed per unit of volume. In DCEI, 
blood flow in large vessels is measured by flow rate Q which is quantity or 
volume of blood passing through a tube of given surface area expressed as 
volume of blood per unit time (unit: mL/min), whereas, blood flow in tissue is 
measured by ‘flow per tissue volume’, expressed as volume of blood per unit 
time and per unit volume of tissue (unit: mL/min/100mL). Flow and volume 
parameters can be measured as a function of plasma rather than blood. The 
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correspondence between the parameters expressed for plasma and those 
expressed for blood involves the haematocrit.   
Main parameters of the microcirculation (Adopted from Cuenod et al 
[507] ) 
 
Physiology 
Marker 
Definition and units 
Tissue blood flow (BF) Blood flow entering (and exiting) a volume of tissue (unit: mL of 
blood/min/100 mL tissue) 
Can be expressed as tissue plasma flow (unit: mL of 
plasma/min/100 mL of tissue) 
Tissue blood volume 
(BV) 
Volume of capillary blood contained in a certain volume of 
tissue. (unit: mL blood/100 mL of tissue OR %) 
Can be expressed as tissue plasma volume (unit: mL 
plasma/100 mL of tissue OR %) 
Mean Transit Time Mean time taken by blood to pass through capillary network 
(unit: seconds) 
Permeability –surface 
area product (PS) 
Rate of flow of molecules through the capillary membranes in a 
certain volume of tissue (unit: mL/min/100mL tissue) 
PS depends on characteristics of both capillary wall and contrast 
agent 
Transfer constant 
(Ktrans) 
Part of molecules the flow into the interstitium 
Extravascular and 
extracellular volume 
fraction (ve) 
Tissue interstitial volume in which contrast may accumulate if 
they cross the endothelial barrier (unit: mL of extracellular 
volume/100mL of tissue OR %).  
The distribution volume is often called the extravascular 
extracellular space (ESS)  
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 Principals of tissue kinetics of contrast agents  
After injection of contrast agent, it enters the tissue capillary network from 
surrounding arterial network, thereafter, depending on endothelial 
permeability, it may pass into the interstitium, followed by passage into 
venous network and finally eliminated by kidneys. The temporal kinetics of 
enhancement depends on general (cardiac output) and local circulatory 
systems (endothelial permeability), the mode of injection (injection rate, dose, 
concentration of contrast) and type of contrast. After injection of contrast, two 
phenomenon occur simultaneously:  
(i) Perfusion in the microcirculatory network and accumulation in the 
interstitium (depending on capillary permeability), followed by  
(ii) Release from the interstitium due to capillary leakage.   
The time course and kinetics of these two phenomenon are different but they 
overlap. Figures below illustrate contrast kinetics and image enhancement 
seen according to the type of capillary network.   
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Contrast kinetic in tissue not permeable to contrast agent (e.g. Brain) 
In tissue where contrast remains confined in 
the microvascular network (for example in 
brain due to blood brain barrier), the and if it is 
completely eliminated by the kidney is the first 
passage, tissue enhancement would show a 
rapid rise after arrival of the bolus, followed by 
rapid exponential decay to a values close to 
the initial value before the injection.  
 
If the contrast is not eliminated in first pass, 
the second pass (blue line) is visible as a 
second peak, which is much lower than first 
peak.  
Contrast kinetic in tissue not permeable to contrast agent (e.g. Brain) 
Permeable capillary endothelium 
allows contrast agent accumulation 
in the interstitium, which is 
eliminated later once the 
concentration of contrast in plasma 
becomes lower than interstitium  
The tissue enhancement seen on 
DCEI is the product of contrast 
agent in capillary network and the 
interstitium   
 
  
1st Peak  
2nd Peak  
Accumulation of contrast in 
the interstitium 
Elimination of contrast 
from interstitium later 
Tissue enhancement is due 
to contrast in capillaries 
and interstitium  
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Measurement of tissue kinetic of contrast agents by DCEI 
The passage of contrast through capillary network is very fast (in order of 
seconds). Also the capillary networks spread over few millimetres only. 
Therefore, DCEI involves scanning sequence with high temporal (fast image 
acquisition) and spatial (think slices) resolution. Hence, DCEI involves 
repeated acquisition of images on the same or several slices after injection of 
contrast agent to obtain signal enhancement kinetics in the tissues (see figure 
below).  
Sequential acquisition for DCEI and tissue enhancement curve (Adopted 
from Cuenod et al [507] ) 
 
The tissue enhancement by passage of contrast agent can be divided into 4 
phases: 
1. The arrival of contrast into the capillary network. There is rapid 
increment of contrast into capillary network and very fast image 
acquisition speed is required to record tissue enhancement. This phase 
depends on tissue perfusion flow rate.  
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2. The first peak occurs when maximum contrast (in plasma) volume is in 
the capillary network (blue line); thereafter, the volume of contrast in 
capillaries decline due to passage into the interstitium and venous 
system for elimination by kidneys. This phase depends on tissue blood 
volume.  
3. The leakage of contrast into the interstitium (green line) causes a 
sustained enhancement on DCEI. This phase depends on capillary 
endothelial permeability and surface area. 
4. A second peak (slow) occurs as the contrast reaches maximum 
concentration within interstitium (more than plasma in capillaries); 
thereafter, the contrast passes back in to capillaries to be eliminated by 
kidneys. This phase depends on tissue interstitial volume   
Components of tissue enhancement curve. (Adopted from Cuenod et al 
[507] ) 
 
  
  
1
 
2 
3 4 
Tissue 
blood flow 
Tissue blood 
volume 
Permeability x surface 
Tissue interstitial volume = 
extra vascular extracellular 
space fraction 
Tissue enhancement curve 
Plasma 
Interstitium 
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Measuring DCEI parameters of tissue microvascular circulation.  
The derivation of DCEI parameters of tissue microvascular circulation involves 
the following steps: 
1) Conversion of tissue enhancement signal into contrast concentration 
2) Measurement of arterial input function 
3) Application of mathematical tracer-kinetic models to derive DCEI 
parameters 
Conversion of tissue signal enhancement into contrast concentration 
All DCE methods are based on the standard tracer kinetic theory of linear and 
stationary systems. Linearity in this case means that the tissue response is 
assumed proportional to the injected dose, stationary means that the 
response is independent from the time of injection. If this is the case, then 
time-dependent tissue concentration ct(t) is related to the time-dependent 
concentration ca(t) in a supplying blood vessel by the convolution with a 
residue function R(t): 
𝑐𝑡(𝑡) =  𝐹𝑝. 𝑅(𝑡) ⊗  𝑐𝑎(𝑡)  
where, Fp is the plasma flow that’s carries contrast agent, ⊗ denotes 
convolution, ca(t) is the arterial input function and R(t) is the tissue 
characteristic time course which reflects the distribution of contrast transit 
times through the tissue.  
For DCE-CT, the tissue signal enhancement (unit: Hounsfield) has linear 
relationship to contrast concentration. This can be expressed as: 
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𝑐(𝑡) = 𝑘. (𝑆(𝑡) −  𝑆0)  
where, k is proportionality constant, S(t) is time dependent signal 
enhancement and S0 is the pre-contrast signal. 
However, for DCE-MRI, the tissue signal enhancement is not directly 
proportional to contrast concentration. The tissue signal enhancement is 
weighted with specific physical and chemical parameters such as longitudinal 
and transverse relaxation times or the tissue proton density. The signal also 
depends on various parameters of the imaging sequence. Therefore, different 
approximations are applied with different limitation in accuracy, precision and 
practical convenience for measurement of dynamic parameters. These 
include: 
1) Relative signal enhancement: this method normalises signal change 
to baseline value. It uses relative signal enhancement as an 
approximation to the concentration: 
𝑐(𝑡) =  
𝑅10
𝑟1
 
𝑆(𝑡) − 𝑆0
𝑆0
 
 where, R10 is the pre-contrast relaxivity rate and r1 is the relaxivity of 
contrast agent (independent of tissue type; calculated from phantom 
data) 
2) Absolute MR units: this approach involves converting DCE-MRI 
signal in to functions R1(t) which measures the relaxation rate as a 
function of time. The R1(t) has linear relation with concentration, 
expressed as: 
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𝑐(𝑡) =  
𝑅1(𝑡) − 𝑅10
𝑟1
 
The conversion of S(t) to R1(t) results in significant sacrifice of 
temporal resolution. 
Arterial Input Function 
All physiological models require measurement of contrast kinetics in the artery 
supplying the capillary beds in tissue of interest. The AIF (ct(t)) can be derived 
in the same was as tissue concentration. By taking the arterial supply into 
account, it is possible to obtain representative quantitative parameters that 
can be compared from one patient to another or for the same patient between 
two examinations. There are three methods of obtaining AIF: 
1. AIF measured in a large artery: for example for DCEI of intra-
abdominal viscera. Due to time-delay between passage of bolus in the 
large artery where AIF is measured and its arrival in capillary beds in 
tissue of interest, a Bolus Arrive Time (BAT) must be added to the 
model. A bolus dispersion between AIF measure site and capillary bed 
can also lead to error in parametric calculations [508].  
2. AIF measured in a small artery: for examples for DCEI of brain. Care 
should be taken to minimise partial volume effects and motion 
artefacts. 
3. Population AIF: a mean AIF corresponding to average values obtained 
in a population is used when no vessel is available. This technique is 
conventionally used in Tofts model.  The technique does not take into 
account individual variability between patients [509].  
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An intermediate approach is to use population AIF and to correct these 
using individual values measured in a small artery [510]. 
Mathematical calculations of DCEI parameters – tracer kinetic models 
Mathematical models help dissect out the components of microcirculation that 
constitute the tissue contrast enhancement curve. The derived parameters 
represent kinetics of contrast agent through the capillary network, which 
provide vital insight into microcirculatory physiology. There are three modes 
used to derive physiological parameters from tissue enhancement curve: 
1. Qualitative (visual) analysis: Each tissue has exclusive enhancement 
curve. This method focuses on shape of the curve to distinguish 
between benign and malignant lesions [511].  
2. Semi-quantitative analysis: This method derives heuristics parameters 
from tissue enhancement curve (see figure below). The most commonly 
used semi-quantitative parameters used in ‘Area Under the Curve 
(AUC)’. Mathematical models have been applied to this mode to provide 
precise definition of the parameters [512] 
3. Quantitative analysis (with physiological model). The parameters 
derived by model-based analysis of tissue enhancement curve are 
relatively close to actual tissue physiology. The models take in to 
account exchanges between arterial blood, the plasma and the 
interstitial space.  
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Qualitative and Semi-quantitative analysis (Adopted from Cuenod et al 
[507] ) 
Qualitative analysis: A rapid 
peak (wash-in) and descent 
(wash-out) of malignant lesion 
compared to slow peak and 
wash-out plateau of malignant 
lesion.   
Semi-Quantitative analysis: 
Two tissues are compared. 
This analysis is useful when 
internal reference is available. 
For example distinguishing 
between normal (Tissue 1) and 
ischaemic tissue (Tissue 2).  
 
  
Malignant Tissue 
Benign Tissue 
Time 
Signal 
X
	
X
	
X	 X	
X	 X	
X	
X	
X	X	
X	
X	
X	
X	X	
X	
X	
X	
Sl
op
e 
of
 c
ur
ve
 2
 
Time 
Signal 
Peak 
height 2 
Peak 
height 1 
S
lo
p
e
 o
f 
c
u
rv
e
 1
 AUC 
AUC 
Tissue1 
Tissue 2 
Time to 
peak 
Time to 
peak 
 APPENDIX III  
 
382 
Modes of tissue contrast enhancement curves 
Mode Types Measurements/Models 
Qualitative n/a Wash-in – filling phase; Peak – peak 
intensity; Wash-out – elimination 
phase,  
Semi-
Quantitative 
Without 
mathematical 
model 
Peak height, time to peak, slop of 
curve, Area under the curve (AUC),  
etc. 
With 
mathematical 
model 
Various. (see ref. [512]) 
Quantitative  Tissue perfusion 
models 
Deconvolution; Axel; Ostergaard - 
Sorensen 
Permeability 
model 
Neglecting Blood Volume: Toft-Kety 
; Brix; Larsson; Patel 
With blood volume but without 
return: Patlak; Miles; Shames-Brash 
With blood volume return: Extended 
Kety or Toft General Kinetic Model; 
Larsson 
Complete model 
with exchanges 
Without return: Cuenod-Pradel-de 
Bazelaire 
With return: Adiabatic approximation 
of tissue homogeneity; St Lawrence 
and Lee; Two-compartment 
exchange; Brix2; Comprehensive 
model (Cuenod-Balvay); 2CX 
Sourbron-Buckley; Larsson; 
Distributed parameter model; Koh-
Dennis Cheong – Bisdas; 
Physiologically based pharmokinetic 
modelling; Brochot-Bios 
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IV Pharmacokinetic Models   
DCE-MRI 
Pharmacokinetic analysis of DCE-MRI is the most widely used method of 
measuring vessel permeability changes, analyses typically being derived from 
variations of the Tofts’ two-compartment kinetic model [513] (mathematically 
equivalent to Kety’s dynamic model [514]), see figure below. It consists of a 
plasma volume connected to a large extracellular space throughout most 
body and also connected to a lesion through a leaky membrane. The lesion 
compartment is small enough not to influence the overall plasma 
concentration. The kidneys drains the contrast from plasma, and hence from 
extracellular space. The model is based on following assumptions: 
 There is fast mixing of contrast in plasma after bolus injection  
 The contrast agent concentration in a given compartment is uniformly 
distributed (that is capillary flow in the lesion must be high enough to 
prevent plasma concentration from being locally depleted).  
 Inter-compartmental flux is linearly proportional to the concentration in 
each compartment 
 Parameters have not changed during data acquisition 
 Relaxivity of gadolinium contrast agent is directly proportional to its 
concentration 
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Toft’s two compartmental model  
 
Cp(t)- time-varying blood plasma concentration, AIF – arterial input function, 
Vp – total blood plasma volume, Ktrans – volume constant transfer, kep- rate 
constant, ve – volume of extravascular extracellular space, Ct(t) – time-varying 
tracer concentration in tissue. 
The compartmental model is used to obtain three principal parameters [423]: 
the transfer constant (Ktrans), the extravascular extracellular space (EES) 
fractional volume (ve), and the rate constant (kep). The transfer constant and 
the EES relate to the fundamental physiology, whereas the rate constant is 
the ratio of the transfer constant to the EES, described by following formula: 
𝑘𝑒𝑝 =
𝐾𝑡𝑟𝑎𝑛𝑠
𝑣𝑒
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The total Gd concentration in a voxel or region of interest (ROI) is the sum of 
the EES contribution (which usually dominates, since ve ≈ 10 – 60%) and the 
intravascular contribution which is always small and can be ignored (vp ≈ 1-
10%) [364]. 
In this model, the bolus of injected contrast agent (Gd- chelates) gives time 
varying blood plasma concentration (Cp(t) or AIF) which can be measured in 
each subject, or else a population mean can be used. Following the work of 
Tofts and Kermode [513], the input function (Cp(t)) was approximated by a bi-
exponential function that was scaled according to the administered dose of 
Gd-DTPA: 
𝐶𝑝(𝑡) =  𝐷[𝑎1 exp(−𝑚1𝑡) +  𝑎2exp (−𝑚2𝑡) 
where, D is the dose of Gd-DTPA (mmol/kg body weight), a1 and a2 are the 
amplitudes of the components and m1 and m2 are their rate constants. The 
fast component (a1,m1) corresponds to equilibrium between plasma and 
extracellular space (which is relatively well connected; (a2,m2) corresponds to 
emptying of these two well coupled compartments to the kidneys.  
From the capillaries, the contrast diffuses into the extravascular extracellular 
space and assessments of tissue perfusion and permeability can be derived 
from the shape of the observed wash-in and wash-out curves. The transfer 
constant Ktrans (often called wash-in rate) characterises the diffusive transport 
of low-molecular-weight Gd chelates across capillary epithelium [423] and 
hence represents a constant of proportionality. Depending on vascular 
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permeability, the compartmental model can be modified to accommodate the 
following variations in physiology: 
1. High permeability (Flow-Limited model): For blood vessels where 
diffusion is rapid (that is when extraction fraction during the first pass of 
the contrast agent is high, as typically found in tumours), perfusion will 
determine contrast agent distribution and Ktrans approximates to tissue 
blood flow per unit volume [423].  The relationship between tissue 
concentration (Ct) and arterial concentration of contrast can be 
mathematically expressed as:  
𝑑𝐶𝑡
𝑑𝑡
=  𝐹𝜌(1 − 𝐻𝑐𝑡)(
𝐶𝑝 −  𝐶𝑡
𝑣𝑒
) 
where, F is perfusion of whole blood per unit mass of tissue, ρ is tissue 
density, Hct is haematocrit and ve is total EES volume. 
2. Low permeability (PS-limited model): There are circumstances 
where transport out of the vasculature does not significantly deplete 
intravascular contrast medium concentration (that is, tissue with a 
lower first pass extraction fraction). The blood plasma can be 
considered as a single pool, with equal arterial and venous 
concentration. This is typically found in some brain tumours, which 
have a largely intact blood-brain barrier, but also occurs in extracranial 
tumours after treatment with chemotherapy and/or late after 
radiotherapy, and in fibrotic lesions and in some normal tissues. The 
rate of uptake (Ktrans) approximates to the product of permeability and 
the surface area (permeability surface area product, PS) [350, 515]. 
The transport equation is:  
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𝑑𝐶𝑡
𝑑𝑡
=  𝑃𝑆𝜌(
𝐶𝑝 −  𝐶𝑡
𝑣𝑒
) 
3. Mixed permeability (flow and perfusion-limited models): The 
contrast uptake may be limited by both blood flow and permeability. 
This is represented as  
𝑑𝐶𝑡
𝑑𝑡
=  𝐸𝐹𝜌(1 − 𝐻𝑐𝑡)(
𝐶𝑝 −  𝐶𝑡
𝑣𝑒
) 
where, E is the initial extraction ratio [516]; it is the fractional reduction 
in capillary blood concentration as it passes through tissue.  In a flow-
limited case, the extraction is complete (E=1) and the transport 
equation reduces to ‘flow limited equation’. In permeability-limited case, 
there is limited extraction (E = PS/F (1-Hct)) and the transport equation 
reduces to ‘permeability limited equation’.  
4. Clearance model: After a variable time, the contrast agent diffuses 
back into the vasculature (described by the wash-out rate constant or 
kep) from where it is excreted usually by the kidneys. Washout of 
contrast medium is faster when capillary permeability is very high, due 
to a typically rapid return of contrast medium into the blood. Hence the 
distribution clearance (CLd) can be defined for two connected 
compartments. This is mathematically expressed as: 
𝑑𝐶𝑡
𝑑𝑡
=  
𝐶𝐿𝑑
𝑉𝑡
(
𝐶𝑝 −  𝐶𝑡
𝑣𝑒
) 
where CLd /Vt defines clearance per unit volume.  
The transfer constant can be physically interpreted as follows: Ktrans = Fρ (1-
Hct) under flow limited conditions, Ktrans = PSρ under permeability limited 
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conditions, Ktrans = EFρ (1 – Hct) under mixed permeability conditions and 
Ktrans = CLd /Vt under clearance paradigm. Hence 
𝑑𝐶𝑡
𝑑𝑡
=  𝐾𝑡𝑟𝑎𝑛𝑠(
𝐶𝑝 − 𝐶𝑡
𝑣𝑒
) 
or 
𝑑𝐶𝑡
𝑑𝑡
=  𝐾𝑡𝑟𝑎𝑛𝑠𝐶𝑝 −  𝑘𝑒𝑝𝐶𝑡 
Therefore, in summary, the time-varying concentration of contrast in tissue at 
a unit time (dCt/dt) is determined by blood plasma concentration and two 
additional parameters, the transfer constant (Ktrans) and the EES fractional 
volume (ve), (or alternatively, Ktrans and the rate constant kep). The time course 
of the contrast agent in the tissue can be described by the following equation: 
𝐶𝑡(𝑡) =  𝐾
𝑡𝑟𝑎𝑛𝑠 × [𝐶𝑝(𝑡) ⊗ exp( − 𝑘𝑒𝑝 ×  𝑡) 
where, Ct (t) represents Gd concentration in tissue at time t;  Cp(t)  represents 
the Gd concentration in arterial blood plasma at time t; Ktrans is the transfer 
constant for transport of plasma to EES; kep represents the arte constant for 
the transport from EES to plasma; and ⊗ denotes convolution.  
Other quantitative kinetic parameters that can be derived from 
pharmacokinetic modelling of DCE-MRI data include the fraction plasma 
volume (vp) and the fractional extravascular, extracellular space (ve, or simply 
leakage space).  
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A model simulation using typical Ktrans values for tumors [513] 
1) The initial slope depends on 
Ktrans, and is independent of ve. 
The graph show effects of 
increasing Ktrans with fixed ve 
=10% 
 
2) The final peak value depends 
on ve. Tumours with large ve take 
longer to reach their peak. The 
graph shows effect of increasing 
ve with fixed Ktrans =0.1 min-1 
 
3) The shape of the curve is 
determined by kep, and if Ktrans is 
increased whilst keeping kep fixed, 
the curve increases in amplitude 
but retains the same shape. 
(Constant kep = 2 min-1) 
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DCE-CT 
Compartmental Analysis 
Compartmental analysis can be either single compartment or double-
compartment method. The single compartment method is based on Fick’s 
principals and assumes that intravascular and extravascular spaces are single 
compartment [373]. The perfusion parameters are calculated using the 
maximum slope or peak height of the tissue contrast enhancement curve 
normalised to the arterial input function. This method ignores venous outflow 
at the time of initial maximum slope, which may lead to underestimation of BF 
[373, 517]. The double-compartment model is based on Patlak analysis; it 
assumes intravascular and extravascular spaces to be separate 
compartments. The rate of contrast passage from intravascular to 
extravascular compartments is characterised by rate constant ‘K’; the 
exchange from extravascular back into intravascular compartment is 
quantified by rate constant K/ve. The model allows calculation of BV and 
capillary permeability. The compartmental models require only three images: 
baselines, immediately before and after the maximal tissue contrast 
enhancement. Although, analysis of only three images can help reduce 
motion artefacts, however, any image noise can lead to miscalculation of 
parameters estimates. The compartmental model is used for organs with 
complex circulation (for example spleen, liver, kidney)[517, 518]. 
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Deconvolution Analysis:   
This model is based on the use of arterial and tissue time-concentration 
curves to calculate impulse residue function (IRF), which represents the 
fraction of contrast that remains in the tissue as time evolves after a bolus of 
injection into the arterial input. This model assumes that the concentration of 
contrast material in tissue is linearly dependent on the input arterial 
concentration when the BF is constant and ignores any leakage into the 
interstitial space. The height of the IRF curve reflects the tissue perfusion and 
area under the curve provides the relative BV estimation [517]. For the 
estimation of capillary permeability, a distributed model (Jonson Wilson 
model) is used. The deconvolution method requires inclusion of complete time 
series of images for calculation. Therefore, this method is resistant to image 
noise, but liable to motion artefact. Deconvolution analysis is particularly 
useful to measure organs with lower perfusion (<20mL/min per 100 mL) or 
lower perfusion values seen in tumour after treatment response [517].    
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Mathematical Models for DCE CT parametric analysis (adopted from 
Garcia-Figueiras et al [370]) 
Model Measure Assumptions Acquisition 
Advantages 
and 
Disadvantages 
Single 
Compartment 
(Ficks): 
maximal slope 
or peak height 
of tissue 
concentration 
curve 
normalised to 
arterial input 
function 
BF 
No venous 
flow 
45s 
(length), <2 
s intervals 
Less sensitive 
to movement 
Double-
Compartment 
(Patlak): 
quantifies 
passage of 
contrast from 
intravascular 
into 
extravascular 
space 
EF, BV 
Well-mixed 
compartments; 
one-way 
transfer only 
<2 min 
(length), <5 
s intervals 
Better for 
organs having 
complex 
microcirculation 
(kidney, spleen) 
Deconvolution 
(Johnson 
Wilson 
distributed 
parameters): 
use of arterial 
and tissue time 
concentration 
curves to 
calculate 
impulse 
residue 
function for 
tissue 
BF, BV, 
EF 
Constrained 
impulse 
residue 
function 
<2.5 min 
(length), < 2 
s interval in 
first pass, < 
15 s interval 
in delayed 
phase 
Less sensitive 
to noise, uses 
lower tube 
current, higher 
temporal 
resolution 
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Glossary of terms used commonly used in DCE (perfusion) CT (adopted 
from Kambadakone et al [372]) 
Perfusion 
parameter 
Definition Marker Units 
Blood Flow (BF) 
or Perfusion 
Flow rate from 
vasculature in 
tissue region 
Tumour 
vascularity; 
Tumour grade 
mL per 100 
g/min 
Blood Volume 
(BV) 
Volume of flowing 
blood within a 
vasculature in 
tissue region 
Tumour 
vascularity 
mL per 100 g 
Mean Transit 
Time (MTT) 
Average time taken 
to travel from artery 
to vein 
Perfusion 
pressure 
Seconds 
Permeability-
Surface area 
product (PS) 
Total flux from 
plasma to 
interstitial space 
Immature 
leaky vessels 
mL per 100 
g/min 
Time To Peak 
(TTP) 
Time of arrival of 
contrast in major 
arterial vessels to 
the peak 
enhancement 
Perfusion 
pressure 
seconds 
Peak 
Enhancement 
intensity (PEI) 
Maximum increase 
in tissue density 
after contrast 
injection 
Tissue blood 
volume 
HU 
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V Units of Measure 
The unit volume of tissue is expressed per 100 mL rather than grams as 
cross-sectional imaging devices provide data on tissue volumes. The use of 
mL overcomes the problem of conversion by density (ρ), which may be 
unknown for the tissue of interest (lung parenchyma, bone, etc.). (Adopted 
from Toft et al.[423])  
Quantity Definition Unit 
Cab Tracer concentration in the arterial blood mM 
Cap Tracer concentration in the arterial plasma mM 
Ctp Tracer concentration in the tissue plasma mM 
Cvp Tracer concentration in the venous plasma mM 
Ce Tracer concentration in the interstitium mM 
Ct Tracer concentration in the tissue mM 
Cvb Tracer concentration in the venous blood mM 
Cvp Tracer concentration in the venous plasma mM 
E Initial extraction fraction None (%) 
Hct Hematocrit: Ca = (1-Hct)Cp None (%) 
Ft 
Perfusion or blood flow rate per unit volume of 
tissue 
mL/min/100 
mL 
Ftp 
Perfusion or plasma flow rate per unit volume of 
tissue 
mL/min/100 
mL 
 APPENDIX V   
 
396 
P 
Permeability per unit surface area of capillary 
wall cm/min 
S 
Surface area of capillary wall per unit volume of 
tissue cm2/100 mL 
P x S 
Permeability-surface area product per unit 
volume of tissue 
mL/min/100 
mL 
Ktrans or 
EFp 
Constant volume transfer or extraction fraction 
Ã— or plasma perfusion rate 
mL/min/100 
mL 
Vb Total volume of blood mL 
Ve Total volume of interstitium mL 
Vp Total volume of plasma mL 
vs Blood volume fraction per volume of tissue None (%) 
vp Plasma volume fraction per volume of tissue None () 
ve Interstitial volume fraction per volume of tissue None (%) 
MTT Mean transit time s 
HPI 
Hepatic perfusion index: arterial infusion/total 
infusion % 
s:second
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